dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
that O
has O
activity O
against O
multiple O
imatinib-resistant O
BCR-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O
study O
, O
we O
demonstrate O
significant O
inhibitory O
activity O
of O
dasatinib O
against O
both O
wild-type O
KIT O
and O
the O
KITD816V O
mutation O
in O
the O
nanomolar O
range O
in O
in O
vitro O
and O
cell-based O
kinase O
assays O
. O
Additionally O
, O
dasatinib O
leads O
to O
growth O
inhibition O
of O
a O
KITD816V-harboring O
human O
masto-cytosis O
cell O
line O
. O
Significantly O
, O
dasatinib O
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O
from O
patients O
with O
systemic O
mastocytosis O
while O
sparing O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O
study O
, O
we O
demonstrate O
significant O
inhibitory O
activity O
of O
dasatinib O
against O
both O
wild-type O
KIT B
and O
the O
KITD816V O
mutation O
in O
the O
nanomolar O
range O
in O
in O
vitro O
and O
cell-based O
kinase O
assays O
. O
Additionally O
, O
dasatinib O
leads O
to O
growth O
inhibition O
of O
a O
KITD816V-harboring O
human O
masto-cytosis O
cell O
line O
. O
Significantly O
, O
dasatinib O
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O
from O
patients O
with O
systemic O
mastocytosis O
while O
sparing O
other O
hematopoietic O
cells O
. O
Computer O
modeling O
suggests O
that O
the O
KITD816V O
mutation O
destabilizes O
the O
inactive O
conformation O
of O
the O
KIT O
activation O
loop O
to O
which O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O
study O
, O
we O
demonstrate O
significant O
inhibitory O
activity O
of O
dasatinib O
against O
both O
wild-type O
KIT O
and O
the O
KITD816V O
mutation O
in O
the O
nanomolar O
range O
in O
in O
vitro O
and O
cell-based O
kinase O
assays O
. O
Additionally O
, O
dasatinib O
leads O
to O
growth O
inhibition O
of O
a O
KITD816V-harboring O
human O
masto-cytosis O
cell O
line O
. O
Significantly O
, O
dasatinib O
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O
from O
patients O
with O
systemic O
mastocytosis O
while O
sparing O
other O
hematopoietic O
cells O
. O
Computer O
modeling O
suggests O
that O
the O
KITD816V O
mutation O
destabilizes O
the O
inactive O
conformation O
of O
the O
KIT O
activation O
loop O
to O
which O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Dasatinib O
(BMS-35482 O
) O
inhibits O
KITD816V O
, O
an O
imatinib-resistant O
activating O
mutation O
that O
triggers O
neoplastic O
growth O
in O
most O
patients O
with O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O

Dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
patients O
with O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O
date O
, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD816V O
. O
Dasatinib O
(BMS-354825) O
is O
a O
novel O
orally O
bioavailable O
SRC/ABL O
inhibitor O
that O
has O
activity O
against O
multiple O
imatinib-resistant O
BCR-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O

Dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
patients O
with O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O
date O
, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD816V O
. O
Dasatinib O
(BMS-354825) O
is O
a O
novel O
orally O
bioavailable O
SRC/ABL O
inhibitor O
that O
has O
activity O
against O
multiple O
imatinib-resistant O
BCR-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O
date O
, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD816V O
. O
Dasatinib O
( O
BMS-354825 O
is O
a O
novel O
orally O
bioavailable O
SRC/ABL O
inhibitor O
that O
has O
activity O
against O
multiple O
imatinib-resistant O
BCR-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O
date O
, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD816V O
. O
Dasatinib O
( O
BMS-354825 O
is O
a O
novel O
orally O
bioavailable O
SRC/ABL O
inhibitor O
that O
has O
activity O
against O
multiple O
imatinib-resistant O
BCR-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O

donepezil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cholinesterase O
inhibitors O
for O
Alzheimer's O
disease.BACKGROUND O
: O
Since O
the O
introduction O
of O
the O
first O
cholinesterase B
inhibitor O
(ChEI) O
in O
1997 O
, O
most O
clinicians O
and O
probably O
most O
patients O
would O
consider O
the O
cholinergic O
drugs O
, O
donepezil O
galantamine O
and O
rivastigmine O
, O
to O
be O
the O
first O
line O
pharmacotherapy O
for O
mild O
to O
moderate O
Alzheimer's O
disease.The O
drugs O
have O
slightly O
different O
pharmacological O
properties O
, O
but O
they O
all O
work O
by O
inhibiting O
the O
breakdown O
of O
acetylcholine O
, O
an O
important O
neurotransmitter O
associated O
with O
memory O
, O
by O
blocking O
the O
enzyme O
acetylcholinesterase O
. O
The O
most O
that O
these O
drugs O
could O
achieve O

donepezil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cholinesterase O
inhibitors O
for O
Alzheimer's O
disease.BACKGROUND O
: O
Since O
the O
introduction O
of O
the O
first O
cholinesterase O
inhibitor O
(ChEI) O
in O
1997 O
, O
most O
clinicians O
and O
probably O
most O
patients O
would O
consider O
the O
cholinergic O
drugs O
, O
donepezil O
galantamine O
and O
rivastigmine O
, O
to O
be O
the O
first O
line O
pharmacotherapy O
for O
mild O
to O
moderate O
Alzheimer's O
disease.The O
drugs O
have O
slightly O
different O
pharmacological O
properties O
, O
but O
they O
all O
work O
by O
inhibiting O
the O
breakdown O
of O
acetylcholine O
, O
an O
important O
neurotransmitter O
associated O
with O
memory O
, O
by O
blocking O
the O
enzyme O
acetylcholinesterase O
. O
The O
most O
that O
these O
drugs O
could O
achieve O

galantamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cholinesterase O
inhibitors O
for O
Alzheimer's O
disease.BACKGROUND O
: O
Since O
the O
introduction O
of O
the O
first O
cholinesterase B
inhibitor O
(ChEI) O
in O
1997 O
, O
most O
clinicians O
and O
probably O
most O
patients O
would O
consider O
the O
cholinergic O
drugs O
, O
donepezil O
, O
galantamine O
and O
rivastigmine O
, O
to O
be O
the O
first O
line O
pharmacotherapy O
for O
mild O
to O
moderate O
Alzheimer's O
disease.The O
drugs O
have O
slightly O
different O
pharmacological O
properties O
, O
but O
they O
all O
work O
by O
inhibiting O
the O
breakdown O
of O
acetylcholine O
, O
an O
important O
neurotransmitter O
associated O
with O
memory O
, O
by O
blocking O
the O
enzyme O
acetylcholinesterase O
. O
The O
most O
that O
these O
drugs O
could O
achieve O
is O

galantamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cholinesterase O
inhibitors O
for O
Alzheimer's O
disease.BACKGROUND O
: O
Since O
the O
introduction O
of O
the O
first O
cholinesterase O
inhibitor O
(ChEI) O
in O
1997 O
, O
most O
clinicians O
and O
probably O
most O
patients O
would O
consider O
the O
cholinergic O
drugs O
, O
donepezil O
, O
galantamine O
and O
rivastigmine O
, O
to O
be O
the O
first O
line O
pharmacotherapy O
for O
mild O
to O
moderate O
Alzheimer's O
disease.The O
drugs O
have O
slightly O
different O
pharmacological O
properties O
, O
but O
they O
all O
work O
by O
inhibiting O
the O
breakdown O
of O
acetylcholine O
, O
an O
important O
neurotransmitter O
associated O
with O
memory O
, O
by O
blocking O
the O
enzyme O
acetylcholinesterase O
. O
The O
most O
that O
these O
drugs O
could O
achieve O
is O

rivastigmine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cholinesterase O
inhibitors O
for O
Alzheimer's O
disease.BACKGROUND O
: O
Since O
the O
introduction O
of O
the O
first O
cholinesterase B
inhibitor O
(ChEI) O
in O
1997 O
, O
most O
clinicians O
and O
probably O
most O
patients O
would O
consider O
the O
cholinergic O
drugs O
, O
donepezil O
, O
galantamine O
and O
rivastigmine O
to O
be O
the O
first O
line O
pharmacotherapy O
for O
mild O
to O
moderate O
Alzheimer's O
disease.The O
drugs O
have O
slightly O
different O
pharmacological O
properties O
, O
but O
they O
all O
work O
by O
inhibiting O
the O
breakdown O
of O
acetylcholine O
, O
an O
important O
neurotransmitter O
associated O
with O
memory O
, O
by O
blocking O
the O
enzyme O
acetylcholinesterase O
. O
The O
most O
that O
these O
drugs O
could O
achieve O
is O
to O
modify O

rivastigmine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cholinesterase O
inhibitors O
for O
Alzheimer's O
disease.BACKGROUND O
: O
Since O
the O
introduction O
of O
the O
first O
cholinesterase O
inhibitor O
(ChEI) O
in O
1997 O
, O
most O
clinicians O
and O
probably O
most O
patients O
would O
consider O
the O
cholinergic O
drugs O
, O
donepezil O
, O
galantamine O
and O
rivastigmine O
to O
be O
the O
first O
line O
pharmacotherapy O
for O
mild O
to O
moderate O
Alzheimer's O
disease.The O
drugs O
have O
slightly O
different O
pharmacological O
properties O
, O
but O
they O
all O
work O
by O
inhibiting O
the O
breakdown O
of O
acetylcholine O
, O
an O
important O
neurotransmitter O
associated O
with O
memory O
, O
by O
blocking O
the O
enzyme O
acetylcholinesterase O
. O
The O
most O
that O
these O
drugs O
could O
achieve O
is O
to O
modify O

acetylcholine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
first O
cholinesterase O
inhibitor O
(ChEI) O
in O
1997 O
, O
most O
clinicians O
and O
probably O
most O
patients O
would O
consider O
the O
cholinergic O
drugs O
, O
donepezil O
, O
galantamine O
and O
rivastigmine O
, O
to O
be O
the O
first O
line O
pharmacotherapy O
for O
mild O
to O
moderate O
Alzheimer's O
disease.The O
drugs O
have O
slightly O
different O
pharmacological O
properties O
, O
but O
they O
all O
work O
by O
inhibiting O
the O
breakdown O
of O
acetylcholine O
an O
important O
neurotransmitter O
associated O
with O
memory O
, O
by O
blocking O
the O
enzyme O
acetylcholinesterase O
. O
The O
most O
that O
these O
drugs O
could O
achieve O
is O
to O
modify O
the O
manifestations O
of O
Alzheimer's O
disease O
. O
Cochrane O
reviews O
of O
each O
ChEI O
for O
Alzheimer's O
disease O
have O
been O
completed O
(Birks O
2005 O
, O
Birks O
2005b O
and O
Loy O
2005) O
. O
Despite O
the O
evidence O
from O
the O

lysine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
and O
the O
action O
of O
potential O
drugs O
. O
Two O
dimer O
conformations O
were O
observed O
: O
a O
symmetric O
form O
with O
two O
open O
surface O
channels O
capable O
of O
binding O
substrate O
or O
cofactor O
, O
and O
an O
asymmetric O
form O
in O
which O
only O
one O
of O
the O
surface O
channels O
appears O
capable O
of O
binding O
and O
acetylating O
polyamines O
. O
SSAT B
was O
found O
to O
self-acetylate O
lysine O
26 O
in O
the O
presence O
of O
AcCoA O
and O
absence O
of O
substrate O
, O
a O
reaction O
apparently O
catalzyed O
by O
AcCoA O
bound O
in O
the O
second O
channel O
of O
the O
asymmetric O
dimer O
. O
These O
unexpected O
and O
intriguing O
complexities O
seem O
likely O
to O
have O
some O
as O
yet O
undefined O
role O
in O
regulating O
SSAT O
activity O
or O
stability O
as O
a O
part O
of O

polyamine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
lysine-26 O
in O
the O
presence O
of O
AcCoA O
and O
absence O
of O
substrate O
, O
a O
reaction O
apparently O
catalzyed O
by O
AcCoA O
bound O
in O
the O
second O
channel O
of O
the O
asymmetric O
dimer O
. O
These O
unexpected O
and O
intriguing O
complexities O
seem O
likely O
to O
have O
some O
as O
yet O
undefined O
role O
in O
regulating O
SSAT B
activity O
or O
stability O
as O
a O
part O
of O
polyamine O
homeostasis O
. O
Sequence O
signatures O
group O
SSAT O
with O
proteins O
that O
appear O
to O
have O
thialysine O
Nepsilon-acetyltransferase O
activity O
. O

polyamine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Structures O
of O
wild-type O
and O
mutant O
human O
spermidine/spermine O
N1-acetyltransferase O
, O
a O
potential O
therapeutic O
drug O
target.Spermidine/spermine O
N1-acetyltransferase O
(SSAT) O
is O
a O
key O
enzyme O
in O
the O
control O
of O
polyamine O
levels O
in O
human O
cells O
, O
as O
acetylation O
of O
spermidine O
and O
spermine O
triggers O
export O
or O
degradation O
. O
Increased O
intracellular O
polyamine O
levels O
accompany O
several O
types O
of O
cancers O
as O
well O
as O
other O
human O
diseases O
, O
and O
compounds O
that O
affect O
the O
expression O
, O
activity O
, O
or O
stability O
of O
SSAT O
are O
being O
explored O
as O
potential O
therapeutic O
drugs O
. O
We O
have O

spermidine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Structures O
of O
wild-type O
and O
mutant O
human O
spermidine/spermine O
N1-acetyltransferase O
, O
a O
potential O
therapeutic O
drug O
target.Spermidine/spermine O
N1-acetyltransferase O
(SSAT) O
is O
a O
key O
enzyme O
in O
the O
control O
of O
polyamine O
levels O
in O
human O
cells O
, O
as O
acetylation O
of O
spermidine O
and O
spermine O
triggers O
export O
or O
degradation O
. O
Increased O
intracellular O
polyamine O
levels O
accompany O
several O
types O
of O
cancers O
as O
well O
as O
other O
human O
diseases O
, O
and O
compounds O
that O
affect O
the O
expression O
, O
activity O
, O
or O
stability O
of O
SSAT O
are O
being O
explored O
as O
potential O
therapeutic O
drugs O
. O
We O
have O
expressed O
human O
SSAT O
from O
the O
cloned O
cDNA O
in O

spermine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Structures O
of O
wild-type O
and O
mutant O
human O
spermidine/spermine O
N1-acetyltransferase O
, O
a O
potential O
therapeutic O
drug O
target.Spermidine/spermine O
N1-acetyltransferase O
(SSAT) O
is O
a O
key O
enzyme O
in O
the O
control O
of O
polyamine O
levels O
in O
human O
cells O
, O
as O
acetylation O
of O
spermidine O
and O
spermine O
triggers O
export O
or O
degradation O
. O
Increased O
intracellular O
polyamine O
levels O
accompany O
several O
types O
of O
cancers O
as O
well O
as O
other O
human O
diseases O
, O
and O
compounds O
that O
affect O
the O
expression O
, O
activity O
, O
or O
stability O
of O
SSAT O
are O
being O
explored O
as O
potential O
therapeutic O
drugs O
. O
We O
have O
expressed O
human O
SSAT O
from O
the O
cloned O
cDNA O
in O
Escherichia O
coli O

hydrogen O
acts O
as O
PART-OF O
for O
what O
entity O
? O
entire O
length O
of O
the O
IL-2R O
beta O
and O
gamma(c) O
subunits O
. O
Helix O
A O
of O
IL-2 B
wedges O
tightly O
between O
IL-2R O
beta O
and O
gamma(c) O
to O
form O
a O
three-way O
junction O
that O
coalesces O
into O
a O
composite O
binding O
site O
for O
the O
final O
gamma(c) O
recruitment O
. O
The O
IL-2/gamma(c) O
interface O
itself O
exhibits O
the O
smallest O
buried O
surface O
and O
the O
fewest O
hydrogen O
bonds O
in O
the O
complex O
, O
which O
is O
consistent O
with O
its O
promiscuous O
use O
in O
other O
cytokine O
receptor O
complexes O
. O

rifampicin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
rifampicin O
on O
other O
drugs O
can O
result O
in O
their O
altered O
metabolism O
or O
transportation O
that O
are O
metabolised O
by O
cytochromes B
P450 I
or O
transported O
by O
p-glycoprotein O
in O
the O
gastrointestinal O
tract O
and O
liver O
. O
This O
review O
paper O
summarises O
recent O
findings O
with O
emphases O
on O
the O
molecular O
mechanisms O
used O
to O
explain O
these O
broad O
drug-drug O
interactions O
. O
In O
general O
, O
rifampicin O
can O
act O
on O
a O
pattern O
: O
rifampicin O
activates O
the O
nuclear O
pregnane O
X O
receptor O
that O
in O
turn O
affects O
cytochromes O
P450 O
, O
glucuronosyltransferases O
and O
p-glycoprotein O
activities O
. O
This O
pattern O
of O
action O
may O
explain O
many O
of O
the O
rifampicin O
inducing O
drug-drug O
interactions O
. O
However O
, O
effects O
through O
other O
mechanisms O
have O
also O
been O
reported O
and O
these O
make O
any O
explanation O

rifampicin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
in O
their O
altered O
metabolism O
or O
transportation O
that O
are O
metabolised O
by O
cytochromes O
P450 O
or O
transported O
by O
p-glycoprotein O
in O
the O
gastrointestinal O
tract O
and O
liver O
. O
This O
review O
paper O
summarises O
recent O
findings O
with O
emphases O
on O
the O
molecular O
mechanisms O
used O
to O
explain O
these O
broad O
drug-drug O
interactions O
. O
In O
general O
, O
rifampicin O
can O
act O
on O
a O
pattern O
: O
rifampicin O
activates O
the O
nuclear O
pregnane O
X O
receptor O
that O
in O
turn O
affects O
cytochromes O
P450 O
, O
glucuronosyltransferases B
and O
p-glycoprotein O
activities O
. O
This O
pattern O
of O
action O
may O
explain O
many O
of O
the O
rifampicin O
inducing O
drug-drug O
interactions O
. O
However O
, O
effects O
through O
other O
mechanisms O
have O
also O
been O
reported O
and O
these O
make O
any O
explanation O
of O
such O
drug-drug O
interactions O
more O
complex O
. O

rifampicin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
in O
their O
altered O
metabolism O
or O
transportation O
that O
are O
metabolised O
by O
cytochromes O
P450 O
or O
transported O
by O
p-glycoprotein B
in O
the O
gastrointestinal O
tract O
and O
liver O
. O
This O
review O
paper O
summarises O
recent O
findings O
with O
emphases O
on O
the O
molecular O
mechanisms O
used O
to O
explain O
these O
broad O
drug-drug O
interactions O
. O
In O
general O
, O
rifampicin O
can O
act O
on O
a O
pattern O
: O
rifampicin O
activates O
the O
nuclear O
pregnane O
X O
receptor O
that O
in O
turn O
affects O
cytochromes O
P450 O
, O
glucuronosyltransferases O
and O
p-glycoprotein O
activities O
. O
This O
pattern O
of O
action O
may O
explain O
many O
of O
the O
rifampicin O
inducing O
drug-drug O
interactions O
. O
However O
, O
effects O
through O
other O
mechanisms O
have O
also O
been O
reported O
and O
these O
make O
any O
explanation O
of O
such O
drug-drug O
interactions O
more O
complex O
. O

rifampicin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
rifampicin O
on O
other O
drugs O
can O
result O
in O
their O
altered O
metabolism O
or O
transportation O
that O
are O
metabolised O
by O
cytochromes O
P450 O
or O
transported O
by O
p-glycoprotein O
in O
the O
gastrointestinal O
tract O
and O
liver O
. O
This O
review O
paper O
summarises O
recent O
findings O
with O
emphases O
on O
the O
molecular O
mechanisms O
used O
to O
explain O
these O
broad O
drug-drug O
interactions O
. O
In O
general O
, O
rifampicin O
can O
act O
on O
a O
pattern O
: O
rifampicin O
activates O
the O
nuclear O
pregnane O
X O
receptor O
that O
in O
turn O
affects O
cytochromes O
P450 O
, O
glucuronosyltransferases B
and O
p-glycoprotein O
activities O
. O
This O
pattern O
of O
action O
may O
explain O
many O
of O
the O
rifampicin O
inducing O
drug-drug O
interactions O
. O
However O
, O
effects O
through O
other O
mechanisms O
have O
also O
been O
reported O
and O
these O
make O
any O
explanation O

rifampicin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
rifampicin O
on O
other O
drugs O
can O
result O
in O
their O
altered O
metabolism O
or O
transportation O
that O
are O
metabolised O
by O
cytochromes O
P450 O
or O
transported O
by O
p-glycoprotein B
in O
the O
gastrointestinal O
tract O
and O
liver O
. O
This O
review O
paper O
summarises O
recent O
findings O
with O
emphases O
on O
the O
molecular O
mechanisms O
used O
to O
explain O
these O
broad O
drug-drug O
interactions O
. O
In O
general O
, O
rifampicin O
can O
act O
on O
a O
pattern O
: O
rifampicin O
activates O
the O
nuclear O
pregnane O
X O
receptor O
that O
in O
turn O
affects O
cytochromes O
P450 O
, O
glucuronosyltransferases O
and O
p-glycoprotein O
activities O
. O
This O
pattern O
of O
action O
may O
explain O
many O
of O
the O
rifampicin O
inducing O
drug-drug O
interactions O
. O
However O
, O
effects O
through O
other O
mechanisms O
have O
also O
been O
reported O
and O
these O
make O
any O
explanation O

rifampicin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
in O
their O
altered O
metabolism O
or O
transportation O
that O
are O
metabolised O
by O
cytochromes B
P450 I
or O
transported O
by O
p-glycoprotein O
in O
the O
gastrointestinal O
tract O
and O
liver O
. O
This O
review O
paper O
summarises O
recent O
findings O
with O
emphases O
on O
the O
molecular O
mechanisms O
used O
to O
explain O
these O
broad O
drug-drug O
interactions O
. O
In O
general O
, O
rifampicin O
can O
act O
on O
a O
pattern O
: O
rifampicin O
activates O
the O
nuclear O
pregnane O
X O
receptor O
that O
in O
turn O
affects O
cytochromes O
P450 O
, O
glucuronosyltransferases O
and O
p-glycoprotein O
activities O
. O
This O
pattern O
of O
action O
may O
explain O
many O
of O
the O
rifampicin O
inducing O
drug-drug O
interactions O
. O
However O
, O
effects O
through O
other O
mechanisms O
have O
also O
been O
reported O
and O
these O
make O
any O
explanation O
of O
such O
drug-drug O
interactions O
more O
complex O
. O

rifampicin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Roles O
of O
rifampici O
in O
drug-drug O
interactions O
: O
underlying O
molecular O
mechanisms O
involving O
the O
nuclear O
pregnane O
X O
receptor.Rifampicin O
, O
an O
important O
drug O
in O
the O
treatment O
of O
tuberculosis O
, O
is O
used O
extensively O
despite O
its O
broad O
effects O
on O
drug-drug O
interactions O
, O
creating O
serious O
problems O
. O
The O
clinical O
importance O
of O
such O
interactions O
includes O
autoinduction O
leading O
to O
suboptimal O
or O
failed O
treatment O
. O
The O
concomitantly O

rifampicin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
in O
their O
altered O
metabolism O
or O
transportation O
that O
are O
metabolised O
by O
cytochromes O
P450 O
or O
transported O
by O
p-glycoprotein O
in O
the O
gastrointestinal O
tract O
and O
liver O
. O
This O
review O
paper O
summarises O
recent O
findings O
with O
emphases O
on O
the O
molecular O
mechanisms O
used O
to O
explain O
these O
broad O
drug-drug O
interactions O
. O
In O
general O
, O
rifampicin O
can O
act O
on O
a O
pattern O
: O
rifampicin O
activates O
the O
nuclear B
pregnane I
X I
receptor I
that O
in O
turn O
affects O
cytochromes O
P450 O
, O
glucuronosyltransferases O
and O
p-glycoprotein O
activities O
. O
This O
pattern O
of O
action O
may O
explain O
many O
of O
the O
rifampicin O
inducing O
drug-drug O
interactions O
. O
However O
, O
effects O
through O
other O
mechanisms O
have O
also O
been O
reported O
and O
these O
make O
any O
explanation O
of O
such O
drug-drug O
interactions O
more O
complex O
. O

rifampicin O
acts O
as O
AGONIST-ACTIVATOR O
for O
what O
entity O
? O
rifampicin O
on O
other O
drugs O
can O
result O
in O
their O
altered O
metabolism O
or O
transportation O
that O
are O
metabolised O
by O
cytochromes O
P450 O
or O
transported O
by O
p-glycoprotein O
in O
the O
gastrointestinal O
tract O
and O
liver O
. O
This O
review O
paper O
summarises O
recent O
findings O
with O
emphases O
on O
the O
molecular O
mechanisms O
used O
to O
explain O
these O
broad O
drug-drug O
interactions O
. O
In O
general O
, O
rifampicin O
can O
act O
on O
a O
pattern O
: O
rifampicin O
activates O
the O
nuclear B
pregnane I
X I
receptor I
that O
in O
turn O
affects O
cytochromes O
P450 O
, O
glucuronosyltransferases O
and O
p-glycoprotein O
activities O
. O
This O
pattern O
of O
action O
may O
explain O
many O
of O
the O
rifampicin O
inducing O
drug-drug O
interactions O
. O
However O
, O
effects O
through O
other O
mechanisms O
have O
also O
been O
reported O
and O
these O
make O
any O
explanation O

rifampicin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
underlying O
molecular O
mechanisms O
involving O
the O
nuclear O
pregnane O
X O
receptor.Rifampicin O
, O
an O
important O
drug O
in O
the O
treatment O
of O
tuberculosis O
, O
is O
used O
extensively O
despite O
its O
broad O
effects O
on O
drug-drug O
interactions O
, O
creating O
serious O
problems O
. O
The O
clinical O
importance O
of O
such O
interactions O
includes O
autoinduction O
leading O
to O
suboptimal O
or O
failed O
treatment O
. O
The O
concomitantly O
administered O
effects O
of O
rifampicin O
on O
other O
drugs O
can O
result O
in O
their O
altered O
metabolism O
or O
transportation O
that O
are O
metabolised O
by O
cytochromes O
P450 O
or O
transported O
by O
p-glycoprotein B
in O
the O
gastrointestinal O
tract O
and O
liver O
. O
This O
review O
paper O
summarises O
recent O
findings O
with O
emphases O
on O
the O
molecular O
mechanisms O
used O
to O
explain O
these O
broad O
drug-drug O
interactions O
. O
In O
general O
, O
rifampicin O

rifampicin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
underlying O
molecular O
mechanisms O
involving O
the O
nuclear O
pregnane O
X O
receptor.Rifampicin O
, O
an O
important O
drug O
in O
the O
treatment O
of O
tuberculosis O
, O
is O
used O
extensively O
despite O
its O
broad O
effects O
on O
drug-drug O
interactions O
, O
creating O
serious O
problems O
. O
The O
clinical O
importance O
of O
such O
interactions O
includes O
autoinduction O
leading O
to O
suboptimal O
or O
failed O
treatment O
. O
The O
concomitantly O
administered O
effects O
of O
rifampicin O
on O
other O
drugs O
can O
result O
in O
their O
altered O
metabolism O
or O
transportation O
that O
are O
metabolised O
by O
cytochromes B
P450 I
or O
transported O
by O
p-glycoprotein O
in O
the O
gastrointestinal O
tract O
and O
liver O
. O
This O
review O
paper O
summarises O
recent O
findings O
with O
emphases O
on O
the O
molecular O
mechanisms O
used O
to O
explain O
these O
broad O
drug-drug O
interactions O
. O
In O
general O
, O
rifampicin O

Ethanol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
were O
also O
compared O
with O
alcohol-naive O
alcohol O
non-preferring O
rats O
(NP) O
rats O
. O
Packing O
density O
of O
GS B
and O
GFAP-immunoreactive O
(IR) O
astrocytes O
was O
measured O
in O
sections O
from O
the O
prelimbic O
cortex O
(PLC) O
using O
the O
optical O
disector O
probe O
. O
An O
alcohol O
deprivation O
effect O
was O
observed O
in O
P O
rats O
with O
withdrawals O
during O
a O
6-month O
ethanol O
drinking O
period O
. O
Ethanol O
withdrawal O
significantly O
increased O
the O
packing O
density O
of O
GS- O
and O
GFAP-IR O
astrocytes O
in O
the O
PLC O
of O
P O
rats O
as O
compared O
with O
P O
rats O
with O
continuous O
access O
to O
ethanol O
. O
In O
addition O
, O
there O
was O
a O
positive O
correlation O
between O
the O
pre-withdrawal O
ethanol O
consumption O
and O
the O
packing O
density O
of O
GS-IR O
astrocytes O
. O
The O
present O
results O

Ethanol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
were O
also O
compared O
with O
alcohol-naive O
alcohol O
non-preferring O
rats O
(NP) O
rats O
. O
Packing O
density O
of O
GS O
and O
GFAP-immunoreactive O
(IR) O
astrocytes O
was O
measured O
in O
sections O
from O
the O
prelimbic O
cortex O
(PLC) O
using O
the O
optical O
disector O
probe O
. O
An O
alcohol O
deprivation O
effect O
was O
observed O
in O
P O
rats O
with O
withdrawals O
during O
a O
6-month O
ethanol O
drinking O
period O
. O
Ethanol O
withdrawal O
significantly O
increased O
the O
packing O
density O
of O
GS- O
and O
GFAP-IR O
astrocytes O
in O
the O
PLC O
of O
P O
rats O
as O
compared O
with O
P O
rats O
with O
continuous O
access O
to O
ethanol O
. O
In O
addition O
, O
there O
was O
a O
positive O
correlation O
between O
the O
pre-withdrawal O
ethanol O
consumption O
and O
the O
packing O
density O
of O
GS-IR O
astrocytes O
. O
The O
present O
results O

ethanol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
in O
P O
rats O
with O
withdrawals O
during O
a O
6-month O
ethanol O
drinking O
period O
. O
Ethanol O
withdrawal O
significantly O
increased O
the O
packing O
density O
of O
GS- O
and O
GFAP-IR O
astrocytes O
in O
the O
PLC O
of O
P O
rats O
as O
compared O
with O
P O
rats O
with O
continuous O
access O
to O
ethanol O
. O
In O
addition O
, O
there O
was O
a O
positive O
correlation O
between O
the O
pre-withdrawal O
ethanol O
consumption O
and O
the O
packing O
density O
of O
GS-IR O
astrocytes O
. O
The O
present O
results O
suggest O
the O
involvement O
of O
astrocytes O
in O
the O
regulation O
of O
the O
glutamatergic O
activation O
associated O
with O
withdrawal O
from O
free-choice O
ethanol O
consumption O
and O
point O
to O
differential O
adaptations O
of O
GS B
and O
GFAP O
to O
prolonged O
alcohol O
drinking O
in O
the O
PLC O
of O
P O
rats O
. O

ethanol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
as O
compared O
with O
P O
rats O
with O
continuous O
access O
to O
ethanol O
. O
In O
addition O
, O
there O
was O
a O
positive O
correlation O
between O
the O
pre-withdrawal O
ethanol O
consumption O
and O
the O
packing O
density O
of O
GS-IR O
astrocytes O
. O
The O
present O
results O
suggest O
the O
involvement O
of O
astrocytes O
in O
the O
regulation O
of O
the O
glutamatergic O
activation O
associated O
with O
withdrawal O
from O
free-choice O
ethanol O
consumption O
and O
point O
to O
differential O
adaptations O
of O
GS B
and O
GFAP O
to O
prolonged O
alcohol O
drinking O
in O
the O
PLC O
of O
P O
rats O
. O

ethanol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
as O
compared O
with O
P O
rats O
with O
continuous O
access O
to O
ethanol O
. O
In O
addition O
, O
there O
was O
a O
positive O
correlation O
between O
the O
pre-withdrawal O
ethanol O
consumption O
and O
the O
packing O
density O
of O
GS-IR O
astrocytes O
. O
The O
present O
results O
suggest O
the O
involvement O
of O
astrocytes O
in O
the O
regulation O
of O
the O
glutamatergic O
activation O
associated O
with O
withdrawal O
from O
free-choice O
ethanol O
consumption O
and O
point O
to O
differential O
adaptations O
of O
GS O
and O
GFAP B
to O
prolonged O
alcohol O
drinking O
in O
the O
PLC O
of O
P O
rats O
. O

ethanol O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Withdrawal O
from O
free-choice O
ethano O
consumption O
results O
in O
increased O
packing O
density O
of O
glutamine O
synthetase-immunoreactive O
astrocytes O
in O
the O
prelimbic O
cortex O
of O
alcohol-preferring O
rats.Excess O
activation O
of O
glutamatergic O
neurotransmission O
in O
the O
cerebral O
cortex O
following O
ethanol O
withdrawal O
is O
considered O
to O
contribute O
to O
significant O
behavioural O
disturbances O
, O
and O
to O
alcohol O
craving O
. O
Astrocytes O
may O
play O
a O
role O
in O
these O
manifestations O
because O

glutamine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
cortex O
of O
alcohol-preferring O
rats.Excess O
activation O
of O
glutamatergic O
neurotransmission O
in O
the O
cerebral O
cortex O
following O
ethanol O
withdrawal O
is O
considered O
to O
contribute O
to O
significant O
behavioural O
disturbances O
, O
and O
to O
alcohol O
craving O
. O
Astrocytes O
may O
play O
a O
role O
in O
these O
manifestations O
because O
astrocytes O
are O
essential O
in O
the O
regulation O
of O
released O
glutamate O
and O
its O
conversion O
to O
glutamine O
through O
the O
enzyme O
glutamine B
synthetase I
(GS) O
. O
However O
, O
it O
is O
unclear O
if O
withdrawal O
from O
free-choice O
ethanol O
drinking O
causes O
changes O
in O
the O
numbers O
of O
astrocytes O
expressing O
GS O
or O
the O
cytoskeletal O
protein O
of O
astrocytes O
glial O
fibrillary O
acidic O
protein O
(GFAP) O
. O
Alcohol-preferring O
(P) O
rats O
exposed O
to O
free-choice O
ethanol O
drinking O
were O
either O
maintained O
without O
forced O

glutamine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
cortex O
of O
alcohol-preferring O
rats.Excess O
activation O
of O
glutamatergic O
neurotransmission O
in O
the O
cerebral O
cortex O
following O
ethanol O
withdrawal O
is O
considered O
to O
contribute O
to O
significant O
behavioural O
disturbances O
, O
and O
to O
alcohol O
craving O
. O
Astrocytes O
may O
play O
a O
role O
in O
these O
manifestations O
because O
astrocytes O
are O
essential O
in O
the O
regulation O
of O
released O
glutamate O
and O
its O
conversion O
to O
glutamine O
through O
the O
enzyme O
glutamine O
synthetase O
(GS) O
. O
However O
, O
it O
is O
unclear O
if O
withdrawal O
from O
free-choice O
ethanol O
drinking O
causes O
changes O
in O
the O
numbers O
of O
astrocytes O
expressing O
GS B
or O
the O
cytoskeletal O
protein O
of O
astrocytes O
glial O
fibrillary O
acidic O
protein O
(GFAP) O
. O
Alcohol-preferring O
(P) O
rats O
exposed O
to O
free-choice O
ethanol O
drinking O
were O
either O
maintained O
without O
forced O

glutamate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
synthetase-immunoreactive O
astrocytes O
in O
the O
prelimbic O
cortex O
of O
alcohol-preferring O
rats.Excess O
activation O
of O
glutamatergic O
neurotransmission O
in O
the O
cerebral O
cortex O
following O
ethanol O
withdrawal O
is O
considered O
to O
contribute O
to O
significant O
behavioural O
disturbances O
, O
and O
to O
alcohol O
craving O
. O
Astrocytes O
may O
play O
a O
role O
in O
these O
manifestations O
because O
astrocytes O
are O
essential O
in O
the O
regulation O
of O
released O
glutamate O
and O
its O
conversion O
to O
glutamine O
through O
the O
enzyme O
glutamine B
synthetase I
(GS) O
. O
However O
, O
it O
is O
unclear O
if O
withdrawal O
from O
free-choice O
ethanol O
drinking O
causes O
changes O
in O
the O
numbers O
of O
astrocytes O
expressing O
GS O
or O
the O
cytoskeletal O
protein O
of O
astrocytes O
glial O
fibrillary O
acidic O
protein O
(GFAP) O
. O
Alcohol-preferring O
(P) O
rats O
exposed O
to O
free-choice O
ethanol O
drinking O

glutamate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
synthetase-immunoreactive O
astrocytes O
in O
the O
prelimbic O
cortex O
of O
alcohol-preferring O
rats.Excess O
activation O
of O
glutamatergic O
neurotransmission O
in O
the O
cerebral O
cortex O
following O
ethanol O
withdrawal O
is O
considered O
to O
contribute O
to O
significant O
behavioural O
disturbances O
, O
and O
to O
alcohol O
craving O
. O
Astrocytes O
may O
play O
a O
role O
in O
these O
manifestations O
because O
astrocytes O
are O
essential O
in O
the O
regulation O
of O
released O
glutamate O
and O
its O
conversion O
to O
glutamine O
through O
the O
enzyme O
glutamine O
synthetase O
(GS) O
. O
However O
, O
it O
is O
unclear O
if O
withdrawal O
from O
free-choice O
ethanol O
drinking O
causes O
changes O
in O
the O
numbers O
of O
astrocytes O
expressing O
GS B
or O
the O
cytoskeletal O
protein O
of O
astrocytes O
glial O
fibrillary O
acidic O
protein O
(GFAP) O
. O
Alcohol-preferring O
(P) O
rats O
exposed O
to O
free-choice O
ethanol O
drinking O

PLP O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
results O
in O
low O
levels O
of O
PLP O
, O
which O
is O
the O
active O
cofactor O
for O
113 O
known O
enzymatic O
reactions O
, O
including O
the O
formation O
of O
many O
key O
neurotransmitters O
. O
CONCLUSIONS O
: O
Total O
vitamin O
B6 O
is O
abnormally O
high O
in O
autism O
, O
consistent O
with O
previous O
reports O
of O
an O
impaired O
pyridoxal B
kinase I
for O
the O
conversion O
of O
pyridoxine O
and O
pyridoxal O
to O
PLP O
This O
may O
explain O
the O
many O
published O
studies O
of O
benefits O
of O
high-dose O
vitamin O
B6 O
supplementation O
in O
some O
children O
and O
adults O
with O
autism O
. O

pyridoxine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
pyridoxine O
to O
PLP O
results O
in O
low O
levels O
of O
PLP O
, O
which O
is O
the O
active O
cofactor O
for O
113 O
known O
enzymatic O
reactions O
, O
including O
the O
formation O
of O
many O
key O
neurotransmitters O
. O
CONCLUSIONS O
: O
Total O
vitamin O
B6 O
is O
abnormally O
high O
in O
autism O
, O
consistent O
with O
previous O
reports O
of O
an O
impaired O
pyridoxal B
kinase I
for O
the O
conversion O
of O
pyridoxine O
and O
pyridoxal O
to O
PLP O
. O
This O
may O
explain O
the O
many O
published O
studies O
of O
benefits O
of O
high-dose O
vitamin O
B6 O
supplementation O
in O
some O
children O
and O
adults O
with O
autism O
. O

pyridoxal O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
to O
PLP O
results O
in O
low O
levels O
of O
PLP O
, O
which O
is O
the O
active O
cofactor O
for O
113 O
known O
enzymatic O
reactions O
, O
including O
the O
formation O
of O
many O
key O
neurotransmitters O
. O
CONCLUSIONS O
: O
Total O
vitamin O
B6 O
is O
abnormally O
high O
in O
autism O
, O
consistent O
with O
previous O
reports O
of O
an O
impaired O
pyridoxal B
kinase I
for O
the O
conversion O
of O
pyridoxine O
and O
pyridoxal O
to O
PLP O
. O
This O
may O
explain O
the O
many O
published O
studies O
of O
benefits O
of O
high-dose O
vitamin O
B6 O
supplementation O
in O
some O
children O
and O
adults O
with O
autism O
. O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
New O
assignments O
for O
multitasking O
signal O
transduction O
inhibitors.An O
article O
presented O
in O
this O
issue O
of O
Molecular O
Pharmacology O
(p O
. O
1527) O
provides O
an O
intriguing O
example O
of O
how O
tyrosine O
kinase B
inhibitors O
can O
be O
put O
to O
many O
uses O
. O
In O
this O
article O
, O
the O
action O
of O
dasatinib O
(BMS-354825) O
is O
contrasted O
with O
that O
of O
imatinib O
, O
a O
kinase O
inhibitor O
that O
is O
currently O
being O
used O
to O
treat O
chronic O
myelogenous O
leukemia O
and O
other O
disorders O
. O
Both O
pharmacologic O
inhibitors O
target O
several O
tyrosine O
kinases O
, O
including O
Bcr-Abl O
and O
the O
platelet-derived O
growth O
factor O
receptor O
(PDGFR) O
. O
Up O
to O
this O
point O
, O
the O
PDGFR O
has O
not O
been O
a O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
New O
assignments O
for O
multitasking O
signal O
transduction O
inhibitors.An O
article O
presented O
in O
this O
issue O
of O
Molecular O
Pharmacology O
(p O
. O
1527) O
provides O
an O
intriguing O
example O
of O
how O
tyrosine O
kinase B
inhibitors O
can O
be O
put O
to O
many O
uses O
. O
In O
this O
article O
, O
the O
action O
of O
dasatinib O
( O
BMS-354825 O
is O
contrasted O
with O
that O
of O
imatinib O
, O
a O
kinase O
inhibitor O
that O
is O
currently O
being O
used O
to O
treat O
chronic O
myelogenous O
leukemia O
and O
other O
disorders O
. O
Both O
pharmacologic O
inhibitors O
target O
several O
tyrosine O
kinases O
, O
including O
Bcr-Abl O
and O
the O
platelet-derived O
growth O
factor O
receptor O
(PDGFR) O
. O
Up O
to O
this O
point O
, O
the O
PDGFR O
has O
not O
been O
a O
primary O

imatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
New O
assignments O
for O
multitasking O
signal O
transduction O
inhibitors.An O
article O
presented O
in O
this O
issue O
of O
Molecular O
Pharmacology O
(p O
. O
1527) O
provides O
an O
intriguing O
example O
of O
how O
tyrosine O
kinase B
inhibitors O
can O
be O
put O
to O
many O
uses O
. O
In O
this O
article O
, O
the O
action O
of O
dasatinib O
(BMS-354825) O
is O
contrasted O
with O
that O
of O
imatinib O
a O
kinase O
inhibitor O
that O
is O
currently O
being O
used O
to O
treat O
chronic O
myelogenous O
leukemia O
and O
other O
disorders O
. O
Both O
pharmacologic O
inhibitors O
target O
several O
tyrosine O
kinases O
, O
including O
Bcr-Abl O
and O
the O
platelet-derived O
growth O
factor O
receptor O
(PDGFR) O
. O
Up O
to O
this O
point O
, O
the O
PDGFR O
has O
not O
been O
a O
primary O
therapeutic O
target O
for O
this O
class O
of O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
treat O
chronic O
myelogenous O
leukemia O
and O
other O
disorders O
. O
Both O
pharmacologic O
inhibitors O
target O
several O
tyrosine O
kinases O
, O
including O
Bcr-Abl O
and O
the O
platelet-derived O
growth O
factor O
receptor O
(PDGFR) O
. O
Up O
to O
this O
point O
, O
the O
PDGFR B
has O
not O
been O
a O
primary O
therapeutic O
target O
for O
this O
class O
of O
agents O
. O
The O
work O
of O
Chen O
and O
colleagues O
shows O
that O
dasatinib O
is O
a O
particularly O
potent O
inhibitor O
of O
PDGFR O
and O
that O
the O
compound O
also O
targets O
Src O
kinase O
. O
The O
authors O
suggest O
that O
this O
combination O
of O
activities O
could O
be O
useful O
in O
the O
treatment O
of O
vascular O
obstructive O
diseases O
. O
Although O
a O
lack O
of O
absolute O
specificity O
has O
typically O
been O
regarded O
as O
a O
pharmacologic O
drawback O
, O
this O
study O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
treat O
chronic O
myelogenous O
leukemia O
and O
other O
disorders O
. O
Both O
pharmacologic O
inhibitors O
target O
several O
tyrosine O
kinases O
, O
including O
Bcr-Abl O
and O
the O
platelet-derived O
growth O
factor O
receptor O
(PDGFR) O
. O
Up O
to O
this O
point O
, O
the O
PDGFR O
has O
not O
been O
a O
primary O
therapeutic O
target O
for O
this O
class O
of O
agents O
. O
The O
work O
of O
Chen O
and O
colleagues O
shows O
that O
dasatinib O
is O
a O
particularly O
potent O
inhibitor O
of O
PDGFR O
and O
that O
the O
compound O
also O
targets O
Src O
kinase O
. O
The O
authors O
suggest O
that O
this O
combination O
of O
activities O
could O
be O
useful O
in O
the O
treatment O
of O
vascular O
obstructive O
diseases O
. O
Although O
a O
lack O
of O
absolute O
specificity O
has O
typically O
been O
regarded O
as O
a O
pharmacologic O
drawback O
, O
this O
study O

prostaglandins O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Involvement O
of O
EP1 B
and O
EP2 O
receptors O
in O
the O
regulation O
of O
the O
Na,K-ATPase O
by O
prostaglandin O
in O
MDCK O
cells.Prostaglandins O
are O
key O
regulators O
of O
ion O
transport O
in O
the O
kidney O
. O
In O
MDCK O
cells O
, O
which O
model O
distal O
tubule O
cells O
, O
the O
transcription O
of O
the O
Na,K-ATPase O
beta1 O
subunit O
is O
regulated O
by O
PGE1 O
and O
PGE2 O
. O
To O
identify O
the O
EP O
receptors O
that O
mediate O
transcriptional O
regulation O
, O
transient O
transfection O
studies O
are O
conducted O
using O
the O

prostaglandins O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Involvement O
of O
EP1 O
and O
EP2 B
receptors I
in O
the O
regulation O
of O
the O
Na,K-ATPase O
by O
prostaglandin O
in O
MDCK O
cells.Prostaglandins O
are O
key O
regulators O
of O
ion O
transport O
in O
the O
kidney O
. O
In O
MDCK O
cells O
, O
which O
model O
distal O
tubule O
cells O
, O
the O
transcription O
of O
the O
Na,K-ATPase O
beta1 O
subunit O
is O
regulated O
by O
PGE1 O
and O
PGE2 O
. O
To O
identify O
the O
EP O
receptors O
that O
mediate O
transcriptional O
regulation O
, O
transient O
transfection O
studies O
are O
conducted O
using O
the O

prostaglandins O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Involvement O
of O
EP1 O
and O
EP2 O
receptors O
in O
the O
regulation O
of O
the O
Na,K-ATPase B
by O
prostaglandin O
in O
MDCK O
cells.Prostaglandins O
are O
key O
regulators O
of O
ion O
transport O
in O
the O
kidney O
. O
In O
MDCK O
cells O
, O
which O
model O
distal O
tubule O
cells O
, O
the O
transcription O
of O
the O
Na,K-ATPase O
beta1 O
subunit O
is O
regulated O
by O
PGE1 O
and O
PGE2 O
. O
To O
identify O
the O
EP O
receptors O
that O
mediate O
transcriptional O
regulation O
, O
transient O
transfection O
studies O
are O
conducted O
using O
the O

PGE1 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O
addition O
to O
this O
evidence O
(for O
the O
involvement O
of O
EP2 O
receptors) O
, O
evidence O
for O
the O
involvement O
of O
EP1 B
receptors I
in O
the O
PGE1 O
mediated O
stimulation O
of O
Na,K-ATPase O
beta O
subunit O
gene O
transcription O
includes O
the O
stimulatory O
effect O
of O
17-phenyl O
trinor O
PGE2 O
, O
as O
well O
as O
the O
inhibitory O
effects O
of O
SC-51089 O
. O
Also O
consistent O
with O
the O
involvement O
of O
Gq O
coupled O
EP1 O
receptors O
, O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKCI O
vector O
(encoding O
the O
PKC O
inhibitory O
domain) O
, O
the O

PGE1 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
involvement O
of O
EP2 O
receptors) O
, O
evidence O
for O
the O
involvement O
of O
EP1 B
receptors I
in O
the O
PGE1 O
mediated O
stimulation O
of O
Na,K-ATPase O
beta O
subunit O
gene O
transcription O
includes O
the O
stimulatory O
effect O
of O
17-phenyl O
trinor O
PGE2 O
, O
as O
well O
as O
the O
inhibitory O
effects O
of O
SC-51089 O
. O
Also O
consistent O
with O
the O
involvement O
of O
Gq O
coupled O
EP1 O
receptors O
, O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKCI O
vector O
(encoding O
the O
PKC O
inhibitory O
domain) O
, O
the O
PKC O
inhibitor O
Go O
6976 O
, O
thapsigargin O
, O
as O
well O
as O
the O
calmodulin O
antagonists O
W7 O
and O
W13 O
. O

PGE1 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O
addition O
to O
this O
evidence O
(for O
the O
involvement O
of O
EP2 O
receptors) O
, O
evidence O
for O
the O
involvement O
of O
EP1 O
receptors O
in O
the O
PGE1 O
mediated O
stimulation O
of O
Na,K-ATPase B
beta I
subunit O
gene O
transcription O
includes O
the O
stimulatory O
effect O
of O
17-phenyl O
trinor O
PGE2 O
, O
as O
well O
as O
the O
inhibitory O
effects O
of O
SC-51089 O
. O
Also O
consistent O
with O
the O
involvement O
of O
Gq O
coupled O
EP1 O
receptors O
, O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKCI O
vector O
(encoding O
the O
PKC O
inhibitory O
domain) O
, O
the O

17-phenyl O
trinor O
PGE2 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O
addition O
to O
this O
evidence O
(for O
the O
involvement O
of O
EP2 O
receptors) O
, O
evidence O
for O
the O
involvement O
of O
EP1 O
receptors O
in O
the O
PGE1 O
mediated O
stimulation O
of O
Na,K-ATPase B
beta I
subunit O
gene O
transcription O
includes O
the O
stimulatory O
effect O
of O
17-phenyl O
trinor O
PGE2 O
as O
well O
as O
the O
inhibitory O
effects O
of O
SC-51089 O
. O
Also O
consistent O
with O
the O
involvement O
of O
Gq O
coupled O
EP1 O
receptors O
, O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKCI O
vector O
(encoding O
the O
PKC O
inhibitory O
domain) O
, O
the O
PKC O
inhibitor O
Go O
6976 O
, O
thapsigargin O
, O
as O
well O
as O
the O
calmodulin O
antagonists O
W7 O
and O
W13 O
. O

SC-51089 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O
addition O
to O
this O
evidence O
(for O
the O
involvement O
of O
EP2 O
receptors) O
, O
evidence O
for O
the O
involvement O
of O
EP1 O
receptors O
in O
the O
PGE1 O
mediated O
stimulation O
of O
Na,K-ATPase B
beta I
subunit O
gene O
transcription O
includes O
the O
stimulatory O
effect O
of O
17-phenyl O
trinor O
PGE2 O
, O
as O
well O
as O
the O
inhibitory O
effects O
of O
SC-51089 O
Also O
consistent O
with O
the O
involvement O
of O
Gq O
coupled O
EP1 O
receptors O
, O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKCI O
vector O
(encoding O
the O
PKC O
inhibitory O
domain) O
, O
the O
PKC O
inhibitor O
Go O
6976 O
, O
thapsigargin O
, O
as O
well O
as O
the O
calmodulin O
antagonists O
W7 O
and O
W13 O
. O

thapsigargin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
beta O
subunit O
gene O
transcription O
includes O
the O
stimulatory O
effect O
of O
17-phenyl O
trinor O
PGE2 O
, O
as O
well O
as O
the O
inhibitory O
effects O
of O
SC-51089 O
. O
Also O
consistent O
with O
the O
involvement O
of O
Gq O
coupled O
EP1 O
receptors O
, O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKCI O
vector O
(encoding O
the O
PKC B
inhibitory O
domain) O
, O
the O
PKC O
inhibitor O
Go O
6976 O
, O
thapsigargin O
as O
well O
as O
the O
calmodulin O
antagonists O
W7 O
and O
W13 O
. O

Go O
6976 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
Na,K-ATPase O
beta O
subunit O
gene O
transcription O
includes O
the O
stimulatory O
effect O
of O
17-phenyl O
trinor O
PGE2 O
, O
as O
well O
as O
the O
inhibitory O
effects O
of O
SC-51089 O
. O
Also O
consistent O
with O
the O
involvement O
of O
Gq O
coupled O
EP1 O
receptors O
, O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKCI O
vector O
(encoding O
the O
PKC B
inhibitory O
domain) O
, O
the O
PKC O
inhibitor O
Go O
6976 O
thapsigargin O
, O
as O
well O
as O
the O
calmodulin O
antagonists O
W7 O
and O
W13 O
. O

17-phenyl O
trinor O
PGE2 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
of O
the O
Na,K-ATPase O
beta1 O
subunit O
is O
regulated O
by O
PGE1 O
and O
PGE2 O
. O
To O
identify O
the O
EP O
receptors O
that O
mediate O
transcriptional O
regulation O
, O
transient O
transfection O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 B
and O
EP2 O
receptors O
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O

17-phenyl O
trinor O
PGE2 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
of O
the O
Na,K-ATPase O
beta1 O
subunit O
is O
regulated O
by O
PGE1 O
and O
PGE2 O
. O
To O
identify O
the O
EP O
receptors O
that O
mediate O
transcriptional O
regulation O
, O
transient O
transfection O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 B
and O
EP2 O
receptors O
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O

butaprost O
acts O
as O
AGONIST O
for O
what O
entity O
? O
by O
PGE1 O
and O
PGE2 O
. O
To O
identify O
the O
EP O
receptors O
that O
mediate O
transcriptional O
regulation O
, O
transient O
transfection O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 O
and O
EP2 B
receptors I
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O

butaprost O
acts O
as O
AGONIST O
for O
what O
entity O
? O
by O
PGE1 O
and O
PGE2 O
. O
To O
identify O
the O
EP O
receptors O
that O
mediate O
transcriptional O
regulation O
, O
transient O
transfection O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 O
and O
EP2 B
receptors O
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O

SC-51089 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
transcriptional O
regulation O
, O
transient O
transfection O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 B
and O
EP2 O
receptors O
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O

SC-51089 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
transcriptional O
regulation O
, O
transient O
transfection O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 B
and O
EP2 O
receptors O
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O

SC-51089 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
transcriptional O
regulation O
, O
transient O
transfection O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 B
and O
EP2 O
receptors O
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O

AH O
6809 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 B
and O
EP2 O
receptors O
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O
addition O
to O
this O
evidence O
(for O

AH O
6809 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 O
and O
EP2 B
receptors I
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O
addition O
to O
this O
evidence O
(for O

AH O
6809 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 B
and O
EP2 O
receptors O
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O
addition O
to O
this O
evidence O
(for O

AH O
6809 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 O
and O
EP2 B
receptors O
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O
addition O
to O
this O
evidence O
(for O

W7 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
effect O
of O
17-phenyl O
trinor O
PGE2 O
, O
as O
well O
as O
the O
inhibitory O
effects O
of O
SC-51089 O
. O
Also O
consistent O
with O
the O
involvement O
of O
Gq O
coupled O
EP1 O
receptors O
, O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKCI O
vector O
(encoding O
the O
PKC O
inhibitory O
domain) O
, O
the O
PKC O
inhibitor O
Go O
6976 O
, O
thapsigargin O
, O
as O
well O
as O
the O
calmodulin B
antagonists O
W7 O
and O
W13 O
. O

W13 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
17-phenyl O
trinor O
PGE2 O
, O
as O
well O
as O
the O
inhibitory O
effects O
of O
SC-51089 O
. O
Also O
consistent O
with O
the O
involvement O
of O
Gq O
coupled O
EP1 O
receptors O
, O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKCI O
vector O
(encoding O
the O
PKC O
inhibitory O
domain) O
, O
the O
PKC O
inhibitor O
Go O
6976 O
, O
thapsigargin O
, O
as O
well O
as O
the O
calmodulin B
antagonists O
W7 O
and O
W13 O

AH O
6809 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 B
and O
EP2 O
receptors O
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O
addition O
to O
this O
evidence O
(for O

AH O
6809 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 O
and O
EP2 B
receptors O
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O
addition O
to O
this O
evidence O
(for O

U0126 O
acts O
as O
NOT O
for O
what O
entity O
? O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
PKG O
, O
ERK1/2 O
, O
JNK O
, O
and O
beta-catenin O
are O
independent O
targets O
for O
sulindac O
in O
vitro O
. O
Pharmacologic O
activation O
of O
PKG O
with O
YC-1 O
increases O
JNK B
phosphorylation O
and O
induces O
apoptosis O
in O
colon O
cancer O
cells O
without O
modulating O
ERK1/2 O
phosphorylation O
or O
beta-catenin O
protein O
expression O
. O
Inhibition O
of O
ERK1/2 O
with O
U0126 O
induces O
apoptosis O
but O
fails O
to O
activate O
JNK O
phosphorylation O
or O
down-regulate O
beta-catenin O
protein O
expression O
. O
Cotreatment O
with O
U0126 O
and O
YC-1 O
synergistically O
increases O
apoptosis O
in O
colorectal O
cancer O
cells O
and O
recapitulates O
the O
effects O
of O
sulindac O
treatment O
on O
ERK1/2 O
, O
JNK O
, O
and O
beta-catenin O
. O
These O
results O
indicate O
that O
sulindac O
metabolites O
modulate O
ERK1/2 O
and O
PKG O
pathways O
independently O

U0126 O
acts O
as O
NOT O
for O
what O
entity O
? O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
PKG O
, O
ERK1/2 O
, O
JNK O
, O
and O
beta-catenin B
are O
independent O
targets O
for O
sulindac O
in O
vitro O
. O
Pharmacologic O
activation O
of O
PKG O
with O
YC-1 O
increases O
JNK O
phosphorylation O
and O
induces O
apoptosis O
in O
colon O
cancer O
cells O
without O
modulating O
ERK1/2 O
phosphorylation O
or O
beta-catenin O
protein O
expression O
. O
Inhibition O
of O
ERK1/2 O
with O
U0126 O
induces O
apoptosis O
but O
fails O
to O
activate O
JNK O
phosphorylation O
or O
down-regulate O
beta-catenin O
protein O
expression O
. O
Cotreatment O
with O
U0126 O
and O
YC-1 O
synergistically O
increases O
apoptosis O
in O
colorectal O
cancer O
cells O
and O
recapitulates O
the O
effects O
of O
sulindac O
treatment O
on O
ERK1/2 O
, O
JNK O
, O
and O
beta-catenin O
. O
These O
results O
indicate O
that O
sulindac O
metabolites O
modulate O
ERK1/2 O
and O
PKG O
pathways O
independently O

sulindac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
beta-catenin O
protein O
expression O
. O
Inhibition O
of O
ERK1/2 O
with O
U0126 O
induces O
apoptosis O
but O
fails O
to O
activate O
JNK O
phosphorylation O
or O
down-regulate O
beta-catenin O
protein O
expression O
. O
Cotreatment O
with O
U0126 O
and O
YC-1 O
synergistically O
increases O
apoptosis O
in O
colorectal O
cancer O
cells O
and O
recapitulates O
the O
effects O
of O
sulindac O
treatment O
on O
ERK1/2 O
, O
JNK O
, O
and O
beta-catenin O
. O
These O
results O
indicate O
that O
sulindac O
metabolites O
modulate O
ERK1/2 O
and O
PKG B
pathways O
independently O
in O
colon O
cancer O
cells O
and O
suggest O
that O
the O
full O
apoptotic O
effect O
of O
sulindac O
is O
mediated O
by O
more O
than O
one O
pathway O
. O
Using O
similar O
combinatorial O
approaches O
in O
vivo O
may O
provide O
more O
effective O
, O
less O
toxic O
chemopreventive O
and O
chemotherapeutic O
strategies O
. O
Such O
therapies O
could O
dramatically O
reduce O
the O

U0126 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
targets O
for O
sulindac O
in O
vitro O
. O
Pharmacologic O
activation O
of O
PKG O
with O
YC-1 O
increases O
JNK B
phosphorylation O
and O
induces O
apoptosis O
in O
colon O
cancer O
cells O
without O
modulating O
ERK1/2 O
phosphorylation O
or O
beta-catenin O
protein O
expression O
. O
Inhibition O
of O
ERK1/2 O
with O
U0126 O
induces O
apoptosis O
but O
fails O
to O
activate O
JNK O
phosphorylation O
or O
down-regulate O
beta-catenin O
protein O
expression O
. O
Cotreatment O
with O
U0126 O
and O
YC-1 O
synergistically O
increases O
apoptosis O
in O
colorectal O
cancer O
cells O
and O
recapitulates O
the O
effects O
of O
sulindac O
treatment O
on O
ERK1/2 O
, O
JNK O
, O
and O
beta-catenin O
. O
These O
results O
indicate O
that O
sulindac O
metabolites O
modulate O
ERK1/2 O
and O
PKG O
pathways O
independently O
in O
colon O
cancer O
cells O
and O
suggest O
that O
the O
full O
apoptotic O
effect O
of O
sulindac O
is O
mediated O
by O

YC-1 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
sulindac O
in O
vitro O
. O
Pharmacologic O
activation O
of O
PKG O
with O
YC-1 O
increases O
JNK B
phosphorylation O
and O
induces O
apoptosis O
in O
colon O
cancer O
cells O
without O
modulating O
ERK1/2 O
phosphorylation O
or O
beta-catenin O
protein O
expression O
. O
Inhibition O
of O
ERK1/2 O
with O
U0126 O
induces O
apoptosis O
but O
fails O
to O
activate O
JNK O
phosphorylation O
or O
down-regulate O
beta-catenin O
protein O
expression O
. O
Cotreatment O
with O
U0126 O
and O
YC-1 O
synergistically O
increases O
apoptosis O
in O
colorectal O
cancer O
cells O
and O
recapitulates O
the O
effects O
of O
sulindac O
treatment O
on O
ERK1/2 O
, O
JNK O
, O
and O
beta-catenin O
. O
These O
results O
indicate O
that O
sulindac O
metabolites O
modulate O
ERK1/2 O
and O
PKG O
pathways O
independently O
in O
colon O
cancer O
cells O
and O
suggest O
that O
the O
full O
apoptotic O
effect O
of O
sulindac O
is O
mediated O
by O
more O
than O

sulindac O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
induces O
apoptosis O
in O
colon O
cancer O
cells O
without O
modulating O
ERK1/2 O
phosphorylation O
or O
beta-catenin O
protein O
expression O
. O
Inhibition O
of O
ERK1/2 O
with O
U0126 O
induces O
apoptosis O
but O
fails O
to O
activate O
JNK B
phosphorylation O
or O
down-regulate O
beta-catenin O
protein O
expression O
. O
Cotreatment O
with O
U0126 O
and O
YC-1 O
synergistically O
increases O
apoptosis O
in O
colorectal O
cancer O
cells O
and O
recapitulates O
the O
effects O
of O
sulindac O
treatment O
on O
ERK1/2 O
, O
JNK O
, O
and O
beta-catenin O
. O
These O
results O
indicate O
that O
sulindac O
metabolites O
modulate O
ERK1/2 O
and O
PKG O
pathways O
independently O
in O
colon O
cancer O
cells O
and O
suggest O
that O
the O
full O
apoptotic O
effect O
of O
sulindac O
is O
mediated O
by O
more O
than O
one O
pathway O
. O
Using O
similar O
combinatorial O
approaches O
in O
vivo O
may O
provide O
more O
effective O
, O
less O

Sulindac O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
human O
and O
animal O
data O
support O
the O
ability O
of O
nonsteroidal O
anti-inflammatory O
drugs O
to O
cause O
regression O
of O
existing O
colon O
tumors O
and O
prevent O
new O
tumor O
formation O
. O
The O
mechanism O
by O
which O
the O
nonsteroidal O
anti-inflammatory O
drug O
sulindac O
prevents O
tumor O
growth O
is O
poorly O
understood O
and O
seems O
complex O
as O
sulindac O
can O
modulate O
several O
growth-related O
signaling O
pathways O
. O
Sulindac O
metabolites O
simultaneously O
(a) O
increase O
cellular O
cyclic O
GMP O
and O
subsequently O
activate O
cyclic B
GMP-dependent I
protein I
kinase I
(PKG); O
(b) O
activate O
c-jun O
NH2-terminal O
kinase O
(JNK); O
(c) O
inhibit O
extracellular O
signal-regulated O
kinase O
1/2 O
(ERK1/2); O
and O
(d) O
decrease O
beta-catenin O
protein O
expression O
at O
times O
and O
doses O
consistent O
with O
apoptosis O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O

Sulindac O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
human O
and O
animal O
data O
support O
the O
ability O
of O
nonsteroidal O
anti-inflammatory O
drugs O
to O
cause O
regression O
of O
existing O
colon O
tumors O
and O
prevent O
new O
tumor O
formation O
. O
The O
mechanism O
by O
which O
the O
nonsteroidal O
anti-inflammatory O
drug O
sulindac O
prevents O
tumor O
growth O
is O
poorly O
understood O
and O
seems O
complex O
as O
sulindac O
can O
modulate O
several O
growth-related O
signaling O
pathways O
. O
Sulindac O
metabolites O
simultaneously O
(a) O
increase O
cellular O
cyclic O
GMP O
and O
subsequently O
activate O
cyclic O
GMP-dependent O
protein O
kinase O
(PKG); O
(b) O
activate O
c-jun O
NH2-terminal O
kinase O
(JNK); O
(c) O
inhibit O
extracellular O
signal-regulated O
kinase O
1/2 O
(ERK1/2); O
and O
(d) O
decrease O
beta-catenin O
protein O
expression O
at O
times O
and O
doses O
consistent O
with O
apoptosis O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O

U0126 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
targets O
for O
sulindac O
in O
vitro O
. O
Pharmacologic O
activation O
of O
PKG O
with O
YC-1 O
increases O
JNK O
phosphorylation O
and O
induces O
apoptosis O
in O
colon O
cancer O
cells O
without O
modulating O
ERK1/2 O
phosphorylation O
or O
beta-catenin B
protein O
expression O
. O
Inhibition O
of O
ERK1/2 O
with O
U0126 O
induces O
apoptosis O
but O
fails O
to O
activate O
JNK O
phosphorylation O
or O
down-regulate O
beta-catenin O
protein O
expression O
. O
Cotreatment O
with O
U0126 O
and O
YC-1 O
synergistically O
increases O
apoptosis O
in O
colorectal O
cancer O
cells O
and O
recapitulates O
the O
effects O
of O
sulindac O
treatment O
on O
ERK1/2 O
, O
JNK O
, O
and O
beta-catenin O
. O
These O
results O
indicate O
that O
sulindac O
metabolites O
modulate O
ERK1/2 O
and O
PKG O
pathways O
independently O
in O
colon O
cancer O
cells O
and O
suggest O
that O
the O
full O
apoptotic O
effect O
of O
sulindac O
is O
mediated O
by O

YC-1 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
sulindac O
in O
vitro O
. O
Pharmacologic O
activation O
of O
PKG O
with O
YC-1 O
increases O
JNK O
phosphorylation O
and O
induces O
apoptosis O
in O
colon O
cancer O
cells O
without O
modulating O
ERK1/2 O
phosphorylation O
or O
beta-catenin B
protein O
expression O
. O
Inhibition O
of O
ERK1/2 O
with O
U0126 O
induces O
apoptosis O
but O
fails O
to O
activate O
JNK O
phosphorylation O
or O
down-regulate O
beta-catenin O
protein O
expression O
. O
Cotreatment O
with O
U0126 O
and O
YC-1 O
synergistically O
increases O
apoptosis O
in O
colorectal O
cancer O
cells O
and O
recapitulates O
the O
effects O
of O
sulindac O
treatment O
on O
ERK1/2 O
, O
JNK O
, O
and O
beta-catenin O
. O
These O
results O
indicate O
that O
sulindac O
metabolites O
modulate O
ERK1/2 O
and O
PKG O
pathways O
independently O
in O
colon O
cancer O
cells O
and O
suggest O
that O
the O
full O
apoptotic O
effect O
of O
sulindac O
is O
mediated O
by O
more O
than O

sulindac O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
induces O
apoptosis O
in O
colon O
cancer O
cells O
without O
modulating O
ERK1/2 O
phosphorylation O
or O
beta-catenin B
protein O
expression O
. O
Inhibition O
of O
ERK1/2 O
with O
U0126 O
induces O
apoptosis O
but O
fails O
to O
activate O
JNK O
phosphorylation O
or O
down-regulate O
beta-catenin O
protein O
expression O
. O
Cotreatment O
with O
U0126 O
and O
YC-1 O
synergistically O
increases O
apoptosis O
in O
colorectal O
cancer O
cells O
and O
recapitulates O
the O
effects O
of O
sulindac O
treatment O
on O
ERK1/2 O
, O
JNK O
, O
and O
beta-catenin O
. O
These O
results O
indicate O
that O
sulindac O
metabolites O
modulate O
ERK1/2 O
and O
PKG O
pathways O
independently O
in O
colon O
cancer O
cells O
and O
suggest O
that O
the O
full O
apoptotic O
effect O
of O
sulindac O
is O
mediated O
by O
more O
than O
one O
pathway O
. O
Using O
similar O
combinatorial O
approaches O
in O
vivo O
may O
provide O
more O
effective O
, O
less O

Sulindac O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
human O
and O
animal O
data O
support O
the O
ability O
of O
nonsteroidal O
anti-inflammatory O
drugs O
to O
cause O
regression O
of O
existing O
colon O
tumors O
and O
prevent O
new O
tumor O
formation O
. O
The O
mechanism O
by O
which O
the O
nonsteroidal O
anti-inflammatory O
drug O
sulindac O
prevents O
tumor O
growth O
is O
poorly O
understood O
and O
seems O
complex O
as O
sulindac O
can O
modulate O
several O
growth-related O
signaling O
pathways O
. O
Sulindac O
metabolites O
simultaneously O
(a) O
increase O
cellular O
cyclic O
GMP O
and O
subsequently O
activate O
cyclic O
GMP-dependent O
protein O
kinase O
(PKG); O
(b) O
activate O
c-jun O
NH2-terminal O
kinase O
(JNK); O
(c) O
inhibit O
extracellular O
signal-regulated O
kinase O
1/2 O
(ERK1/2); O
and O
(d) O
decrease O
beta-catenin B
protein O
expression O
at O
times O
and O
doses O
consistent O
with O
apoptosis O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O

Sulindac O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
human O
and O
animal O
data O
support O
the O
ability O
of O
nonsteroidal O
anti-inflammatory O
drugs O
to O
cause O
regression O
of O
existing O
colon O
tumors O
and O
prevent O
new O
tumor O
formation O
. O
The O
mechanism O
by O
which O
the O
nonsteroidal O
anti-inflammatory O
drug O
sulindac O
prevents O
tumor O
growth O
is O
poorly O
understood O
and O
seems O
complex O
as O
sulindac O
can O
modulate O
several O
growth-related O
signaling O
pathways O
. O
Sulindac O
metabolites O
simultaneously O
(a) O
increase O
cellular O
cyclic O
GMP O
and O
subsequently O
activate O
cyclic O
GMP-dependent O
protein O
kinase O
(PKG); O
(b) O
activate O
c-jun B
NH2-terminal I
kinase I
(JNK); O
(c) O
inhibit O
extracellular O
signal-regulated O
kinase O
1/2 O
(ERK1/2); O
and O
(d) O
decrease O
beta-catenin O
protein O
expression O
at O
times O
and O
doses O
consistent O
with O
apoptosis O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O

Sulindac O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
human O
and O
animal O
data O
support O
the O
ability O
of O
nonsteroidal O
anti-inflammatory O
drugs O
to O
cause O
regression O
of O
existing O
colon O
tumors O
and O
prevent O
new O
tumor O
formation O
. O
The O
mechanism O
by O
which O
the O
nonsteroidal O
anti-inflammatory O
drug O
sulindac O
prevents O
tumor O
growth O
is O
poorly O
understood O
and O
seems O
complex O
as O
sulindac O
can O
modulate O
several O
growth-related O
signaling O
pathways O
. O
Sulindac O
metabolites O
simultaneously O
(a) O
increase O
cellular O
cyclic O
GMP O
and O
subsequently O
activate O
cyclic O
GMP-dependent O
protein O
kinase O
(PKG); O
(b) O
activate O
c-jun O
NH2-terminal O
kinase O
(JNK); O
(c) O
inhibit O
extracellular O
signal-regulated O
kinase O
1/2 O
(ERK1/2); O
and O
(d) O
decrease O
beta-catenin O
protein O
expression O
at O
times O
and O
doses O
consistent O
with O
apoptosis O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O

Glyphosate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Herbicidal O
inhibitors O
of O
amino O
acid O
biosynthesis O
and O
herbicide-tolerant O
crops.Acetohydroxyacid O
synthase O
(AHAS) O
inhibitors O
interfere O
with O
branched-chain O
amino O
acid O
biosynthesis O
by O
inhibiting O
AHAS O
. O
Glyphosate O
affects O
aromatic O
amino O
acid O
biosynthesis O
by O
inhibiting O
5-enolpyruvylshikimate-3-phosphate B
synthase I
(EPSPS) O
. O
Glufosinate O
inhibits O
glutamine O
synthetase O
and O
blocks O
biosynthesis O
of O
glutamine O
. O
AHAS O
gene O
variants O
that O
confer O
tolerance O
to O
AHAS O
inhibitors O
have O
been O
discovered O
in O
plants O
through O
selection O
or O
mutagenesis O
. O
Imidazolinone-tolerant O
crops O
have O
been O
commercialized O
based O
on O
these O
AHAS O
gene O
variants O
. O
A O

Glyphosate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Herbicidal O
inhibitors O
of O
amino O
acid O
biosynthesis O
and O
herbicide-tolerant O
crops.Acetohydroxyacid O
synthase O
(AHAS) O
inhibitors O
interfere O
with O
branched-chain O
amino O
acid O
biosynthesis O
by O
inhibiting O
AHAS O
. O
Glyphosate O
affects O
aromatic O
amino O
acid O
biosynthesis O
by O
inhibiting O
5-enolpyruvylshikimate-3-phosphate O
synthase O
(EPSPS) O
. O
Glufosinate O
inhibits O
glutamine O
synthetase O
and O
blocks O
biosynthesis O
of O
glutamine O
. O
AHAS O
gene O
variants O
that O
confer O
tolerance O
to O
AHAS O
inhibitors O
have O
been O
discovered O
in O
plants O
through O
selection O
or O
mutagenesis O
. O
Imidazolinone-tolerant O
crops O
have O
been O
commercialized O
based O
on O
these O
AHAS O
gene O
variants O
. O
A O

Glufosinate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Herbicidal O
inhibitors O
of O
amino O
acid O
biosynthesis O
and O
herbicide-tolerant O
crops.Acetohydroxyacid O
synthase O
(AHAS) O
inhibitors O
interfere O
with O
branched-chain O
amino O
acid O
biosynthesis O
by O
inhibiting O
AHAS O
. O
Glyphosate O
affects O
aromatic O
amino O
acid O
biosynthesis O
by O
inhibiting O
5-enolpyruvylshikimate-3-phosphate O
synthase O
(EPSPS) O
. O
Glufosinate O
inhibits O
glutamine B
synthetase I
and O
blocks O
biosynthesis O
of O
glutamine O
. O
AHAS O
gene O
variants O
that O
confer O
tolerance O
to O
AHAS O
inhibitors O
have O
been O
discovered O
in O
plants O
through O
selection O
or O
mutagenesis O
. O
Imidazolinone-tolerant O
crops O
have O
been O
commercialized O
based O
on O
these O
AHAS O
gene O
variants O
. O
A O
modified O
maize O
EPSPS O
gene O
and O
CP4-EPSPS O
gene O
from O
Agrobacterium O
sp O
. O
have O

glutamine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Herbicidal O
inhibitors O
of O
amino O
acid O
biosynthesis O
and O
herbicide-tolerant O
crops.Acetohydroxyacid O
synthase O
(AHAS) O
inhibitors O
interfere O
with O
branched-chain O
amino O
acid O
biosynthesis O
by O
inhibiting O
AHAS O
. O
Glyphosate O
affects O
aromatic O
amino O
acid O
biosynthesis O
by O
inhibiting O
5-enolpyruvylshikimate-3-phosphate O
synthase O
(EPSPS) O
. O
Glufosinate O
inhibits O
glutamine B
synthetase I
and O
blocks O
biosynthesis O
of O
glutamine O
AHAS O
gene O
variants O
that O
confer O
tolerance O
to O
AHAS O
inhibitors O
have O
been O
discovered O
in O
plants O
through O
selection O
or O
mutagenesis O
. O
Imidazolinone-tolerant O
crops O
have O
been O
commercialized O
based O
on O
these O
AHAS O
gene O
variants O
. O
A O
modified O
maize O
EPSPS O
gene O
and O
CP4-EPSPS O
gene O
from O
Agrobacterium O
sp O
. O
have O
been O
used O
to O
transform O
plants O
for O
target-based O
tolerance O

loperamide O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
present O
study O
, O
apolipoprotein O
E O
was O
coupled O
by O
chemical O
methods O
to O
nanoparticles O
made O
of O
human O
serum O
albumin O
(HSA-NP) O
. O
Loperamide O
, O
which O
does O
not O
cross O
the O
blood-brain O
barrier O
but O
exerts O
antinociceptive O
effects O
after O
direct O
injection O
into O
the O
brain O
, O
was O
used O
as O
model O
drug O
. O
Apolipoprotein O
E O
was O
chemically O
bound O
via O
linkers O
to O
loperamide O
loaded O
HSA-NP O
. O
This O
preparation O
induced O
antinociceptive O
effects O
in O
the O
tail-flick O
test O
in O
ICR O
mice O
after O
i.v O
. O
injection O
. O
In O
contrast O
, O
nanoparticles O
linked O
to O
apolipoprotein O
E O
variants O
that O
do O
not O
recognize O
lipoprotein O
receptors O
failed O
to O
induce O
these O
effects O
. O
These O
results O
indicate O
that O
apolipoprotein O
E O
attached O
to O
the O
surface O
of O
nanoparticles O
facilitates O

loperamide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
present O
study O
, O
apolipoprotein O
E O
was O
coupled O
by O
chemical O
methods O
to O
nanoparticles O
made O
of O
human O
serum O
albumin O
(HSA-NP) O
. O
Loperamide O
, O
which O
does O
not O
cross O
the O
blood-brain O
barrier O
but O
exerts O
antinociceptive O
effects O
after O
direct O
injection O
into O
the O
brain O
, O
was O
used O
as O
model O
drug O
. O
Apolipoprotein B
E I
was O
chemically O
bound O
via O
linkers O
to O
loperamide O
loaded O
HSA-NP O
. O
This O
preparation O
induced O
antinociceptive O
effects O
in O
the O
tail-flick O
test O
in O
ICR O
mice O
after O
i.v O
. O
injection O
. O
In O
contrast O
, O
nanoparticles O
linked O
to O
apolipoprotein O
E O
variants O
that O
do O
not O
recognize O
lipoprotein O
receptors O
failed O
to O
induce O
these O
effects O
. O
These O
results O
indicate O
that O
apolipoprotein O
E O
attached O
to O
the O
surface O
of O
nanoparticles O
facilitates O

Citalopram O
acts O
as O
NOT O
for O
what O
entity O
? O
as O
an O
adaptive O
response O
to O
the O
sustained O
elevation O
of O
extracellular O
NE O
levels O
observed O
in O
these O
mice O
. O
A O
pronounced O
NET B
knockout-induced O
shortening O
of O
the O
immobility O
time O
in O
the O
TST O
(by O
ca O
50%) O
compared O
to O
WT O
mice O
was O
not O
reduced O
any O
further O
by O
NET-inhibiting O
ADs O
such O
as O
reboxetine O
, O
desipramine O
, O
and O
imipramine O
. O
Citalopram O
which O
is O
devoid O
of O
affinity O
for O
the O
NET O
, O
exerted O
a O
significant O
reduction O
of O
immobility O
time O
in O
the O
NET-/- O
mice O
. O
In O
the O
FST O
, O
reboxetine O
, O
desipramine O
, O
imipramine O
, O
and O
citalopram O
administered O
acutely O
did O
not O
reduce O
any O
further O
the O
immobility O
time O
shortened O
by O
NET O
knockout O
itself O
(ca O
25%); O
however O
, O
antidepressant-like O
action O
of O
repeatedly O

[3H]CGP12177 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
as O
the O
response O
in O
the O
forced O
swim O
test O
(FST) O
and O
in O
the O
tail O
suspension O
test O
(TST) O
upon O
treatment O
with O
ADs O
that O
display O
different O
pharmacological O
profiles O
. O
In O
both O
tests O
, O
the O
NET-/- O
mice O
behaved O
like O
wild-type O
(WT) O
mice O
acutely O
treated O
with O
ADs O
. O
Autoradiographic O
studies O
showed O
decreased O
binding O
of O
the O
beta-adrenergic O
ligand O
[3H]CGP12177 O
in O
the O
cerebral O
cortex O
of O
NET-/- O
mice O
, O
indicating O
the O
changes O
at O
the O
level O
of O
beta-adrenergic B
receptors I
similar O
to O
those O
obtained O
with O
ADs O
treatment O
. O
The O
binding O
of O
[3H]prazosin O
to O
alpha1-adrenergic O
receptors O
in O
the O
cerebral O
cortex O
of O
NET-/- O
mice O
was O
also O
decreased O
, O
most O
probably O
as O
an O
adaptive O
response O
to O
the O
sustained O

[3H]prazosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
tests O
, O
the O
NET-/- O
mice O
behaved O
like O
wild-type O
(WT) O
mice O
acutely O
treated O
with O
ADs O
. O
Autoradiographic O
studies O
showed O
decreased O
binding O
of O
the O
beta-adrenergic O
ligand O
[3H]CGP12177 O
in O
the O
cerebral O
cortex O
of O
NET-/- O
mice O
, O
indicating O
the O
changes O
at O
the O
level O
of O
beta-adrenergic O
receptors O
similar O
to O
those O
obtained O
with O
ADs O
treatment O
. O
The O
binding O
of O
[3H]prazosin O
to O
alpha1-adrenergic B
receptors I
in O
the O
cerebral O
cortex O
of O
NET-/- O
mice O
was O
also O
decreased O
, O
most O
probably O
as O
an O
adaptive O
response O
to O
the O
sustained O
elevation O
of O
extracellular O
NE O
levels O
observed O
in O
these O
mice O
. O
A O
pronounced O
NET O
knockout-induced O
shortening O
of O
the O
immobility O
time O
in O
the O
TST O
(by O
ca O
50%) O
compared O
to O
WT O

NE O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
behavioral O
reactions O
monitored O
by O
this O
test O
. O
From O
the O
present O
study O
, O
it O
may O
be O
concluded O
that O
mice O
lacking O
the O
NET O
may O
represent O
a O
good O
model O
of O
some O
aspects O
of O
depression-resistant O
behavior O
, O
paralleled O
with O
alterations O
in O
the O
expression O
of O
adrenergic O
receptors O
, O
which O
result O
as O
an O
adaptation O
to O
elevated O
levels O
of O
extracellular O
NE O

reboxetine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
also O
decreased O
, O
most O
probably O
as O
an O
adaptive O
response O
to O
the O
sustained O
elevation O
of O
extracellular O
NE O
levels O
observed O
in O
these O
mice O
. O
A O
pronounced O
NET B
knockout-induced O
shortening O
of O
the O
immobility O
time O
in O
the O
TST O
(by O
ca O
50%) O
compared O
to O
WT O
mice O
was O
not O
reduced O
any O
further O
by O
NET-inhibiting O
ADs O
such O
as O
reboxetine O
desipramine O
, O
and O
imipramine O
. O
Citalopram O
, O
which O
is O
devoid O
of O
affinity O
for O
the O
NET O
, O
exerted O
a O
significant O
reduction O
of O
immobility O
time O
in O
the O
NET-/- O
mice O
. O
In O
the O
FST O
, O
reboxetine O
, O
desipramine O
, O
imipramine O
, O
and O
citalopram O
administered O
acutely O
did O
not O
reduce O
any O
further O
the O
immobility O
time O
shortened O
by O
NET O
knockout O
itself O
(ca O
25%); O
however O
, O

desipramine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
decreased O
, O
most O
probably O
as O
an O
adaptive O
response O
to O
the O
sustained O
elevation O
of O
extracellular O
NE O
levels O
observed O
in O
these O
mice O
. O
A O
pronounced O
NET B
knockout-induced O
shortening O
of O
the O
immobility O
time O
in O
the O
TST O
(by O
ca O
50%) O
compared O
to O
WT O
mice O
was O
not O
reduced O
any O
further O
by O
NET-inhibiting O
ADs O
such O
as O
reboxetine O
, O
desipramine O
and O
imipramine O
. O
Citalopram O
, O
which O
is O
devoid O
of O
affinity O
for O
the O
NET O
, O
exerted O
a O
significant O
reduction O
of O
immobility O
time O
in O
the O
NET-/- O
mice O
. O
In O
the O
FST O
, O
reboxetine O
, O
desipramine O
, O
imipramine O
, O
and O
citalopram O
administered O
acutely O
did O
not O
reduce O
any O
further O
the O
immobility O
time O
shortened O
by O
NET O
knockout O
itself O
(ca O
25%); O
however O
, O
antidepressant-like O

imipramine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
probably O
as O
an O
adaptive O
response O
to O
the O
sustained O
elevation O
of O
extracellular O
NE O
levels O
observed O
in O
these O
mice O
. O
A O
pronounced O
NET B
knockout-induced O
shortening O
of O
the O
immobility O
time O
in O
the O
TST O
(by O
ca O
50%) O
compared O
to O
WT O
mice O
was O
not O
reduced O
any O
further O
by O
NET-inhibiting O
ADs O
such O
as O
reboxetine O
, O
desipramine O
, O
and O
imipramine O
Citalopram O
, O
which O
is O
devoid O
of O
affinity O
for O
the O
NET O
, O
exerted O
a O
significant O
reduction O
of O
immobility O
time O
in O
the O
NET-/- O
mice O
. O
In O
the O
FST O
, O
reboxetine O
, O
desipramine O
, O
imipramine O
, O
and O
citalopram O
administered O
acutely O
did O
not O
reduce O
any O
further O
the O
immobility O
time O
shortened O
by O
NET O
knockout O
itself O
(ca O
25%); O
however O
, O
antidepressant-like O
action O
of O

Reboxetine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
stress O
disorder O
: O
a O
double-blind O
, O
fixed-dosage O
, O
controlled O
trial.BACKGROUND O
: O
Motor O
vehicle O
accidents O
(MVAs) O
are O
a O
leading O
cause O
of O
posttraumatic O
stress O
disorder O
(PTSD) O
in O
the O
general O
population O
. O
Alterations O
in O
norepinephrine O
and O
serotonin O
systems O
have O
been O
proposed O
as O
mechanisms O
involved O
in O
the O
pathophysiology O
of O
the O
condition O
, O
with O
treatment O
directed O
at O
these O
neurotransmitter O
systems O
. O
Reboxetine O
a O
selective O
norepinephrine O
reuptake O
inhibitor O
, O
exhibits O
high O
affinity O
and O
selectivity O
for O
the O
human O
norepinephrine O
transporter O
. O
Inasmuch O
as O
PTSD O
may O
be O
associated O
with O
dysregulation O
of O
noradrenergic O
activity O
, O
the O
present O
double-blind O
randomized O
clinical O
trial O
intended O
to O
evaluate O
reboxetine's O
efficacy O
in O
the O
management O
of O
MVA-related O
PTSD O
and O
to O
compare O
its O
efficacy O
with O

Reboxetine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
stress O
disorder O
: O
a O
double-blind O
, O
fixed-dosage O
, O
controlled O
trial.BACKGROUND O
: O
Motor O
vehicle O
accidents O
(MVAs) O
are O
a O
leading O
cause O
of O
posttraumatic O
stress O
disorder O
(PTSD) O
in O
the O
general O
population O
. O
Alterations O
in O
norepinephrine O
and O
serotonin O
systems O
have O
been O
proposed O
as O
mechanisms O
involved O
in O
the O
pathophysiology O
of O
the O
condition O
, O
with O
treatment O
directed O
at O
these O
neurotransmitter O
systems O
. O
Reboxetine O
a O
selective O
norepinephrine O
reuptake O
inhibitor O
, O
exhibits O
high O
affinity O
and O
selectivity O
for O
the O
human O
norepinephrine O
transporter O
. O
Inasmuch O
as O
PTSD O
may O
be O
associated O
with O
dysregulation O
of O
noradrenergic O
activity O
, O
the O
present O
double-blind O
randomized O
clinical O
trial O
intended O
to O
evaluate O
reboxetine's O
efficacy O
in O
the O
management O
of O
MVA-related O
PTSD O
and O
to O
compare O
its O
efficacy O
with O

methimazole O
acts O
as O
NOT O
for O
what O
entity O
? O
of O
hyperthyroidism O
and O
explains O
the O
well O
known O
observation O
that O
the O
"microsomal" O
antigen O
is O
particularly O
abundant O
in O
glands O
of O
Graves' O
patients O
. O
The O
modulation O
of O
M/TPO-Ag B
surface O
expression O
by O
TSH O
can O
explain O
the O
decrease O
of O
circulating O
anti-MAb O
observed O
during O
L-thyroxine O
therapy O
in O
hypothyroid O
patients O
with O
Hashimoto's O
thyroiditis O
. O
Other O
agents O
, O
such O
as O
methimazole O
and O
sodium O
iodide O
, O
which O
influence O
thyroid O
cell O
function O
, O
do O
not O
directly O
interfere O
with O
the O
expression O
of O
M/TPO-Ag O
. O
Cytokines O
, O
such O
as O
gamma-interferon O
, O
interleukin-1 O
, O
and O
interleukin-6 O
have O
been O
shown O
to O
inhibit O
the O
TSH-induced O
increase O
of O
TPO O
mRNA O
, O
but O
further O
investigations O
are O
required O
to O
elucidate O
the O
exact O
role O
of O
cytokines O
in O
the O

sodium O
iodide O
acts O
as O
NOT O
for O
what O
entity O
? O
and O
explains O
the O
well O
known O
observation O
that O
the O
"microsomal" O
antigen O
is O
particularly O
abundant O
in O
glands O
of O
Graves' O
patients O
. O
The O
modulation O
of O
M/TPO-Ag B
surface O
expression O
by O
TSH O
can O
explain O
the O
decrease O
of O
circulating O
anti-MAb O
observed O
during O
L-thyroxine O
therapy O
in O
hypothyroid O
patients O
with O
Hashimoto's O
thyroiditis O
. O
Other O
agents O
, O
such O
as O
methimazole O
and O
sodium O
iodide O
which O
influence O
thyroid O
cell O
function O
, O
do O
not O
directly O
interfere O
with O
the O
expression O
of O
M/TPO-Ag O
. O
Cytokines O
, O
such O
as O
gamma-interferon O
, O
interleukin-1 O
, O
and O
interleukin-6 O
have O
been O
shown O
to O
inhibit O
the O
TSH-induced O
increase O
of O
TPO O
mRNA O
, O
but O
further O
investigations O
are O
required O
to O
elucidate O
the O
exact O
role O
of O
cytokines O
in O
the O
regulation O
of O
M/TPO-Ag O

cAMP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
expression O
of O
the O
microsomal/peroxidase O
antigen O
(M/TPO-Ag) O
in O
thyroid O
cells O
is O
induced O
by O
TSH O
, O
through O
pathways O
which O
involve O
intracellular O
cAMP O
accumulation O
and O
protein O
synthesis O
. O
These O
data O
have O
been O
found O
true O
in O
any O
thyroid O
system O
studied O
so O
far O
, O
both O
in O
terms O
of O
immunologic O
and O
enzymatic O
activity O
of O
TPO O
. O
TSH O
and O
cAMP O
also O
increase O
the O
levels O
of O
the O
specific O
mRNA O
for O
TPO B
in O
thyroid O
cells O
from O
different O
species O
. O
Whether O
this O
phenomenon O
is O
due O
to O
a O
direct O
transcriptional O
regulation O
of O
the O
TPO O
gene O
, O
as O
shown O
in O
dog O
thyroid O
cells O
, O
or O
to O
posttranscriptional O
effects O
, O
as O
it O
would O
appear O
in O
FRTL-5 O
cells O
, O
remains O
to O

cAMP O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
The O
microsomal/peroxidase O
antigen O
: O
modulation O
of O
its O
expression O
in O
thyroid O
cells.Evidence O
has O
accumulated O
in O
the O
last O
few O
years O
that O
the O
expression O
of O
the O
microsomal/peroxidase B
antigen I
(M/TPO-Ag) O
in O
thyroid O
cells O
is O
induced O
by O
TSH O
, O
through O
pathways O
which O
involve O
intracellular O
cAMP O
accumulation O
and O
protein O
synthesis O
. O
These O
data O
have O
been O
found O
true O
in O
any O
thyroid O
system O
studied O
so O
far O
, O
both O
in O
terms O
of O
immunologic O
and O
enzymatic O
activity O
of O
TPO O
. O
TSH O
and O
cAMP O
also O
increase O
the O
levels O
of O
the O
specific O
mRNA O
for O
TPO O
in O
thyroid O
cells O
from O
different O
species O
. O
Whether O
this O
phenomenon O

cAMP O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
The O
microsomal/peroxidase O
antigen O
: O
modulation O
of O
its O
expression O
in O
thyroid O
cells.Evidence O
has O
accumulated O
in O
the O
last O
few O
years O
that O
the O
expression O
of O
the O
microsomal/peroxidase O
antigen O
(M/TPO-Ag) O
in O
thyroid O
cells O
is O
induced O
by O
TSH O
, O
through O
pathways O
which O
involve O
intracellular O
cAMP O
accumulation O
and O
protein O
synthesis O
. O
These O
data O
have O
been O
found O
true O
in O
any O
thyroid O
system O
studied O
so O
far O
, O
both O
in O
terms O
of O
immunologic O
and O
enzymatic O
activity O
of O
TPO O
. O
TSH O
and O
cAMP O
also O
increase O
the O
levels O
of O
the O
specific O
mRNA O
for O
TPO O
in O
thyroid O
cells O
from O
different O
species O
. O
Whether O
this O
phenomenon O

nitrogen O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
by O
suppressing O
gene O
expression O
of O
lipogenic O
enzymes O
, O
including O
acetyl-CoA O
carboxylase O
(ACC) O
. O
In O
order O
to O
elucidate O
the O
mechanism O
of O
this O
regulation O
, O
the O
effect O
of O
dietary O
SPI O
on O
promoter O
(PI O
and O
PII) O
specific O
gene O
expression O
of O
ACC O
alpha O
was O
investigated O
. O
Rats O
were O
fed O
experimental O
diets O
containing O
SPI O
or O
casein B
as O
a O
nitrogen O
source O
. O
SPI O
feeding O
decreased O
the O
hepatic O
contents O
of O
total O
ACC O
mRNA O
as O
well O
as O
triglyceride O
(TG) O
content O
, O
but O
dietary O
SPI O
affected O
the O
amount O
of O
sterol-regulatory O
element O
binding O
protein O
(SREBP)-1 O
mRNA O
and O
protein O
very O
little O
. O
The O
amount O
of O
ACC O
mRNA O
transcribed O
from O
PII O
promoter O
containing O
SRE O
was O
not O
significantly O
affected O

Theophylline O
acts O
as O
NOT O
for O
what O
entity O
? O
the O
gene O
expression O
of O
secretory O
proteins O
and O
phosphodiesterases O
in O
the O
submaxillary O
gland O
. O
Male O
F344 O
rats O
received O
saline O
or O
theophylline O
(50 O
mg/kg) O
intraperitoneally O
for O
4 O
days O
. O
The O
gene O
expressions O
for O
the O
secretory O
protein O
, O
cystatin O
S O
(CysS) O
, O
and O
PDE O
subfamilies O
3A O
and O
4D O
in O
the O
submaxillary O
gland O
were O
quantified O
using O
RT-PCR O
. O
Theophylline O
exposure O
resulted O
in O
a O
sustained O
increase O
in O
mRNA O
expression O
for O
CysS O
and O
PDE3A O
, O
but O
PDE4D B
gene O
expression O
was O
unchanged O
. O
Our O
results O
suggest O
that O
submaxillary O
hypertrophy O
is O
primarily O
caused O
by O
the O
enhanced O
transcription O
of O
CysS O
, O
and O
that O
the O
transcription O
of O
each O
PDE O
subfamily O
gene O
is O
regulated O
differently O
. O

theophylline O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Changes O
in O
submaxillary O
gland O
gene O
expression O
in O
F344 O
rats O
by O
multiple O
dosing O
of O
theophylline.Multiple O
exposure O
to O
theophylline O
, O
a O
phosphodiesterase O
(PDE) O
inhibitor O
, O
induces O
acinar O
hypertrophy O
in O
the O
salivary O
gland O
. O
This O
study O
examined O
the O
effect O
of O
theophylline O
on O
the O
gene O
expression O
of O
secretory O
proteins O
and O
phosphodiesterases B
in O
the O
submaxillary O
gland O
. O
Male O
F344 O
rats O
received O
saline O
or O
theophylline O
(50 O
mg/kg) O
intraperitoneally O
for O
4 O
days O
. O
The O
gene O
expressions O
for O
the O
secretory O
protein O
, O
cystatin O
S O
(CysS) O
, O
and O
PDE O
subfamilies O
3A O
and O
4D O
in O
the O
submaxillary O
gland O
were O
quantified O
using O

Theophylline O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
gene O
expression O
of O
secretory O
proteins O
and O
phosphodiesterases O
in O
the O
submaxillary O
gland O
. O
Male O
F344 O
rats O
received O
saline O
or O
theophylline O
(50 O
mg/kg) O
intraperitoneally O
for O
4 O
days O
. O
The O
gene O
expressions O
for O
the O
secretory O
protein O
, O
cystatin O
S O
(CysS) O
, O
and O
PDE O
subfamilies O
3A O
and O
4D O
in O
the O
submaxillary O
gland O
were O
quantified O
using O
RT-PCR O
. O
Theophylline O
exposure O
resulted O
in O
a O
sustained O
increase O
in O
mRNA O
expression O
for O
CysS B
and O
PDE3A O
, O
but O
PDE4D O
gene O
expression O
was O
unchanged O
. O
Our O
results O
suggest O
that O
submaxillary O
hypertrophy O
is O
primarily O
caused O
by O
the O
enhanced O
transcription O
of O
CysS O
, O
and O
that O
the O
transcription O
of O
each O
PDE O
subfamily O
gene O
is O
regulated O
differently O
. O

Theophylline O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
gene O
expression O
of O
secretory O
proteins O
and O
phosphodiesterases O
in O
the O
submaxillary O
gland O
. O
Male O
F344 O
rats O
received O
saline O
or O
theophylline O
(50 O
mg/kg) O
intraperitoneally O
for O
4 O
days O
. O
The O
gene O
expressions O
for O
the O
secretory O
protein O
, O
cystatin O
S O
(CysS) O
, O
and O
PDE O
subfamilies O
3A O
and O
4D O
in O
the O
submaxillary O
gland O
were O
quantified O
using O
RT-PCR O
. O
Theophylline O
exposure O
resulted O
in O
a O
sustained O
increase O
in O
mRNA O
expression O
for O
CysS O
and O
PDE3A O
, O
but O
PDE4D O
gene O
expression O
was O
unchanged O
. O
Our O
results O
suggest O
that O
submaxillary O
hypertrophy O
is O
primarily O
caused O
by O
the O
enhanced O
transcription O
of O
CysS O
, O
and O
that O
the O
transcription O
of O
each O
PDE O
subfamily O
gene O
is O
regulated O
differently O
. O

theophylline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Changes O
in O
submaxillary O
gland O
gene O
expression O
in O
F344 O
rats O
by O
multiple O
dosing O
of O
theophylline.Multiple O
exposure O
to O
theophylline O
a O
phosphodiesterase O
(PDE) O
inhibitor O
, O
induces O
acinar O
hypertrophy O
in O
the O
salivary O
gland O
. O
This O
study O
examined O
the O
effect O
of O
theophylline O
on O
the O
gene O
expression O
of O
secretory O
proteins O
and O
phosphodiesterases O
in O
the O
submaxillary O
gland O
. O
Male O
F344 O
rats O
received O
saline O
or O
theophylline O
(50 O
mg/kg) O
intraperitoneally O
for O
4 O
days O
. O
The O
gene O
expressions O
for O
the O

theophylline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Changes O
in O
submaxillary O
gland O
gene O
expression O
in O
F344 O
rats O
by O
multiple O
dosing O
of O
theophylline.Multiple O
exposure O
to O
theophylline O
a O
phosphodiesterase B
(PDE) O
inhibitor O
, O
induces O
acinar O
hypertrophy O
in O
the O
salivary O
gland O
. O
This O
study O
examined O
the O
effect O
of O
theophylline O
on O
the O
gene O
expression O
of O
secretory O
proteins O
and O
phosphodiesterases O
in O
the O
submaxillary O
gland O
. O
Male O
F344 O
rats O
received O
saline O
or O
theophylline O
(50 O
mg/kg) O
intraperitoneally O
for O
4 O
days O
. O
The O
gene O
expressions O
for O
the O

RSD1235 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
repolarization O
in O
isolated O
rabbit O
Purkinje O
fibers O
, O
and O
can O
initiate O
the O
formation O
of O
early O
afterdepolarizations O
, O
and O
extra O
beats O
. O
These O
actions O
can O
lead O
to O
the O
development O
of O
a O
serious O
ventricular O
tachycardia O
, O
torsades O
de O
pointes O
, O
in O
animal O
models O
and O
patients O
. O
However O
, O
pretreatment O
with O
agents O
that O
block O
late O
I(Na) O
, O
like O
lidocaine O
, O
mexiletine O
, O
and O
RSD1235 O
a O
novel O
mixed O
ion B
channel I
blocker O
for O
the O
rapid O
pharmacologic O
conversion O
of O
atrial O
fibrillation O
, O
significantly O
attenuates O
the O
prolonging O
effects O
of O
Class O
III O
agents O
or O
those O
induced O
by O
ATX-II O
, O
a O
specific O
toxin O
that O
delays O
Na O
channel O
inactivation O
and O
amplifies O
late O
I(Na) O
greatly O
, O
mimicking O
LQT3 O
. O
The O
Na O
channel O
block O
caused O
by O

lidocaine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
a O
novel O
mixed O
ion O
channel O
blocker O
for O
the O
rapid O
pharmacologic O
conversion O
of O
atrial O
fibrillation O
, O
significantly O
attenuates O
the O
prolonging O
effects O
of O
Class O
III O
agents O
or O
those O
induced O
by O
ATX-II O
, O
a O
specific O
toxin O
that O
delays O
Na B
channel I
inactivation O
and O
amplifies O
late O
I(Na) O
greatly O
, O
mimicking O
LQT3 O
. O
The O
Na O
channel O
block O
caused O
by O
lidocaine O
and O
RSD1235 O
can O
be O
through O
the O
open O
or O
inactivated O
states O
of O
the O
channel O
, O
but O
both O
equivalently O
inhibit O
a O
late O
component O
of O
Na O
current O
(I(Na)) O
, O
recorded O
at O
22 O
degrees O
C O
using O
whole-cell O
patch O
clamp O
of O
Nav O
1.5 O
expressed O
in O
HEK O
cells O
. O
These O
protective O
actions O
of O
lidocaine O
, O
mexiletine O
, O
and O
RSD1235 O
may O

RSD1235 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mixed O
ion O
channel O
blocker O
for O
the O
rapid O
pharmacologic O
conversion O
of O
atrial O
fibrillation O
, O
significantly O
attenuates O
the O
prolonging O
effects O
of O
Class O
III O
agents O
or O
those O
induced O
by O
ATX-II O
, O
a O
specific O
toxin O
that O
delays O
Na B
channel I
inactivation O
and O
amplifies O
late O
I(Na) O
greatly O
, O
mimicking O
LQT3 O
. O
The O
Na O
channel O
block O
caused O
by O
lidocaine O
and O
RSD1235 O
can O
be O
through O
the O
open O
or O
inactivated O
states O
of O
the O
channel O
, O
but O
both O
equivalently O
inhibit O
a O
late O
component O
of O
Na O
current O
(I(Na)) O
, O
recorded O
at O
22 O
degrees O
C O
using O
whole-cell O
patch O
clamp O
of O
Nav O
1.5 O
expressed O
in O
HEK O
cells O
. O
These O
protective O
actions O
of O
lidocaine O
, O
mexiletine O
, O
and O
RSD1235 O
may O
result O
, O
at O

NO O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
motif O
participating O
to O
the O
stability O
of O
an O
active O
dimer O
in O
the O
mammalian O
isoforms O
. O
The O
unique O
properties O
of O
HNS B
make O
it O
an O
excellent O
model O
system O
for O
probing O
how O
the O
heme O
environment O
tunes O
NO O
dynamics O
and O
for O
comparing O
it O
to O
the O
endothelial O
NO O
synthase O
heme O
domain O
(eNOS(HD)) O
using O
ultrafast O
transient O
spectroscopy O
. O
NO O
rebinding O
in O
HNS O
from O
Staphylococcus O
aureus O
(SA-HNS) O
is O
faster O
than O
that O
measured O
for O
either O
Bacillus O
anthracis O
(BA-HNS) O
or O
for O
eNOS(HD) O
in O
both O
oxidized O
and O
reduced O
forms O
in O
the O
presence O
of O
arginine O
. O
To O
test O
whether O
these O
distinct O
rates O
arise O
from O
different O
energy O
barriers O
for O
NO O
recombination O
, O
we O
measured O
rebinding O
kinetics O

NO O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
motif O
participating O
to O
the O
stability O
of O
an O
active O
dimer O
in O
the O
mammalian O
isoforms O
. O
The O
unique O
properties O
of O
HNS O
make O
it O
an O
excellent O
model O
system O
for O
probing O
how O
the O
heme O
environment O
tunes O
NO O
dynamics O
and O
for O
comparing O
it O
to O
the O
endothelial O
NO O
synthase O
heme O
domain O
(eNOS(HD)) O
using O
ultrafast O
transient O
spectroscopy O
. O
NO O
rebinding O
in O
HNS O
from O
Staphylococcus O
aureus O
(SA-HNS) O
is O
faster O
than O
that O
measured O
for O
either O
Bacillus O
anthracis O
(BA-HNS) O
or O
for O
eNOS(HD) O
in O
both O
oxidized O
and O
reduced O
forms O
in O
the O
presence O
of O
arginine O
. O
To O
test O
whether O
these O
distinct O
rates O
arise O
from O
different O
energy O
barriers O
for O
NO O
recombination O
, O
we O
measured O
rebinding O
kinetics O

NO O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
motif O
participating O
to O
the O
stability O
of O
an O
active O
dimer O
in O
the O
mammalian O
isoforms O
. O
The O
unique O
properties O
of O
HNS O
make O
it O
an O
excellent O
model O
system O
for O
probing O
how O
the O
heme O
environment O
tunes O
NO O
dynamics O
and O
for O
comparing O
it O
to O
the O
endothelial O
NO O
synthase O
heme O
domain O
(eNOS(HD)) O
using O
ultrafast O
transient O
spectroscopy O
. O
NO O
rebinding O
in O
HNS O
from O
Staphylococcus O
aureus O
(SA-HNS) O
is O
faster O
than O
that O
measured O
for O
either O
Bacillus O
anthracis O
(BA-HNS) O
or O
for O
eNOS(HD) O
in O
both O
oxidized O
and O
reduced O
forms O
in O
the O
presence O
of O
arginine O
. O
To O
test O
whether O
these O
distinct O
rates O
arise O
from O
different O
energy O
barriers O
for O
NO O
recombination O
, O
we O
measured O
rebinding O
kinetics O

NO O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
motif O
participating O
to O
the O
stability O
of O
an O
active O
dimer O
in O
the O
mammalian O
isoforms O
. O
The O
unique O
properties O
of O
HNS O
make O
it O
an O
excellent O
model O
system O
for O
probing O
how O
the O
heme O
environment O
tunes O
NO O
dynamics O
and O
for O
comparing O
it O
to O
the O
endothelial O
NO O
synthase O
heme O
domain O
(eNOS(HD)) O
using O
ultrafast O
transient O
spectroscopy O
. O
NO O
rebinding O
in O
HNS O
from O
Staphylococcus O
aureus O
(SA-HNS) O
is O
faster O
than O
that O
measured O
for O
either O
Bacillus O
anthracis O
(BA-HNS) O
or O
for O
eNOS(HD) B
in O
both O
oxidized O
and O
reduced O
forms O
in O
the O
presence O
of O
arginine O
. O
To O
test O
whether O
these O
distinct O
rates O
arise O
from O
different O
energy O
barriers O
for O
NO O
recombination O
, O
we O
measured O
rebinding O
kinetics O

NO O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Dynamics O
of O
N O
rebinding O
to O
the O
heme B
domain I
of I
NO I
synthase-like I
proteins I
from O
bacterial O
pathogens.Some O
Gram-positive O
bacterial O
pathogens O
harbor O
a O
gene O
that O
encodes O
a O
protein O
(HNS O
, O
Heme O
domain O
of O
NO O
Synthase-like O
proteins) O
with O
striking O
sequence O
identity O
to O
the O
oxygenase O
domain O
of O
mammalian O
NO O
synthases O
(NOS) O
. O
However O
, O
they O
lack O
the O
N-terminal O
and O
the O

EPA O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
mRNA O
levels O
in O
macrophages O
. O
GW9662 O
, O
a O
PPARgamma B
antagonist O
, O
prevented O
(P O
< O
0.01) O
the O
lutein-induced O
iNOS O
mRNA O
downregulation O
in O
HD11 O
cells O
. O
LG101208 O
, O
a O
RXR O
antagonist O
, O
prevented O
(P O
< O
0.01) O
iNOS O
upregulation O
induced O
by O
10 O
micromol/L O
lutein O
and O
iNOS O
mRNA O
downregulation O
induced O
by O
100 O
micromol/L O
lutein O
. O
We O
conclude O
that O
lutein O
and O
EPA O
interact O
through O
the O
PPARgamma O
and O
RXR O
pathways O
to O
modulate O
iNOS O
mRNA O
. O

EPA O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
mRNA O
levels O
in O
macrophages O
. O
GW9662 O
, O
a O
PPARgamma O
antagonist O
, O
prevented O
(P O
< O
0.01) O
the O
lutein-induced O
iNOS O
mRNA O
downregulation O
in O
HD11 O
cells O
. O
LG101208 O
, O
a O
RXR B
antagonist O
, O
prevented O
(P O
< O
0.01) O
iNOS O
upregulation O
induced O
by O
10 O
micromol/L O
lutein O
and O
iNOS O
mRNA O
downregulation O
induced O
by O
100 O
micromol/L O
lutein O
. O
We O
conclude O
that O
lutein O
and O
EPA O
interact O
through O
the O
PPARgamma O
and O
RXR O
pathways O
to O
modulate O
iNOS O
mRNA O
. O

eicosapentaenoic O
acid O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Lutein O
and O
eicosapentaenoic O
aci O
interact O
to O
modify O
iNOS O
mRNA O
levels O
through O
the O
PPARgamma/RXR O
pathway O
in O
chickens O
and O
HD11 O
cell O
lines.Two O
experiments O
were O
conducted O
to O
investigate O
the O
effect O
of O
lutein O
and O
fat O
or O
eicosapentaenoic O
acid O
(EPA) O
interaction O
on O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
PPARs O
alpha O
, O
beta O
, O
and O
gamma O
, O
and O
retinoic O
acid O
X O
receptor O
(RXR) O

eicosapentaenoic O
acid O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Lutein O
and O
eicosapentaenoic O
aci O
interact O
to O
modify O
iNOS O
mRNA O
levels O
through O
the O
PPARgamma/RXR O
pathway O
in O
chickens O
and O
HD11 O
cell O
lines.Two O
experiments O
were O
conducted O
to O
investigate O
the O
effect O
of O
lutein O
and O
fat O
or O
eicosapentaenoic O
acid O
(EPA) O
interaction O
on O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
PPARs O
alpha O
, O
beta O
, O
and O
gamma O
, O
and O
retinoic O
acid O
X O
receptor O
(RXR) O

EPA O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
mRNA O
levels O
in O
macrophages O
. O
GW9662 O
, O
a O
PPARgamma O
antagonist O
, O
prevented O
(P O
< O
0.01) O
the O
lutein-induced O
iNOS B
mRNA O
downregulation O
in O
HD11 O
cells O
. O
LG101208 O
, O
a O
RXR O
antagonist O
, O
prevented O
(P O
< O
0.01) O
iNOS O
upregulation O
induced O
by O
10 O
micromol/L O
lutein O
and O
iNOS O
mRNA O
downregulation O
induced O
by O
100 O
micromol/L O
lutein O
. O
We O
conclude O
that O
lutein O
and O
EPA O
interact O
through O
the O
PPARgamma O
and O
RXR O
pathways O
to O
modulate O
iNOS O
mRNA O
. O

eicosapentaenoic O
acid O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Lutein O
and O
eicosapentaenoic O
aci O
interact O
to O
modify O
iNOS B
mRNA O
levels O
through O
the O
PPARgamma/RXR O
pathway O
in O
chickens O
and O
HD11 O
cell O
lines.Two O
experiments O
were O
conducted O
to O
investigate O
the O
effect O
of O
lutein O
and O
fat O
or O
eicosapentaenoic O
acid O
(EPA) O
interaction O
on O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
PPARs O
alpha O
, O
beta O
, O
and O
gamma O
, O
and O
retinoic O
acid O
X O
receptor O
(RXR) O

GW9662 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
to O
100 O
micromol/L O
decreased O
iNOS B
mRNA O
. O
Increasing O
lutein O
with O
high O
fat O
(6%) O
or O
EPA O
(15 O
micromol/L O
EPA) O
increased O
PPARgamma O
and O
RXRalpha O
mRNA O
levels O
. O
Lutein O
increased O
PPARalpha O
mRNA O
levels O
in O
both O
macrophages O
(P O
< O
0.01) O
and O
HD11 O
(P O
= O
0.01) O
cells O
and O
RXRgamma O
(P O
< O
0.01) O
mRNA O
levels O
in O
macrophages O
. O
GW9662 O
a O
PPARgamma O
antagonist O
, O
prevented O
(P O
< O
0.01) O
the O
lutein-induced O
iNOS O
mRNA O
downregulation O
in O
HD11 O
cells O
. O
LG101208 O
, O
a O
RXR O
antagonist O
, O
prevented O
(P O
< O
0.01) O
iNOS O
upregulation O
induced O
by O
10 O
micromol/L O
lutein O
and O
iNOS O
mRNA O
downregulation O
induced O
by O
100 O
micromol/L O
lutein O
. O
We O
conclude O
that O
lutein O
and O
EPA O
interact O
through O
the O
PPARgamma O

GW9662 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
to O
100 O
micromol/L O
decreased O
iNOS O
mRNA O
. O
Increasing O
lutein O
with O
high O
fat O
(6%) O
or O
EPA O
(15 O
micromol/L O
EPA) O
increased O
PPARgamma B
and O
RXRalpha O
mRNA O
levels O
. O
Lutein O
increased O
PPARalpha O
mRNA O
levels O
in O
both O
macrophages O
(P O
< O
0.01) O
and O
HD11 O
(P O
= O
0.01) O
cells O
and O
RXRgamma O
(P O
< O
0.01) O
mRNA O
levels O
in O
macrophages O
. O
GW9662 O
a O
PPARgamma O
antagonist O
, O
prevented O
(P O
< O
0.01) O
the O
lutein-induced O
iNOS O
mRNA O
downregulation O
in O
HD11 O
cells O
. O
LG101208 O
, O
a O
RXR O
antagonist O
, O
prevented O
(P O
< O
0.01) O
iNOS O
upregulation O
induced O
by O
10 O
micromol/L O
lutein O
and O
iNOS O
mRNA O
downregulation O
induced O
by O
100 O
micromol/L O
lutein O
. O
We O
conclude O
that O
lutein O
and O
EPA O
interact O
through O
the O
PPARgamma O

Melatonin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Effect O
of O
ramelteon O
(TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
(ramelteon O
, O
TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
(N-acetyl-5-HT) O
, O
a O
ligand O
of O
MT3 B
biding O
site O
, O
also O
had O
no O
impairment O
on O
the O
performance O
, O
per O
se O
. O
However O
, O
in O
combination O
with O
a O
low O
dose O
of O
diazepam O
(3mg/kg O
, O
p.o.) O
, O
treatment O
with O
melatonin O
and O
N-acetyl-5-HT O
exacerbated O
the O
impairment O
by O
diazepam O
. O
Ramelteon O
had O
no O
significant O
effect O
on O
the O
diazepam-induced O
impairment O
of O

N-acetyl-5-hydroxytryptamine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
of O
ramelteon O
(TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
(ramelteon O
, O
TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
(N-acetyl-5-HT) O
, O
a O
ligand O
of O
MT3 B
biding O
site O
, O
also O
had O
no O
impairment O
on O
the O
performance O
, O
per O
se O
. O
However O
, O
in O
combination O
with O
a O
low O
dose O
of O
diazepam O
(3mg/kg O
, O
p.o.) O
, O
treatment O
with O
melatonin O
and O
N-acetyl-5-HT O
exacerbated O
the O
impairment O
by O
diazepam O
. O
Ramelteon O
had O
no O
significant O
effect O
on O
the O
diazepam-induced O
impairment O
of O
motor O
coordination O
. O

N-acetyl-5-HT O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
(TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
(ramelteon O
, O
TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
( O
N-acetyl-5-HT O
 O
, O
a O
ligand O
of O
MT3 B
biding O
site O
, O
also O
had O
no O
impairment O
on O
the O
performance O
, O
per O
se O
. O
However O
, O
in O
combination O
with O
a O
low O
dose O
of O
diazepam O
(3mg/kg O
, O
p.o.) O
, O
treatment O
with O
melatonin O
and O
N-acetyl-5-HT O
exacerbated O
the O
impairment O
by O
diazepam O
. O
Ramelteon O
had O
no O
significant O
effect O
on O
the O
diazepam-induced O
impairment O
of O
motor O
coordination O
. O

ramelteon O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Effect O
of O
ramelteon O
(TAK-375) O
, O
a O
selective O
MT1/MT2 B
receptor I
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
( O
ramelteon O
TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
(N-acetyl-5-HT) O
, O
a O
ligand O
of O
MT3 O
biding O
site O
, O
also O
had O
no O
impairment O
on O
the O
performance O
, O
per O

TAK-375 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Effect O
of O
ramelteon O
(TAK-375) O
, O
a O
selective O
MT1/MT2 B
receptor I
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
(ramelteon O
, O
TAK-375 O
 O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
(N-acetyl-5-HT) O
, O
a O
ligand O
of O
MT3 O
biding O
site O
, O
also O
had O
no O
impairment O
on O
the O
performance O
, O
per O

ramelteon O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Effect O
of O
ramelteo O
(TAK-375) O
, O
a O
selective O
MT1/MT2 B
receptor I
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
(ramelteon O
, O
TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
(N-acetyl-5-HT) O
, O

TAK-375 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Effect O
of O
ramelteon O
(TAK-37 O
) O
, O
a O
selective O
MT1/MT2 B
receptor I
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
(ramelteon O
, O
TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
(N-acetyl-5-HT) O
, O

(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Effect O
of O
ramelteon O
(TAK-375) O
, O
a O
selective O
MT1/MT2 B
receptor I
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
(ramelteon O
, O
TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
(N-acetyl-5-HT) O
, O
a O
ligand O
of O
MT3 O
biding O
site O
, O
also O
had O
no O
impairment O
on O
the O
performance O
, O

sorafenib O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O
either O
directly O
on O
the O
tumor O
(through O
inhibition O
of O
Raf B
and O
Kit O
signaling) O
and/or O
on O
tumor O
angiogenesis O
(through O
inhibition O
of O
VEGFR O
and O
PDGFR O
signaling) O
. O
In O
phase O
I O
and O
phase O
II O
clinical O
trials O
, O
sorafenib O
showed O
limited O
side O
effects O
and O
, O
more O
importantly O
, O
disease O

sorafenib O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O
either O
directly O
on O
the O
tumor O
(through O
inhibition O
of O
Raf O
and O
Kit B
signaling) O
and/or O
on O
tumor O
angiogenesis O
(through O
inhibition O
of O
VEGFR O
and O
PDGFR O
signaling) O
. O
In O
phase O
I O
and O
phase O
II O
clinical O
trials O
, O
sorafenib O
showed O
limited O
side O
effects O
and O
, O
more O
importantly O
, O
disease O

sorafenib O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O
either O
directly O
on O
the O
tumor O
(through O
inhibition O
of O
Raf O
and O
Kit O
signaling) O
and/or O
on O
tumor O
angiogenesis O
(through O
inhibition O
of O
VEGFR B
and O
PDGFR O
signaling) O
. O
In O
phase O
I O
and O
phase O
II O
clinical O
trials O
, O
sorafenib O
showed O
limited O
side O
effects O
and O
, O
more O
importantly O
, O
disease O

sorafenib O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O
either O
directly O
on O
the O
tumor O
(through O
inhibition O
of O
Raf O
and O
Kit O
signaling) O
and/or O
on O
tumor O
angiogenesis O
(through O
inhibition O
of O
VEGFR O
and O
PDGFR B
signaling) O
. O
In O
phase O
I O
and O
phase O
II O
clinical O
trials O
, O
sorafenib O
showed O
limited O
side O
effects O
and O
, O
more O
importantly O
, O
disease O

BAY O
43-9006 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-900 O
 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine B
kinases I
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O

BAY O
43-9006 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-900 O
 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O

BAY O
43-9006 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-900 O
 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O

BAY O
43-9006 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-900 O
 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O

BAY O
43-9006 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-900 O
 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O

BAY O
43-9006 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-900 O
 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O

Nexavar O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexava O
) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine B
kinases I
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O

Nexavar O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexava O
) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O

Nexavar O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexava O
) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O

Nexavar O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexava O
) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O

Nexavar O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexava O
) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O

Nexavar O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexava O
) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular B
endothelial I
growth I
factor I
receptor I
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived B
growth I
factor I
receptor I
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O

biaryl O
urea O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O
oncogenic O
activation O
of O
the O
Ras/RAF O
pathway O
may O
lead O
to O
a O
sustained O
proliferative O
signal O
resulting O
in O
tumor O
growth O
and O
progression O
, O
inhibition O
of O
this O
pathway O
represents O
an O
attractive O
approach O
for O
cancer O
drug O
discovery O
. O
A O
novel O
class O
of O
biaryl O
urea O
that O
inhibits O
C-RAF B
kinase O
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches O
. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY O
43-9006 O
(Sorafenib O
, O
Nexavar) O
, O
which O
has O
recently O
been O
approved O
by O
the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials O
. O
Sorafenib O
inhibited O

biaryl O
urea O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O
oncogenic O
activation O
of O
the O
Ras/RAF O
pathway O
may O
lead O
to O
a O
sustained O
proliferative O
signal O
resulting O
in O
tumor O
growth O
and O
progression O
, O
inhibition O
of O
this O
pathway O
represents O
an O
attractive O
approach O
for O
cancer O
drug O
discovery O
. O
A O
novel O
class O
of O
biaryl O
urea O
that O
inhibits O
C-RAF O
kinase B
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches O
. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY O
43-9006 O
(Sorafenib O
, O
Nexavar) O
, O
which O
has O
recently O
been O
approved O
by O
the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials O
. O
Sorafenib O
inhibited O

Sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
biaryl O
urea O
that O
inhibits O
C-RAF O
kinase B
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches O
. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY O
43-9006 O
(Sorafenib O
, O
Nexavar) O
, O
which O
has O
recently O
been O
approved O
by O
the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O

Sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
biaryl O
urea O
that O
inhibits O
C-RAF B
kinase O
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches O
. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY O
43-9006 O
(Sorafenib O
, O
Nexavar) O
, O
which O
has O
recently O
been O
approved O
by O
the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O

Sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
biaryl O
urea O
that O
inhibits O
C-RAF O
kinase O
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches O
. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY O
43-9006 O
(Sorafenib O
, O
Nexavar) O
, O
which O
has O
recently O
been O
approved O
by O
the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF B
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O

Sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
biaryl O
urea O
that O
inhibits O
C-RAF O
kinase O
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches O
. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY O
43-9006 O
(Sorafenib O
, O
Nexavar) O
, O
which O
has O
recently O
been O
approved O
by O
the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E B
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O

pyruvate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
species O
in O
osteoblasts.We O
demonstrated O
previously O
that O
exogenous O
pyruvate O
has O
a O
protective O
action O
against O
cell O
death O
by O
hydrogen O
peroxide O
in O
cultured O
osteoblasts O
through O
a O
mechanism O
associated O
with O
its O
antioxidative O
property O
. O
In O
the O
present O
study O
, O
we O
have O
evaluated O
possible O
participation O
of O
monocarboxylate B
transporters I
(MCTs) O
responsible O
for O
the O
bidirectional O
membrane O
transport O
of O
pyruvate O
in O
the O
cytoprotective O
property O
in O
osteoblasts O
. O
Expression O
of O
the O
MCT2 O
isoform O
was O
found O
in O
cultured O
rat O
calvarial O
osteoblasts O
and O
in O
osteoblasts O
located O
on O
mouse O
tibia O
at O
both O
mRNA O
and O
protein O
levels O
. O
The O
accumulation O
of O
[14C]pyruvate O
occurred O
in O
a O
temperature- O
and O
pH-dependent O
manner O
in O
osteoblasts O
cultured O
for O
7 O
days O
with O

pyruvate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
species O
in O
osteoblasts.We O
demonstrated O
previously O
that O
exogenous O
pyruvate O
has O
a O
protective O
action O
against O
cell O
death O
by O
hydrogen O
peroxide O
in O
cultured O
osteoblasts O
through O
a O
mechanism O
associated O
with O
its O
antioxidative O
property O
. O
In O
the O
present O
study O
, O
we O
have O
evaluated O
possible O
participation O
of O
monocarboxylate O
transporters O
(MCTs) O
responsible O
for O
the O
bidirectional O
membrane O
transport O
of O
pyruvate O
in O
the O
cytoprotective O
property O
in O
osteoblasts O
. O
Expression O
of O
the O
MCT2 O
isoform O
was O
found O
in O
cultured O
rat O
calvarial O
osteoblasts O
and O
in O
osteoblasts O
located O
on O
mouse O
tibia O
at O
both O
mRNA O
and O
protein O
levels O
. O
The O
accumulation O
of O
[14C]pyruvate O
occurred O
in O
a O
temperature- O
and O
pH-dependent O
manner O
in O
osteoblasts O
cultured O
for O
7 O
days O
with O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Herein O
, O
we O
determined O
that O
a O
fiveamino O
acid O
C-terminal O
deletion O
of O
LeuRS O
, O
which O
does O
not O
complement O
a O
null O
strain O
, O
can O
form O
a O
ternary O
complex O
with O
the O
bI4 O
intron O
and O
its O
maturase O
splicing O
partner O
. O
However O
, O
the O
complex O
fails O
to O
stimulate O
splicing O
activity O
. O
The O
x-ray O
co-crystal O
structure O
of O
LeuRS O
showed O
that O
a O
C O
terminal O
extension O
of O
about O
60 O
amino O
acids O
forms O
a O
discrete O
domain O
, O
which O
is O
unique O
among O
the O
LeuRSs B
and O
interacts O
with O
the O
corner O
of O
the O
L-shaped O
tRNALeu O
. O
Interestingly O
, O
deletion O
of O
the O
entire O
yeast O
mitochondrial O
LeuRS O
C-terminal O
domain O
enhanced O
its O
aminoacylation O
and O
amino O
acid O
editing O
activities O
. O
In O
striking O
contrast O
, O
deletion O
of O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
fiveamino O
acid O
C-terminal O
deletion O
of O
LeuRS O
, O
which O
does O
not O
complement O
a O
null O
strain O
, O
can O
form O
a O
ternary O
complex O
with O
the O
bI4 O
intron O
and O
its O
maturase O
splicing O
partner O
. O
However O
, O
the O
complex O
fails O
to O
stimulate O
splicing O
activity O
. O
The O
x-ray O
co-crystal O
structure O
of O
LeuRS O
showed O
that O
a O
C-terminal O
extension O
of O
about O
60 O
amino O
acids O
forms O
a O
discrete O
domain O
, O
which O
is O
unique O
among O
the O
LeuRSs B
and O
interacts O
with O
the O
corner O
of O
the O
L-shaped O
tRNALeu O
. O
Interestingly O
, O
deletion O
of O
the O
entire O
yeast O
mitochondrial O
LeuRS O
C-terminal O
domain O
enhanced O
its O
aminoacylation O
and O
amino O
acid O
editing O
activities O
. O
In O
striking O
contrast O
, O
deletion O
of O
the O
corresponding O
C-terminal O
domain O
of O
Escherichia O
coli O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
complex O
fails O
to O
stimulate O
splicing O
activity O
. O
The O
x-ray O
co-crystal O
structure O
of O
LeuRS O
showed O
that O
a O
C-terminal O
extension O
of O
about O
60 O
amino O
acids O
forms O
a O
discrete O
domain O
, O
which O
is O
unique O
among O
the O
LeuRSs O
and O
interacts O
with O
the O
corner O
of O
the O
L-shaped O
tRNALeu O
. O
Interestingly O
, O
deletion O
of O
the O
entire O
yeast B
mitochondrial I
LeuRS I
C O
terminal O
domain O
enhanced O
its O
aminoacylation O
and O
amino O
acid O
editing O
activities O
. O
In O
striking O
contrast O
, O
deletion O
of O
the O
corresponding O
C-terminal O
domain O
of O
Escherichia O
coli O
LeuRS O
abolished O
aminoacylation O
of O
tRNALeu O
and O
also O
amino O
acid O
editing O
of O
mischarged O
tRNA O
molecules O
. O
These O
results O
suggest O
that O
the O
role O
of O
the O
leucine-specific O
C-terminal O
domain O
in O
tRNA O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
The O
x-ray O
co-crystal O
structure O
of O
LeuRS O
showed O
that O
a O
C-terminal O
extension O
of O
about O
60 O
amino O
acids O
forms O
a O
discrete O
domain O
, O
which O
is O
unique O
among O
the O
LeuRSs O
and O
interacts O
with O
the O
corner O
of O
the O
L-shaped O
tRNALeu O
. O
Interestingly O
, O
deletion O
of O
the O
entire O
yeast B
mitochondrial I
LeuRS I
C-terminal O
domain O
enhanced O
its O
aminoacylation O
and O
amino O
acid O
editing O
activities O
. O
In O
striking O
contrast O
, O
deletion O
of O
the O
corresponding O
C-terminal O
domain O
of O
Escherichia O
coli O
LeuRS O
abolished O
aminoacylation O
of O
tRNALeu O
and O
also O
amino O
acid O
editing O
of O
mischarged O
tRNA O
molecules O
. O
These O
results O
suggest O
that O
the O
role O
of O
the O
leucine-specific O
C-terminal O
domain O
in O
tRNA O
recognition O
for O
aminoacylation O
and O
amino O
acid O
editing O
has O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
of O
about O
60 O
amino O
acids O
forms O
a O
discrete O
domain O
, O
which O
is O
unique O
among O
the O
LeuRSs O
and O
interacts O
with O
the O
corner O
of O
the O
L-shaped O
tRNALeu O
. O
Interestingly O
, O
deletion O
of O
the O
entire O
yeast O
mitochondrial O
LeuRS O
C-terminal O
domain O
enhanced O
its O
aminoacylation O
and O
amino O
acid O
editing O
activities O
. O
In O
striking O
contrast O
, O
deletion O
of O
the O
corresponding O
C O
terminal O
domain O
of O
Escherichia B
coli I
LeuRS I
abolished O
aminoacylation O
of O
tRNALeu O
and O
also O
amino O
acid O
editing O
of O
mischarged O
tRNA O
molecules O
. O
These O
results O
suggest O
that O
the O
role O
of O
the O
leucine-specific O
C-terminal O
domain O
in O
tRNA O
recognition O
for O
aminoacylation O
and O
amino O
acid O
editing O
has O
adapted O
differentially O
and O
with O
surprisingly O
opposite O
effects O
. O
We O
propose O

leucyl O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Functional O
divergence O
of O
a O
unique O
C-terminal O
domain O
of O
leucy O
-tRNA O
synthetase O
to O
accommodate O
its O
splicing O
and O
aminoacylation O
roles.Leucyl-tRNA O
synthetase O
(LeuRS) O
performs O
dual O
essential O
roles O
in O
group O
I O
intron O
RNA O
splicing O
as O
well O
as O
protein O
synthesis O
within O
the O
yeast O
mitochondria O
. O
Deletions O
of O
the O
C O
terminus O
differentially O
impact O
the O
two O
functions O
of O
the O
enzyme O
in O
splicing O
and O
aminoacylation O
in O
vivo O
. O

Leucyl O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Functional O
divergence O
of O
a O
unique O
C-terminal O
domain O
of O
leucyl-tRNA O
synthetase O
to O
accommodate O
its O
splicing O
and O
aminoacylation O
roles O
. O
Leucyl O
tRNA O
synthetase O
(LeuRS) O
performs O
dual O
essential O
roles O
in O
group O
I O
intron O
RNA O
splicing O
as O
well O
as O
protein O
synthesis O
within O
the O
yeast O
mitochondria O
. O
Deletions O
of O
the O
C O
terminus O
differentially O
impact O
the O
two O
functions O
of O
the O
enzyme O
in O
splicing O
and O
aminoacylation O
in O
vivo O
. O
Herein O
, O
we O
determined O
that O
a O
fiveamino O
acid O
C-terminal O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
among O
the O
LeuRSs O
and O
interacts O
with O
the O
corner O
of O
the O
L-shaped O
tRNALeu O
. O
Interestingly O
, O
deletion O
of O
the O
entire O
yeast O
mitochondrial O
LeuRS O
C-terminal O
domain O
enhanced O
its O
aminoacylation O
and O
amino O
acid O
editing O
activities O
. O
In O
striking O
contrast O
, O
deletion O
of O
the O
corresponding O
C-terminal O
domain O
of O
Escherichia B
coli I
LeuRS I
abolished O
aminoacylation O
of O
tRNALeu O
and O
also O
amino O
acid O
editing O
of O
mischarged O
tRNA O
molecules O
. O
These O
results O
suggest O
that O
the O
role O
of O
the O
leucine-specific O
C-terminal O
domain O
in O
tRNA O
recognition O
for O
aminoacylation O
and O
amino O
acid O
editing O
has O
adapted O
differentially O
and O
with O
surprisingly O
opposite O
effects O
. O
We O
propose O
that O
the O
secondary O
role O
of O
yeast O
mitochondrial O
LeuRS O
in O
RNA O
splicing O
has O
impacted O
the O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
These O
results O
suggest O
that O
the O
role O
of O
the O
leucine-specific O
C-terminal O
domain O
in O
tRNA O
recognition O
for O
aminoacylation O
and O
amino O
acid O
editing O
has O
adapted O
differentially O
and O
with O
surprisingly O
opposite O
effects O
. O
We O
propose O
that O
the O
secondary O
role O
of O
yeast B
mitochondrial I
LeuRS I
in O
RNA O
splicing O
has O
impacted O
the O
functional O
evolution O
of O
this O
critical O
C O
terminal O
domain O
. O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
aminoacylation O
roles.Leucyl-tRNA O
synthetase O
(LeuRS) O
performs O
dual O
essential O
roles O
in O
group O
I O
intron O
RNA O
splicing O
as O
well O
as O
protein O
synthesis O
within O
the O
yeast O
mitochondria O
. O
Deletions O
of O
the O
C O
terminus O
differentially O
impact O
the O
two O
functions O
of O
the O
enzyme O
in O
splicing O
and O
aminoacylation O
in O
vivo O
. O
Herein O
, O
we O
determined O
that O
a O
fiveamino O
acid O
C O
terminal O
deletion O
of O
LeuRS O
, O
which O
does O
not O
complement O
a O
null O
strain O
, O
can O
form O
a O
ternary O
complex O
with O
the O
bI4 O
intron O
and O
its O
maturase O
splicing O
partner O
. O
However O
, O
the O
complex O
fails O
to O
stimulate O
splicing O
activity O
. O
The O
x-ray O
co-crystal O
structure O
of O
LeuRS B
showed O
that O
a O
C-terminal O
extension O
of O
about O
60 O
amino O
acids O

anthranilic O
acid O
sulfonamides O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Discovery O
and O
optimization O
of O
anthranilic O
acid O
sulfonamides O
as O
inhibitors O
of O
methionine O
aminopeptidase-2 O
: O
a O
structural O
basis O
for O
the O
reduction O
of O
albumin O
binding.Methionine O
aminopeptidase-2 O
(MetAP2) O
is O
a O
novel O
target O
for O
cancer O
therapy O
. O
As O
part O
of O
an O
effort O
to O
discover O
orally O
active O
reversible O
inhibitors O
of O
MetAP2 O
, O
a O
series O
of O
anthranilic O
acid O
sulfonamides O
with O
micromolar O
affinities O
for O
human O
MetAP2 B
were O
identified O
using O
affinity O
selection O
by O
mass O
spectrometry O
(ASMS) O
screening O
. O
These O
micromolar O
hits O
were O
rapidly O
improved O
to O
nanomolar O
leads O
on O
the O
basis O
of O
insights O
from O
protein O
crystallography; O
however O
, O
the O
compounds O
displayed O
extensive O
binding O
to O
human O
serum O
albumin O
and O
had O
limited O
activity O
in O

anthranilic O
acid O
sulfonamides O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Discovery O
and O
optimization O
of O
anthranilic O
acid O
sulfonamides O
as O
inhibitors O
of O
methionine O
aminopeptidase-2 O
: O
a O
structural O
basis O
for O
the O
reduction O
of O
albumin O
binding.Methionine O
aminopeptidase-2 O
(MetAP2) O
is O
a O
novel O
target O
for O
cancer O
therapy O
. O
As O
part O
of O
an O
effort O
to O
discover O
orally O
active O
reversible O
inhibitors O
of O
MetAP2 O
, O
a O
series O
of O
anthranilic O
acid O
sulfonamides O
with O
micromolar O
affinities O
for O
human B
MetAP2 I
were O
identified O
using O
affinity O
selection O
by O
mass O
spectrometry O
(ASMS) O
screening O
. O
These O
micromolar O
hits O
were O
rapidly O
improved O
to O
nanomolar O
leads O
on O
the O
basis O
of O
insights O
from O
protein O
crystallography; O
however O
, O
the O
compounds O
displayed O
extensive O
binding O
to O
human O
serum O
albumin O
and O
had O
limited O
activity O
in O

anthranilic O
acid O
sulfonamides O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Discovery O
and O
optimization O
of O
anthranilic O
acid O
sulfonamide O
as O
inhibitors O
of O
methionine O
aminopeptidase-2 O
: O
a O
structural O
basis O
for O
the O
reduction O
of O
albumin O
binding.Methionine O
aminopeptidase-2 O
(MetAP2) O
is O
a O
novel O
target O
for O
cancer O
therapy O
. O
As O
part O
of O
an O
effort O
to O
discover O
orally O
active O
reversible O
inhibitors O
of O
MetAP2 O
, O
a O
series O
of O
anthranilic O
acid O
sulfonamides O
with O
micromolar O
affinities O
for O
human O
MetAP2 O

anthranilic O
acid O
sulfonamides O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Discovery O
and O
optimization O
of O
anthranilic O
acid O
sulfonamide O
as O
inhibitors O
of O
methionine O
aminopeptidase-2 O
: O
a O
structural O
basis O
for O
the O
reduction O
of O
albumin B
binding.Methionine O
aminopeptidase-2 O
(MetAP2) O
is O
a O
novel O
target O
for O
cancer O
therapy O
. O
As O
part O
of O
an O
effort O
to O
discover O
orally O
active O
reversible O
inhibitors O
of O
MetAP2 O
, O
a O
series O
of O
anthranilic O
acid O
sulfonamides O
with O
micromolar O
affinities O
for O
human O
MetAP2 O

Nor-NOHA O
acts O
as O
NOT O
for O
what O
entity O
? O
Nor-NOHA O
dose-dependently O
increased O
the O
NOS B
activity O
and O
the O
NO O
release O
with O
maximal O
effects O
at O
20 O
microM O
. O
Extracellular O
L-arginine O
also O
dose-dependently O
increased O
NO O
release O
and O
arginase O
activity O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
in O
the O
presence O
of O
100 O
microM O
L-arginine O
, O
NOS O
activity O
and O
NO O
release O
were O
similar O
in O
untreated O
and O
Nor-NOHA O
treated O
cells O
. O
However O
, O
despite O
activation O
of O
L-arginine O
uptake O
, O
the O
inhibition O
of O
arginase O
activity O
by O
Nor-NOHA O
was O
still O
significant O
. O
The O
depletion O
of O
freely O
exchangeable O
L-arginine O
pools O
with O
extracellular O
L-lysine O
did O
not O
prevent O
Nor-NOHA O
from O
increasing O
the O
NO O
release O
. O
This O
indicates O
the O
presence O
of O
pools O
, O
which O
are O
accessible O
to O
NOS O
and O

N(omega)-hydroxy-nor-L-arginine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O

N(omega)-hydroxy-nor-L-arginine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases B
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O

N(omega)-hydroxy-nor-L-arginine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine B
transporter I
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O

Nor-NOHA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
( O
Nor-NOHA O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O

Nor-NOHA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases B
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
( O
Nor-NOHA O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O

Nor-NOHA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
( O
Nor-NOHA O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine B
transporter I
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O

Nor-NOHA O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O
the O
NOS B
activity O
and O
the O
NO O
release O
with O
maximal O
effects O
at O
20 O
microM O
. O
Extracellular O
L-arginine O
also O
dose-dependently O
increased O
NO O
release O
and O
arginase O
activity O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
in O
the O
presence O
of O
100 O
microM O
L-arginine O
, O
NOS O
activity O
and O
NO O
release O
were O
similar O
in O
untreated O
and O
Nor-NOHA-treated O

L-arginine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase B
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O
the O
NOS O
activity O
and O
the O
NO O
release O
with O
maximal O
effects O
at O
20 O
microM O
. O
Extracellular O
L-arginine O
also O
dose-dependently O
increased O
NO O
release O
and O
arginase O
activity O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
in O
the O
presence O
of O
100 O
microM O
L-arginine O
, O
NOS O
activity O
and O
NO O
release O
were O
similar O
in O
untreated O
and O
Nor-NOHA-treated O
cells O
. O
However O
, O
despite O
activation O
of O
L-arginine O
uptake O
, O
the O
inhibition O
of O
arginase O
activity O
by O
Nor-NOHA O
was O
still O
significant O
. O

N(omega)-hydroxy-nor-L-arginine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase B
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O

Nor-NOHA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase B
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
( O
Nor-NOHA O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O

Nor-NOHA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
mitochondrial O
arginase B
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O
the O
NOS O
activity O
and O
the O
NO O
release O
with O
maximal O
effects O
at O
20 O
microM O
. O
Extracellular O
L-arginine O
also O
dose-dependently O
increased O
NO O
release O
and O
arginase O
activity O
. O
When O
HUVECs O
were O

Nor-NOHA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
20 O
microM O
. O
Extracellular O
L-arginine O
also O
dose-dependently O
increased O
NO O
release O
and O
arginase B
activity O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
in O
the O
presence O
of O
100 O
microM O
L-arginine O
, O
NOS O
activity O
and O
NO O
release O
were O
similar O
in O
untreated O
and O
Nor-NOHA-treated O
cells O
. O
However O
, O
despite O
activation O
of O
L-arginine O
uptake O
, O
the O
inhibition O
of O
arginase O
activity O
by O
Nor-NOHA O
was O
still O
significant O
. O
The O
depletion O
of O
freely O
exchangeable O
L-arginine O
pools O
with O
extracellular O
L-lysine O
did O
not O
prevent O
Nor-NOHA O
from O
increasing O
the O
NO O
release O
. O
This O
indicates O
the O
presence O
of O
pools O
, O
which O
are O
accessible O
to O
NOS O
and O
arginase O
, O
but O
not O
exchangeable O
. O
Interestingly O
, O
the O
mitochondrial O
arginase O
II O
was O
constitutively O
expressed O
, O
whereas O
the O
cytosolic O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
L-lysine O
did O
not O
prevent O
Nor-NOHA O
from O
increasing O
the O
NO O
release O
. O
This O
indicates O
the O
presence O
of O
pools O
, O
which O
are O
accessible O
to O
NOS O
and O
arginase O
, O
but O
not O
exchangeable O
. O
Interestingly O
, O
the O
mitochondrial O
arginase B
II I
was O
constitutively O
expressed O
, O
whereas O
the O
cytosolic O
arginase O
I O
was O
barely O
detectable O
in O
HUVECs O
. O
These O
data O
suggest O
that O
endothelial O
NO O
synthesis O
depends O
on O
the O
activity O
of O
arginase O
II O
in O
mitochondria O
and O
l-arginine O
carriers O
in O
cell O
membrane O
. O

nitric O
oxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive B
nitric-oxide I
synthase I
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O

nitric O
oxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O

nitric O
oxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase B
I I
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O

nitric O
oxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases B
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
( O
NO O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive B
nitric-oxide I
synthase I
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
( O
NO O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
( O
NO O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase B
I I
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
( O
NO O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O

nitric-oxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mitochondrial B
arginase I
II I
modulates O
nitric-oxid O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O

L-arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mitochondrial B
arginase I
II I
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginin O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O

L-arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
the O
common O
substrate O
of O
constitutive B
nitric-oxide I
synthase I
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O

L-arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O

L-arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase B
I I
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O

L-arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O

Adrenaline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
inhibits O
insulin O
secretion O
via O
pertussis O
toxin-sensitive O
mechanisms O
. O
Since O
voltage-dependent O
Ca2+ O
currents O
play O
a O
key O
role O
in O
insulin O
secretion O
, O
we O
examined O
whether O
adrenaline O
modulates O
voltage-dependent O
Ca2+ O
currents O
of O
the O
rat O
insulinoma O
cell O
line O
, O
RINm5F O
. O
In O
the O
whole-cell O
configuration O
of O
the O
patch-clamp O
technique O
, O
dihydropyridine- O
but O
not O
omega-conotoxin-sensitive O
Ca2+ O
currents O
were O
identified O
. O
Adrenaline O
via O
alpha B
2-adrenoceptors I
inhibited O
the O
Ca2+ O
currents O
by O
about O
50% O
. O
Somatostatin O
which O
also O
inhibits O
insulin O
secretion O
was O
less O
efficient O
(inhibition O
by O
20%) O
. O
The O
hormonal O
inhibition O
of O
Ca2+ O
currents O
was O
not O
affected O
by O
intracellularly O
applied O
cAMP O
but O
blocked O
by O
the O
intracellularly O
applied O
GDP O
analog O
guanosine O
5'-O-(2-thiodiphosphate) O
and O
by O
pretreatment O
of O

adrenaline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
about O
40% O
in O
a O
pertussis O
toxin-insensitive O
manner O
. O
Immunoblot O
experiments O
performed O
with O
antibodies O
generated O
against O
synthetic O
peptides O
revealed O
that O
membranes O
of O
RINm5F O
cells O
possess O
four O
pertussis O
toxin-sensitive O
G-proteins O
including O
Gi1 O
, O
Gi2 O
, O
Go2 O
, O
and O
another O
Go O
subtype O
, O
most O
likely O
representing O
Go1 O
. O
In O
membranes O
of O
control O
but O
not O
of O
pertussis O
toxin-treated O
cells O
, O
adrenaline O
via O
alpha B
2-adrenoceptors I
stimulated O
incorporation O
of O
the O
photo-reactive O
GTP O
analog O
[alpha-32P]GTP O
azidoanilide O
into O
pertussis O
toxin O
substrates O
comigrating O
with O
the O
alpha-subunits O
of O
Gi2 O
, O
Go2 O
, O
and O
the O
not O
further O
identified O
Go O
subtype O
. O
The O
present O
findings O
indicate O
that O
activated O
alpha O
2-adrenoceptors O
of O
RINm5F O
cells O
interact O
with O
multiple O
G-proteins O
, O
i.e O
. O
two O
forms O
of O

adrenaline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
pertussis O
toxin O
substrates O
comigrating O
with O
the O
alpha-subunits O
of O
Gi2 O
, O
Go2 O
, O
and O
the O
not O
further O
identified O
Go O
subtype O
. O
The O
present O
findings O
indicate O
that O
activated O
alpha O
2-adrenoceptors O
of O
RINm5F O
cells O
interact O
with O
multiple O
G-proteins O
, O
i.e O
. O
two O
forms O
of O
Go O
and O
with O
Gi2 O
. O
These O
G-proteins B
are O
likely O
to O
be O
involved O
in O
the O
adrenaline O
induced O
inhibition O
of O
dihydropyridine-sensitive O
Ca2+ O
currents O
and O
in O
other O
signal O
transduction O
pathways O
contributing O
to O
the O
adrenaline-induced O
inhibition O
of O
insulin O
secretion O
. O

adrenaline O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Go O
subtype O
. O
The O
present O
findings O
indicate O
that O
activated O
alpha O
2-adrenoceptors O
of O
RINm5F O
cells O
interact O
with O
multiple O
G-proteins O
, O
i.e O
. O
two O
forms O
of O
Go O
and O
with O
Gi2 O
. O
These O
G-proteins O
are O
likely O
to O
be O
involved O
in O
the O
adrenaline-induced O
inhibition O
of O
dihydropyridine-sensitive O
Ca2+ O
currents O
and O
in O
other O
signal O
transduction O
pathways O
contributing O
to O
the O
adrenaline O
induced O
inhibition O
of O
insulin B
secretion O
. O

Somatostatin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
play O
a O
key O
role O
in O
insulin B
secretion O
, O
we O
examined O
whether O
adrenaline O
modulates O
voltage-dependent O
Ca2+ O
currents O
of O
the O
rat O
insulinoma O
cell O
line O
, O
RINm5F O
. O
In O
the O
whole-cell O
configuration O
of O
the O
patch-clamp O
technique O
, O
dihydropyridine- O
but O
not O
omega-conotoxin-sensitive O
Ca2+ O
currents O
were O
identified O
. O
Adrenaline O
via O
alpha O
2-adrenoceptors O
inhibited O
the O
Ca2+ O
currents O
by O
about O
50% O
. O
Somatostatin O
which O
also O
inhibits O
insulin O
secretion O
was O
less O
efficient O
(inhibition O
by O
20%) O
. O
The O
hormonal O
inhibition O
of O
Ca2+ O
currents O
was O
not O
affected O
by O
intracellularly O
applied O
cAMP O
but O
blocked O
by O
the O
intracellularly O
applied O
GDP O
analog O
guanosine O
5'-O-(2-thiodiphosphate) O
and O
by O
pretreatment O
of O
cells O
with O
pertussis O
toxin O
. O
In O
contrast O
to O
adrenaline O
and O
somatostatin O
, O
galanin O
, O

Adrenaline O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Involvement O
of O
pertussis O
toxin-sensitive O
G-proteins O
in O
the O
hormonal O
inhibition O
of O
dihydropyridine-sensitive O
Ca2+ O
currents O
in O
an O
insulin-secreting O
cell O
line O
(RINm5F) O
. O
Adrenaline O
inhibits O
insulin B
secretion O
via O
pertussis O
toxin-sensitive O
mechanisms O
. O
Since O
voltage-dependent O
Ca2+ O
currents O
play O
a O
key O
role O
in O
insulin O
secretion O
, O
we O
examined O
whether O
adrenaline O
modulates O
voltage-dependent O
Ca2+ O
currents O
of O
the O
rat O
insulinoma O
cell O
line O
, O
RINm5F O
. O
In O
the O
whole-cell O
configuration O
of O
the O
patch-clamp O
technique O
, O
dihydropyridine- O
but O
not O
omega-conotoxin-sensitive O
Ca2+ O
currents O
were O
identified O
. O

adrenaline O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
by O
about O
50% O
. O
Somatostatin O
which O
also O
inhibits O
insulin B
secretion O
was O
less O
efficient O
(inhibition O
by O
20%) O
. O
The O
hormonal O
inhibition O
of O
Ca2+ O
currents O
was O
not O
affected O
by O
intracellularly O
applied O
cAMP O
but O
blocked O
by O
the O
intracellularly O
applied O
GDP O
analog O
guanosine O
5'-O-(2-thiodiphosphate) O
and O
by O
pretreatment O
of O
cells O
with O
pertussis O
toxin O
. O
In O
contrast O
to O
adrenaline O
and O
somatostatin O
, O
galanin O
, O
another O
inhibitor O
of O
insulin O
secretion O
, O
reduced O
Ca2+ O
currents O
by O
about O
40% O
in O
a O
pertussis O
toxin-insensitive O
manner O
. O
Immunoblot O
experiments O
performed O
with O
antibodies O
generated O
against O
synthetic O
peptides O
revealed O
that O
membranes O
of O
RINm5F O
cells O
possess O
four O
pertussis O
toxin-sensitive O
G-proteins O
including O
Gi1 O
, O
Gi2 O
, O
Go2 O
, O
and O
another O
Go O
subtype O
, O
most O
likely O

somatostatin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
50% O
. O
Somatostatin O
which O
also O
inhibits O
insulin B
secretion O
was O
less O
efficient O
(inhibition O
by O
20%) O
. O
The O
hormonal O
inhibition O
of O
Ca2+ O
currents O
was O
not O
affected O
by O
intracellularly O
applied O
cAMP O
but O
blocked O
by O
the O
intracellularly O
applied O
GDP O
analog O
guanosine O
5'-O-(2-thiodiphosphate) O
and O
by O
pretreatment O
of O
cells O
with O
pertussis O
toxin O
. O
In O
contrast O
to O
adrenaline O
and O
somatostatin O
galanin O
, O
another O
inhibitor O
of O
insulin O
secretion O
, O
reduced O
Ca2+ O
currents O
by O
about O
40% O
in O
a O
pertussis O
toxin-insensitive O
manner O
. O
Immunoblot O
experiments O
performed O
with O
antibodies O
generated O
against O
synthetic O
peptides O
revealed O
that O
membranes O
of O
RINm5F O
cells O
possess O
four O
pertussis O
toxin-sensitive O
G-proteins O
including O
Gi1 O
, O
Gi2 O
, O
Go2 O
, O
and O
another O
Go O
subtype O
, O
most O
likely O
representing O
Go1 O
. O

octreotide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
currently O
commercially O
available O
somatostatin O
analogs O
(SA) O
octreotide O
and O
lanreotide O
. O
Such O
resistance O
is O
related O
to O
an O
overall O
reduction O
of O
somatostatin O
receptor O
(SSTR) O
density O
or O
to O
a O
differentiated O
expression O
of O
SSTR O
subtypes O
. O
There O
are O
five O
known O
SSTR O
subtypes O
. O
SSTR2 B
and O
SSTR5 O
are O
usually O
expressed O
in O
GH-secreting O
pituitary O
tumors O
, O
and O
both O
octreotide O
and O
lanreotide O
bind O
preferentially O
to O
SSTR2 O
and O
, O
to O
a O
lesser O
extent O
, O
to O
SSTR5 O
. O
SA O
inhibitory O
effects O
on O
GH O
secretion O
and O
tumor O
cell O
proliferation O
can O
occur O
together O
or O
be O
dissociated O
events O
, O
depending O
on O
the O
tumor O
expression O
of O
SSTR O
subtypes O
involved O
in O
each O
mechanism O
. O
The O
development O
of O
specific O
somatostatin O
subtypes O
analogs O
, O

octreotide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
currently O
commercially O
available O
somatostatin O
analogs O
(SA) O
octreotide O
and O
lanreotide O
. O
Such O
resistance O
is O
related O
to O
an O
overall O
reduction O
of O
somatostatin O
receptor O
(SSTR) O
density O
or O
to O
a O
differentiated O
expression O
of O
SSTR O
subtypes O
. O
There O
are O
five O
known O
SSTR O
subtypes O
. O
SSTR2 O
and O
SSTR5 B
are O
usually O
expressed O
in O
GH-secreting O
pituitary O
tumors O
, O
and O
both O
octreotide O
and O
lanreotide O
bind O
preferentially O
to O
SSTR2 O
and O
, O
to O
a O
lesser O
extent O
, O
to O
SSTR5 O
. O
SA O
inhibitory O
effects O
on O
GH O
secretion O
and O
tumor O
cell O
proliferation O
can O
occur O
together O
or O
be O
dissociated O
events O
, O
depending O
on O
the O
tumor O
expression O
of O
SSTR O
subtypes O
involved O
in O
each O
mechanism O
. O
The O
development O
of O
specific O
somatostatin O
subtypes O
analogs O
, O

lanreotide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
commercially O
available O
somatostatin O
analogs O
(SA) O
octreotide O
and O
lanreotide O
. O
Such O
resistance O
is O
related O
to O
an O
overall O
reduction O
of O
somatostatin O
receptor O
(SSTR) O
density O
or O
to O
a O
differentiated O
expression O
of O
SSTR O
subtypes O
. O
There O
are O
five O
known O
SSTR O
subtypes O
. O
SSTR2 B
and O
SSTR5 O
are O
usually O
expressed O
in O
GH-secreting O
pituitary O
tumors O
, O
and O
both O
octreotide O
and O
lanreotide O
bind O
preferentially O
to O
SSTR2 O
and O
, O
to O
a O
lesser O
extent O
, O
to O
SSTR5 O
. O
SA O
inhibitory O
effects O
on O
GH O
secretion O
and O
tumor O
cell O
proliferation O
can O
occur O
together O
or O
be O
dissociated O
events O
, O
depending O
on O
the O
tumor O
expression O
of O
SSTR O
subtypes O
involved O
in O
each O
mechanism O
. O
The O
development O
of O
specific O
somatostatin O
subtypes O
analogs O
, O
mainly O
for O

lanreotide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
commercially O
available O
somatostatin O
analogs O
(SA) O
octreotide O
and O
lanreotide O
. O
Such O
resistance O
is O
related O
to O
an O
overall O
reduction O
of O
somatostatin O
receptor O
(SSTR) O
density O
or O
to O
a O
differentiated O
expression O
of O
SSTR O
subtypes O
. O
There O
are O
five O
known O
SSTR O
subtypes O
. O
SSTR2 O
and O
SSTR5 B
are O
usually O
expressed O
in O
GH-secreting O
pituitary O
tumors O
, O
and O
both O
octreotide O
and O
lanreotide O
bind O
preferentially O
to O
SSTR2 O
and O
, O
to O
a O
lesser O
extent O
, O
to O
SSTR5 O
. O
SA O
inhibitory O
effects O
on O
GH O
secretion O
and O
tumor O
cell O
proliferation O
can O
occur O
together O
or O
be O
dissociated O
events O
, O
depending O
on O
the O
tumor O
expression O
of O
SSTR O
subtypes O
involved O
in O
each O
mechanism O
. O
The O
development O
of O
specific O
somatostatin O
subtypes O
analogs O
, O
mainly O
for O

catecholamines O
acts O
as O
NOT O
for O
what O
entity O
? O
adipocyte O
size O
was O
unchanged O
, O
suggesting O
that O
ANXA1 O
is O
required O
for O
the O
maintenance O
of O
adipocyte O
and/or O
preadipocyte O
cell O
number O
. O
Epididymal O
tissue O
from O
wild-type O
mice O
responded O
in O
vitro O
to O
noradrenaline O
and O
isoprenaline O
with O
increased O
glycerol O
release O
, O
reduced O
IL-6 O
release O
, O
and O
increased O
cAMP O
accumulation O
. O
Qualitatively O
similar O
but O
significantly O
attenuated O
responses O
to O
the O
catecholamines O
were O
observed O
in O
tissue O
from O
ANXA1-null O
mice O
, O
an O
effect O
that O
was O
not O
associated O
with O
changes O
in O
beta-adrenoceptor B
mRNA O
expression O
. O
Lipopolysaccharide O
(LPS) O
also O
stimulated O
lipolysis O
in O
vitro O
, O
but O
its O
effects O
were O
muted O
by O
ANXA1 O
gene O
deletion O
. O
By O
contrast O
, O
LPS O
failed O
to O
influence O
IL-6 O
release O
from O
wild-type O
tissue O
but O
stimulated O
the O

noradrenaline O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
analysis O
in O
wild-type O
tissue O
and O
localized O
predominantly O
to O
the O
stromal-vascular O
compartment O
. O
Epididymal O
fat O
pad O
mass O
was O
reduced O
by O
ANXA1 O
gene O
deletion O
, O
but O
adipocyte O
size O
was O
unchanged O
, O
suggesting O
that O
ANXA1 O
is O
required O
for O
the O
maintenance O
of O
adipocyte O
and/or O
preadipocyte O
cell O
number O
. O
Epididymal O
tissue O
from O
wild-type O
mice O
responded O
in O
vitro O
to O
noradrenaline O
and O
isoprenaline O
with O
increased O
glycerol O
release O
, O
reduced O
IL-6 B
release O
, O
and O
increased O
cAMP O
accumulation O
. O
Qualitatively O
similar O
but O
significantly O
attenuated O
responses O
to O
the O
catecholamines O
were O
observed O
in O
tissue O
from O
ANXA1-null O
mice O
, O
an O
effect O
that O
was O
not O
associated O
with O
changes O
in O
beta-adrenoceptor O
mRNA O
expression O
. O
Lipopolysaccharide O
(LPS) O
also O
stimulated O
lipolysis O
in O
vitro O
, O
but O

isoprenaline O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
wild-type O
tissue O
and O
localized O
predominantly O
to O
the O
stromal-vascular O
compartment O
. O
Epididymal O
fat O
pad O
mass O
was O
reduced O
by O
ANXA1 O
gene O
deletion O
, O
but O
adipocyte O
size O
was O
unchanged O
, O
suggesting O
that O
ANXA1 O
is O
required O
for O
the O
maintenance O
of O
adipocyte O
and/or O
preadipocyte O
cell O
number O
. O
Epididymal O
tissue O
from O
wild-type O
mice O
responded O
in O
vitro O
to O
noradrenaline O
and O
isoprenaline O
with O
increased O
glycerol O
release O
, O
reduced O
IL-6 B
release O
, O
and O
increased O
cAMP O
accumulation O
. O
Qualitatively O
similar O
but O
significantly O
attenuated O
responses O
to O
the O
catecholamines O
were O
observed O
in O
tissue O
from O
ANXA1-null O
mice O
, O
an O
effect O
that O
was O
not O
associated O
with O
changes O
in O
beta-adrenoceptor O
mRNA O
expression O
. O
Lipopolysaccharide O
(LPS) O
also O
stimulated O
lipolysis O
in O
vitro O
, O
but O
its O
effects O

lysine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
also O
a O
prolactinoma O
. O
Sequence O
analysis O
of O
the O
MEN1 B
gene O
from O
leukocyte O
genomic O
DNA O
revealed O
heterozygous O
mutations O
in O
both O
probands O
. O
The O
Turkish O
patient O
and O
her O
affected O
relatives O
all O
had O
a O
heterozygous O
A O
to O
G O
transition O
at O
codon O
557 O
(AAG-->GAG) O
of O
exon O
10 O
of O
MEN1 O
that O
results O
in O
a O
replacement O
of O
lysine O
by O
glutamic O
acid O
. O
The O
Chinese O
index O
patient O
and O
one O
of O
her O
siblings O
had O
a O
heterozygous O
mutation O
at O
codon O
418 O
of O
exon O
9 O
(GAC-->TAT) O
that O
results O
in O
a O
substitution O
of O
aspartic O
acid O
by O
tyrosine O
. O
In O
conclusion O
, O
we O
have O
identified O
2 O
novel O
missense O
mutations O
in O
the O
MEN1 O
gene O
. O

glutamic O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
prolactinoma O
. O
Sequence O
analysis O
of O
the O
MEN1 B
gene O
from O
leukocyte O
genomic O
DNA O
revealed O
heterozygous O
mutations O
in O
both O
probands O
. O
The O
Turkish O
patient O
and O
her O
affected O
relatives O
all O
had O
a O
heterozygous O
A O
to O
G O
transition O
at O
codon O
557 O
(AAG-->GAG) O
of O
exon O
10 O
of O
MEN1 O
that O
results O
in O
a O
replacement O
of O
lysine O
by O
glutamic O
acid O
The O
Chinese O
index O
patient O
and O
one O
of O
her O
siblings O
had O
a O
heterozygous O
mutation O
at O
codon O
418 O
of O
exon O
9 O
(GAC-->TAT) O
that O
results O
in O
a O
substitution O
of O
aspartic O
acid O
by O
tyrosine O
. O
In O
conclusion O
, O
we O
have O
identified O
2 O
novel O
missense O
mutations O
in O
the O
MEN1 O
gene O
. O

bromfenac O
sodium O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase B
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O
was O
induced O
by O

bromfenac O
sodium O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase O
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O
was O
induced O
by O

Ketorolac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
complete O
inhibition O
of O
FITC-dextran O
leakage O
and O
PGE(2) O
production O
in O
the O
anterior O
chamber O
of O
treated O
eyes O
. O
There O
was O
also O
a O
79% O
inhibition O
(p O
< O
0.001) O
of O
FITC-dextran O
leakage O
in O
the O
contralateral O
eyes O
of O
bromfenac-treated O
rabbits O
, O
and O
a O
22.5% O
inhibition O
(not O
statistically O
significant) O
in O
the O
contralateral O
eyes O
of O
ketorolac-treated O
rabbits O
. O
CONCLUSIONS O
: O
Ketorolac O
is O
relatively O
COX-1 B
selective O
while O
bromfenac O
is O
potently O
selective O
for O
COX-2 O
over O
COX-1 O
. O
In O
the O
animal O
model O
, O
both O
ketorolac O
0.4% O
and O
bromfenac O
0.09% O
demonstrated O
maximal O
anti-inflammatory O
activity O
in O
treated O
eyes O
. O
Only O
bromfenac O
0.09% O
had O
a O
significant O
effect O
on O
the O
contralateral O
eye O
, O
suggesting O
possible O
systemic O
absorption O
of O
this O
drug O
. O

bromfenac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
PGE(2) O
production O
in O
the O
anterior O
chamber O
of O
treated O
eyes O
. O
There O
was O
also O
a O
79% O
inhibition O
(p O
< O
0.001) O
of O
FITC-dextran O
leakage O
in O
the O
contralateral O
eyes O
of O
bromfenac-treated O
rabbits O
, O
and O
a O
22.5% O
inhibition O
(not O
statistically O
significant) O
in O
the O
contralateral O
eyes O
of O
ketorolac-treated O
rabbits O
. O
CONCLUSIONS O
: O
Ketorolac O
is O
relatively O
COX-1 O
selective O
while O
bromfenac O
is O
potently O
selective O
for O
COX-2 B
over O
COX-1 O
. O
In O
the O
animal O
model O
, O
both O
ketorolac O
0.4% O
and O
bromfenac O
0.09% O
demonstrated O
maximal O
anti-inflammatory O
activity O
in O
treated O
eyes O
. O
Only O
bromfenac O
0.09% O
had O
a O
significant O
effect O
on O
the O
contralateral O
eye O
, O
suggesting O
possible O
systemic O
absorption O
of O
this O
drug O
. O

bromfenac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
PGE(2) O
production O
in O
the O
anterior O
chamber O
of O
treated O
eyes O
. O
There O
was O
also O
a O
79% O
inhibition O
(p O
< O
0.001) O
of O
FITC-dextran O
leakage O
in O
the O
contralateral O
eyes O
of O
bromfenac-treated O
rabbits O
, O
and O
a O
22.5% O
inhibition O
(not O
statistically O
significant) O
in O
the O
contralateral O
eyes O
of O
ketorolac-treated O
rabbits O
. O
CONCLUSIONS O
: O
Ketorolac O
is O
relatively O
COX-1 B
selective O
while O
bromfenac O
is O
potently O
selective O
for O
COX-2 O
over O
COX-1 O
. O
In O
the O
animal O
model O
, O
both O
ketorolac O
0.4% O
and O
bromfenac O
0.09% O
demonstrated O
maximal O
anti-inflammatory O
activity O
in O
treated O
eyes O
. O
Only O
bromfenac O
0.09% O
had O
a O
significant O
effect O
on O
the O
contralateral O
eye O
, O
suggesting O
possible O
systemic O
absorption O
of O
this O
drug O
. O

bromfenac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase B
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
( O
bromfenac O
 O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O
was O
induced O
by O

bromfenac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase O
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
( O
bromfenac O
 O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O
was O
induced O
by O

Ketorolac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
eyes O
were O
treated O
with O
vehicle O
. O
All O
animals O
were O
treated O
twice O
: O
2 O
hours O
and O
1 O
hour O
before O
LPS O
. O
MAIN O
OUTCOME O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O
COX-1 B
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 O
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O

Ketorolac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
eyes O
were O
treated O
with O
vehicle O
. O
All O
animals O
were O
treated O
twice O
: O
2 O
hours O
and O
1 O
hour O
before O
LPS O
. O
MAIN O
OUTCOME O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O
COX-1 O
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 B
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O

bromfenac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O
COX-1 O
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 B
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O
FITC-dextran O
leakage O
and O
PGE(2) O
production O
in O
the O
anterior O
chamber O
of O
treated O
eyes O
. O
There O
was O
also O
a O
79% O
inhibition O
(p O

bromfenac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O
COX-1 B
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 O
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O
FITC-dextran O
leakage O
and O
PGE(2) O
production O
in O
the O
anterior O
chamber O
of O
treated O
eyes O
. O
There O
was O
also O
a O
79% O
inhibition O
(p O

ketorolac O
tromethamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase B
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O

ketorolac O
tromethamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase O
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O

ketorolac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase B
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
( O
ketorolac O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O

ketorolac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase O
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
( O
ketorolac O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O

Ketorolac O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
eyes O
were O
treated O
with O
vehicle O
. O
All O
animals O
were O
treated O
twice O
: O
2 O
hours O
and O
1 O
hour O
before O
LPS O
. O
MAIN O
OUTCOME O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O
COX-1 O
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 B
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O

Ketorolac O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
eyes O
were O
treated O
with O
vehicle O
. O
All O
animals O
were O
treated O
twice O
: O
2 O
hours O
and O
1 O
hour O
before O
LPS O
. O
MAIN O
OUTCOME O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O
COX-1 B
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 O
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O

bromfenac O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O
COX-1 B
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 O
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O
FITC-dextran O
leakage O
and O
PGE(2) O
production O
in O
the O
anterior O
chamber O
of O
treated O
eyes O
. O
There O
was O
also O
a O
79% O
inhibition O
(p O

bromfenac O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O
COX-1 O
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 B
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O
FITC-dextran O
leakage O
and O
PGE(2) O
production O
in O
the O
anterior O
chamber O
of O
treated O
eyes O
. O
There O
was O
also O
a O
79% O
inhibition O
(p O

bromfenac O
sodium O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase B
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodiu O
.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O

ketorolac O
tromethamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase B
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamin O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O

prostaglandin O
E(2) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase O
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase B
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O
was O
induced O
by O
intravenous O
injection O
of O
10 O
microg/kg O
lipopolysaccharide O
(LPS) O
. O
In O
study O
animals O
, O
one O
eye O
was O
treated O

PGE(2) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
cyclooxygenase O
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase B
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
( O
PGE(2) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O
was O
induced O
by O
intravenous O
injection O
of O
10 O
microg/kg O
lipopolysaccharide O
(LPS) O
. O
In O
study O
animals O
, O
one O
eye O
was O
treated O
with O

methyl O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Methyl O
transfer O
in O
glycine O
N-methyltransferase O
. O
A O
theoretical O
study.Density O
functional O
theory O
calculations O
using O
the O
hybrid O
functional O
B3LYP O
have O
been O
performed O
to O
study O
the O
methyl O
transfer O
step O
in O
glycine B
N-methyltransferase I
(GNMT) O
. O
This O
enzyme O
catalyzes O
the O
S-adenosyl-L-methionine O
(SAM)-dependent O
methylation O
of O
glycine O
to O
form O
sarcosine O
. O
The O
starting O
point O
for O
the O
calculations O
is O
the O
recent O
X-ray O
crystal O
structure O
of O
GNMT O
complexed O
with O
SAM O
and O
acetate O
. O
Several O
quantum O
chemical O
models O
with O
different O
sizes O
, O
employing O
up O
to O
98 O
atoms O
, O

methyl O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Methyl O
transfer O
in O
glycine O
N-methyltransferase O
. O
A O
theoretical O
study.Density O
functional O
theory O
calculations O
using O
the O
hybrid O
functional O
B3LYP O
have O
been O
performed O
to O
study O
the O
methyl O
transfer O
step O
in O
glycine O
N-methyltransferase O
(GNMT) O
. O
This O
enzyme O
catalyzes O
the O
S-adenosyl-L-methionine O
(SAM)-dependent O
methylation O
of O
glycine O
to O
form O
sarcosine O
. O
The O
starting O
point O
for O
the O
calculations O
is O
the O
recent O
X-ray O
crystal O
structure O
of O
GNMT B
complexed O
with O
SAM O
and O
acetate O
. O
Several O
quantum O
chemical O
models O
with O
different O
sizes O
, O
employing O
up O
to O
98 O
atoms O
, O

SAM O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
functional O
theory O
calculations O
using O
the O
hybrid O
functional O
B3LYP O
have O
been O
performed O
to O
study O
the O
methyl O
transfer O
step O
in O
glycine O
N-methyltransferase O
(GNMT) O
. O
This O
enzyme O
catalyzes O
the O
S-adenosyl-L-methionine O
(SAM)-dependent O
methylation O
of O
glycine O
to O
form O
sarcosine O
. O
The O
starting O
point O
for O
the O
calculations O
is O
the O
recent O
X-ray O
crystal O
structure O
of O
GNMT B
complexed O
with O
SAM O
and O
acetate O
. O
Several O
quantum O
chemical O
models O
with O
different O
sizes O
, O
employing O
up O
to O
98 O
atoms O
, O
were O
used O
. O
The O
calculations O
demonstrate O
that O
the O
suggested O
mechanism O
, O
where O
the O
methyl O
group O
is O
transferred O
in O
a O
single O
S(N)2 O
step O
, O
is O
thermodynamically O
plausible O
. O
By O
adding O
or O
eliminating O
various O
groups O
at O
the O
active O
site O
, O
it O
was O

mesalamine O
acts O
as O
NOT O
for O
what O
entity O
? O
of O
water) O
CRDs O
were O
produced O
in O
conscious O
rats O
, O
and O
colorectal O
sensitivity O
and O
pain O
were O
assessed O
by O
measuring O
the O
abdominal O
withdrawal O
response O
and O
spinal O
c-Fos O
expression O
. O
In O
healthy O
rats O
, O
ATB-429 O
dose O
dependently O
(25 O
, O
50 O
, O
or O
100 O
mg/kg) O
attenuated O
CRD-induced O
hypersensitivity O
and O
significantly O
inhibited O
CRD-induced O
overexpression O
of O
spinal O
c-FOS B
mRNA O
, O
whereas O
mesalamine O
had O
no O
effect O
. O
ATB-429-induced O
antinociception O
was O
reversed O
by O
glibenclamide O
, O
a O
ATP-sensitive O
K(+) O
(K(ATP)) O
channel O
inhibitor O
. O
The O
antinociceptive O
effect O
of O
ATB-429 O
was O
maintained O
in O
a O
rodent O
model O
of O
postinflammatory O
hypersensitivity O
(4 O
weeks O
after O
colitis O
induction) O
. O
At O
a O
dose O
of O
100 O
mg/kg O
, O
ATB-429 O
reversed O
the O
allodynic O
response O
caused O
by O
CRD O
in O

mesalamine O
acts O
as O
NOT O
for O
what O
entity O
? O
was O
maintained O
in O
a O
rodent O
model O
of O
postinflammatory O
hypersensitivity O
(4 O
weeks O
after O
colitis O
induction) O
. O
At O
a O
dose O
of O
100 O
mg/kg O
, O
ATB-429 O
reversed O
the O
allodynic O
response O
caused O
by O
CRD O
in O
postcolitic O
rats O
. O
Colonic O
cyclooxygenase-2 B
and O
interkeukin-1beta O
mRNA O
and O
spinal O
c-FOS O
mRNA O
expression O
were O
significantly O
down-regulated O
by O
ATB-429 O
, O
but O
not O
by O
mesalamine O
ATB-429 O
, O
but O
not O
mesalamine O
, O
increased O
blood O
concentrations O
of O
H(2)S O
in O
both O
healthy O
and O
postcolitic O
rats O
. O
Taken O
together O
, O
these O
data O
suggest O
that O
ATB-429 O
inhibits O
hypersensitivity O
induced O
by O
CRD O
in O
both O
healthy O
and O
postcolitic O
, O
allodynic O
rats O
by O
a O
K(ATP) O
channel-mediated O
mechanism O
. O
This O
study O
provides O
evidence O
that O
H(2)S-releasing O
drugs O
might O
have O
beneficial O

mesalamine O
acts O
as O
NOT O
for O
what O
entity O
? O
was O
maintained O
in O
a O
rodent O
model O
of O
postinflammatory O
hypersensitivity O
(4 O
weeks O
after O
colitis O
induction) O
. O
At O
a O
dose O
of O
100 O
mg/kg O
, O
ATB-429 O
reversed O
the O
allodynic O
response O
caused O
by O
CRD O
in O
postcolitic O
rats O
. O
Colonic O
cyclooxygenase-2 O
and O
interkeukin-1beta B
mRNA O
and O
spinal O
c-FOS O
mRNA O
expression O
were O
significantly O
down-regulated O
by O
ATB-429 O
, O
but O
not O
by O
mesalamine O
ATB-429 O
, O
but O
not O
mesalamine O
, O
increased O
blood O
concentrations O
of O
H(2)S O
in O
both O
healthy O
and O
postcolitic O
rats O
. O
Taken O
together O
, O
these O
data O
suggest O
that O
ATB-429 O
inhibits O
hypersensitivity O
induced O
by O
CRD O
in O
both O
healthy O
and O
postcolitic O
, O
allodynic O
rats O
by O
a O
K(ATP) O
channel-mediated O
mechanism O
. O
This O
study O
provides O
evidence O
that O
H(2)S-releasing O
drugs O
might O
have O
beneficial O

mesalamine O
acts O
as O
NOT O
for O
what O
entity O
? O
was O
maintained O
in O
a O
rodent O
model O
of O
postinflammatory O
hypersensitivity O
(4 O
weeks O
after O
colitis O
induction) O
. O
At O
a O
dose O
of O
100 O
mg/kg O
, O
ATB-429 O
reversed O
the O
allodynic O
response O
caused O
by O
CRD O
in O
postcolitic O
rats O
. O
Colonic O
cyclooxygenase-2 O
and O
interkeukin-1beta O
mRNA O
and O
spinal O
c-FOS B
mRNA O
expression O
were O
significantly O
down-regulated O
by O
ATB-429 O
, O
but O
not O
by O
mesalamine O
ATB-429 O
, O
but O
not O
mesalamine O
, O
increased O
blood O
concentrations O
of O
H(2)S O
in O
both O
healthy O
and O
postcolitic O
rats O
. O
Taken O
together O
, O
these O
data O
suggest O
that O
ATB-429 O
inhibits O
hypersensitivity O
induced O
by O
CRD O
in O
both O
healthy O
and O
postcolitic O
, O
allodynic O
rats O
by O
a O
K(ATP) O
channel-mediated O
mechanism O
. O
This O
study O
provides O
evidence O
that O
H(2)S-releasing O
drugs O
might O
have O
beneficial O

ATB-429 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
allodynic O
response O
caused O
by O
CRD O
in O
postcolitic O
rats O
. O
Colonic O
cyclooxygenase-2 O
and O
interkeukin-1beta O
mRNA O
and O
spinal O
c-FOS O
mRNA O
expression O
were O
significantly O
down-regulated O
by O
ATB-429 O
, O
but O
not O
by O
mesalamine O
. O
ATB-429 O
, O
but O
not O
mesalamine O
, O
increased O
blood O
concentrations O
of O
H(2)S O
in O
both O
healthy O
and O
postcolitic O
rats O
. O
Taken O
together O
, O
these O
data O
suggest O
that O
ATB-429 O
inhibits O
hypersensitivity O
induced O
by O
CRD O
in O
both O
healthy O
and O
postcolitic O
, O
allodynic O
rats O
by O
a O
K(ATP) O
channel-mediated O
mechanism O
. O
This O
study O
provides O
evidence O
that O
H(2)S-releasing O
drugs O
might O
have O
beneficial O
effects O
in O
the O
treatment O
of O
painful O
intestinal O
disorders O
. O

ATB-429 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
to O
colorectal O
distension O
(CRD) O
, O
a O
model O
that O
mimics O
some O
features O
of O
IBS O
, O
in O
healthy O
and O
postcolitic O
rats O
. O
Four O
graded O
(0.4-1.6 O
ml O
of O
water) O
CRDs O
were O
produced O
in O
conscious O
rats O
, O
and O
colorectal O
sensitivity O
and O
pain O
were O
assessed O
by O
measuring O
the O
abdominal O
withdrawal O
response O
and O
spinal O
c-Fos O
expression O
. O
In O
healthy O
rats O
, O
ATB-429 O
dose O
dependently O
(25 O
, O
50 O
, O
or O
100 O
mg/kg) O
attenuated O
CRD-induced O
hypersensitivity O
and O
significantly O
inhibited O
CRD-induced O
overexpression O
of O
spinal O
c-FOS B
mRNA O
, O
whereas O
mesalamine O
had O
no O
effect O
. O
ATB-429-induced O
antinociception O
was O
reversed O
by O
glibenclamide O
, O
a O
ATP-sensitive O
K(+) O
(K(ATP)) O
channel O
inhibitor O
. O
The O
antinociceptive O
effect O
of O
ATB-429 O
was O
maintained O
in O
a O
rodent O
model O
of O
postinflammatory O

ATB-429 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
antinociceptive O
effect O
of O
ATB-429 O
was O
maintained O
in O
a O
rodent O
model O
of O
postinflammatory O
hypersensitivity O
(4 O
weeks O
after O
colitis O
induction) O
. O
At O
a O
dose O
of O
100 O
mg/kg O
, O
ATB-429 O
reversed O
the O
allodynic O
response O
caused O
by O
CRD O
in O
postcolitic O
rats O
. O
Colonic O
cyclooxygenase-2 B
and O
interkeukin-1beta O
mRNA O
and O
spinal O
c-FOS O
mRNA O
expression O
were O
significantly O
down-regulated O
by O
ATB-429 O
but O
not O
by O
mesalamine O
. O
ATB-429 O
, O
but O
not O
mesalamine O
, O
increased O
blood O
concentrations O
of O
H(2)S O
in O
both O
healthy O
and O
postcolitic O
rats O
. O
Taken O
together O
, O
these O
data O
suggest O
that O
ATB-429 O
inhibits O
hypersensitivity O
induced O
by O
CRD O
in O
both O
healthy O
and O
postcolitic O
, O
allodynic O
rats O
by O
a O
K(ATP) O
channel-mediated O
mechanism O
. O
This O
study O
provides O
evidence O
that O
H(2)S-releasing O

ATB-429 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
antinociceptive O
effect O
of O
ATB-429 O
was O
maintained O
in O
a O
rodent O
model O
of O
postinflammatory O
hypersensitivity O
(4 O
weeks O
after O
colitis O
induction) O
. O
At O
a O
dose O
of O
100 O
mg/kg O
, O
ATB-429 O
reversed O
the O
allodynic O
response O
caused O
by O
CRD O
in O
postcolitic O
rats O
. O
Colonic O
cyclooxygenase-2 O
and O
interkeukin-1beta B
mRNA O
and O
spinal O
c-FOS O
mRNA O
expression O
were O
significantly O
down-regulated O
by O
ATB-429 O
but O
not O
by O
mesalamine O
. O
ATB-429 O
, O
but O
not O
mesalamine O
, O
increased O
blood O
concentrations O
of O
H(2)S O
in O
both O
healthy O
and O
postcolitic O
rats O
. O
Taken O
together O
, O
these O
data O
suggest O
that O
ATB-429 O
inhibits O
hypersensitivity O
induced O
by O
CRD O
in O
both O
healthy O
and O
postcolitic O
, O
allodynic O
rats O
by O
a O
K(ATP) O
channel-mediated O
mechanism O
. O
This O
study O
provides O
evidence O
that O
H(2)S-releasing O

ATB-429 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
antinociceptive O
effect O
of O
ATB-429 O
was O
maintained O
in O
a O
rodent O
model O
of O
postinflammatory O
hypersensitivity O
(4 O
weeks O
after O
colitis O
induction) O
. O
At O
a O
dose O
of O
100 O
mg/kg O
, O
ATB-429 O
reversed O
the O
allodynic O
response O
caused O
by O
CRD O
in O
postcolitic O
rats O
. O
Colonic O
cyclooxygenase-2 O
and O
interkeukin-1beta O
mRNA O
and O
spinal O
c-FOS B
mRNA O
expression O
were O
significantly O
down-regulated O
by O
ATB-429 O
but O
not O
by O
mesalamine O
. O
ATB-429 O
, O
but O
not O
mesalamine O
, O
increased O
blood O
concentrations O
of O
H(2)S O
in O
both O
healthy O
and O
postcolitic O
rats O
. O
Taken O
together O
, O
these O
data O
suggest O
that O
ATB-429 O
inhibits O
hypersensitivity O
induced O
by O
CRD O
in O
both O
healthy O
and O
postcolitic O
, O
allodynic O
rats O
by O
a O
K(ATP) O
channel-mediated O
mechanism O
. O
This O
study O
provides O
evidence O
that O
H(2)S-releasing O

glibenclamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
colorectal O
sensitivity O
and O
pain O
were O
assessed O
by O
measuring O
the O
abdominal O
withdrawal O
response O
and O
spinal O
c-Fos O
expression O
. O
In O
healthy O
rats O
, O
ATB-429 O
dose O
dependently O
(25 O
, O
50 O
, O
or O
100 O
mg/kg) O
attenuated O
CRD-induced O
hypersensitivity O
and O
significantly O
inhibited O
CRD-induced O
overexpression O
of O
spinal O
c-FOS O
mRNA O
, O
whereas O
mesalamine O
had O
no O
effect O
. O
ATB-429-induced O
antinociception O
was O
reversed O
by O
glibenclamide O
a O
ATP-sensitive B
K(+) I
(K(ATP)) I
channel I
inhibitor O
. O
The O
antinociceptive O
effect O
of O
ATB-429 O
was O
maintained O
in O
a O
rodent O
model O
of O
postinflammatory O
hypersensitivity O
(4 O
weeks O
after O
colitis O
induction) O
. O
At O
a O
dose O
of O
100 O
mg/kg O
, O
ATB-429 O
reversed O
the O
allodynic O
response O
caused O
by O
CRD O
in O
postcolitic O
rats O
. O
Colonic O
cyclooxygenase-2 O
and O
interkeukin-1beta O
mRNA O
and O
spinal O

Tyr O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
MT-2 O
cells O
. O
The O
positive O
clone O
M15 O
could O
bind O
specifically O
to O
MT-2 O
cell O
and O
PHA-activated O
peripheral O
blood O
monouclear O
cells O
. O
Amino O
acid O
sequence O
analysis O
identified O
6 O
sequences O
, O
all O
of O
which O
contained O
hydrophilic O
residues O
, O
and O
5 O
of O
these O
6 O
sequences O
included O
Tyr O
, O
Phe O
and O
Leu O
conservative O
residues O
. O
CONCLUSION O
: O
The O
peptide O
sequences O
containing O
Tyr O
Phe O
conservative O
residues O
identified O
in O
this O
study O
can O
bind O
to O
cell O
surface O
IL-2Ralpha O
. O

Phe O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cells O
. O
The O
positive O
clone O
M15 O
could O
bind O
specifically O
to O
MT-2 O
cell O
and O
PHA-activated O
peripheral O
blood O
monouclear O
cells O
. O
Amino O
acid O
sequence O
analysis O
identified O
6 O
sequences O
, O
all O
of O
which O
contained O
hydrophilic O
residues O
, O
and O
5 O
of O
these O
6 O
sequences O
included O
Tyr O
, O
Phe O
and O
Leu O
conservative O
residues O
. O
CONCLUSION O
: O
The O
peptide O
sequences O
containing O
Tyr O
, O
Phe O
conservative O
residues O
identified O
in O
this O
study O
can O
bind O
to O
cell O
surface O
IL-2Ralpha O
. O

cisplatin O
acts O
as O
NOT O
for O
what O
entity O
? O
RNA O
interference-triggered O
reversal O
of O
ABCC2-dependent O
cisplatin O
resistance O
in O
human O
cancer O
cells.The O
adenosine B
triphosphate I
binding I
cassette I
(ABC)-transporter I
ABCC2 O
(MRP2/cMOAT) O
can O
mediate O
resistance O
against O
the O
commonly O
used O
anticancer O
drugs O
cisplatin O
and O
paclitaxel O
. O
To O
overcome O
the O
ABCC2-depending O
drug O
resistance O
, O
two O
specific O
anti-ABCC2 O
small O
interfering O
RNAs O
(siRNAs) O
were O
designed O
for O
transient O
triggering O
of O
the O
gene-silencing O
RNA O
interference O
(RNAi) O
pathway O
in O
the O
cisplatin-resistant O
human O
ovarian O
carcinoma O
cell O
line O
A2780RCIS O
. O
Since O
both O
siRNAs O
showed O
biological O
activity O
, O
for O
stable O
inhibition O
of O
ABCC2 O
a O
corresponding O

cisplatin O
acts O
as O
NOT O
for O
what O
entity O
? O
RNA O
interference-triggered O
reversal O
of O
ABCC2-dependent O
cisplatin O
resistance O
in O
human O
cancer O
cells.The O
adenosine O
triphosphate O
binding O
cassette O
(ABC)-transporter O
ABCC2 B
(MRP2/cMOAT) O
can O
mediate O
resistance O
against O
the O
commonly O
used O
anticancer O
drugs O
cisplatin O
and O
paclitaxel O
. O
To O
overcome O
the O
ABCC2-depending O
drug O
resistance O
, O
two O
specific O
anti-ABCC2 O
small O
interfering O
RNAs O
(siRNAs) O
were O
designed O
for O
transient O
triggering O
of O
the O
gene-silencing O
RNA O
interference O
(RNAi) O
pathway O
in O
the O
cisplatin-resistant O
human O
ovarian O
carcinoma O
cell O
line O
A2780RCIS O
. O
Since O
both O
siRNAs O
showed O
biological O
activity O
, O
for O
stable O
inhibition O
of O
ABCC2 O
a O
corresponding O

cisplatin O
acts O
as O
NOT O
for O
what O
entity O
? O
RNA O
interference-triggered O
reversal O
of O
ABCC2-dependent O
cisplatin O
resistance O
in O
human O
cancer O
cells.The O
adenosine O
triphosphate O
binding O
cassette O
(ABC)-transporter O
ABCC2 O
(MRP2/cMOAT) O
can O
mediate O
resistance O
against O
the O
commonly O
used O
anticancer O
drugs O
cisplatin O
and O
paclitaxel O
. O
To O
overcome O
the O
ABCC2-depending O
drug O
resistance O
, O
two O
specific O
anti-ABCC2 O
small O
interfering O
RNAs O
(siRNAs) O
were O
designed O
for O
transient O
triggering O
of O
the O
gene-silencing O
RNA O
interference O
(RNAi) O
pathway O
in O
the O
cisplatin-resistant O
human O
ovarian O
carcinoma O
cell O
line O
A2780RCIS O
. O
Since O
both O
siRNAs O
showed O
biological O
activity O
, O
for O
stable O
inhibition O
of O
ABCC2 O
a O
corresponding O

cisplatin O
acts O
as O
NOT O
for O
what O
entity O
? O
RNA O
interference-triggered O
reversal O
of O
ABCC2-dependent O
cisplatin O
resistance O
in O
human O
cancer O
cells.The O
adenosine O
triphosphate O
binding O
cassette O
(ABC)-transporter O
ABCC2 O
(MRP2/cMOAT) O
can O
mediate O
resistance O
against O
the O
commonly O
used O
anticancer O
drugs O
cisplatin O
and O
paclitaxel O
. O
To O
overcome O
the O
ABCC2-depending O
drug O
resistance O
, O
two O
specific O
anti-ABCC2 O
small O
interfering O
RNAs O
(siRNAs) O
were O
designed O
for O
transient O
triggering O
of O
the O
gene-silencing O
RNA O
interference O
(RNAi) O
pathway O
in O
the O
cisplatin-resistant O
human O
ovarian O
carcinoma O
cell O
line O
A2780RCIS O
. O
Since O
both O
siRNAs O
showed O
biological O
activity O
, O
for O
stable O
inhibition O
of O
ABCC2 O
a O
corresponding O

paclitaxel O
acts O
as O
NOT O
for O
what O
entity O
? O
RNA O
interference-triggered O
reversal O
of O
ABCC2-dependent O
cisplatin O
resistance O
in O
human O
cancer O
cells.The O
adenosine B
triphosphate I
binding I
cassette I
(ABC)-transporter I
ABCC2 O
(MRP2/cMOAT) O
can O
mediate O
resistance O
against O
the O
commonly O
used O
anticancer O
drugs O
cisplatin O
and O
paclitaxel O
To O
overcome O
the O
ABCC2-depending O
drug O
resistance O
, O
two O
specific O
anti-ABCC2 O
small O
interfering O
RNAs O
(siRNAs) O
were O
designed O
for O
transient O
triggering O
of O
the O
gene-silencing O
RNA O
interference O
(RNAi) O
pathway O
in O
the O
cisplatin-resistant O
human O
ovarian O
carcinoma O
cell O
line O
A2780RCIS O
. O
Since O
both O
siRNAs O
showed O
biological O
activity O
, O
for O
stable O
inhibition O
of O
ABCC2 O
a O
corresponding O
short O
hairpin O

paclitaxel O
acts O
as O
NOT O
for O
what O
entity O
? O
RNA O
interference-triggered O
reversal O
of O
ABCC2-dependent O
cisplatin O
resistance O
in O
human O
cancer O
cells.The O
adenosine O
triphosphate O
binding O
cassette O
(ABC)-transporter O
ABCC2 B
(MRP2/cMOAT) O
can O
mediate O
resistance O
against O
the O
commonly O
used O
anticancer O
drugs O
cisplatin O
and O
paclitaxel O
To O
overcome O
the O
ABCC2-depending O
drug O
resistance O
, O
two O
specific O
anti-ABCC2 O
small O
interfering O
RNAs O
(siRNAs) O
were O
designed O
for O
transient O
triggering O
of O
the O
gene-silencing O
RNA O
interference O
(RNAi) O
pathway O
in O
the O
cisplatin-resistant O
human O
ovarian O
carcinoma O
cell O
line O
A2780RCIS O
. O
Since O
both O
siRNAs O
showed O
biological O
activity O
, O
for O
stable O
inhibition O
of O
ABCC2 O
a O
corresponding O
short O
hairpin O

paclitaxel O
acts O
as O
NOT O
for O
what O
entity O
? O
RNA O
interference-triggered O
reversal O
of O
ABCC2-dependent O
cisplatin O
resistance O
in O
human O
cancer O
cells.The O
adenosine O
triphosphate O
binding O
cassette O
(ABC)-transporter O
ABCC2 O
(MRP2/cMOAT) O
can O
mediate O
resistance O
against O
the O
commonly O
used O
anticancer O
drugs O
cisplatin O
and O
paclitaxel O
To O
overcome O
the O
ABCC2-depending O
drug O
resistance O
, O
two O
specific O
anti-ABCC2 O
small O
interfering O
RNAs O
(siRNAs) O
were O
designed O
for O
transient O
triggering O
of O
the O
gene-silencing O
RNA O
interference O
(RNAi) O
pathway O
in O
the O
cisplatin-resistant O
human O
ovarian O
carcinoma O
cell O
line O
A2780RCIS O
. O
Since O
both O
siRNAs O
showed O
biological O
activity O
, O
for O
stable O
inhibition O
of O
ABCC2 O
a O
corresponding O
short O
hairpin O

paclitaxel O
acts O
as O
NOT O
for O
what O
entity O
? O
RNA O
interference-triggered O
reversal O
of O
ABCC2-dependent O
cisplatin O
resistance O
in O
human O
cancer O
cells.The O
adenosine O
triphosphate O
binding O
cassette O
(ABC)-transporter O
ABCC2 O
(MRP2/cMOAT) O
can O
mediate O
resistance O
against O
the O
commonly O
used O
anticancer O
drugs O
cisplatin O
and O
paclitaxel O
To O
overcome O
the O
ABCC2-depending O
drug O
resistance O
, O
two O
specific O
anti-ABCC2 O
small O
interfering O
RNAs O
(siRNAs) O
were O
designed O
for O
transient O
triggering O
of O
the O
gene-silencing O
RNA O
interference O
(RNAi) O
pathway O
in O
the O
cisplatin-resistant O
human O
ovarian O
carcinoma O
cell O
line O
A2780RCIS O
. O
Since O
both O
siRNAs O
showed O
biological O
activity O
, O
for O
stable O
inhibition O
of O
ABCC2 O
a O
corresponding O
short O
hairpin O

cisplatin O
acts O
as O
NOT O
for O
what O
entity O
? O
RNA O
interference-triggered O
reversal O
of O
ABCC2-dependent O
cisplati O
resistance O
in O
human O
cancer O
cells.The O
adenosine O
triphosphate O
binding O
cassette O
(ABC)-transporter O
ABCC2 B
(MRP2/cMOAT) O
can O
mediate O
resistance O
against O
the O
commonly O
used O
anticancer O
drugs O
cisplatin O
and O
paclitaxel O
. O
To O
overcome O
the O
ABCC2-depending O
drug O
resistance O
, O
two O
specific O
anti-ABCC2 O
small O
interfering O
RNAs O
(siRNAs) O
were O
designed O
for O
transient O
triggering O
of O
the O
gene-silencing O
RNA O
interference O
(RNAi) O
pathway O

tryptophan O
acts O
as O
PART-OF O
for O
what O
entity O
? O
It O
did O
not O
bind O
to O
mammalian O
GnRH O
receptors O
expressed O
in O
different O
types O
of O
cell O
nor O
did O
it O
exhibit O
agonist O
or O
antagonist O
properties O
on O
types O
I O
or O
II O
GnRH O
receptors O
expressed O
in O
COS-7 O
cells O
. O
Bovine O
primers O
facilitated O
cloning O
of O
ovine O
GnRH-II B
DNA O
. O
A O
premature O
stop O
codon O
(TGA) O
replaces O
the O
expected O
tryptophan O
codon O
at O
position O
seven O
of O
GnRH-II O
in O
sheep O
DNA O
. O
Thus O
, O
both O
species O
possess O
prepro-GnRH-II O
genes O
encoding O
inactive O
peptides O
, O
as O
previously O
described O
for O
chimpanzee O
GnRH-II O
. O
The O
updated O
bovine O
type O
II O
GnRH O
receptor O
gene O
sequence O
revealed O
inactivation O
by O
frame O
shifts O
, O
premature O
stop O
codons O
, O
and O
nucleotide O
changes O
specifying O
nonconservative O
replacement O
of O
amino O

nucleotide O
acts O
as O
PART-OF O
for O
what O
entity O
? O
stop O
codon O
(TGA) O
replaces O
the O
expected O
tryptophan O
codon O
at O
position O
seven O
of O
GnRH-II O
in O
sheep O
DNA O
. O
Thus O
, O
both O
species O
possess O
prepro-GnRH-II O
genes O
encoding O
inactive O
peptides O
, O
as O
previously O
described O
for O
chimpanzee O
GnRH-II O
. O
The O
updated O
bovine B
type I
II I
GnRH I
receptor I
gene O
sequence O
revealed O
inactivation O
by O
frame O
shifts O
, O
premature O
stop O
codons O
, O
and O
nucleotide O
changes O
specifying O
nonconservative O
replacement O
of O
amino O
acid O
residues O
, O
similar O
to O
inactivation O
of O
sheep O
type O
II O
GnRH O
receptor O
. O
Spliced O
RNA O
transcripts O
from O
the O
disrupted O
receptor O
gene O
were O
not O
detected O
in O
bovine O
pituitary O
. O
In O
contrast O
, O
bovine O
prepro-GnRH-I O
and O
type O
I O
GnRH O
receptor O
genes O
are O
intact O
, O
encoding O
well-conserved O
protein O
sequences O
. O
These O
findings O
, O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
tryptophan O
codon O
at O
position O
seven O
of O
GnRH-II O
in O
sheep O
DNA O
. O
Thus O
, O
both O
species O
possess O
prepro-GnRH-II O
genes O
encoding O
inactive O
peptides O
, O
as O
previously O
described O
for O
chimpanzee O
GnRH-II O
. O
The O
updated O
bovine B
type I
II I
GnRH I
receptor I
gene O
sequence O
revealed O
inactivation O
by O
frame O
shifts O
, O
premature O
stop O
codons O
, O
and O
nucleotide O
changes O
specifying O
nonconservative O
replacement O
of O
amino O
acid O
residues O
, O
similar O
to O
inactivation O
of O
sheep O
type O
II O
GnRH O
receptor O
. O
Spliced O
RNA O
transcripts O
from O
the O
disrupted O
receptor O
gene O
were O
not O
detected O
in O
bovine O
pituitary O
. O
In O
contrast O
, O
bovine O
prepro-GnRH-I O
and O
type O
I O
GnRH O
receptor O
genes O
are O
intact O
, O
encoding O
well-conserved O
protein O
sequences O
. O
These O
findings O
, O
and O
previous O
descriptions O
of O
inactivation O
of O
the O

arginine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Bovine O
and O
ovine O
gonadotropin-releasing O
hormone O
(GnRH)-II O
ligand O
precursors O
and O
type O
II O
GnRH O
receptor O
genes O
are O
functionally O
inactivated.The O
decapeptide O
sequence O
of O
GnRH-II B
is O
conserved O
in O
all O
jawed O
vertebrate O
species O
studied O
to O
date O
. O
New O
data O
for O
cattle O
(Bos O
taurus) O
indicates O
a O
gene O
encoding O
GnRH-II O
decapeptide O
possessing O
arginine O
(codon O
: O
CGG) O
rather O
than O
tryptophan O
(TGG) O
at O
position O
three O
in O
the O
mature O
peptide O
. O
This O
substitution O
is O
unique O
. O
We O
confirmed O
the O
DNA O
sequence O
after O
cloning O
part O
of O
the O
bovine O
prepro-GnRH-II O
gene O
. O
Bovine O
GnRH-II O
peptide O
was O
synthesized O
and O
pharmacologically O
characterized O
. O
It O
did O
not O
bind O
to O
mammalian O
GnRH O
receptors O
expressed O
in O
different O

CGG O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Bovine O
and O
ovine O
gonadotropin-releasing O
hormone O
(GnRH)-II O
ligand O
precursors O
and O
type O
II O
GnRH O
receptor O
genes O
are O
functionally O
inactivated.The O
decapeptide O
sequence O
of O
GnRH-II B
is O
conserved O
in O
all O
jawed O
vertebrate O
species O
studied O
to O
date O
. O
New O
data O
for O
cattle O
(Bos O
taurus) O
indicates O
a O
gene O
encoding O
GnRH-II O
decapeptide O
possessing O
arginine O
(codon O
: O
CGG O
rather O
than O
tryptophan O
(TGG) O
at O
position O
three O
in O
the O
mature O
peptide O
. O
This O
substitution O
is O
unique O
. O
We O
confirmed O
the O
DNA O
sequence O
after O
cloning O
part O
of O
the O
bovine O
prepro-GnRH-II O
gene O
. O
Bovine O
GnRH-II O
peptide O
was O
synthesized O
and O
pharmacologically O
characterized O
. O
It O
did O
not O
bind O
to O
mammalian O
GnRH O
receptors O
expressed O
in O
different O
types O
of O

tryptophan O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Bovine O
and O
ovine O
gonadotropin-releasing O
hormone O
(GnRH)-II O
ligand O
precursors O
and O
type O
II O
GnRH O
receptor O
genes O
are O
functionally O
inactivated.The O
decapeptide O
sequence O
of O
GnRH-II B
is O
conserved O
in O
all O
jawed O
vertebrate O
species O
studied O
to O
date O
. O
New O
data O
for O
cattle O
(Bos O
taurus) O
indicates O
a O
gene O
encoding O
GnRH-II O
decapeptide O
possessing O
arginine O
(codon O
: O
CGG) O
rather O
than O
tryptophan O
(TGG) O
at O
position O
three O
in O
the O
mature O
peptide O
. O
This O
substitution O
is O
unique O
. O
We O
confirmed O
the O
DNA O
sequence O
after O
cloning O
part O
of O
the O
bovine O
prepro-GnRH-II O
gene O
. O
Bovine O
GnRH-II O
peptide O
was O
synthesized O
and O
pharmacologically O
characterized O
. O
It O
did O
not O
bind O
to O
mammalian O
GnRH O
receptors O
expressed O
in O
different O
types O
of O
cell O
nor O
did O

TGG O
acts O
as O
PART-OF O
for O
what O
entity O
? O
ovine O
gonadotropin-releasing O
hormone O
(GnRH)-II O
ligand O
precursors O
and O
type O
II O
GnRH O
receptor O
genes O
are O
functionally O
inactivated.The O
decapeptide O
sequence O
of O
GnRH-II B
is O
conserved O
in O
all O
jawed O
vertebrate O
species O
studied O
to O
date O
. O
New O
data O
for O
cattle O
(Bos O
taurus) O
indicates O
a O
gene O
encoding O
GnRH-II O
decapeptide O
possessing O
arginine O
(codon O
: O
CGG) O
rather O
than O
tryptophan O
( O
TGG O
at O
position O
three O
in O
the O
mature O
peptide O
. O
This O
substitution O
is O
unique O
. O
We O
confirmed O
the O
DNA O
sequence O
after O
cloning O
part O
of O
the O
bovine O
prepro-GnRH-II O
gene O
. O
Bovine O
GnRH-II O
peptide O
was O
synthesized O
and O
pharmacologically O
characterized O
. O
It O
did O
not O
bind O
to O
mammalian O
GnRH O
receptors O
expressed O
in O
different O
types O
of O
cell O
nor O
did O
it O

methionine O
acts O
as O
NOT O
for O
what O
entity O
? O
Liver O
choline O
dehydrogenase O
and O
kidney O
betaine-homocysteine B
methyltransferase I
expression O
are O
not O
affected O
by O
methionin O
or O
choline O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT O
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O

methionine O
acts O
as O
NOT O
for O
what O
entity O
? O
Liver O
choline B
dehydrogenase I
and O
kidney O
betaine-homocysteine O
methyltransferase O
expression O
are O
not O
affected O
by O
methionin O
or O
choline O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT O
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O

choline O
acts O
as O
NOT O
for O
what O
entity O
? O
Liver O
choline O
dehydrogenase O
and O
kidney O
betaine-homocysteine B
methyltransferase I
expression O
are O
not O
affected O
by O
methionine O
or O
cholin O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT O
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O
amounts O
, O
but O

choline O
acts O
as O
NOT O
for O
what O
entity O
? O
Liver O
choline B
dehydrogenase I
and O
kidney O
betaine-homocysteine O
methyltransferase O
expression O
are O
not O
affected O
by O
methionine O
or O
cholin O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT O
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O
amounts O
, O
but O

Met O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Liver O
choline O
dehydrogenase O
and O
kidney O
betaine-homocysteine O
methyltransferase O
expression O
are O
not O
affected O
by O
methionine O
or O
choline O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT B
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O
amounts O
, O
but O
it O
is O
not O
known O
whether O
kidney O
BHMT O
expression O
is O
regulated O
by O
dietary O
Met O
or O
choline O
. O
Similarly O
, O
CHDH O
activity O
is O
highest O
in O
the O
liver O
and O
kidney O
, O
but O
the O
regulation O
of O
its O
expression O
by O
diet O
has O

choline O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
choline O
dehydrogenase O
and O
kidney O
betaine-homocysteine O
methyltransferase O
expression O
are O
not O
affected O
by O
methionine O
or O
choline O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT B
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O
amounts O
, O
but O
it O
is O
not O
known O
whether O
kidney O
BHMT O
expression O
is O
regulated O
by O
dietary O
Met O
or O
choline O
. O
Similarly O
, O
CHDH O
activity O
is O
highest O
in O
the O
liver O
and O
kidney O
, O
but O
the O
regulation O
of O
its O
expression O
by O
diet O
has O
not O
been O

choline O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
(0.125 O
, O
0.3 O
, O
or O
0.8%) O
and O
choline O
(0 O
or O
25 O
mmol/kg O
diet) O
. O
Liver O
and O
kidney O
BHMT B
and O
CHDH O
were O
assessed O
using O
enzymatic O
, O
Western O
blot O
, O
and O
real-time O
PCR O
analyses O
. O
Liver O
samples O
were O
also O
fixed O
for O
histological O
analysis O
. O
Liver O
BHMT O
activity O
was O
1.3-fold O
higher O
in O
rats O
fed O
the O
Met O
deficient O
diet O
containing O
choline O
which O
was O
reflected O
in O
corresponding O
increases O
in O
mRNA O
content O
and O
immunodetectable O
protein O
. O
Independent O
of O
dietary O
choline O
, O
supplemental O
Met O
increased O
hepatic O
BHMT O
activity O
approximately O
30% O
. O
Kidney O
BHMT O
and O
liver O
CHDH O
expression O
were O
refractory O
to O
these O
diets O
. O
Some O
degree O
of O
fatty O
liver O
developed O
in O
all O
rats O
fed O
a O
choline-devoid O
diet O
, O
indicating O

choline O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
CHDH O
were O
assessed O
using O
enzymatic O
, O
Western O
blot O
, O
and O
real-time O
PCR O
analyses O
. O
Liver O
samples O
were O
also O
fixed O
for O
histological O
analysis O
. O
Liver O
BHMT B
activity O
was O
1.3-fold O
higher O
in O
rats O
fed O
the O
Met O
deficient O
diet O
containing O
choline O
, O
which O
was O
reflected O
in O
corresponding O
increases O
in O
mRNA O
content O
and O
immunodetectable O
protein O
. O
Independent O
of O
dietary O
choline O
supplemental O
Met O
increased O
hepatic O
BHMT O
activity O
approximately O
30% O
. O
Kidney O
BHMT O
and O
liver O
CHDH O
expression O
were O
refractory O
to O
these O
diets O
. O
Some O
degree O
of O
fatty O
liver O
developed O
in O
all O
rats O
fed O
a O
choline-devoid O
diet O
, O
indicating O
that O
supplemental O
Met O
cannot O
completely O
compensate O
for O
the O
lack O
of O
dietary O
choline O
in O
growing O
rats O
. O

Met O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
assessed O
using O
enzymatic O
, O
Western O
blot O
, O
and O
real-time O
PCR O
analyses O
. O
Liver O
samples O
were O
also O
fixed O
for O
histological O
analysis O
. O
Liver O
BHMT B
activity O
was O
1.3-fold O
higher O
in O
rats O
fed O
the O
Met O
deficient O
diet O
containing O
choline O
, O
which O
was O
reflected O
in O
corresponding O
increases O
in O
mRNA O
content O
and O
immunodetectable O
protein O
. O
Independent O
of O
dietary O
choline O
, O
supplemental O
Met O
increased O
hepatic O
BHMT O
activity O
approximately O
30% O
. O
Kidney O
BHMT O
and O
liver O
CHDH O
expression O
were O
refractory O
to O
these O
diets O
. O
Some O
degree O
of O
fatty O
liver O
developed O
in O
all O
rats O
fed O
a O
choline-devoid O
diet O
, O
indicating O
that O
supplemental O
Met O
cannot O
completely O
compensate O
for O
the O
lack O
of O
dietary O
choline O
in O
growing O
rats O
. O

choline O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(0.125 O
, O
0.3 O
, O
or O
0.8%) O
and O
choline O
(0 O
or O
25 O
mmol/kg O
diet) O
. O
Liver O
and O
kidney O
BHMT B
and O
CHDH O
were O
assessed O
using O
enzymatic O
, O
Western O
blot O
, O
and O
real-time O
PCR O
analyses O
. O
Liver O
samples O
were O
also O
fixed O
for O
histological O
analysis O
. O
Liver O
BHMT O
activity O
was O
1.3-fold O
higher O
in O
rats O
fed O
the O
Met O
deficient O
diet O
containing O
choline O
which O
was O
reflected O
in O
corresponding O
increases O
in O
mRNA O
content O
and O
immunodetectable O
protein O
. O
Independent O
of O
dietary O
choline O
, O
supplemental O
Met O
increased O
hepatic O
BHMT O
activity O
approximately O
30% O
. O
Kidney O
BHMT O
and O
liver O
CHDH O
expression O
were O
refractory O
to O
these O
diets O
. O
Some O
degree O
of O
fatty O
liver O
developed O
in O
all O
rats O
fed O
a O
choline-devoid O
diet O
, O
indicating O

choline O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Liver O
choline O
dehydrogenase O
and O
kidney O
betaine-homocysteine O
methyltransferase O
expression O
are O
not O
affected O
by O
methionine O
or O
choline O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT O
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O
amounts O
, O
but O
it O
is O
not O
known O
whether O
kidney O
BHMT O
expression O
is O
regulated O
by O
dietary O
Met O
or O
choline O
. O
Similarly O
, O

choline O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Liver O
choline O
dehydrogenase O
and O
kidney O
betaine-homocysteine O
methyltransferase O
expression O
are O
not O
affected O
by O
methionine O
or O
choline O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT O
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O
amounts O
, O
but O
it O
is O
not O
known O
whether O
kidney O
BHMT O
expression O
is O
regulated O
by O
dietary O
Met O
or O
choline O
. O
Similarly O
, O

choline O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Liver O
choline O
dehydrogenase O
and O
kidney O
betaine-homocysteine B
methyltransferase I
expression O
are O
not O
affected O
by O
methionine O
or O
choline O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT O
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O
amounts O
, O
but O
it O
is O
not O
known O
whether O
kidney O
BHMT O
expression O
is O
regulated O
by O
dietary O
Met O
or O
choline O
. O
Similarly O
, O

choline O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Liver O
choline O
dehydrogenase O
and O
kidney O
betaine-homocysteine O
methyltransferase O
expression O
are O
not O
affected O
by O
methionine O
or O
choline O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT B
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O
amounts O
, O
but O
it O
is O
not O
known O
whether O
kidney O
BHMT O
expression O
is O
regulated O
by O
dietary O
Met O
or O
choline O
. O
Similarly O
, O

clenbuterol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Relative O
myotoxic O
and O
haemodynamic O
effects O
of O
the O
beta-agonists O
fenoterol O
and O
clenbuterol O
measured O
in O
conscious O
unrestrained O
rats.The O
beta(2)-adrenoceptor O
(beta(2)-AR) O
agonists O
clenbuterol O
and O
fenoterol O
have O
similar O
beneficial O
effects O
in O
animal O
models O
of O
heart O
failure O
. O
However O
, O
large O
doses O
of O
clenbuterol O
can O
induce O
cardiomyocyte O
death O
, O
and O
it O
is O
not O
known O
which O
of O
these O
agents O
has O
the O
most O
favourable O
therapeutic O
profile O
. O
We O
have O
investigated O
the O
cardiotoxicity O
of O
clenbuterol O
and O
fenoterol O
alongside O
that O
of O
isoprenaline O
, O

clenbuterol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Relative O
myotoxic O
and O
haemodynamic O
effects O
of O
the O
beta-agonists O
fenoterol O
and O
clenbuterol O
measured O
in O
conscious O
unrestrained O
rats.The O
beta(2)-adrenoceptor B
(beta(2)-AR) O
agonists O
clenbuterol O
and O
fenoterol O
have O
similar O
beneficial O
effects O
in O
animal O
models O
of O
heart O
failure O
. O
However O
, O
large O
doses O
of O
clenbuterol O
can O
induce O
cardiomyocyte O
death O
, O
and O
it O
is O
not O
known O
which O
of O
these O
agents O
has O
the O
most O
favourable O
therapeutic O
profile O
. O
We O
have O
investigated O
the O
cardiotoxicity O
of O
clenbuterol O
and O
fenoterol O
alongside O
that O
of O
isoprenaline O
, O

fenoterol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Relative O
myotoxic O
and O
haemodynamic O
effects O
of O
the O
beta-agonists O
fenoterol O
and O
clenbuterol O
measured O
in O
conscious O
unrestrained O
rats.The O
beta(2)-adrenoceptor O
(beta(2)-AR) O
agonists O
clenbuterol O
and O
fenoterol O
have O
similar O
beneficial O
effects O
in O
animal O
models O
of O
heart O
failure O
. O
However O
, O
large O
doses O
of O
clenbuterol O
can O
induce O
cardiomyocyte O
death O
, O
and O
it O
is O
not O
known O
which O
of O
these O
agents O
has O
the O
most O
favourable O
therapeutic O
profile O
. O
We O
have O
investigated O
the O
cardiotoxicity O
of O
clenbuterol O
and O
fenoterol O
alongside O
that O
of O
isoprenaline O
, O
and O
compared O

fenoterol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Relative O
myotoxic O
and O
haemodynamic O
effects O
of O
the O
beta-agonists O
fenoterol O
and O
clenbuterol O
measured O
in O
conscious O
unrestrained O
rats.The O
beta(2)-adrenoceptor B
(beta(2)-AR) O
agonists O
clenbuterol O
and O
fenoterol O
have O
similar O
beneficial O
effects O
in O
animal O
models O
of O
heart O
failure O
. O
However O
, O
large O
doses O
of O
clenbuterol O
can O
induce O
cardiomyocyte O
death O
, O
and O
it O
is O
not O
known O
which O
of O
these O
agents O
has O
the O
most O
favourable O
therapeutic O
profile O
. O
We O
have O
investigated O
the O
cardiotoxicity O
of O
clenbuterol O
and O
fenoterol O
alongside O
that O
of O
isoprenaline O
, O
and O
compared O

bisoprolol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
of O
0.3 O
mmol O
kg(-1) O
fenoterol O
or O
isoprenaline O
, O
but O
not O
clenbuterol O
, O
induced O
significant O
cardiomyocyte O
apoptosis O
(0.4 O
+/- O
0.05%; O
P O
< O
0.05) O
. O
At O
3 O
mmol O
kg(-1) O
, O
all O
agonists O
induced O
apoptosis O
(fenoterol O
, O
1.1 O
+/- O
0.1%; O
isoprenaline O
, O
0.9 O
+/- O
0.8%; O
and O
clenbuterol O
, O
0.4 O
+/- O
0.07%; O
P O
< O
0.05) O
. O
beta(1)-Adrenoceptor B
antagonism O
(10 O
mg O
kg(-1) O
bisoprolol O
prevented O
92% O
(P O
< O
0.05) O
of O
apoptosis O
induced O
by O
all O
three O
agonists O
, O
but O
clenbuterol-induced O
apoptosis O
could O
also O
be O
prevented O
by O
96% O
(P O
< O
0.05) O
by O
beta(2)-AR O
antagonism O
(10 O
mg O
kg(-1) O
ICI O
118 O
551) O
. O
Clenbuterol O
decreased O
diastolic O
(1.3- O
to O
1.6-fold; O
P O
< O
0.05) O
and O
systolic O
blood O
pressure O
(1.3-fold; O
P O
< O

Fingolimod O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
inhibitor O
is O
currently O
in O
phase O
II O
clinical O
trials.FK778 O
, O
is O
a O
synthetic O
malononitrilamide O
that O
targets O
the O
critical O
enzyme O
of O
the O
de O
novo O
pyrimidine O
synthesis O
, O
dihydroorotic O
acid O
dehydrogenase O
, O
and O
receptor-associated O
tyrosine O
kinases O
has O
completed O
phase O
II O
trials O
. O
FK778 O
also O
shows O
antiviral O
activities O
that O
have O
been O
tested O
in O
patients O
with O
polyomavirus O
nephropathy O
. O
Fingolimod O
(FTY720) O
, O
a O
synthetic O
sphingosine B
phosphate I
receptor I
modulator O
that O
reduces O
the O
recirculation O
of O
lymphocytes O
to O
blood O
and O
peripheral O
tissues O
including O
inflammatory O
lesions O
and O
graft O
sites O
is O
undergoing O
phase O
III O
trials O
. O
Although O
the O
efficacy O
of O
fingolimod O
is O
similar O
to O
MMF O
in O
patients O
receiving O
full O
doses O
of O
ciclosporin O
, O
safety O
issues O
such O
as O

FTY720 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
currently O
in O
phase O
II O
clinical O
trials.FK778 O
, O
is O
a O
synthetic O
malononitrilamide O
that O
targets O
the O
critical O
enzyme O
of O
the O
de O
novo O
pyrimidine O
synthesis O
, O
dihydroorotic O
acid O
dehydrogenase O
, O
and O
receptor-associated O
tyrosine O
kinases O
has O
completed O
phase O
II O
trials O
. O
FK778 O
also O
shows O
antiviral O
activities O
that O
have O
been O
tested O
in O
patients O
with O
polyomavirus O
nephropathy O
. O
Fingolimod O
( O
FTY720 O
 O
, O
a O
synthetic O
sphingosine B
phosphate I
receptor I
modulator O
that O
reduces O
the O
recirculation O
of O
lymphocytes O
to O
blood O
and O
peripheral O
tissues O
including O
inflammatory O
lesions O
and O
graft O
sites O
is O
undergoing O
phase O
III O
trials O
. O
Although O
the O
efficacy O
of O
fingolimod O
is O
similar O
to O
MMF O
in O
patients O
receiving O
full O
doses O
of O
ciclosporin O
, O
safety O
issues O
such O
as O

FK778 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
tyrosine O
kinase O
(JAK)-3 O
show O
some O
selectivity O
for O
cells O
of O
the O
lymphoid O
lineage O
and O
have O
been O
shown O
to O
be O
effective O
in O
late O
preclinical O
transplant O
models O
. O
The O
most O
frequent O
adverse O
effects O
have O
been O
related O
to O
nonspecific O
binding O
to O
JAK2 O
kinases O
. O
CP-690550 O
, O
a O
JAK3 O
inhibitor O
is O
currently O
in O
phase O
II O
clinical O
trials O
. O
FK778 O
is O
a O
synthetic O
malononitrilamide O
that O
targets O
the O
critical O
enzyme O
of O
the O
de O
novo O
pyrimidine O
synthesis O
, O
dihydroorotic O
acid O
dehydrogenase O
, O
and O
receptor-associated O
tyrosine O
kinases O
has O
completed O
phase O
II O
trials O
. O
FK778 O
also O
shows O
antiviral O
activities O
that O
have O
been O
tested O
in O
patients O
with O
polyomavirus O
nephropathy O
. O
Fingolimod O
(FTY720) O
, O
a O
synthetic O
sphingosine O
phosphate O
receptor O
modulator O

FK778 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
tyrosine O
kinase O
(JAK)-3 O
show O
some O
selectivity O
for O
cells O
of O
the O
lymphoid O
lineage O
and O
have O
been O
shown O
to O
be O
effective O
in O
late O
preclinical O
transplant O
models O
. O
The O
most O
frequent O
adverse O
effects O
have O
been O
related O
to O
nonspecific O
binding O
to O
JAK2 O
kinases O
. O
CP-690550 O
, O
a O
JAK3 O
inhibitor O
is O
currently O
in O
phase O
II O
clinical O
trials O
. O
FK778 O
is O
a O
synthetic O
malononitrilamide O
that O
targets O
the O
critical O
enzyme O
of O
the O
de O
novo O
pyrimidine O
synthesis O
, O
dihydroorotic O
acid O
dehydrogenase O
, O
and O
receptor-associated B
tyrosine I
kinases I
has O
completed O
phase O
II O
trials O
. O
FK778 O
also O
shows O
antiviral O
activities O
that O
have O
been O
tested O
in O
patients O
with O
polyomavirus O
nephropathy O
. O
Fingolimod O
(FTY720) O
, O
a O
synthetic O
sphingosine O
phosphate O
receptor O
modulator O

malononitrilamide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
show O
some O
selectivity O
for O
cells O
of O
the O
lymphoid O
lineage O
and O
have O
been O
shown O
to O
be O
effective O
in O
late O
preclinical O
transplant O
models O
. O
The O
most O
frequent O
adverse O
effects O
have O
been O
related O
to O
nonspecific O
binding O
to O
JAK2 O
kinases O
. O
CP-690550 O
, O
a O
JAK3 O
inhibitor O
is O
currently O
in O
phase O
II O
clinical O
trials.FK778 O
, O
is O
a O
synthetic O
malononitrilamide O
that O
targets O
the O
critical O
enzyme O
of O
the O
de O
novo O
pyrimidine O
synthesis O
, O
dihydroorotic O
acid O
dehydrogenase O
, O
and O
receptor-associated O
tyrosine O
kinases O
has O
completed O
phase O
II O
trials O
. O
FK778 O
also O
shows O
antiviral O
activities O
that O
have O
been O
tested O
in O
patients O
with O
polyomavirus O
nephropathy O
. O
Fingolimod O
(FTY720) O
, O
a O
synthetic O
sphingosine O
phosphate O
receptor O
modulator O
that O
reduces O
the O
recirculation O

malononitrilamide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
show O
some O
selectivity O
for O
cells O
of O
the O
lymphoid O
lineage O
and O
have O
been O
shown O
to O
be O
effective O
in O
late O
preclinical O
transplant O
models O
. O
The O
most O
frequent O
adverse O
effects O
have O
been O
related O
to O
nonspecific O
binding O
to O
JAK2 O
kinases O
. O
CP-690550 O
, O
a O
JAK3 O
inhibitor O
is O
currently O
in O
phase O
II O
clinical O
trials.FK778 O
, O
is O
a O
synthetic O
malononitrilamide O
that O
targets O
the O
critical O
enzyme O
of O
the O
de O
novo O
pyrimidine O
synthesis O
, O
dihydroorotic O
acid O
dehydrogenase O
, O
and O
receptor-associated B
tyrosine I
kinases I
has O
completed O
phase O
II O
trials O
. O
FK778 O
also O
shows O
antiviral O
activities O
that O
have O
been O
tested O
in O
patients O
with O
polyomavirus O
nephropathy O
. O
Fingolimod O
(FTY720) O
, O
a O
synthetic O
sphingosine O
phosphate O
receptor O
modulator O
that O
reduces O
the O
recirculation O

CP-690550 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
organs O
from O
expanded O
criteria O
donors O
. O
Inhibitors O
of O
the O
Janus O
protein O
tyrosine O
kinase O
(JAK)-3 O
show O
some O
selectivity O
for O
cells O
of O
the O
lymphoid O
lineage O
and O
have O
been O
shown O
to O
be O
effective O
in O
late O
preclinical O
transplant O
models O
. O
The O
most O
frequent O
adverse O
effects O
have O
been O
related O
to O
nonspecific O
binding O
to O
JAK2 O
kinases O
. O
CP-690550 O
a O
JAK3 B
inhibitor O
is O
currently O
in O
phase O
II O
clinical O
trials.FK778 O
, O
is O
a O
synthetic O
malononitrilamide O
that O
targets O
the O
critical O
enzyme O
of O
the O
de O
novo O
pyrimidine O
synthesis O
, O
dihydroorotic O
acid O
dehydrogenase O
, O
and O
receptor-associated O
tyrosine O
kinases O
has O
completed O
phase O
II O
trials O
. O
FK778 O
also O
shows O
antiviral O
activities O
that O
have O
been O
tested O
in O
patients O
with O

progestins O
acts O
as O
NOT O
for O
what O
entity O
? O
protective O
function O
of O
17 O
beta-estradiol O
in O
aldosterone O
salt-treated O
rats.Controversial O
results O
obtained O
from O
human O
and O
animal O
studies O
on O
the O
prevention O
of O
heart O
disease O
by O
estrogens O
and O
progestins O
warrant O
a O
better O
understanding O
of O
nuclear O
hormone O
receptor O
function O
and O
interaction O
. O
To O
address O
this O
issue O
and O
taking O
into O
account O
that O
effects O
of O
synthetic O
progestins O
are O
not O
only O
referable O
to O
action O
through O
the O
progesterone B
receptor I
but O
may O
also O
be O
mediated O
by O
other O
steroid O
receptors O
, O
we O
characterized O
cardiovascular O
function O
and O
inflammatory O
gene O
expression O
in O
aldosterone O
salt-treated O
rats O
on O
long-term O
administration O
of O
17beta-estradiol O
, O
medroxyprogesterone O
acetate O
, O
and O
drospirenone O
, O
a O
new O
progestogen O
exhibiting O
antimineralocorticoid O
activity O
. O
The O
complex O
pattern O

progestins O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
protective O
function O
of O
17 O
beta-estradiol O
in O
aldosterone O
salt-treated O
rats.Controversial O
results O
obtained O
from O
human O
and O
animal O
studies O
on O
the O
prevention O
of O
heart O
disease O
by O
estrogens O
and O
progestins O
warrant O
a O
better O
understanding O
of O
nuclear O
hormone O
receptor O
function O
and O
interaction O
. O
To O
address O
this O
issue O
and O
taking O
into O
account O
that O
effects O
of O
synthetic O
progestins O
are O
not O
only O
referable O
to O
action O
through O
the O
progesterone O
receptor O
but O
may O
also O
be O
mediated O
by O
other O
steroid O
receptors O
, O
we O
characterized O
cardiovascular O
function O
and O
inflammatory O
gene O
expression O
in O
aldosterone O
salt-treated O
rats O
on O
long-term O
administration O
of O
17beta-estradiol O
, O
medroxyprogesterone O
acetate O
, O
and O
drospirenone O
, O
a O
new O
progestogen O
exhibiting O
antimineralocorticoid O
activity O
. O
The O
complex O
pattern O

17beta-estradiol O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
a O
new O
progestogen O
exhibiting O
antimineralocorticoid O
activity O
. O
The O
complex O
pattern O
of O
cardiovascular O
injury O
in O
ovariectomized O
Wistar O
rats O
induced O
by O
chronic O
aldosterone O
infusion O
plus O
a O
high-salt O
diet O
was O
significantly O
attenuated O
in O
sham-ovariectomized O
rats O
and O
by O
coadministration O
of O
17beta-estradiol O
in O
ovariectomized O
animals O
after O
8 O
weeks O
of O
continuous O
treatment O
. O
The O
beneficial O
role O
of O
17beta-estradiol O
on O
blood O
pressure O
, O
cardiac O
hypertrophy O
, O
vascular O
osteopontin B
expression O
, O
perivascular O
fibrosis O
, O
and O
impaired O
NO-dependent O
relaxation O
of O
isolated O
aortic O
rings O
was O
completely O
abrogated O
by O
coadministration O
of O
medroxyprogesterone O
acetate O
. O
In O
contrast O
, O
drospirenone O
was O
either O
neutral O
or O
additive O
to O
17beta-estradiol O
in O
protecting O
against O
aldosterone O
salt-induced O
cardiovascular O
injury O
and O
inflammation O
. O
The O
current O
results O
support O

medroxyprogesterone O
acetate O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
significantly O
attenuated O
in O
sham-ovariectomized O
rats O
and O
by O
coadministration O
of O
17beta-estradiol O
in O
ovariectomized O
animals O
after O
8 O
weeks O
of O
continuous O
treatment O
. O
The O
beneficial O
role O
of O
17beta-estradiol O
on O
blood O
pressure O
, O
cardiac O
hypertrophy O
, O
vascular O
osteopontin B
expression O
, O
perivascular O
fibrosis O
, O
and O
impaired O
NO-dependent O
relaxation O
of O
isolated O
aortic O
rings O
was O
completely O
abrogated O
by O
coadministration O
of O
medroxyprogesterone O
acetate O
In O
contrast O
, O
drospirenone O
was O
either O
neutral O
or O
additive O
to O
17beta-estradiol O
in O
protecting O
against O
aldosterone O
salt-induced O
cardiovascular O
injury O
and O
inflammation O
. O
The O
current O
results O
support O
the O
hypothesis O
of O
complex O
interactions O
among O
estrogen O
, O
progesterone O
, O
glucocorticoid O
, O
androgen O
, O
and O
mineralocorticoid O
receptor O
signaling O
in O
cardiovascular O
injury O
and O
inflammation O
. O
Novel O
progestins O
, O
such O
as O
drospirenone O
, O
confer O
superior O

Licofelone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
femoral O
arteries O
, O
and O
they O
were O
randomized O
to O
receive O
10 O
mg/kg/day O
licofelone O
or O
5 O
mg/kg/day O
rofecoxib O
or O
no O
treatment O
during O
4 O
weeks O
with O
atherogenic O
diet O
in O
all O
cases O
. O
Ten O
healthy O
rabbits O
were O
used O
as O
controls O
. O
Neutrophils O
and O
platelets O
were O
isolated O
from O
peripheral O
blood O
of O
rabbits O
for O
ex O
vivo O
studies O
. O
Licofelone O
reduced O
intima/media O
ratio O
in O
injured O
arteries O
, O
the O
macrophages O
infiltration O
in O
the O
neointimal O
area O
, O
monocyte B
chemoattractant I
protein-1 I
(MCP-1) O
gene O
expression O
, O
and O
the O
activation O
of O
nuclear O
factor-kappaB O
in O
rabbit O
atheroma O
. O
Moreover O
, O
licofelone O
inhibited O
COX-2 O
and O
5-LOX O
protein O
expression O
in O
vascular O
lesions O
. O
Rofecoxib O
only O
diminished O
COX-2 O
protein O
expression O
and O
MCP-1 O
gene O
expression O

Licofelone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
femoral O
arteries O
, O
and O
they O
were O
randomized O
to O
receive O
10 O
mg/kg/day O
licofelone O
or O
5 O
mg/kg/day O
rofecoxib O
or O
no O
treatment O
during O
4 O
weeks O
with O
atherogenic O
diet O
in O
all O
cases O
. O
Ten O
healthy O
rabbits O
were O
used O
as O
controls O
. O
Neutrophils O
and O
platelets O
were O
isolated O
from O
peripheral O
blood O
of O
rabbits O
for O
ex O
vivo O
studies O
. O
Licofelone O
reduced O
intima/media O
ratio O
in O
injured O
arteries O
, O
the O
macrophages O
infiltration O
in O
the O
neointimal O
area O
, O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
gene O
expression O
, O
and O
the O
activation O
of O
nuclear O
factor-kappaB O
in O
rabbit O
atheroma O
. O
Moreover O
, O
licofelone O
inhibited O
COX-2 O
and O
5-LOX O
protein O
expression O
in O
vascular O
lesions O
. O
Rofecoxib O
only O
diminished O
COX-2 O
protein O
expression O
and O
MCP-1 B
gene O
expression O

Licofelone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
femoral O
arteries O
, O
and O
they O
were O
randomized O
to O
receive O
10 O
mg/kg/day O
licofelone O
or O
5 O
mg/kg/day O
rofecoxib O
or O
no O
treatment O
during O
4 O
weeks O
with O
atherogenic O
diet O
in O
all O
cases O
. O
Ten O
healthy O
rabbits O
were O
used O
as O
controls O
. O
Neutrophils O
and O
platelets O
were O
isolated O
from O
peripheral O
blood O
of O
rabbits O
for O
ex O
vivo O
studies O
. O
Licofelone O
reduced O
intima/media O
ratio O
in O
injured O
arteries O
, O
the O
macrophages O
infiltration O
in O
the O
neointimal O
area O
, O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
gene O
expression O
, O
and O
the O
activation O
of O
nuclear B
factor-kappaB I
in O
rabbit O
atheroma O
. O
Moreover O
, O
licofelone O
inhibited O
COX-2 O
and O
5-LOX O
protein O
expression O
in O
vascular O
lesions O
. O
Rofecoxib O
only O
diminished O
COX-2 O
protein O
expression O
and O
MCP-1 O
gene O
expression O

licofelone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
rabbits O
were O
used O
as O
controls O
. O
Neutrophils O
and O
platelets O
were O
isolated O
from O
peripheral O
blood O
of O
rabbits O
for O
ex O
vivo O
studies O
. O
Licofelone O
reduced O
intima/media O
ratio O
in O
injured O
arteries O
, O
the O
macrophages O
infiltration O
in O
the O
neointimal O
area O
, O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
gene O
expression O
, O
and O
the O
activation O
of O
nuclear O
factor-kappaB O
in O
rabbit O
atheroma O
. O
Moreover O
, O
licofelone O
inhibited O
COX-2 B
and O
5-LOX O
protein O
expression O
in O
vascular O
lesions O
. O
Rofecoxib O
only O
diminished O
COX-2 O
protein O
expression O
and O
MCP-1 O
gene O
expression O
in O
vascular O
atheroma O
. O
Prostaglandin O
E(2) O
in O
rabbit O
plasma O
was O
attenuated O
by O
both O
drugs O
. O
Licofelone O
almost O
abolished O
5-LOX O
activity O
by O
inhibiting O
leukotriene O
B4 O
generation O
in O
rabbit O
neutrophils O
and O
prevented O
platelet O
thromboxane O

licofelone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
rabbits O
were O
used O
as O
controls O
. O
Neutrophils O
and O
platelets O
were O
isolated O
from O
peripheral O
blood O
of O
rabbits O
for O
ex O
vivo O
studies O
. O
Licofelone O
reduced O
intima/media O
ratio O
in O
injured O
arteries O
, O
the O
macrophages O
infiltration O
in O
the O
neointimal O
area O
, O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
gene O
expression O
, O
and O
the O
activation O
of O
nuclear O
factor-kappaB O
in O
rabbit O
atheroma O
. O
Moreover O
, O
licofelone O
inhibited O
COX-2 O
and O
5-LOX B
protein O
expression O
in O
vascular O
lesions O
. O
Rofecoxib O
only O
diminished O
COX-2 O
protein O
expression O
and O
MCP-1 O
gene O
expression O
in O
vascular O
atheroma O
. O
Prostaglandin O
E(2) O
in O
rabbit O
plasma O
was O
attenuated O
by O
both O
drugs O
. O
Licofelone O
almost O
abolished O
5-LOX O
activity O
by O
inhibiting O
leukotriene O
B4 O
generation O
in O
rabbit O
neutrophils O
and O
prevented O
platelet O
thromboxane O

Rofecoxib O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
from O
peripheral O
blood O
of O
rabbits O
for O
ex O
vivo O
studies O
. O
Licofelone O
reduced O
intima/media O
ratio O
in O
injured O
arteries O
, O
the O
macrophages O
infiltration O
in O
the O
neointimal O
area O
, O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
gene O
expression O
, O
and O
the O
activation O
of O
nuclear O
factor-kappaB O
in O
rabbit O
atheroma O
. O
Moreover O
, O
licofelone O
inhibited O
COX-2 B
and O
5-LOX O
protein O
expression O
in O
vascular O
lesions O
. O
Rofecoxib O
only O
diminished O
COX-2 O
protein O
expression O
and O
MCP-1 O
gene O
expression O
in O
vascular O
atheroma O
. O
Prostaglandin O
E(2) O
in O
rabbit O
plasma O
was O
attenuated O
by O
both O
drugs O
. O
Licofelone O
almost O
abolished O
5-LOX O
activity O
by O
inhibiting O
leukotriene O
B4 O
generation O
in O
rabbit O
neutrophils O
and O
prevented O
platelet O
thromboxane O
B2 O
production O
from O
whole O
blood O
. O
Licofelone O
reduces O
neointimal O
formation O
and O

Rofecoxib O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
from O
peripheral O
blood O
of O
rabbits O
for O
ex O
vivo O
studies O
. O
Licofelone O
reduced O
intima/media O
ratio O
in O
injured O
arteries O
, O
the O
macrophages O
infiltration O
in O
the O
neointimal O
area O
, O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
gene O
expression O
, O
and O
the O
activation O
of O
nuclear O
factor-kappaB O
in O
rabbit O
atheroma O
. O
Moreover O
, O
licofelone O
inhibited O
COX-2 O
and O
5-LOX O
protein O
expression O
in O
vascular O
lesions O
. O
Rofecoxib O
only O
diminished O
COX-2 O
protein O
expression O
and O
MCP-1 B
gene O
expression O
in O
vascular O
atheroma O
. O
Prostaglandin O
E(2) O
in O
rabbit O
plasma O
was O
attenuated O
by O
both O
drugs O
. O
Licofelone O
almost O
abolished O
5-LOX O
activity O
by O
inhibiting O
leukotriene O
B4 O
generation O
in O
rabbit O
neutrophils O
and O
prevented O
platelet O
thromboxane O
B2 O
production O
from O
whole O
blood O
. O
Licofelone O
reduces O
neointimal O
formation O
and O

rofecoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
enzymes O
, O
may O
have O
a O
better O
cardiovascular O
profile O
that O
cycloxygenase-2 O
inhibitors O
due O
to O
cycloxygenase-1 O
blockade-mediated O
antithrombotic O
effect O
and O
a O
better O
gastrointestinal O
tolerability O
. O
We O
examined O
the O
anti-inflammatory O
effect O
of O
licofelone O
on O
atherosclerotic O
lesions O
as O
well O
as O
in O
isolated O
neutrophils O
from O
whole O
blood O
of O
rabbits O
compared O
with O
a O
selective O
inhibitor O
of O
COX-2 O
, O
rofecoxib O
We O
also O
assessed O
the O
antithrombotic O
effect O
of O
licofelone O
in O
rabbit O
platelet-rich O
plasma O
. O
For O
this O
purpose O
, O
30 O
rabbits O
underwent O
injury O
of O
femoral O
arteries O
, O
and O
they O
were O
randomized O
to O
receive O
10 O
mg/kg/day O
licofelone O
or O
5 O
mg/kg/day O
rofecoxib O
or O
no O
treatment O
during O
4 O
weeks O
with O
atherogenic O
diet O
in O
all O
cases O
. O
Ten O
healthy O

Licofelone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Licofelone O
, O
a O
balanced O
inhibitor O
of O
cyclooxygenase O
and O
5-lipoxygenase O
, O
reduces O
inflammation O
in O
a O
rabbit O
model O
of O
atherosclerosis O
. O
Licofelone O
a O
dual O
anti-inflammatory O
drug O
that O
inhibits O
5-lipoxygenase O
(LOX) O
and O
cyclooxygenase O
(COX) O
enzymes O
, O
may O
have O
a O
better O
cardiovascular O
profile O
that O
cycloxygenase-2 O
inhibitors O
due O
to O
cycloxygenase-1 B
blockade-mediated O
antithrombotic O
effect O
and O
a O
better O
gastrointestinal O
tolerability O
. O
We O
examined O
the O
anti-inflammatory O
effect O
of O
licofelone O
on O
atherosclerotic O
lesions O
as O
well O
as O
in O
isolated O
neutrophils O
from O

Licofelone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Licofelone O
, O
a O
balanced O
inhibitor O
of O
cyclooxygenase O
and O
5-lipoxygenase O
, O
reduces O
inflammation O
in O
a O
rabbit O
model O
of O
atherosclerosis O
. O
Licofelone O
a O
dual O
anti-inflammatory O
drug O
that O
inhibits O
5-lipoxygenase B
(LOX) O
and O
cyclooxygenase O
(COX) O
enzymes O
, O
may O
have O
a O
better O
cardiovascular O
profile O
that O
cycloxygenase-2 O
inhibitors O
due O
to O
cycloxygenase-1 O
blockade-mediated O
antithrombotic O
effect O
and O
a O
better O
gastrointestinal O
tolerability O
. O
We O
examined O
the O
anti-inflammatory O
effect O
of O
licofelone O
on O
atherosclerotic O
lesions O
as O
well O
as O
in O
isolated O
neutrophils O
from O

Licofelone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Licofelone O
, O
a O
balanced O
inhibitor O
of O
cyclooxygenase O
and O
5-lipoxygenase O
, O
reduces O
inflammation O
in O
a O
rabbit O
model O
of O
atherosclerosis O
. O
Licofelone O
a O
dual O
anti-inflammatory O
drug O
that O
inhibits O
5-lipoxygenase O
(LOX) O
and O
cyclooxygenase O
(COX) O
enzymes O
, O
may O
have O
a O
better O
cardiovascular O
profile O
that O
cycloxygenase-2 O
inhibitors O
due O
to O
cycloxygenase-1 O
blockade-mediated O
antithrombotic O
effect O
and O
a O
better O
gastrointestinal O
tolerability O
. O
We O
examined O
the O
anti-inflammatory O
effect O
of O
licofelone O
on O
atherosclerotic O
lesions O
as O
well O
as O
in O
isolated O
neutrophils O
from O

Licofelone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Licofelone O
, O
a O
balanced O
inhibitor O
of O
cyclooxygenase B
and O
5-lipoxygenase O
, O
reduces O
inflammation O
in O
a O
rabbit O
model O
of O
atherosclerosis O
. O
Licofelone O
a O
dual O
anti-inflammatory O
drug O
that O
inhibits O
5-lipoxygenase O
(LOX) O
and O
cyclooxygenase O
(COX) O
enzymes O
, O
may O
have O
a O
better O
cardiovascular O
profile O
that O
cycloxygenase-2 O
inhibitors O
due O
to O
cycloxygenase-1 O
blockade-mediated O
antithrombotic O
effect O
and O
a O
better O
gastrointestinal O
tolerability O
. O
We O
examined O
the O
anti-inflammatory O
effect O
of O
licofelone O
on O
atherosclerotic O
lesions O
as O
well O
as O
in O
isolated O
neutrophils O
from O

Licofelone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Licofelone O
, O
a O
balanced O
inhibitor O
of O
cyclooxygenase O
and O
5-lipoxygenase O
, O
reduces O
inflammation O
in O
a O
rabbit O
model O
of O
atherosclerosis O
. O
Licofelone O
a O
dual O
anti-inflammatory O
drug O
that O
inhibits O
5-lipoxygenase O
(LOX) O
and O
cyclooxygenase O
(COX) O
enzymes O
, O
may O
have O
a O
better O
cardiovascular O
profile O
that O
cycloxygenase-2 O
inhibitors O
due O
to O
cycloxygenase-1 O
blockade-mediated O
antithrombotic O
effect O
and O
a O
better O
gastrointestinal O
tolerability O
. O
We O
examined O
the O
anti-inflammatory O
effect O
of O
licofelone O
on O
atherosclerotic O
lesions O
as O
well O
as O
in O
isolated O
neutrophils O
from O

Licofelone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
gene O
expression O
, O
and O
the O
activation O
of O
nuclear O
factor-kappaB O
in O
rabbit O
atheroma O
. O
Moreover O
, O
licofelone O
inhibited O
COX-2 O
and O
5-LOX B
protein O
expression O
in O
vascular O
lesions O
. O
Rofecoxib O
only O
diminished O
COX-2 O
protein O
expression O
and O
MCP-1 O
gene O
expression O
in O
vascular O
atheroma O
. O
Prostaglandin O
E(2) O
in O
rabbit O
plasma O
was O
attenuated O
by O
both O
drugs O
. O
Licofelone O
almost O
abolished O
5-LOX O
activity O
by O
inhibiting O
leukotriene O
B4 O
generation O
in O
rabbit O
neutrophils O
and O
prevented O
platelet O
thromboxane O
B2 O
production O
from O
whole O
blood O
. O
Licofelone O
reduces O
neointimal O
formation O
and O
inflammation O
in O
an O
atherosclerotic O
rabbit O
model O
more O
markedly O
than O
rofecoxib O
. O
This O
effect O
, O
together O
with O
the O
antiplatelet O
activity O
of O
licofelone O
, O
suggests O
that O
this O
drug O

leukotriene O
B4 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
the O
activation O
of O
nuclear O
factor-kappaB O
in O
rabbit O
atheroma O
. O
Moreover O
, O
licofelone O
inhibited O
COX-2 O
and O
5-LOX B
protein O
expression O
in O
vascular O
lesions O
. O
Rofecoxib O
only O
diminished O
COX-2 O
protein O
expression O
and O
MCP-1 O
gene O
expression O
in O
vascular O
atheroma O
. O
Prostaglandin O
E(2) O
in O
rabbit O
plasma O
was O
attenuated O
by O
both O
drugs O
. O
Licofelone O
almost O
abolished O
5-LOX O
activity O
by O
inhibiting O
leukotriene O
B4 O
generation O
in O
rabbit O
neutrophils O
and O
prevented O
platelet O
thromboxane O
B2 O
production O
from O
whole O
blood O
. O
Licofelone O
reduces O
neointimal O
formation O
and O
inflammation O
in O
an O
atherosclerotic O
rabbit O
model O
more O
markedly O
than O
rofecoxib O
. O
This O
effect O
, O
together O
with O
the O
antiplatelet O
activity O
of O
licofelone O
, O
suggests O
that O
this O
drug O
may O
have O
a O
favorable O
cardiovascular O
profile O
. O

thromboxane O
B2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
licofelone O
inhibited O
COX-2 O
and O
5-LOX B
protein O
expression O
in O
vascular O
lesions O
. O
Rofecoxib O
only O
diminished O
COX-2 O
protein O
expression O
and O
MCP-1 O
gene O
expression O
in O
vascular O
atheroma O
. O
Prostaglandin O
E(2) O
in O
rabbit O
plasma O
was O
attenuated O
by O
both O
drugs O
. O
Licofelone O
almost O
abolished O
5-LOX O
activity O
by O
inhibiting O
leukotriene O
B4 O
generation O
in O
rabbit O
neutrophils O
and O
prevented O
platelet O
thromboxane O
B2 O
production O
from O
whole O
blood O
. O
Licofelone O
reduces O
neointimal O
formation O
and O
inflammation O
in O
an O
atherosclerotic O
rabbit O
model O
more O
markedly O
than O
rofecoxib O
. O
This O
effect O
, O
together O
with O
the O
antiplatelet O
activity O
of O
licofelone O
, O
suggests O
that O
this O
drug O
may O
have O
a O
favorable O
cardiovascular O
profile O
. O

Dexamethasone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
to O
dexamethasone O
and O
prednisolone O
in O
the O
same O
depressed O
patients.RATIONALE O
: O
Patients O
with O
major O
depression O
show O
hypothalamic-pituitary-adrenal O
(HPA) O
axis O
hyperactivity O
, O
but O
the O
mechanisms O
underlying O
this O
abnormality O
are O
still O
unclear O
. O
OBJECTIVES O
: O
We O
have O
compared O
two O
synthetic O
glucorticoids O
, O
dexamethasone O
and O
prednisolone O
, O
in O
their O
ability O
to O
suppress O
the O
hypothalamic-pituitary-adrenal O
(HPA) O
axis O
in O
depressed O
patients O
. O
Dexamethasone O
probes O
glucocorticoid B
receptor I
(GR) O
function O
, O
while O
prednisolone O
probes O
both O
GR O
and O
mineralocorticoid O
receptor O
(MR) O
function O
. O
MATERIALS O
AND O
METHODS O
: O
We O
used O
a O
single-blind O
, O
repeated-measure O
design O
. O
We O
administered O
placebo O
, O
prednisolone O
(5 O
mg) O
or O
dexamethasone O
(0.5 O
mg) O
, O
at O
22:00 O
, O
to O
18 O
severe O
, O
treatment-resistant O
depressed O
inpatients O
(15 O
of O
them O
with O
a O
history O
of O

Dexamethasone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
to O
dexamethasone O
and O
prednisolone O
in O
the O
same O
depressed O
patients.RATIONALE O
: O
Patients O
with O
major O
depression O
show O
hypothalamic-pituitary-adrenal O
(HPA) O
axis O
hyperactivity O
, O
but O
the O
mechanisms O
underlying O
this O
abnormality O
are O
still O
unclear O
. O
OBJECTIVES O
: O
We O
have O
compared O
two O
synthetic O
glucorticoids O
, O
dexamethasone O
and O
prednisolone O
, O
in O
their O
ability O
to O
suppress O
the O
hypothalamic-pituitary-adrenal O
(HPA) O
axis O
in O
depressed O
patients O
. O
Dexamethasone O
probes O
glucocorticoid O
receptor O
(GR) O
function O
, O
while O
prednisolone O
probes O
both O
GR B
and O
mineralocorticoid O
receptor O
(MR) O
function O
. O
MATERIALS O
AND O
METHODS O
: O
We O
used O
a O
single-blind O
, O
repeated-measure O
design O
. O
We O
administered O
placebo O
, O
prednisolone O
(5 O
mg) O
or O
dexamethasone O
(0.5 O
mg) O
, O
at O
22:00 O
, O
to O
18 O
severe O
, O
treatment-resistant O
depressed O
inpatients O
(15 O
of O
them O
with O
a O
history O
of O

prednisolone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
depressed O
patients.RATIONALE O
: O
Patients O
with O
major O
depression O
show O
hypothalamic-pituitary-adrenal O
(HPA) O
axis O
hyperactivity O
, O
but O
the O
mechanisms O
underlying O
this O
abnormality O
are O
still O
unclear O
. O
OBJECTIVES O
: O
We O
have O
compared O
two O
synthetic O
glucorticoids O
, O
dexamethasone O
and O
prednisolone O
, O
in O
their O
ability O
to O
suppress O
the O
hypothalamic-pituitary-adrenal O
(HPA) O
axis O
in O
depressed O
patients O
. O
Dexamethasone O
probes O
glucocorticoid O
receptor O
(GR) O
function O
, O
while O
prednisolone O
probes O
both O
GR B
and O
mineralocorticoid O
receptor O
(MR) O
function O
. O
MATERIALS O
AND O
METHODS O
: O
We O
used O
a O
single-blind O
, O
repeated-measure O
design O
. O
We O
administered O
placebo O
, O
prednisolone O
(5 O
mg) O
or O
dexamethasone O
(0.5 O
mg) O
, O
at O
22:00 O
, O
to O
18 O
severe O
, O
treatment-resistant O
depressed O
inpatients O
(15 O
of O
them O
with O
a O
history O
of O
childhood O
trauma) O
and O
14 O
healthy O
volunteers O
. O
On O

prednisolone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
depressed O
patients.RATIONALE O
: O
Patients O
with O
major O
depression O
show O
hypothalamic-pituitary-adrenal O
(HPA) O
axis O
hyperactivity O
, O
but O
the O
mechanisms O
underlying O
this O
abnormality O
are O
still O
unclear O
. O
OBJECTIVES O
: O
We O
have O
compared O
two O
synthetic O
glucorticoids O
, O
dexamethasone O
and O
prednisolone O
, O
in O
their O
ability O
to O
suppress O
the O
hypothalamic-pituitary-adrenal O
(HPA) O
axis O
in O
depressed O
patients O
. O
Dexamethasone O
probes O
glucocorticoid O
receptor O
(GR) O
function O
, O
while O
prednisolone O
probes O
both O
GR O
and O
mineralocorticoid B
receptor I
(MR) O
function O
. O
MATERIALS O
AND O
METHODS O
: O
We O
used O
a O
single-blind O
, O
repeated-measure O
design O
. O
We O
administered O
placebo O
, O
prednisolone O
(5 O
mg) O
or O
dexamethasone O
(0.5 O
mg) O
, O
at O
22:00 O
, O
to O
18 O
severe O
, O
treatment-resistant O
depressed O
inpatients O
(15 O
of O
them O
with O
a O
history O
of O
childhood O
trauma) O
and O
14 O
healthy O
volunteers O
. O
On O

prednisolone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
depressed O
patients.RATIONALE O
: O
Patients O
with O
major O
depression O
show O
hypothalamic-pituitary-adrenal O
(HPA) O
axis O
hyperactivity O
, O
but O
the O
mechanisms O
underlying O
this O
abnormality O
are O
still O
unclear O
. O
OBJECTIVES O
: O
We O
have O
compared O
two O
synthetic O
glucorticoids O
, O
dexamethasone O
and O
prednisolone O
, O
in O
their O
ability O
to O
suppress O
the O
hypothalamic-pituitary-adrenal O
(HPA) O
axis O
in O
depressed O
patients O
. O
Dexamethasone O
probes O
glucocorticoid O
receptor O
(GR) O
function O
, O
while O
prednisolone O
probes O
both O
GR O
and O
mineralocorticoid O
receptor O
(MR) O
function O
. O
MATERIALS O
AND O
METHODS O
: O
We O
used O
a O
single-blind O
, O
repeated-measure O
design O
. O
We O
administered O
placebo O
, O
prednisolone O
(5 O
mg) O
or O
dexamethasone O
(0.5 O
mg) O
, O
at O
22:00 O
, O
to O
18 O
severe O
, O
treatment-resistant O
depressed O
inpatients O
(15 O
of O
them O
with O
a O
history O
of O
childhood O
trauma) O
and O
14 O
healthy O
volunteers O
. O
On O

prednisolone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
curve O
(AUCs) O
, O
suppression O
by O
dexamethasone O
(0.5 O
mg) O
was O
-85% O
in O
controls O
vs O
-46% O
in O
depressed O
patients O
(p=0.018) O
. O
However O
, O
the O
same O
depressed O
patients O
showed O
normal O
suppression O
by O
prednisolone O
(5 O
mg) O
: O
suppression O
was O
-41% O
in O
controls O
and O
-36% O
in O
depressed O
patients O
(p=0.6) O
. O
CONCLUSIONS O
: O
We O
suggest O
that O
the O
additional O
effects O
of O
prednisolone O
on O
the O
MR B
explain O
the O
different O
responses O
to O
these O
glucocorticoids O
in O
the O
same O
depressed O
patients O
. O

wortmannin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cell O
culture O
model O
[opossum O
kidney O
(OK) O
cell] O
. O
Insulin O
has O
two O
distinct O
phases O
of O
action O
on O
NHE3 O
. O
Chronic O
insulin O
(24 O
h) O
activates O
NHE3 O
through O
the O
classic O
phosphatidylinositol O
3-kinase-serum- O
and O
glucocorticoid-dependent O
kinase O
1 O
(PI3K-SGK1) O
pathway O
as O
insulin O
stimulates O
SGK1 O
phosphorylation O
and O
the O
insulin O
effect O
can O
be O
blocked O
by O
the O
PI3K O
inhibitor O
wortmannin O
or O
a O
dominant-negative O
SGK1 O
. O
We O
showed O
that O
SGK1 O
transcript O
and O
protein O
are O
expressed O
in O
rat O
proximal O
tubule O
and O
OK O
cells O
. O
We O
previously O
showed O
that O
glucocorticoids O
augment O
the O
effect O
of O
insulin O
on O
NHE3 O
(Klisic O
J O
, O
Hu O
MC O
, O
Nief O
V O
, O
Reyes O
L O
, O
Fuster O
D O
, O
Moe O
OW O
, O
Ambuhl O
PM O
. O
Am O
J O
Physiol O

wortmannin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cell O
culture O
model O
[opossum O
kidney O
(OK) O
cell] O
. O
Insulin O
has O
two O
distinct O
phases O
of O
action O
on O
NHE3 O
. O
Chronic O
insulin O
(24 O
h) O
activates O
NHE3 O
through O
the O
classic O
phosphatidylinositol O
3-kinase-serum- O
and O
glucocorticoid-dependent O
kinase O
1 O
(PI3K-SGK1) O
pathway O
as O
insulin O
stimulates O
SGK1 O
phosphorylation O
and O
the O
insulin O
effect O
can O
be O
blocked O
by O
the O
PI3K B
inhibitor O
wortmannin O
or O
a O
dominant-negative O
SGK1 O
. O
We O
showed O
that O
SGK1 O
transcript O
and O
protein O
are O
expressed O
in O
rat O
proximal O
tubule O
and O
OK O
cells O
. O
We O
previously O
showed O
that O
glucocorticoids O
augment O
the O
effect O
of O
insulin O
on O
NHE3 O
(Klisic O
J O
, O
Hu O
MC O
, O
Nief O
V O
, O
Reyes O
L O
, O
Fuster O
D O
, O
Moe O
OW O
, O
Ambuhl O
PM O
. O
Am O
J O
Physiol O

wortmannin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cell O
culture O
model O
[opossum O
kidney O
(OK) O
cell] O
. O
Insulin O
has O
two O
distinct O
phases O
of O
action O
on O
NHE3 O
. O
Chronic O
insulin O
(24 O
h) O
activates O
NHE3 O
through O
the O
classic O
phosphatidylinositol O
3-kinase-serum- O
and O
glucocorticoid-dependent O
kinase O
1 O
(PI3K-SGK1) O
pathway O
as O
insulin O
stimulates O
SGK1 O
phosphorylation O
and O
the O
insulin O
effect O
can O
be O
blocked O
by O
the O
PI3K B
inhibitor O
wortmannin O
or O
a O
dominant-negative O
SGK1 O
. O
We O
showed O
that O
SGK1 O
transcript O
and O
protein O
are O
expressed O
in O
rat O
proximal O
tubule O
and O
OK O
cells O
. O
We O
previously O
showed O
that O
glucocorticoids O
augment O
the O
effect O
of O
insulin O
on O
NHE3 O
(Klisic O
J O
, O
Hu O
MC O
, O
Nief O
V O
, O
Reyes O
L O
, O
Fuster O
D O
, O
Moe O
OW O
, O
Ambuhl O
PM O
. O
Am O
J O
Physiol O

letrozole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
placenta O
, O
brain O
, O
bone O
, O
adipose O
tissue O
and O
breast O
tissue O
. O
In O
breast O
cancer O
, O
intratumoural O
aromatase B
is O
the O
source O
for O
local O
estrogen O
production O
in O
the O
tissue O
. O
Inhibition O
of O
aromatase O
is O
an O
important O
approach O
for O
reducing O
growth O
stimulatory O
effects O
of O
estrogens O
in O
estrogen-dependent O
breast O
cancer O
. O
The O
potent O
and O
selective O
third-generation O
aromatase O
inhibitors O
anastrozole O
, O
letrozole O
and O
exemestane O
were O
introduced O
to O
the O
market O
as O
endocrine O
therapy O
in O
postmenopausal O
patients O
failing O
anti-estrogen O
therapy O
alone O
, O
or O
multiple O
hormonal O
therapies O
. O
Anastrozole O
and O
letrozole O
are O
both O
non-steroidal O
aromatase O
inhibitors O
that O
compete O
with O
the O
substrate O
for O
binding O
to O
the O
enzyme O
active O
site O
. O
Exemestane O
is O
a O
mechanism-based O
steroidal O
inhibitor O
that O
mimics O

Anastrozole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
tissue O
. O
Inhibition O
of O
aromatase B
is O
an O
important O
approach O
for O
reducing O
growth O
stimulatory O
effects O
of O
estrogens O
in O
estrogen-dependent O
breast O
cancer O
. O
The O
potent O
and O
selective O
third-generation O
aromatase O
inhibitors O
anastrozole O
, O
letrozole O
and O
exemestane O
were O
introduced O
to O
the O
market O
as O
endocrine O
therapy O
in O
postmenopausal O
patients O
failing O
anti-estrogen O
therapy O
alone O
, O
or O
multiple O
hormonal O
therapies O
. O
Anastrozole O
and O
letrozole O
are O
both O
non-steroidal O
aromatase O
inhibitors O
that O
compete O
with O
the O
substrate O
for O
binding O
to O
the O
enzyme O
active O
site O
. O
Exemestane O
is O
a O
mechanism-based O
steroidal O
inhibitor O
that O
mimics O
the O
substrate O
, O
is O
converted O
by O
the O
enzyme O
to O
a O
reactive O
intermediate O
, O
and O
results O
in O
inactivation O
of O
aromatase O
. O
These O
third-generation O
aromatase O
inhibitors O
are O

letrozole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
aromatase B
is O
an O
important O
approach O
for O
reducing O
growth O
stimulatory O
effects O
of O
estrogens O
in O
estrogen-dependent O
breast O
cancer O
. O
The O
potent O
and O
selective O
third-generation O
aromatase O
inhibitors O
anastrozole O
, O
letrozole O
and O
exemestane O
were O
introduced O
to O
the O
market O
as O
endocrine O
therapy O
in O
postmenopausal O
patients O
failing O
anti-estrogen O
therapy O
alone O
, O
or O
multiple O
hormonal O
therapies O
. O
Anastrozole O
and O
letrozole O
are O
both O
non-steroidal O
aromatase O
inhibitors O
that O
compete O
with O
the O
substrate O
for O
binding O
to O
the O
enzyme O
active O
site O
. O
Exemestane O
is O
a O
mechanism-based O
steroidal O
inhibitor O
that O
mimics O
the O
substrate O
, O
is O
converted O
by O
the O
enzyme O
to O
a O
reactive O
intermediate O
, O
and O
results O
in O
inactivation O
of O
aromatase O
. O
These O
third-generation O
aromatase O
inhibitors O
are O
currently O
approved O

anastrozole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
ovary O
, O
placenta O
, O
brain O
, O
bone O
, O
adipose O
tissue O
and O
breast O
tissue O
. O
In O
breast O
cancer O
, O
intratumoural O
aromatase B
is O
the O
source O
for O
local O
estrogen O
production O
in O
the O
tissue O
. O
Inhibition O
of O
aromatase O
is O
an O
important O
approach O
for O
reducing O
growth O
stimulatory O
effects O
of O
estrogens O
in O
estrogen-dependent O
breast O
cancer O
. O
The O
potent O
and O
selective O
third-generation O
aromatase O
inhibitors O
anastrozole O
letrozole O
and O
exemestane O
were O
introduced O
to O
the O
market O
as O
endocrine O
therapy O
in O
postmenopausal O
patients O
failing O
anti-estrogen O
therapy O
alone O
, O
or O
multiple O
hormonal O
therapies O
. O
Anastrozole O
and O
letrozole O
are O
both O
non-steroidal O
aromatase O
inhibitors O
that O
compete O
with O
the O
substrate O
for O
binding O
to O
the O
enzyme O
active O
site O
. O
Exemestane O
is O
a O
mechanism-based O
steroidal O
inhibitor O
that O

Estrogens O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Update O
on O
the O
use O
of O
aromatase O
inhibitors O
in O
breast O
cancer O
. O
Estrogens O
are O
biosynthesised O
from O
androgens O
by O
the O
CYP450 B
enzyme O
complex O
called O
aromatase O
. O
Aromatase O
is O
expressed O
in O
the O
ovary O
, O
placenta O
, O
brain O
, O
bone O
, O
adipose O
tissue O
and O
breast O
tissue O
. O
In O
breast O
cancer O
, O
intratumoural O
aromatase O
is O
the O
source O
for O
local O
estrogen O
production O
in O
the O
tissue O
. O
Inhibition O
of O
aromatase O
is O
an O
important O
approach O
for O
reducing O

Estrogens O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Update O
on O
the O
use O
of O
aromatase B
inhibitors O
in O
breast O
cancer O
. O
Estrogens O
are O
biosynthesised O
from O
androgens O
by O
the O
CYP450 O
enzyme O
complex O
called O
aromatase O
. O
Aromatase O
is O
expressed O
in O
the O
ovary O
, O
placenta O
, O
brain O
, O
bone O
, O
adipose O
tissue O
and O
breast O
tissue O
. O
In O
breast O
cancer O
, O
intratumoural O
aromatase O
is O
the O
source O
for O
local O
estrogen O
production O
in O
the O
tissue O
. O
Inhibition O
of O
aromatase O
is O
an O
important O
approach O
for O
reducing O

estrogen O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Update O
on O
the O
use O
of O
aromatase B
inhibitors O
in O
breast O
cancer.Estrogens O
are O
biosynthesised O
from O
androgens O
by O
the O
CYP450 O
enzyme O
complex O
called O
aromatase O
. O
Aromatase O
is O
expressed O
in O
the O
ovary O
, O
placenta O
, O
brain O
, O
bone O
, O
adipose O
tissue O
and O
breast O
tissue O
. O
In O
breast O
cancer O
, O
intratumoural O
aromatase O
is O
the O
source O
for O
local O
estrogen O
production O
in O
the O
tissue O
. O
Inhibition O
of O
aromatase O
is O
an O
important O
approach O
for O
reducing O
growth O
stimulatory O
effects O
of O
estrogens O
in O
estrogen-dependent O
breast O
cancer O
. O
The O
potent O
and O
selective O
third-generation O
aromatase O
inhibitors O
anastrozole O
, O
letrozole O
and O
exemestane O
were O
introduced O
to O
the O
market O
as O
endocrine O
therapy O
in O
postmenopausal O
patients O
failing O
anti-estrogen O
therapy O
alone O
, O
or O

androgens O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Update O
on O
the O
use O
of O
aromatase B
inhibitors O
in O
breast O
cancer.Estrogens O
are O
biosynthesised O
from O
androgens O
by O
the O
CYP450 O
enzyme O
complex O
called O
aromatase O
. O
Aromatase O
is O
expressed O
in O
the O
ovary O
, O
placenta O
, O
brain O
, O
bone O
, O
adipose O
tissue O
and O
breast O
tissue O
. O
In O
breast O
cancer O
, O
intratumoural O
aromatase O
is O
the O
source O
for O
local O
estrogen O
production O
in O
the O
tissue O
. O
Inhibition O
of O
aromatase O
is O
an O
important O
approach O
for O
reducing O
growth O
stimulatory O
effects O
of O

auranofin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 O
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O
MyD88 O
, O
IKKbeta O
, O
and O
p65 O
. O
IRF3 B
activation O
induced O
by O
MyD88-independent O
signaling O
components O
, O
TRIF O
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
Our O
results O
first O
demonstrate O
that O
auranofin O
suppresses O
the O
multiple O
steps O
in O
TLR4 O
signaling O
, O
especially O
the O
homodimerization O
of O
TLR4 O
. O
The O
results O
suggest O
that O
the O
suppression O
of O
TLR4 O
activity O
by O
auranofin O
may O
be O
the O
molecular O
mechanism O
through O
which O
auranofin O
exerts O
anti-rheumatic O
activity O
. O

auranofin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
induced O
by O
MyD88-independent O
signaling O
components O
, O
TRIF O
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
. O
Our O
results O
first O
demonstrate O
that O
auranofin O
suppresses O
the O
multiple O
steps O
in O
TLR4 B
signaling O
, O
especially O
the O
homodimerization O
of O
TLR4 O
. O
The O
results O
suggest O
that O
the O
suppression O
of O
TLR4 O
activity O
by O
auranofin O
may O
be O
the O
molecular O
mechanism O
through O
which O
auranofin O
exerts O
anti-rheumatic O
activity O
. O

auranofin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 O
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O
MyD88 O
, O
IKKbeta O
, O
and O
p65 O
. O
IRF3 O
activation O
induced O
by O
MyD88-independent O
signaling O
components O
, O
TRIF B
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
Our O
results O
first O
demonstrate O
that O
auranofin O
suppresses O
the O
multiple O
steps O
in O
TLR4 O
signaling O
, O
especially O
the O
homodimerization O
of O
TLR4 O
. O
The O
results O
suggest O
that O
the O
suppression O
of O
TLR4 O
activity O
by O
auranofin O
may O
be O
the O
molecular O
mechanism O
through O
which O
auranofin O
exerts O
anti-rheumatic O
activity O
. O

auranofin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 O
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O
MyD88 O
, O
IKKbeta O
, O
and O
p65 O
. O
IRF3 O
activation O
induced O
by O
MyD88-independent O
signaling O
components O
, O
TRIF O
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
Our O
results O
first O
demonstrate O
that O
auranofin O
suppresses O
the O
multiple O
steps O
in O
TLR4 O
signaling O
, O
especially O
the O
homodimerization O
of O
TLR4 O
. O
The O
results O
suggest O
that O
the O
suppression O
of O
TLR4 O
activity O
by O
auranofin O
may O
be O
the O
molecular O
mechanism O
through O
which O
auranofin O
exerts O
anti-rheumatic O
activity O
. O

auranofin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 B
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O
MyD88 O
, O
IKKbeta O
, O
and O
p65 O
. O
IRF3 O
activation O
induced O
by O
MyD88-independent O
signaling O
components O
, O
TRIF O
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
. O
Our O
results O
first O
demonstrate O
that O
auranofin O
suppresses O
the O
multiple O
steps O
in O
TLR4 O
signaling O
, O
especially O
the O
homodimerization O
of O
TLR4 O
. O
The O
results O
suggest O
that O
the O
suppression O
of O
TLR4 O
activity O
by O
auranofin O
may O
be O
the O
molecular O
mechanism O
through O
which O
auranofin O
exerts O
anti-rheumatic O
activity O
. O

auranofin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
TLR O
activation O
is O
closely O
linked O
to O
the O
development O
of O
many O
chronic O
inflammatory O
diseases O
including O
rheumatoid O
arthritis O
. O
Auranofin O
, O
an O
Au(I) O
compound O
, O
is O
a O
well-known O
and O
long-used O
anti-rheumatic O
drug O
. O
However O
, O
the O
mechanism O
as O
to O
how O
auranofin O
relieves O
the O
symptom O
of O
rheumatoid O
arthritis O
has O
not O
been O
fully O
clarified O
. O
Our O
results O
demonstrated O
that O
auranofin O
suppressed O
TLR4-mediated O
activation O
of O
transcription O
factors O
, O
NF-kappaB O
and O
IRF3 O
, O
and O
expression O
of O
COX-2 O
, O
a O
pro-inflammatory O
enzyme O
. O
This O
suppression O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 O
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O

auranofin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
rheumatoid O
arthritis O
has O
not O
been O
fully O
clarified O
. O
Our O
results O
demonstrated O
that O
auranofin O
suppressed O
TLR4-mediated O
activation O
of O
transcription O
factors O
, O
NF-kappaB B
and O
IRF3 O
, O
and O
expression O
of O
COX-2 O
, O
a O
pro-inflammatory O
enzyme O
. O
This O
suppression O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 O
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O
MyD88 O
, O
IKKbeta O
, O
and O
p65 O
. O
IRF3 O
activation O
induced O
by O
MyD88-independent O
signaling O
components O
, O
TRIF O
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
. O
Our O
results O
first O
demonstrate O
that O
auranofin O
suppresses O
the O
multiple O
steps O
in O
TLR4 O
signaling O
, O
especially O
the O
homodimerization O
of O
TLR4 O
. O
The O

auranofin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 B
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O
MyD88 O
, O
IKKbeta O
, O
and O
p65 O
. O
IRF3 O
activation O
induced O
by O
MyD88-independent O
signaling O
components O
, O
TRIF O
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
. O
Our O
results O
first O
demonstrate O
that O
auranofin O
suppresses O
the O
multiple O
steps O
in O
TLR4 O
signaling O
, O
especially O
the O
homodimerization O
of O
TLR4 O
. O
The O
results O
suggest O
that O
the O
suppression O
of O
TLR4 O
activity O
by O
auranofin O
may O
be O
the O
molecular O
mechanism O
through O
which O
auranofin O
exerts O
anti-rheumatic O
activity O
. O

auranofin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
TLR4 O
, O
MyD88 O
, O
IKKbeta O
, O
and O
p65 O
. O
IRF3 O
activation O
induced O
by O
MyD88-independent O
signaling O
components O
, O
TRIF O
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
. O
Our O
results O
first O
demonstrate O
that O
auranofin O
suppresses O
the O
multiple O
steps O
in O
TLR4 B
signaling O
, O
especially O
the O
homodimerization O
of O
TLR4 O
. O
The O
results O
suggest O
that O
the O
suppression O
of O
TLR4 O
activity O
by O
auranofin O
may O
be O
the O
molecular O
mechanism O
through O
which O
auranofin O
exerts O
anti-rheumatic O
activity O
. O

auranofin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
TLR O
activation O
is O
closely O
linked O
to O
the O
development O
of O
many O
chronic O
inflammatory O
diseases O
including O
rheumatoid O
arthritis O
. O
Auranofin O
, O
an O
Au(I) O
compound O
, O
is O
a O
well-known O
and O
long-used O
anti-rheumatic O
drug O
. O
However O
, O
the O
mechanism O
as O
to O
how O
auranofin O
relieves O
the O
symptom O
of O
rheumatoid O
arthritis O
has O
not O
been O
fully O
clarified O
. O
Our O
results O
demonstrated O
that O
auranofin O
suppressed O
TLR4-mediated O
activation O
of O
transcription O
factors O
, O
NF-kappaB O
and O
IRF3 O
, O
and O
expression O
of O
COX-2 O
, O
a O
pro-inflammatory O
enzyme O
. O
This O
suppression O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 B
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O

auranofin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
TLR O
activation O
is O
closely O
linked O
to O
the O
development O
of O
many O
chronic O
inflammatory O
diseases O
including O
rheumatoid O
arthritis O
. O
Auranofin O
, O
an O
Au(I) O
compound O
, O
is O
a O
well-known O
and O
long-used O
anti-rheumatic O
drug O
. O
However O
, O
the O
mechanism O
as O
to O
how O
auranofin O
relieves O
the O
symptom O
of O
rheumatoid O
arthritis O
has O
not O
been O
fully O
clarified O
. O
Our O
results O
demonstrated O
that O
auranofin O
suppressed O
TLR4-mediated O
activation O
of O
transcription O
factors O
, O
NF-kappaB B
and O
IRF3 O
, O
and O
expression O
of O
COX-2 O
, O
a O
pro-inflammatory O
enzyme O
. O
This O
suppression O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 O
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O

auranofin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
TLR O
activation O
is O
closely O
linked O
to O
the O
development O
of O
many O
chronic O
inflammatory O
diseases O
including O
rheumatoid O
arthritis O
. O
Auranofin O
, O
an O
Au(I) O
compound O
, O
is O
a O
well-known O
and O
long-used O
anti-rheumatic O
drug O
. O
However O
, O
the O
mechanism O
as O
to O
how O
auranofin O
relieves O
the O
symptom O
of O
rheumatoid O
arthritis O
has O
not O
been O
fully O
clarified O
. O
Our O
results O
demonstrated O
that O
auranofin O
suppressed O
TLR4-mediated O
activation O
of O
transcription O
factors O
, O
NF-kappaB O
and O
IRF3 O
, O
and O
expression O
of O
COX-2 O
, O
a O
pro-inflammatory O
enzyme O
. O
This O
suppression O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 O
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O

auranofin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
However O
, O
the O
mechanism O
as O
to O
how O
auranofin O
relieves O
the O
symptom O
of O
rheumatoid O
arthritis O
has O
not O
been O
fully O
clarified O
. O
Our O
results O
demonstrated O
that O
auranofin O
suppressed O
TLR4-mediated O
activation O
of O
transcription O
factors O
, O
NF-kappaB O
and O
IRF3 O
, O
and O
expression O
of O
COX-2 O
, O
a O
pro-inflammatory O
enzyme O
. O
This O
suppression O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 B
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O
MyD88 O
, O
IKKbeta O
, O
and O
p65 O
. O
IRF3 O
activation O
induced O
by O
MyD88-independent O
signaling O
components O
, O
TRIF O
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
. O
Our O
results O
first O
demonstrate O
that O
auranofin O
suppresses O
the O

arylhydroxylamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
a O
source O
of O
interindividual O
variability O
in O
response O
to O
aromatic O
amine O
carcinogens O
. O
The O
purpose O
of O
this O
study O
was O
to O
characterize O
the O
identity O
of O
this O
reduction O
pathway O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH B
cytochrome I
b5 I
reductase I
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O

arylhydroxylamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
a O
source O
of O
interindividual O
variability O
in O
response O
to O
aromatic O
amine O
carcinogens O
. O
The O
purpose O
of O
this O
study O
was O
to O
characterize O
the O
identity O
of O
this O
reduction O
pathway O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O

arylhydroxylamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
a O
source O
of O
interindividual O
variability O
in O
response O
to O
aromatic O
amine O
carcinogens O
. O
The O
purpose O
of O
this O
study O
was O
to O
characterize O
the O
identity O
of O
this O
reduction O
pathway O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome B
b5 I
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O

arylhydroxylamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
a O
source O
of O
interindividual O
variability O
in O
response O
to O
aromatic O
amine O
carcinogens O
. O
The O
purpose O
of O
this O
study O
was O
to O
characterize O
the O
identity O
of O
this O
reduction O
pathway O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O

hydroxylamines O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
this O
reduction O
pathway O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human B
b5R I
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O

hydroxylamines O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
this O
reduction O
pathway O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human O
b5R O
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O

aromatic O
amine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human B
b5R I
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O

aromatic O
amine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human O
b5R O
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O

4-aminobiphenyl O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human B
b5R I
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O

4-aminobiphenyl O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human O
b5R O
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O

4-ABP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
( O
4-ABP O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human B
b5R I
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O
Michaelis-Menten O

4-ABP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
( O
4-ABP O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human O
b5R O
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O
Michaelis-Menten O

heterocyclic O
amine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human B
b5R I
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O

heterocyclic O
amine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human O
b5R O
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O

2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human B
b5R I
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O
for O
b5R O

2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human O
b5R O
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O
for O
b5R O

arylhydroxylamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Reductive O
detoxification O
of O
arylhydroxylamin O
carcinogens O
by O
human O
NADH O
cytochrome B
b5 I
reductase O
and O
cytochrome O
b5.Heterocyclic O
and O
aromatic O
amine O
carcinogens O
are O
thought O
to O
lead O
to O
tumor O
initiation O
via O
the O
formation O
of O
DNA O
adducts O
, O
and O
bioactivation O
to O
arylhydroxylamine O
metabolites O
is O
necessary O
for O
reactivity O
with O
DNA O
. O
Carcinogenic O
arylhydroxylamine O
metabolites O
are O
cleared O
by O
a O
microsomal O
, O
NADH-dependent O
, O
oxygen-insensitive O
reduction O

arylhydroxylamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Reductive O
detoxification O
of O
arylhydroxylamin O
carcinogens O
by O
human B
NADH I
cytochrome I
b5 I
reductase I
and O
cytochrome O
b5.Heterocyclic O
and O
aromatic O
amine O
carcinogens O
are O
thought O
to O
lead O
to O
tumor O
initiation O
via O
the O
formation O
of O
DNA O
adducts O
, O
and O
bioactivation O
to O
arylhydroxylamine O
metabolites O
is O
necessary O
for O
reactivity O
with O
DNA O
. O
Carcinogenic O
arylhydroxylamine O
metabolites O
are O
cleared O
by O
a O
microsomal O
, O
NADH-dependent O
, O
oxygen-insensitive O
reduction O

PhIP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
( O
PhIP O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human B
b5R I
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O
for O
b5R O
and O
cyt O

PhIP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
( O
PhIP O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human O
b5R O
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O
for O
b5R O
and O
cyt O

N-hydroxy-4-aminobiphenyl O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
with O
similar O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O
for O
b5R B
and O
cyt O
b5 O
that O
yielded O
the O
highest O
activity O
in O
the O
purified O
system O
was O
also O
similar O
to O
that O
found O
in O
native O
HLM O
( O
approximately O
1:8 O
to O
1:10) O
. O
Polyclonal O
antisera O
to O
either O
b5R O
or O
cyt O
b5 O
significantly O
inhibited O
N-hydroxy-4-aminobiphenyl O
(NHOH-4-ABP) O
reduction O
by O
95 O
and O
89% O
, O
respectively O
, O
and O
immunoreactive O
cyt O
b5 O
protein O
content O
in O
individual O
HLM O
was O
significantly O
correlated O
with O
individual O
reduction O
of O
both O
NHOH-4-ABP O
and O
N-hydroxy-PhIP O
(NHOH-PhIP) O
. O
Finally O
, O
titration O
of O
HLM O
into O
the O
purified O
b5R/cyt O
b5 O
system O
did O
not O
enhance O
the O
efficiency O
of O
reduction O
activity O
. O
We O
conclude O
that O

N-hydroxy-4-aminobiphenyl O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
with O
similar O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O
for O
b5R O
and O
cyt B
b5 I
that O
yielded O
the O
highest O
activity O
in O
the O
purified O
system O
was O
also O
similar O
to O
that O
found O
in O
native O
HLM O
( O
approximately O
1:8 O
to O
1:10) O
. O
Polyclonal O
antisera O
to O
either O
b5R O
or O
cyt O
b5 O
significantly O
inhibited O
N-hydroxy-4-aminobiphenyl O
(NHOH-4-ABP) O
reduction O
by O
95 O
and O
89% O
, O
respectively O
, O
and O
immunoreactive O
cyt O
b5 O
protein O
content O
in O
individual O
HLM O
was O
significantly O
correlated O
with O
individual O
reduction O
of O
both O
NHOH-4-ABP O
and O
N-hydroxy-PhIP O
(NHOH-PhIP) O
. O
Finally O
, O
titration O
of O
HLM O
into O
the O
purified O
b5R/cyt O
b5 O
system O
did O
not O
enhance O
the O
efficiency O
of O
reduction O
activity O
. O
We O
conclude O
that O

NHOH-4-ABP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O
for O
b5R B
and O
cyt O
b5 O
that O
yielded O
the O
highest O
activity O
in O
the O
purified O
system O
was O
also O
similar O
to O
that O
found O
in O
native O
HLM O
( O
approximately O
1:8 O
to O
1:10) O
. O
Polyclonal O
antisera O
to O
either O
b5R O
or O
cyt O
b5 O
significantly O
inhibited O
N-hydroxy-4-aminobiphenyl O
( O
NHOH-4-ABP O
reduction O
by O
95 O
and O
89% O
, O
respectively O
, O
and O
immunoreactive O
cyt O
b5 O
protein O
content O
in O
individual O
HLM O
was O
significantly O
correlated O
with O
individual O
reduction O
of O
both O
NHOH-4-ABP O
and O
N-hydroxy-PhIP O
(NHOH-PhIP) O
. O
Finally O
, O
titration O
of O
HLM O
into O
the O
purified O
b5R/cyt O
b5 O
system O
did O
not O
enhance O
the O
efficiency O
of O
reduction O
activity O
. O
We O
conclude O
that O
b5R O

NHOH-4-ABP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O
for O
b5R O
and O
cyt B
b5 I
that O
yielded O
the O
highest O
activity O
in O
the O
purified O
system O
was O
also O
similar O
to O
that O
found O
in O
native O
HLM O
( O
approximately O
1:8 O
to O
1:10) O
. O
Polyclonal O
antisera O
to O
either O
b5R O
or O
cyt O
b5 O
significantly O
inhibited O
N-hydroxy-4-aminobiphenyl O
( O
NHOH-4-ABP O
reduction O
by O
95 O
and O
89% O
, O
respectively O
, O
and O
immunoreactive O
cyt O
b5 O
protein O
content O
in O
individual O
HLM O
was O
significantly O
correlated O
with O
individual O
reduction O
of O
both O
NHOH-4-ABP O
and O
N-hydroxy-PhIP O
(NHOH-PhIP) O
. O
Finally O
, O
titration O
of O
HLM O
into O
the O
purified O
b5R/cyt O
b5 O
system O
did O
not O
enhance O
the O
efficiency O
of O
reduction O
activity O
. O
We O
conclude O
that O
b5R O

Imatinib O
acts O
as O
NOT O
for O
what O
entity O
? O
on O
in O
vitro O
osteoclast O
apoptosis O
and O
bone O
resorbing O
activity O
. O
Our O
findings O
demonstrate O
that O
imatinib O
dose-dependently O
stimulates O
osteoclast O
apoptosis O
, O
a O
phenomenon O
which O
is O
blocked O
by O
the O
caspase O
I O
inhibitor O
Z-VAD-fmk O
. O
The O
ability O
of O
imatinib O
to O
enhance O
osteoclast O
cell O
death O
was O
accompanied O
by O
a O
dose-dependent O
inhibition O
of O
osteoclast O
bone O
resorbing O
activity O
. O
Imatinib O
was O
also O
found O
to O
inhibit O
M-CSF-induced O
osteoclast O
survival O
as O
well O
as O
M-CSF-induced O
osteoclast O
bone O
resorbing O
activity O
, O
but O
was O
without O
effect O
on O
interleukin B
1alpha I
(IL-1alpha) O
and O
receptor O
activator O
of O
nuclear O
factor O
kappa O
B O
ligand O
(RANKL)-induced O
inhibition O
of O
osteoclasts O
apoptosis O
, O
further O
supporting O
the O
hypothesis O
that O
imatinib O
may O
affect O
mature O
osteoclasts O
through O

Imatinib O
acts O
as O
NOT O
for O
what O
entity O
? O
on O
in O
vitro O
osteoclast O
apoptosis O
and O
bone O
resorbing O
activity O
. O
Our O
findings O
demonstrate O
that O
imatinib O
dose-dependently O
stimulates O
osteoclast O
apoptosis O
, O
a O
phenomenon O
which O
is O
blocked O
by O
the O
caspase O
I O
inhibitor O
Z-VAD-fmk O
. O
The O
ability O
of O
imatinib O
to O
enhance O
osteoclast O
cell O
death O
was O
accompanied O
by O
a O
dose-dependent O
inhibition O
of O
osteoclast O
bone O
resorbing O
activity O
. O
Imatinib O
was O
also O
found O
to O
inhibit O
M-CSF-induced O
osteoclast O
survival O
as O
well O
as O
M-CSF-induced O
osteoclast O
bone O
resorbing O
activity O
, O
but O
was O
without O
effect O
on O
interleukin O
1alpha O
(IL-1alpha) O
and O
receptor O
activator O
of O
nuclear O
factor O
kappa O
B O
ligand O
(RANKL)-induced O
inhibition O
of O
osteoclasts O
apoptosis O
, O
further O
supporting O
the O
hypothesis O
that O
imatinib O
may O
affect O
mature O
osteoclasts O
through O

Imatinib O
acts O
as O
NOT O
for O
what O
entity O
? O
on O
in O
vitro O
osteoclast O
apoptosis O
and O
bone O
resorbing O
activity O
. O
Our O
findings O
demonstrate O
that O
imatinib O
dose-dependently O
stimulates O
osteoclast O
apoptosis O
, O
a O
phenomenon O
which O
is O
blocked O
by O
the O
caspase O
I O
inhibitor O
Z-VAD-fmk O
. O
The O
ability O
of O
imatinib O
to O
enhance O
osteoclast O
cell O
death O
was O
accompanied O
by O
a O
dose-dependent O
inhibition O
of O
osteoclast O
bone O
resorbing O
activity O
. O
Imatinib O
was O
also O
found O
to O
inhibit O
M-CSF-induced O
osteoclast O
survival O
as O
well O
as O
M-CSF-induced O
osteoclast O
bone O
resorbing O
activity O
, O
but O
was O
without O
effect O
on O
interleukin O
1alpha O
(IL-1alpha) O
and O
receptor B
activator I
of I
nuclear I
factor I
kappa I
B I
ligand I
(RANKL)-induced O
inhibition O
of O
osteoclasts O
apoptosis O
, O
further O
supporting O
the O
hypothesis O
that O
imatinib O
may O
affect O
mature O
osteoclasts O
through O

Imatinib O
acts O
as O
NOT O
for O
what O
entity O
? O
on O
in O
vitro O
osteoclast O
apoptosis O
and O
bone O
resorbing O
activity O
. O
Our O
findings O
demonstrate O
that O
imatinib O
dose-dependently O
stimulates O
osteoclast O
apoptosis O
, O
a O
phenomenon O
which O
is O
blocked O
by O
the O
caspase O
I O
inhibitor O
Z-VAD-fmk O
. O
The O
ability O
of O
imatinib O
to O
enhance O
osteoclast O
cell O
death O
was O
accompanied O
by O
a O
dose-dependent O
inhibition O
of O
osteoclast O
bone O
resorbing O
activity O
. O
Imatinib O
was O
also O
found O
to O
inhibit O
M-CSF-induced O
osteoclast O
survival O
as O
well O
as O
M-CSF-induced O
osteoclast O
bone O
resorbing O
activity O
, O
but O
was O
without O
effect O
on O
interleukin O
1alpha O
(IL-1alpha) O
and O
receptor O
activator O
of O
nuclear O
factor O
kappa O
B O
ligand O
(RANKL)-induced O
inhibition O
of O
osteoclasts O
apoptosis O
, O
further O
supporting O
the O
hypothesis O
that O
imatinib O
may O
affect O
mature O
osteoclasts O
through O

imatinib O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
that O
targets O
the O
intracellular O
tyrosine O
kinase O
BCR-ABL O
and O
the O
platelet O
derived O
growth O
factor O
(PDGF) O
receptor O
, O
is O
an O
effective O
inhibitor O
of O
the O
macrophage O
colony O
stimulating O
factor O
(M-CSF) O
receptor O
, O
c-FMS O
. O
Given O
that O
M-CSF B
signalling O
through O
c-FMS O
plays O
an O
important O
role O
in O
osteoclast O
biology O
, O
we O
speculated O
that O
blocking O
such O
a O
pathway O
with O
imatinib O
may O
modulate O
osteoclast O
activity O
. O
Using O
a O
cell O
model O
of O
mature O
rabbit O
osteoclasts O
, O
we O
thus O
investigated O
the O
effect O
of O
imatinib O
on O
in O
vitro O
osteoclast O
apoptosis O
and O
bone O
resorbing O
activity O
. O
Our O
findings O
demonstrate O
that O
imatinib O
dose-dependently O
stimulates O
osteoclast O
apoptosis O
, O
a O
phenomenon O
which O
is O
blocked O
by O
the O
caspase O
I O
inhibitor O
Z-VAD-fmk O
. O
The O

imatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
osteoclast O
bone O
resorbing O
activity O
. O
Imatinib O
was O
also O
found O
to O
inhibit O
M-CSF-induced O
osteoclast O
survival O
as O
well O
as O
M-CSF-induced O
osteoclast O
bone O
resorbing O
activity O
, O
but O
was O
without O
effect O
on O
interleukin O
1alpha O
(IL-1alpha) O
and O
receptor O
activator O
of O
nuclear O
factor O
kappa O
B O
ligand O
(RANKL)-induced O
inhibition O
of O
osteoclasts O
apoptosis O
, O
further O
supporting O
the O
hypothesis O
that O
imatinib O
may O
affect O
mature O
osteoclasts O
through O
the O
inhibition O
of O
c-FMS O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
imatinib O
could O
be O
of O
clinical O
value O
in O
treating O
diseases O
where O
bone O
destruction O
can O
occur O
due O
to O
excessive O
M-CSF O
production O
such O
as O
osteoporosis O
, O
inflammatory-and O
tumor-induced O
osteolysis O
. O

imatinib O
mesylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Imatinib O
mesylate O
(Gleevec) O
enhances O
mature O
osteoclast O
apoptosis O
and O
suppresses O
osteoclast O
bone O
resorbing O
activity.Recent O
studies O
have O
reported O
that O
imatinib O
mesylate O
a O
kinase O
inhibitor O
that O
targets O
the O
intracellular O
tyrosine B
kinase I
BCR-ABL O
and O
the O
platelet O
derived O
growth O
factor O
(PDGF) O
receptor O
, O
is O
an O
effective O
inhibitor O
of O
the O
macrophage O
colony O
stimulating O
factor O
(M-CSF) O
receptor O
, O
c-FMS O
. O
Given O
that O
M-CSF O
signalling O
through O
c-FMS O
plays O
an O
important O
role O
in O
osteoclast O
biology O
, O
we O
speculated O
that O
blocking O
such O

imatinib O
mesylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Imatinib O
mesylate O
(Gleevec) O
enhances O
mature O
osteoclast O
apoptosis O
and O
suppresses O
osteoclast O
bone O
resorbing O
activity.Recent O
studies O
have O
reported O
that O
imatinib O
mesylate O
a O
kinase O
inhibitor O
that O
targets O
the O
intracellular O
tyrosine O
kinase O
BCR-ABL O
and O
the O
platelet O
derived O
growth O
factor O
(PDGF) O
receptor O
, O
is O
an O
effective O
inhibitor O
of O
the O
macrophage O
colony O
stimulating O
factor O
(M-CSF) O
receptor O
, O
c-FMS O
. O
Given O
that O
M-CSF O
signalling O
through O
c-FMS O
plays O
an O
important O
role O
in O
osteoclast O
biology O
, O
we O
speculated O
that O
blocking O
such O

imatinib O
mesylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Imatinib O
mesylate O
(Gleevec) O
enhances O
mature O
osteoclast O
apoptosis O
and O
suppresses O
osteoclast O
bone O
resorbing O
activity.Recent O
studies O
have O
reported O
that O
imatinib O
mesylate O
a O
kinase O
inhibitor O
that O
targets O
the O
intracellular O
tyrosine O
kinase O
BCR-ABL O
and O
the O
platelet O
derived O
growth O
factor O
(PDGF) O
receptor O
, O
is O
an O
effective O
inhibitor O
of O
the O
macrophage O
colony O
stimulating O
factor O
(M-CSF) O
receptor O
, O
c-FMS O
. O
Given O
that O
M-CSF O
signalling O
through O
c-FMS O
plays O
an O
important O
role O
in O
osteoclast O
biology O
, O
we O
speculated O
that O
blocking O
such O

imatinib O
mesylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Imatinib O
mesylate O
(Gleevec) O
enhances O
mature O
osteoclast O
apoptosis O
and O
suppresses O
osteoclast O
bone O
resorbing O
activity.Recent O
studies O
have O
reported O
that O
imatinib O
mesylate O
a O
kinase O
inhibitor O
that O
targets O
the O
intracellular O
tyrosine O
kinase O
BCR-ABL O
and O
the O
platelet O
derived O
growth O
factor O
(PDGF) O
receptor O
, O
is O
an O
effective O
inhibitor O
of O
the O
macrophage O
colony O
stimulating O
factor O
(M-CSF) O
receptor O
, O
c-FMS O
. O
Given O
that O
M-CSF O
signalling O
through O
c-FMS O
plays O
an O
important O
role O
in O
osteoclast O
biology O
, O
we O
speculated O
that O
blocking O
such O

imatinib O
mesylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Imatinib O
mesylate O
(Gleevec) O
enhances O
mature O
osteoclast O
apoptosis O
and O
suppresses O
osteoclast O
bone O
resorbing O
activity.Recent O
studies O
have O
reported O
that O
imatinib O
mesylate O
a O
kinase O
inhibitor O
that O
targets O
the O
intracellular O
tyrosine O
kinase O
BCR-ABL O
and O
the O
platelet O
derived O
growth O
factor O
(PDGF) O
receptor O
, O
is O
an O
effective O
inhibitor O
of O
the O
macrophage O
colony O
stimulating O
factor O
(M-CSF) O
receptor O
, O
c-FMS O
. O
Given O
that O
M-CSF O
signalling O
through O
c-FMS O
plays O
an O
important O
role O
in O
osteoclast O
biology O
, O
we O
speculated O
that O
blocking O
such O

imatinib O
mesylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Imatinib O
mesylate O
(Gleevec) O
enhances O
mature O
osteoclast O
apoptosis O
and O
suppresses O
osteoclast O
bone O
resorbing O
activity.Recent O
studies O
have O
reported O
that O
imatinib O
mesylate O
a O
kinase O
inhibitor O
that O
targets O
the O
intracellular O
tyrosine O
kinase O
BCR-ABL O
and O
the O
platelet O
derived O
growth O
factor O
(PDGF) O
receptor O
, O
is O
an O
effective O
inhibitor O
of O
the O
macrophage O
colony O
stimulating O
factor O
(M-CSF) O
receptor O
, O
c-FMS O
. O
Given O
that O
M-CSF O
signalling O
through O
c-FMS B
plays O
an O
important O
role O
in O
osteoclast O
biology O
, O
we O
speculated O
that O
blocking O
such O

imatinib O
mesylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Imatinib O
mesylate O
(Gleevec) O
enhances O
mature O
osteoclast O
apoptosis O
and O
suppresses O
osteoclast O
bone O
resorbing O
activity.Recent O
studies O
have O
reported O
that O
imatinib O
mesylate O
a O
kinase B
inhibitor O
that O
targets O
the O
intracellular O
tyrosine O
kinase O
BCR-ABL O
and O
the O
platelet O
derived O
growth O
factor O
(PDGF) O
receptor O
, O
is O
an O
effective O
inhibitor O
of O
the O
macrophage O
colony O
stimulating O
factor O
(M-CSF) O
receptor O
, O
c-FMS O
. O
Given O
that O
M-CSF O
signalling O
through O
c-FMS O
plays O
an O
important O
role O
in O
osteoclast O
biology O
, O
we O
speculated O
that O
blocking O
such O

imatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
that O
targets O
the O
intracellular O
tyrosine O
kinase O
BCR-ABL O
and O
the O
platelet O
derived O
growth O
factor O
(PDGF) O
receptor O
, O
is O
an O
effective O
inhibitor O
of O
the O
macrophage O
colony O
stimulating O
factor O
(M-CSF) O
receptor O
, O
c-FMS O
. O
Given O
that O
M-CSF O
signalling O
through O
c-FMS B
plays O
an O
important O
role O
in O
osteoclast O
biology O
, O
we O
speculated O
that O
blocking O
such O
a O
pathway O
with O
imatinib O
may O
modulate O
osteoclast O
activity O
. O
Using O
a O
cell O
model O
of O
mature O
rabbit O
osteoclasts O
, O
we O
thus O
investigated O
the O
effect O
of O
imatinib O
on O
in O
vitro O
osteoclast O
apoptosis O
and O
bone O
resorbing O
activity O
. O
Our O
findings O
demonstrate O
that O
imatinib O
dose-dependently O
stimulates O
osteoclast O
apoptosis O
, O
a O
phenomenon O
which O
is O
blocked O
by O
the O
caspase O
I O
inhibitor O
Z-VAD-fmk O
. O
The O

Imatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
on O
in O
vitro O
osteoclast O
apoptosis O
and O
bone O
resorbing O
activity O
. O
Our O
findings O
demonstrate O
that O
imatinib O
dose-dependently O
stimulates O
osteoclast O
apoptosis O
, O
a O
phenomenon O
which O
is O
blocked O
by O
the O
caspase O
I O
inhibitor O
Z-VAD-fmk O
. O
The O
ability O
of O
imatinib O
to O
enhance O
osteoclast O
cell O
death O
was O
accompanied O
by O
a O
dose-dependent O
inhibition O
of O
osteoclast O
bone O
resorbing O
activity O
. O
Imatinib O
was O
also O
found O
to O
inhibit O
M-CSF-induced O
osteoclast O
survival O
as O
well O
as O
M-CSF-induced O
osteoclast O
bone O
resorbing O
activity O
, O
but O
was O
without O
effect O
on O
interleukin O
1alpha O
(IL-1alpha) O
and O
receptor O
activator O
of O
nuclear O
factor O
kappa O
B O
ligand O
(RANKL)-induced O
inhibition O
of O
osteoclasts O
apoptosis O
, O
further O
supporting O
the O
hypothesis O
that O
imatinib O
may O
affect O
mature O
osteoclasts O
through O

Imatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
on O
in O
vitro O
osteoclast O
apoptosis O
and O
bone O
resorbing O
activity O
. O
Our O
findings O
demonstrate O
that O
imatinib O
dose-dependently O
stimulates O
osteoclast O
apoptosis O
, O
a O
phenomenon O
which O
is O
blocked O
by O
the O
caspase O
I O
inhibitor O
Z-VAD-fmk O
. O
The O
ability O
of O
imatinib O
to O
enhance O
osteoclast O
cell O
death O
was O
accompanied O
by O
a O
dose-dependent O
inhibition O
of O
osteoclast O
bone O
resorbing O
activity O
. O
Imatinib O
was O
also O
found O
to O
inhibit O
M-CSF-induced O
osteoclast O
survival O
as O
well O
as O
M-CSF-induced O
osteoclast O
bone O
resorbing O
activity O
, O
but O
was O
without O
effect O
on O
interleukin O
1alpha O
(IL-1alpha) O
and O
receptor O
activator O
of O
nuclear O
factor O
kappa O
B O
ligand O
(RANKL)-induced O
inhibition O
of O
osteoclasts O
apoptosis O
, O
further O
supporting O
the O
hypothesis O
that O
imatinib O
may O
affect O
mature O
osteoclasts O
through O

moclobemide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
12% O
during O
toloxatone O
(P O
less O
than O
0.001) O
and O
the O
overall O
decrease O
in O
HVA O
was O
38% O
and O
20% O
(P O
less O
than O
0.005) O
on O
moclobemide O
and O
toloxatone O
, O
respectively O
. O
4 O
. O
Before O
the O
next O
drug O
intake O
, O
MAO-A B
inhibition O
, O
as O
judged O
by O
the O
decrease O
of O
plasma O
DHPG O
concentration O
, O
was O
significantly O
different O
from O
placebo O
with O
moclobemide O
but O
not O
with O
toloxatone O
. O
5 O
. O
Moclobemide O
, O
but O
not O
toloxatone O
, O
exerted O
a O
moderate O
, O
but O
significant O
inhibition O
of O
the O
deamination O
of O
5-hydroxytryptamine O
(5-HT) O
as O
judged O
by O
the O
fall O
in O
plasma O
5-HIAA O
concentration O
. O
Neither O
drug O
influenced O
plasma O
NA O
concentration O
. O
6 O
. O
A O
significant O
rise O
in O
urinary O
excretion O
of O
normetanephrine O
was O
observed O
on O
moclobemide O

toloxatone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
less O
than O
0.001) O
and O
the O
overall O
decrease O
in O
HVA O
was O
38% O
and O
20% O
(P O
less O
than O
0.005) O
on O
moclobemide O
and O
toloxatone O
, O
respectively O
. O
4 O
. O
Before O
the O
next O
drug O
intake O
, O
MAO-A B
inhibition O
, O
as O
judged O
by O
the O
decrease O
of O
plasma O
DHPG O
concentration O
, O
was O
significantly O
different O
from O
placebo O
with O
moclobemide O
but O
not O
with O
toloxatone O
5 O
. O
Moclobemide O
, O
but O
not O
toloxatone O
, O
exerted O
a O
moderate O
, O
but O
significant O
inhibition O
of O
the O
deamination O
of O
5-hydroxytryptamine O
(5-HT) O
as O
judged O
by O
the O
fall O
in O
plasma O
5-HIAA O
concentration O
. O
Neither O
drug O
influenced O
plasma O
NA O
concentration O
. O
6 O
. O
A O
significant O
rise O
in O
urinary O
excretion O
of O
normetanephrine O
was O
observed O
on O
moclobemide O
and O
to O
a O
lesser O

moclobemide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Comparison O
of O
the O
monoamine O
oxidase O
inhibiting O
properties O
of O
two O
reversible O
and O
selective O
monoamine B
oxidase-A I
inhibitors O
moclobemide O
and O
toloxatone O
, O
and O
assessment O
of O
their O
effect O
on O
psychometric O
performance O
in O
healthy O
subjects.1 O
. O
The O
effects O
of O
two O
reversible O
, O
predominantly O
monoamine O
oxidase-A O
(MAO-A) O
inhibitors O
, O
moclobemide O
(150 O
mg O
three O
times O
daily) O
and O
toloxatone O
(400-200-400 O
mg O
day-1) O
on O
monoamine O
metabolites O
and O
psychometric O
performance O
were O
compared O
in O
a O
double-blind O
placebo O
controlled O
crossover O
study O
in O
12 O
healthy O
subjects O
. O
2 O
. O
After O
7 O
days O
of O
moclobemide/toloxatone/placebo O
administration O
subjects O
were O
hospitalized O
for O
24 O
h O
on O
day O
8 O
. O
Blood O
samples O
were O
drawn O

moclobemide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Comparison O
of O
the O
monoamine B
oxidase I
inhibiting O
properties O
of O
two O
reversible O
and O
selective O
monoamine O
oxidase-A O
inhibitors O
moclobemid O
and O
toloxatone O
, O
and O
assessment O
of O
their O
effect O
on O
psychometric O
performance O
in O
healthy O
subjects.1 O
. O
The O
effects O
of O
two O
reversible O
, O
predominantly O
monoamine O
oxidase-A O
(MAO-A) O
inhibitors O
, O
moclobemide O
(150 O
mg O
three O
times O
daily) O
and O
toloxatone O
(400-200-400 O
mg O
day-1) O
on O
monoamine O
metabolites O
and O
psychometric O
performance O
were O
compared O
in O
a O
double-blind O
placebo O
controlled O
crossover O
study O

moclobemide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Comparison O
of O
the O
monoamine O
oxidase O
inhibiting O
properties O
of O
two O
reversible O
and O
selective O
monoamine B
oxidase-A I
inhibitors O
moclobemid O
and O
toloxatone O
, O
and O
assessment O
of O
their O
effect O
on O
psychometric O
performance O
in O
healthy O
subjects.1 O
. O
The O
effects O
of O
two O
reversible O
, O
predominantly O
monoamine O
oxidase-A O
(MAO-A) O
inhibitors O
, O
moclobemide O
(150 O
mg O
three O
times O
daily) O
and O
toloxatone O
(400-200-400 O
mg O
day-1) O
on O
monoamine O
metabolites O
and O
psychometric O
performance O
were O
compared O
in O
a O
double-blind O
placebo O
controlled O
crossover O
study O

toloxatone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Comparison O
of O
the O
monoamine B
oxidase I
inhibiting O
properties O
of O
two O
reversible O
and O
selective O
monoamine O
oxidase-A O
inhibitors O
moclobemide O
and O
toloxaton O
 O
, O
and O
assessment O
of O
their O
effect O
on O
psychometric O
performance O
in O
healthy O
subjects.1 O
. O
The O
effects O
of O
two O
reversible O
, O
predominantly O
monoamine O
oxidase-A O
(MAO-A) O
inhibitors O
, O
moclobemide O
(150 O
mg O
three O
times O
daily) O
and O
toloxatone O
(400-200-400 O
mg O
day-1) O
on O
monoamine O
metabolites O
and O
psychometric O
performance O
were O
compared O
in O
a O
double-blind O
placebo O
controlled O
crossover O
study O
in O

toloxatone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Comparison O
of O
the O
monoamine O
oxidase O
inhibiting O
properties O
of O
two O
reversible O
and O
selective O
monoamine B
oxidase-A I
inhibitors O
moclobemide O
and O
toloxaton O
 O
, O
and O
assessment O
of O
their O
effect O
on O
psychometric O
performance O
in O
healthy O
subjects.1 O
. O
The O
effects O
of O
two O
reversible O
, O
predominantly O
monoamine O
oxidase-A O
(MAO-A) O
inhibitors O
, O
moclobemide O
(150 O
mg O
three O
times O
daily) O
and O
toloxatone O
(400-200-400 O
mg O
day-1) O
on O
monoamine O
metabolites O
and O
psychometric O
performance O
were O
compared O
in O
a O
double-blind O
placebo O
controlled O
crossover O
study O
in O

toloxatone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Comparison O
of O
the O
monoamine O
oxidase O
inhibiting O
properties O
of O
two O
reversible O
and O
selective O
monoamine B
oxidase-A I
inhibitors O
moclobemide O
and O
toloxatone O
, O
and O
assessment O
of O
their O
effect O
on O
psychometric O
performance O
in O
healthy O
subjects.1 O
. O
The O
effects O
of O
two O
reversible O
, O
predominantly O
monoamine O
oxidase-A O
(MAO-A) O
inhibitors O
, O
moclobemide O
(150 O
mg O
three O
times O
daily) O
and O
toloxatone O
(400-200-400 O
mg O
day-1) O
on O
monoamine O
metabolites O
and O
psychometric O
performance O
were O
compared O
in O
a O
double-blind O
placebo O
controlled O
crossover O
study O
in O
12 O
healthy O
subjects O
. O
2 O
. O
After O
7 O
days O
of O
moclobemide/toloxatone/placebo O
administration O
subjects O
were O
hospitalized O
for O
24 O
h O
on O
day O
8 O
. O
Blood O
samples O
were O
drawn O
every O
2 O
h O
for O
determination O
of O
plasma O

enalkiren O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkire O
 O
, O
a O
novel O
, O
dipeptide O
renin B
inhibitor.Enalkiren O
(A-64662) O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human O
renin O
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin O
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O
0.1 O
mg/kg O

dipeptide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkiren O
, O
a O
novel O
, O
dipeptid O
renin B
inhibitor.Enalkiren O
(A-64662) O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human O
renin O
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin O
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O
0.1 O
mg/kg O
induced O
little O
hemodynamic O
response O

Enalkiren O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkiren O
, O
a O
novel O
, O
dipeptide O
renin B
inhibitor O
. O
Enalkiren O
(A-64662) O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human O
renin O
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin O
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O
0.1 O
mg/kg O
induced O
little O
hemodynamic O
response O
in O
normotensive O

Enalkiren O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkiren O
, O
a O
novel O
, O
dipeptide O
renin O
inhibitor O
. O
Enalkiren O
(A-64662) O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human B
renin I
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin O
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O
0.1 O
mg/kg O
induced O
little O
hemodynamic O
response O
in O
normotensive O

A-64662 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkiren O
, O
a O
novel O
, O
dipeptide O
renin B
inhibitor.Enalkiren O
( O
A-64662 O
 O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human O
renin O
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin O
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O
0.1 O
mg/kg O
induced O
little O
hemodynamic O
response O
in O
normotensive O

A-64662 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkiren O
, O
a O
novel O
, O
dipeptide O
renin O
inhibitor.Enalkiren O
( O
A-64662 O
 O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human B
renin I
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin O
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O
0.1 O
mg/kg O
induced O
little O
hemodynamic O
response O
in O
normotensive O

enalkiren O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
h) O
. O
Persistent O
pharmacologic O
activity O
without O
evidence O
of O
tachyphylaxis O
was O
demonstrated O
during O
1 O
week O
of O
treatment O
in O
hypertensive O
patients O
. O
The O
observed O
dissociation O
between O
suppression O
of O
PRA O
and O
BP O
response O
and O
the O
recruitment O
of O
dose-related O
BP O
decrements O
, O
despite O
complete O
suppression O
of O
PRA O
, O
are O
unexplained O
phenomena O
. O
The O
results O
of O
clinical O
trials O
with O
enalkiren O
are O
encouraging O
, O
and O
suggest O
that O
renin B
inhibitors O
may O
be O
safe O
, O
useful O
therapeutic O
agents O
in O
the O
management O
of O
hypertension O
. O

Enalkiren O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkiren O
, O
a O
novel O
, O
dipeptide O
renin B
inhibitor.Enalkiren O
(A-64662) O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human O
renin O
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin O
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O
0.1 O
mg/kg O
induced O
little O
hemodynamic O
response O
in O
normotensive O
and O
hypertensive O
volunteers O
despite O
marked O
suppression O
of O
PRA O
. O
However O
, O
at O
doses O
of O
0.3 O
and O
1.2 O
mg/kg O
, O
enalkiren O

Enalkiren O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkiren O
, O
a O
novel O
, O
dipeptide O
renin O
inhibitor.Enalkiren O
(A-64662) O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human O
renin O
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin O
activity O
(PRA) O
and O
angiotensin B
II I
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O
0.1 O
mg/kg O
induced O
little O
hemodynamic O
response O
in O
normotensive O
and O
hypertensive O
volunteers O
despite O
marked O
suppression O
of O
PRA O
. O
However O
, O
at O
doses O
of O
0.3 O
and O
1.2 O
mg/kg O
, O
enalkiren O

dipeptide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkiren O
, O
a O
novel O
, O
dipeptide O
renin B
inhibitor.Enalkiren O
(A-64662) O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human O
renin O
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin O
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O
0.1 O
mg/kg O
induced O
little O
hemodynamic O
response O
in O
normotensive O
and O
hypertensive O
volunteers O
despite O

dipeptide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkiren O
, O
a O
novel O
, O
dipeptide O
renin O
inhibitor.Enalkiren O
(A-64662) O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human B
renin I
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin O
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O
0.1 O
mg/kg O
induced O
little O
hemodynamic O
response O
in O
normotensive O
and O
hypertensive O
volunteers O
despite O

risperidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
level O
had O
been O
established O
, O
so O
these O
parameters O
could O
not O
account O
for O
the O
latency O
period O
required O
for O
clinical O
response O
. O
D2 B
receptor I
occupancy O
at O
48 O
h O
correlated O
positively O
with O
clinical O
improvement O
after O
2 O
weeks O
of O
treatment O
. O
Therefore O
, O
if O
these O
results O
are O
confirmed O
, O
D2 O
receptor O
occupancy O
at O
the O
beginning O
of O
treatment O
with O
risperidone O
may O
be O
a O
predictor O
of O
subsequent O
clinical O
response O
. O

risperidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Dopamine O
D2 O
receptor O
occupancy O
by O
risperidone O
: O
implications O
for O
the O
timing O
and O
magnitude O
of O
clinical O
response.The O
objective O
of O
the O
study O
is O
to O
investigate O
whether O
dopamine B
D2 I
receptor I
occupancy O
by O
risperidone O
and O
plasma O
levels O
over O
time O
can O
account O
for O
therapeutic O
efficacy O
and O
the O
latency O
period O
to O
response O
. O
Thirty-eight O
examinations O
with O
(123)I-IBZM O
single O
photon O
emission O
computed O
tomography O
were O
performed O
on O
22 O
patients O
with O
schizophrenia O
, O
at O
diagnosis O
, O
48 O
h O
after O
starting O
risperidone O
treatment O
and O
at O
a O
stable O
dose O
. O
Risperidone O
plasma O
levels O
were O

risperidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Dopamine B
D2 I
receptor I
occupancy O
by O
risperidon O
 O
: O
implications O
for O
the O
timing O
and O
magnitude O
of O
clinical O
response.The O
objective O
of O
the O
study O
is O
to O
investigate O
whether O
dopamine O
D2 O
receptor O
occupancy O
by O
risperidone O
and O
plasma O
levels O
over O
time O
can O
account O
for O
therapeutic O
efficacy O
and O
the O
latency O
period O
to O
response O
. O
Thirty-eight O
examinations O
with O
(123)I-IBZM O
single O
photon O
emission O
computed O
tomography O

toremifene O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
fractures O
. O
Estrogens O
play O
a O
central O
role O
in O
homeostasis O
of O
the O
normal O
male O
skeleton O
, O
and O
estrogen O
deficiency O
rather O
than O
testosterone O
deficiency O
seems O
to O
be O
primarily O
responsible O
for O
the O
adverse O
skeletal O
effects O
of O
GnRH O
agonists O
. O
In O
randomized O
controlled O
trials O
, O
bisphosphonates O
(pamidronate O
and O
zoledronic O
acid) O
and O
selective O
estrogen B
receptor I
modulators O
(raloxifene O
and O
toremifene O
increased O
bone O
mineral O
density O
in O
GnRH O
agonist-treated O
men O
. O
Two O
ongoing O
large O
randomized O
placebo-controlled O
studies O
will O
prospectively O
define O
fracture O
outcomes O
in O
men O
with O
prostate O
cancer O
and O
assess O
the O
efficacy O
of O
novel O
pharmacologic O
interventions O
(AMG162 O
, O
toremifene) O
during O
GnRH O
agonist O
treatment O
. O

raloxifene O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
clinical O
fractures O
. O
Estrogens O
play O
a O
central O
role O
in O
homeostasis O
of O
the O
normal O
male O
skeleton O
, O
and O
estrogen O
deficiency O
rather O
than O
testosterone O
deficiency O
seems O
to O
be O
primarily O
responsible O
for O
the O
adverse O
skeletal O
effects O
of O
GnRH O
agonists O
. O
In O
randomized O
controlled O
trials O
, O
bisphosphonates O
(pamidronate O
and O
zoledronic O
acid) O
and O
selective O
estrogen B
receptor I
modulators O
( O
raloxifene O
and O
toremifene) O
increased O
bone O
mineral O
density O
in O
GnRH O
agonist-treated O
men O
. O
Two O
ongoing O
large O
randomized O
placebo-controlled O
studies O
will O
prospectively O
define O
fracture O
outcomes O
in O
men O
with O
prostate O
cancer O
and O
assess O
the O
efficacy O
of O
novel O
pharmacologic O
interventions O
(AMG162 O
, O
toremifene) O
during O
GnRH O
agonist O
treatment O
. O

olanzapine O
acts O
as O
NOT O
for O
what O
entity O
? O
significant O
deficits O
on O
the O
match-to-place O
version O
. O
Brain O
tissue O
analyses O
revealed O
that O
neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
hippocampal O
NGF O
, O
BDNF B
and O
ChAT O
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
Neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
BDNF O
and O
ChAT O
in O
the O
frontal O
cortex O
that O
was O
unaffected O
by O
olanzapine O
treatment O
. O
These O
results O
show O
that O
olanzapine O
eliminates O
D2 O
receptor O
priming O
and O
cognitive O
impairment O
and O
also O
alleviates O
decreases O
in O
neurotrophins O
and O
acetylcholinergic O
markers O
produced O
by O
D2 O
priming O
in O
the O
hippocampus O
. O

olanzapine O
acts O
as O
NOT O
for O
what O
entity O
? O
significant O
deficits O
on O
the O
match-to-place O
version O
. O
Brain O
tissue O
analyses O
revealed O
that O
neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
hippocampal O
NGF O
, O
BDNF O
and O
ChAT B
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
Neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
BDNF O
and O
ChAT O
in O
the O
frontal O
cortex O
that O
was O
unaffected O
by O
olanzapine O
treatment O
. O
These O
results O
show O
that O
olanzapine O
eliminates O
D2 O
receptor O
priming O
and O
cognitive O
impairment O
and O
also O
alleviates O
decreases O
in O
neurotrophins O
and O
acetylcholinergic O
markers O
produced O
by O
D2 O
priming O
in O
the O
hippocampus O
. O

quinpirole O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
adulthood O
olanzapine O
treatment O
on O
cognitive O
performance O
and O
neurotrophic B
factor I
content O
in O
male O
and O
female O
rats O
neonatally O
treated O
with O
quinpirol O
.Male O
and O
female O
Sprague-Dawley O
rats O
were O
administered O
quinpirole O
(1 O
mg/kg O
, O
i.p.) O
or O
saline O
once O
daily O
from O
postnatal O
day O
(P)1 O
to O
P21 O
. O
This O
drug O
treatment O
has O
been O
shown O
to O
produce O
long-term O
priming O
of O
the O
D2 O
receptor O
. O
Beginning O
on O
P62 O
, O
rats O
were O
administered O
the O
atypical O
antipsychotic O
olanzapine O
(2.5 O
mg/kg) O
or O
saline O

quinpirole O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
place O
and O
match-to-place O
versions O
of O
the O
Morris O
water O
maze O
(MWM) O
for O
seven O
consecutive O
days O
. O
Dopamine O
D2 B
receptor O
priming O
was O
verified O
through O
a O
yawning O
behavioural O
test O
, O
a O
D2 O
receptor-mediated O
event O
, O
before O
olanzapine O
was O
administered O
as O
well O
as O
after O
olanzapine O
treatment O
and O
behavioural O
testing O
were O
complete O
. O
Results O
showed O
that O
neonatal O
quinpirole O
treatment O
induced O
D2 O
priming O
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
On O
the O
MWM O
place O
version O
, O
D2-primed O
rats O
demonstrated O
a O
significant O
impairment O
that O
was O
eliminated O
by O
olanzapine O
treatment O
, O
but O
olanzapine O
treatment O
to O
animals O
neonatally O
treated O
with O
saline O
produced O
a O
significant O
deficit O
on O
the O
place O
version O
of O
the O
MWM O
. O
There O
were O

olanzapine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
treatment O
to O
animals O
neonatally O
treated O
with O
saline O
produced O
a O
significant O
deficit O
on O
the O
place O
version O
of O
the O
MWM O
. O
There O
were O
no O
significant O
deficits O
on O
the O
match-to-place O
version O
. O
Brain O
tissue O
analyses O
revealed O
that O
neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
hippocampal O
NGF O
, O
BDNF O
and O
ChAT O
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
Neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
BDNF O
and O
ChAT O
in O
the O
frontal O
cortex O
that O
was O
unaffected O
by O
olanzapine O
treatment O
. O
These O
results O
show O
that O
olanzapine O
eliminates O
D2 O
receptor O
priming O
and O
cognitive O
impairment O
and O
also O
alleviates O
decreases O
in O
neurotrophins O
and O
acetylcholinergic O
markers O
produced O
by O
D2 O
priming O
in O
the O

olanzapine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
treatment O
to O
animals O
neonatally O
treated O
with O
saline O
produced O
a O
significant O
deficit O
on O
the O
place O
version O
of O
the O
MWM O
. O
There O
were O
no O
significant O
deficits O
on O
the O
match-to-place O
version O
. O
Brain O
tissue O
analyses O
revealed O
that O
neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
hippocampal O
NGF O
, O
BDNF B
and O
ChAT O
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
Neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
BDNF O
and O
ChAT O
in O
the O
frontal O
cortex O
that O
was O
unaffected O
by O
olanzapine O
treatment O
. O
These O
results O
show O
that O
olanzapine O
eliminates O
D2 O
receptor O
priming O
and O
cognitive O
impairment O
and O
also O
alleviates O
decreases O
in O
neurotrophins O
and O
acetylcholinergic O
markers O
produced O
by O
D2 O
priming O
in O
the O

olanzapine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
treatment O
to O
animals O
neonatally O
treated O
with O
saline O
produced O
a O
significant O
deficit O
on O
the O
place O
version O
of O
the O
MWM O
. O
There O
were O
no O
significant O
deficits O
on O
the O
match-to-place O
version O
. O
Brain O
tissue O
analyses O
revealed O
that O
neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
hippocampal O
NGF O
, O
BDNF O
and O
ChAT B
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
Neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
BDNF O
and O
ChAT O
in O
the O
frontal O
cortex O
that O
was O
unaffected O
by O
olanzapine O
treatment O
. O
These O
results O
show O
that O
olanzapine O
eliminates O
D2 O
receptor O
priming O
and O
cognitive O
impairment O
and O
also O
alleviates O
decreases O
in O
neurotrophins O
and O
acetylcholinergic O
markers O
produced O
by O
D2 O
priming O
in O
the O

olanzapine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
maze O
(MWM) O
for O
seven O
consecutive O
days O
. O
Dopamine O
D2 B
receptor O
priming O
was O
verified O
through O
a O
yawning O
behavioural O
test O
, O
a O
D2 O
receptor-mediated O
event O
, O
before O
olanzapine O
was O
administered O
as O
well O
as O
after O
olanzapine O
treatment O
and O
behavioural O
testing O
were O
complete O
. O
Results O
showed O
that O
neonatal O
quinpirole O
treatment O
induced O
D2 O
priming O
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
On O
the O
MWM O
place O
version O
, O
D2-primed O
rats O
demonstrated O
a O
significant O
impairment O
that O
was O
eliminated O
by O
olanzapine O
treatment O
, O
but O
olanzapine O
treatment O
to O
animals O
neonatally O
treated O
with O
saline O
produced O
a O
significant O
deficit O
on O
the O
place O
version O
of O
the O
MWM O
. O
There O
were O
no O
significant O
deficits O
on O
the O
match-to-place O
version O
. O
Brain O
tissue O

quinpirole O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
place O
version O
, O
D2-primed O
rats O
demonstrated O
a O
significant O
impairment O
that O
was O
eliminated O
by O
olanzapine O
treatment O
, O
but O
olanzapine O
treatment O
to O
animals O
neonatally O
treated O
with O
saline O
produced O
a O
significant O
deficit O
on O
the O
place O
version O
of O
the O
MWM O
. O
There O
were O
no O
significant O
deficits O
on O
the O
match-to-place O
version O
. O
Brain O
tissue O
analyses O
revealed O
that O
neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
hippocampal O
NGF O
, O
BDNF O
and O
ChAT O
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
Neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
BDNF O
and O
ChAT O
in O
the O
frontal O
cortex O
that O
was O
unaffected O
by O
olanzapine O
treatment O
. O
These O
results O
show O
that O
olanzapine O
eliminates O
D2 O
receptor O
priming O
and O
cognitive O

quinpirole O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
place O
version O
, O
D2-primed O
rats O
demonstrated O
a O
significant O
impairment O
that O
was O
eliminated O
by O
olanzapine O
treatment O
, O
but O
olanzapine O
treatment O
to O
animals O
neonatally O
treated O
with O
saline O
produced O
a O
significant O
deficit O
on O
the O
place O
version O
of O
the O
MWM O
. O
There O
were O
no O
significant O
deficits O
on O
the O
match-to-place O
version O
. O
Brain O
tissue O
analyses O
revealed O
that O
neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
hippocampal O
NGF O
, O
BDNF B
and O
ChAT O
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
Neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
BDNF O
and O
ChAT O
in O
the O
frontal O
cortex O
that O
was O
unaffected O
by O
olanzapine O
treatment O
. O
These O
results O
show O
that O
olanzapine O
eliminates O
D2 O
receptor O
priming O
and O
cognitive O

quinpirole O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
place O
version O
, O
D2-primed O
rats O
demonstrated O
a O
significant O
impairment O
that O
was O
eliminated O
by O
olanzapine O
treatment O
, O
but O
olanzapine O
treatment O
to O
animals O
neonatally O
treated O
with O
saline O
produced O
a O
significant O
deficit O
on O
the O
place O
version O
of O
the O
MWM O
. O
There O
were O
no O
significant O
deficits O
on O
the O
match-to-place O
version O
. O
Brain O
tissue O
analyses O
revealed O
that O
neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
hippocampal O
NGF O
, O
BDNF O
and O
ChAT B
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
Neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
BDNF O
and O
ChAT O
in O
the O
frontal O
cortex O
that O
was O
unaffected O
by O
olanzapine O
treatment O
. O
These O
results O
show O
that O
olanzapine O
eliminates O
D2 O
receptor O
priming O
and O
cognitive O

quinpirole O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
neonatally O
treated O
with O
saline O
produced O
a O
significant O
deficit O
on O
the O
place O
version O
of O
the O
MWM O
. O
There O
were O
no O
significant O
deficits O
on O
the O
match-to-place O
version O
. O
Brain O
tissue O
analyses O
revealed O
that O
neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
hippocampal O
NGF O
, O
BDNF B
and O
ChAT O
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
Neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
BDNF O
and O
ChAT O
in O
the O
frontal O
cortex O
that O
was O
unaffected O
by O
olanzapine O
treatment O
. O
These O
results O
show O
that O
olanzapine O
eliminates O
D2 O
receptor O
priming O
and O
cognitive O
impairment O
and O
also O
alleviates O
decreases O
in O
neurotrophins O
and O
acetylcholinergic O
markers O
produced O
by O
D2 O
priming O
in O
the O
hippocampus O
. O

quinpirole O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
neonatally O
treated O
with O
saline O
produced O
a O
significant O
deficit O
on O
the O
place O
version O
of O
the O
MWM O
. O
There O
were O
no O
significant O
deficits O
on O
the O
match-to-place O
version O
. O
Brain O
tissue O
analyses O
revealed O
that O
neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
hippocampal O
NGF O
, O
BDNF O
and O
ChAT B
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
Neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
BDNF O
and O
ChAT O
in O
the O
frontal O
cortex O
that O
was O
unaffected O
by O
olanzapine O
treatment O
. O
These O
results O
show O
that O
olanzapine O
eliminates O
D2 O
receptor O
priming O
and O
cognitive O
impairment O
and O
also O
alleviates O
decreases O
in O
neurotrophins O
and O
acetylcholinergic O
markers O
produced O
by O
D2 O
priming O
in O
the O
hippocampus O
. O

olanzapine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Brain O
tissue O
analyses O
revealed O
that O
neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
hippocampal O
NGF O
, O
BDNF O
and O
ChAT O
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
Neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
BDNF O
and O
ChAT O
in O
the O
frontal O
cortex O
that O
was O
unaffected O
by O
olanzapine O
treatment O
. O
These O
results O
show O
that O
olanzapine O
eliminates O
D2 B
receptor I
priming O
and O
cognitive O
impairment O
and O
also O
alleviates O
decreases O
in O
neurotrophins O
and O
acetylcholinergic O
markers O
produced O
by O
D2 O
priming O
in O
the O
hippocampus O
. O

toluene O
diisocyanate O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
by O
nasal O
hypersensitivity O
. O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC B
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O
by O
the O
exposure O
to O
toluene O
diisocyanate O
(TDI) O
and O
to O
investigate O
the O
effect O
of O
dexamethasone O
on O
the O
above O
mentioned O
allergic O
parameters O
. O
METHODS O
: O
Rats O
were O
sensitized O
and O
provocated O
by O
TDI O
and O
the O
nasal O
allergy-like O
behaviors O
were O
scored O
during O
a O
10 O
minute O
period O
after O
provocation O
. O
Histamine O
content O
and O
HDC O
activity O
in O
the O
nasal O
mucosa O
were O
determined O
using O
fluorometric O

TDI O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC B
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O
by O
the O
exposure O
to O
toluene O
diisocyanate O
( O
TDI O
and O
to O
investigate O
the O
effect O
of O
dexamethasone O
on O
the O
above O
mentioned O
allergic O
parameters O
. O
METHODS O
: O
Rats O
were O
sensitized O
and O
provocated O
by O
TDI O
and O
the O
nasal O
allergy-like O
behaviors O
were O
scored O
during O
a O
10 O
minute O
period O
after O
provocation O
. O
Histamine O
content O
and O
HDC O
activity O
in O
the O
nasal O
mucosa O
were O
determined O
using O
fluorometric O
high O

dexamethasone O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
synthesis O
by O
HDC B
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O
by O
the O
exposure O
to O
toluene O
diisocyanate O
(TDI) O
and O
to O
investigate O
the O
effect O
of O
dexamethasone O
on O
the O
above O
mentioned O
allergic O
parameters O
. O
METHODS O
: O
Rats O
were O
sensitized O
and O
provocated O
by O
TDI O
and O
the O
nasal O
allergy-like O
behaviors O
were O
scored O
during O
a O
10 O
minute O
period O
after O
provocation O
. O
Histamine O
content O
and O
HDC O
activity O
in O
the O
nasal O
mucosa O
were O
determined O
using O
fluorometric O
high O
performance O
liquid O
chromatography O
. O
The O
expression O
of O
HDC O

toluene O
diisocyanate O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
by O
nasal O
hypersensitivity O
. O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC B
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O
by O
the O
exposure O
to O
toluene O
diisocyanate O
(TDI) O
and O
to O
investigate O
the O
effect O
of O
dexamethasone O
on O
the O
above O
mentioned O
allergic O
parameters O
. O
METHODS O
: O
Rats O
were O
sensitized O
and O
provocated O
by O
TDI O
and O
the O
nasal O
allergy-like O
behaviors O
were O
scored O
during O
a O
10 O
minute O
period O
after O
provocation O
. O
Histamine O
content O
and O
HDC O
activity O
in O
the O
nasal O
mucosa O
were O
determined O
using O
fluorometric O

TDI O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC B
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O
by O
the O
exposure O
to O
toluene O
diisocyanate O
( O
TDI O
and O
to O
investigate O
the O
effect O
of O
dexamethasone O
on O
the O
above O
mentioned O
allergic O
parameters O
. O
METHODS O
: O
Rats O
were O
sensitized O
and O
provocated O
by O
TDI O
and O
the O
nasal O
allergy-like O
behaviors O
were O
scored O
during O
a O
10 O
minute O
period O
after O
provocation O
. O
Histamine O
content O
and O
HDC O
activity O
in O
the O
nasal O
mucosa O
were O
determined O
using O
fluorometric O
high O

dexamethasone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
synthesis O
by O
HDC B
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O
by O
the O
exposure O
to O
toluene O
diisocyanate O
(TDI) O
and O
to O
investigate O
the O
effect O
of O
dexamethasone O
on O
the O
above O
mentioned O
allergic O
parameters O
. O
METHODS O
: O
Rats O
were O
sensitized O
and O
provocated O
by O
TDI O
and O
the O
nasal O
allergy-like O
behaviors O
were O
scored O
during O
a O
10 O
minute O
period O
after O
provocation O
. O
Histamine O
content O
and O
HDC O
activity O
in O
the O
nasal O
mucosa O
were O
determined O
using O
fluorometric O
high O
performance O
liquid O
chromatography O
. O
The O
expression O
of O
HDC O

TDI O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
The O
expression O
of O
HDC B
mRNA O
in O
nasal O
mucosa O
was O
determined O
using O
real-time O
quantitative O
reverse O
transcriptase-polymerase O
chain O
reaction O
(RT-PCR) O
. O
RESULTS O
: O
In O
TDI-sensitized O
rats O
, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O

TDI O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
rats O
, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC B
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O
nasal O
hypersensitivity O
. O
Repression O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
by O
dexamethasone O
may O
underlie O
its O
therapeutic O
effect O

TDI O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
The O
expression O
of O
HDC B
mRNA O
in O
nasal O
mucosa O
was O
determined O
using O
real-time O
quantitative O
reverse O
transcriptase-polymerase O
chain O
reaction O
(RT-PCR) O
. O
RESULTS O
: O
In O
TDI-sensitized O
rats O
, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O

TDI O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
rats O
, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC B
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O
nasal O
hypersensitivity O
. O
Repression O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
by O
dexamethasone O
may O
underlie O
its O
therapeutic O
effect O

TDI O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC B
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI O
sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O
nasal O
hypersensitivity O
. O
Repression O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
by O
dexamethasone O
may O
underlie O
its O
therapeutic O
effect O
in O

dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
HDC B
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O
nasal O
hypersensitivity O
. O
Repression O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
by O
dexamethasone O
may O
underlie O
its O
therapeutic O
effect O
in O
the O
treatment O
of O
allergy O
. O

dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
mRNA O
in O
nasal O
mucosa O
was O
determined O
using O
real-time O
quantitative O
reverse O
transcriptase-polymerase O
chain O
reaction O
(RT-PCR) O
. O
RESULTS O
: O
In O
TDI-sensitized O
rats O
, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC B
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O

dexamethasone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
HDC B
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O
nasal O
hypersensitivity O
. O
Repression O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
by O
dexamethasone O
may O
underlie O
its O
therapeutic O
effect O
in O
the O
treatment O
of O
allergy O
. O

dexamethasone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mRNA O
in O
nasal O
mucosa O
was O
determined O
using O
real-time O
quantitative O
reverse O
transcriptase-polymerase O
chain O
reaction O
(RT-PCR) O
. O
RESULTS O
: O
In O
TDI-sensitized O
rats O
, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC B
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O

histamine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Dexamethasone O
suppresses O
histamine O
synthesis O
by O
repressing O
both O
transcription O
and O
activity O
of O
HDC B
in O
allergic O
rats.BACKGROUND O
: O
Histamine O
synthesized O
by O
histidine O
decarboxylase O
(HDC) O
from O
L-histidine O
is O
a O
major O
chemical O
mediator O
in O
the O
development O
of O
nasal O
allergy O
which O
is O
characterized O
by O
nasal O
hypersensitivity O
. O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC O
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O
by O
the O
exposure O
to O
toluene O
diisocyanate O
(TDI) O
and O
to O
investigate O
the O
effect O
of O

Histamine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Dexamethasone O
suppresses O
histamine O
synthesis O
by O
repressing O
both O
transcription O
and O
activity O
of O
HDC O
in O
allergic O
rats.BACKGROUND O
: O
Histamine O
synthesized O
by O
histidine B
decarboxylase I
(HDC) O
from O
L-histidine O
is O
a O
major O
chemical O
mediator O
in O
the O
development O
of O
nasal O
allergy O
which O
is O
characterized O
by O
nasal O
hypersensitivity O
. O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC O
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O

Histamine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Dexamethasone O
suppresses O
histamine O
synthesis O
by O
repressing O
both O
transcription O
and O
activity O
of O
HDC B
in O
allergic O
rats.BACKGROUND O
: O
Histamine O
synthesized O
by O
histidine O
decarboxylase O
(HDC) O
from O
L-histidine O
is O
a O
major O
chemical O
mediator O
in O
the O
development O
of O
nasal O
allergy O
which O
is O
characterized O
by O
nasal O
hypersensitivity O
. O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC O
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O

histamine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Histamine O
content O
, O
HDC B
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O
nasal O
hypersensitivity O
. O
Repression O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
by O
dexamethasone O
may O
underlie O
its O
therapeutic O
effect O
in O
the O
treatment O
of O
allergy O
. O

histamine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Histamine O
content O
, O
HDC B
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O
nasal O
hypersensitivity O
. O
Repression O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
by O
dexamethasone O
may O
underlie O
its O
therapeutic O
effect O
in O
the O
treatment O
of O
allergy O
. O

L-histidine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Dexamethasone O
suppresses O
histamine O
synthesis O
by O
repressing O
both O
transcription O
and O
activity O
of O
HDC O
in O
allergic O
rats.BACKGROUND O
: O
Histamine O
synthesized O
by O
histidine B
decarboxylase I
(HDC) O
from O
L-histidine O
is O
a O
major O
chemical O
mediator O
in O
the O
development O
of O
nasal O
allergy O
which O
is O
characterized O
by O
nasal O
hypersensitivity O
. O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC O
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O

L-histidine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Dexamethasone O
suppresses O
histamine O
synthesis O
by O
repressing O
both O
transcription O
and O
activity O
of O
HDC B
in O
allergic O
rats.BACKGROUND O
: O
Histamine O
synthesized O
by O
histidine O
decarboxylase O
(HDC) O
from O
L-histidine O
is O
a O
major O
chemical O
mediator O
in O
the O
development O
of O
nasal O
allergy O
which O
is O
characterized O
by O
nasal O
hypersensitivity O
. O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC O
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O

methionine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Methionine O
synthase O
reductase O
polymorphisms O
are O
associated O
with O
serum O
osteocalcin O
levels O
in O
postmenopausal O
women.Homocysteine O
(Hcy) O
is O
thought O
to O
play O
an O
important O
role O
in O
the O
development O
of O
osteoporosis O
and O
fracture O
. O
Methionine O
synthase O
reductase O
(MTRR) O
is O
an O
enzyme O
involved O
in O
the O
conversion O
of O
Hcy O
to O
methionine O
We O
hypothesized O
that O
certain O
genetic O
polymorphisms O
of O
MTRR B
leading O
to O
reduced O
enzyme O
activity O
may O
cause O
hyperhomocysteinemia O
and O
affect O
bone O
metabolism O
. O
We O
therefore O
examined O
the O
associations O
of O
the O
A66G O
and O
C524T O
polymorphisms O
of O
the O
MTRR O
gene O
with O
bone O
mineral O
density O
(BMD) O
and O
serum O
osteocalcin O
levels O
in O
postmenopausal O
women O
. O
Although O
we O

methionine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Methionine B
synthase I
reductase I
polymorphisms O
are O
associated O
with O
serum O
osteocalcin O
levels O
in O
postmenopausal O
women.Homocysteine O
(Hcy) O
is O
thought O
to O
play O
an O
important O
role O
in O
the O
development O
of O
osteoporosis O
and O
fracture O
. O
Methionine O
synthase O
reductase O
(MTRR) O
is O
an O
enzyme O
involved O
in O
the O
conversion O
of O
Hcy O
to O
methionine O
We O
hypothesized O
that O
certain O
genetic O
polymorphisms O
of O
MTRR O
leading O
to O
reduced O
enzyme O
activity O
may O
cause O
hyperhomocysteinemia O
and O
affect O
bone O
metabolism O
. O
We O
therefore O
examined O
the O
associations O
of O
the O
A66G O
and O
C524T O
polymorphisms O
of O
the O
MTRR O
gene O
with O
bone O
mineral O
density O
(BMD) O
and O
serum O
osteocalcin O
levels O
in O
postmenopausal O
women O
. O
Although O
we O

Hcy O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Methionine O
synthase O
reductase O
polymorphisms O
are O
associated O
with O
serum O
osteocalcin O
levels O
in O
postmenopausal O
women.Homocysteine O
(Hcy) O
is O
thought O
to O
play O
an O
important O
role O
in O
the O
development O
of O
osteoporosis O
and O
fracture O
. O
Methionine O
synthase O
reductase O
(MTRR) O
is O
an O
enzyme O
involved O
in O
the O
conversion O
of O
Hcy O
to O
methionine O
. O
We O
hypothesized O
that O
certain O
genetic O
polymorphisms O
of O
MTRR B
leading O
to O
reduced O
enzyme O
activity O
may O
cause O
hyperhomocysteinemia O
and O
affect O
bone O
metabolism O
. O
We O
therefore O
examined O
the O
associations O
of O
the O
A66G O
and O
C524T O
polymorphisms O
of O
the O
MTRR O
gene O
with O
bone O
mineral O
density O
(BMD) O
and O
serum O
osteocalcin O
levels O
in O
postmenopausal O
women O
. O

Hcy O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Methionine B
synthase I
reductase I
polymorphisms O
are O
associated O
with O
serum O
osteocalcin O
levels O
in O
postmenopausal O
women.Homocysteine O
(Hcy) O
is O
thought O
to O
play O
an O
important O
role O
in O
the O
development O
of O
osteoporosis O
and O
fracture O
. O
Methionine O
synthase O
reductase O
(MTRR) O
is O
an O
enzyme O
involved O
in O
the O
conversion O
of O
Hcy O
to O
methionine O
. O
We O
hypothesized O
that O
certain O
genetic O
polymorphisms O
of O
MTRR O
leading O
to O
reduced O
enzyme O
activity O
may O
cause O
hyperhomocysteinemia O
and O
affect O
bone O
metabolism O
. O
We O
therefore O
examined O
the O
associations O
of O
the O
A66G O
and O
C524T O
polymorphisms O
of O
the O
MTRR O
gene O
with O
bone O
mineral O
density O
(BMD) O
and O
serum O
osteocalcin O
levels O
in O
postmenopausal O
women O
. O

alcohols O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
peroxidases O
and O
redox-regulated O
transcription O
factors.Analysis O
of O
the O
selenoproteome O
identified O
five O
glutathione O
peroxidases O
(GPxs) O
in O
mammals O
: O
cytosolic O
GPx O
(cGPx O
, O
GPx1) O
, O
phospholipid O
hydroperoxide O
GPx O
(PHGPX O
, O
GPx4) O
, O
plasma O
GPx O
(pGPX O
, O
GPx3) O
, O
gastrointestinal O
GPx O
(GI-GPx O
, O
GPx2) O
and O
, O
in O
humans O
, O
GPx6 O
, O
which O
is O
restricted O
to O
the O
olfactory O
system O
. O
GPxs B
reduce O
hydroperoxides O
to O
the O
corresponding O
alcohols O
by O
means O
of O
glutathione O
(GSH) O
. O
They O
have O
long O
been O
considered O
to O
only O
act O
as O
antioxidant O
enzymes O
. O
Increasing O
evidence O
, O
however O
, O
suggests O
that O
nature O
has O
not O
created O
redundant O
GPxs O
just O
to O
detoxify O
hydroperoxides O
. O
cGPx O
clearly O
acts O
as O
an O
antioxidant O
, O
as O
convincingly O
demonstrated O
in O
GPx1-knockout O
mice O
. O
PHGPx O
specifically O
interferes O
with O
NF-kappaB O
activation O

caffeine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
treatment O
with O
temazepam O
or O
diazepam O
decreased O
seizure O
threshold O
(one O
of O
BDZ O
withdrawal O
signs) O
. O
The O
concomitant O
application O
of O
subconvulsive O
dose O
of O
pentetrazole O
(55.0 O
mg/kg) O
with O
low O
dose O
of O
flumazenil O
(5.0 O
mg/kg) O
- O
a O
BDZ O
receptor O
antagonist O
, O
immediately O
induced O
BDZ O
withdrawal O
signs O
in O
these O
animals O
. O
The O
non-selective O
adenosine B
receptor I
antagonist O
( O
caffeine O
 O
, O
and O
the O
selective O
adenosine O
A1 O
receptor O
antagonist O
(DPCPX) O
, O
injected O
15 O
min O
before O
the O
application O
of O
pentetrazole O
and O
flumazenil O
, O
were O
able O
to O
intensify O
BDZ O
withdrawal O
signs O
in O
mice O
. O
The O
most O
apparent O
effects O
were O
observed O
after O
administration O
of O
DPCPX O
, O
indicating O
that O
the O
adenosine O
A1 O
receptor O
may O
play O
a O
more O
important O

DPCPX O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
(one O
of O
BDZ O
withdrawal O
signs) O
. O
The O
concomitant O
application O
of O
subconvulsive O
dose O
of O
pentetrazole O
(55.0 O
mg/kg) O
with O
low O
dose O
of O
flumazenil O
(5.0 O
mg/kg) O
- O
a O
BDZ O
receptor O
antagonist O
, O
immediately O
induced O
BDZ O
withdrawal O
signs O
in O
these O
animals O
. O
The O
non-selective O
adenosine O
receptor O
antagonist O
(caffeine) O
, O
and O
the O
selective O
adenosine B
A1 I
receptor I
antagonist O
( O
DPCPX O
 O
, O
injected O
15 O
min O
before O
the O
application O
of O
pentetrazole O
and O
flumazenil O
, O
were O
able O
to O
intensify O
BDZ O
withdrawal O
signs O
in O
mice O
. O
The O
most O
apparent O
effects O
were O
observed O
after O
administration O
of O
DPCPX O
, O
indicating O
that O
the O
adenosine O
A1 O
receptor O
may O
play O
a O
more O
important O
role O
in O
these O
effects O
. O
The O
obtained O
data O
demonstrate O

flumazenil O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
the O
involvement O
of O
adenosine O
receptor O
antagonists O
in O
benzodiazepine O
(BDZ) O
withdrawal O
signs O
, O
observed O
as O
the O
seizure O
susceptibility O
in O
mice O
. O
The O
discontinuation O
of O
chronic O
treatment O
with O
temazepam O
or O
diazepam O
decreased O
seizure O
threshold O
(one O
of O
BDZ O
withdrawal O
signs) O
. O
The O
concomitant O
application O
of O
subconvulsive O
dose O
of O
pentetrazole O
(55.0 O
mg/kg) O
with O
low O
dose O
of O
flumazenil O
(5.0 O
mg/kg) O
- O
a O
BDZ B
receptor I
antagonist O
, O
immediately O
induced O
BDZ O
withdrawal O
signs O
in O
these O
animals O
. O
The O
non-selective O
adenosine O
receptor O
antagonist O
(caffeine) O
, O
and O
the O
selective O
adenosine O
A1 O
receptor O
antagonist O
(DPCPX) O
, O
injected O
15 O
min O
before O
the O
application O
of O
pentetrazole O
and O
flumazenil O
, O
were O
able O
to O
intensify O
BDZ O
withdrawal O
signs O
in O
mice O
. O
The O

flupentixol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Occupancy O
of O
dopamine O
D(1) O
, O
D O
(2) O
and O
serotonin B
(2A) I
receptors I
in O
schizophrenic O
patients O
treated O
with O
flupentixo O
in O
comparison O
with O
risperidone O
and O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) O
and O
5-HT(2A) O
receptors O
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O

risperidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Occupancy O
of O
dopamine O
D(1) O
, O
D O
(2) O
and O
serotonin B
(2A) I
receptors I
in O
schizophrenic O
patients O
treated O
with O
flupentixol O
in O
comparison O
with O
risperidon O
and O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) O
and O
5-HT(2A) O
receptors O
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O

haloperidol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Occupancy O
of O
dopamine O
D(1) O
, O
D O
(2) O
and O
serotonin B
(2A) I
receptors I
in O
schizophrenic O
patients O
treated O
with O
flupentixol O
in O
comparison O
with O
risperidone O
and O
haloperido O
.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) O
and O
5-HT(2A) O
receptors O
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O
interaction O

flupentixol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
about O
0.7 O
ng/ml O
serum O
. O
5-HT(2A) B
and O
D(1)-RO O
was O
20 O
+/- O
10% O
and O
20 O
+/- O
5% O
(mean O
, O
SEM) O
. O
Under O
HAL O
, O
D(1)-RO O
was O
14 O
+/- O
6% O
and O
under O
RIS O
not O
significantly O
different O
from O
zero O
. O
CONCLUSIONS O
: O
We O
were O
able O
to O
demonstrate O
a O
moderate O
5-HT(2A) O
and O
D(1) O
occupancy O
under O
clinically O
relevant O
doses O
of O
flupentixol O
albeit O
lower O
than O
expected O
from O
in O
vitro O
data O
and O
clearly O
below O
saturation O
. O
Therefore O
, O
if O
flupentixol's O
efficacy O
on O
negative O
symptoms O
is O
based O
on O
its O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
, O
it O
should O
be O
highly O
dependent O
on O
serum O
concentration O
and O
thus O
on O
dosage O
and O
metabolism O
. O
However O
, O
these O
data O
suggest O
that O
mechanisms O

flupentixol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
about O
0.7 O
ng/ml O
serum O
. O
5-HT(2A) O
and O
D(1)-RO O
was O
20 O
+/- O
10% O
and O
20 O
+/- O
5% O
(mean O
, O
SEM) O
. O
Under O
HAL O
, O
D(1)-RO O
was O
14 O
+/- O
6% O
and O
under O
RIS O
not O
significantly O
different O
from O
zero O
. O
CONCLUSIONS O
: O
We O
were O
able O
to O
demonstrate O
a O
moderate O
5-HT(2A) O
and O
D(1) B
occupancy O
under O
clinically O
relevant O
doses O
of O
flupentixol O
albeit O
lower O
than O
expected O
from O
in O
vitro O
data O
and O
clearly O
below O
saturation O
. O
Therefore O
, O
if O
flupentixol's O
efficacy O
on O
negative O
symptoms O
is O
based O
on O
its O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
, O
it O
should O
be O
highly O
dependent O
on O
serum O
concentration O
and O
thus O
on O
dosage O
and O
metabolism O
. O
However O
, O
these O
data O
suggest O
that O
mechanisms O

FLX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Occupancy O
of O
dopamine O
D(1) O
, O
D O
(2) O
and O
serotonin O
(2A) O
receptors O
in O
schizophrenic O
patients O
treated O
with O
flupentixol O
in O
comparison O
with O
risperidone O
and O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) O
and O
5-HT(2A) O
receptors O
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
. O
OBJECTIVES O
: O
To O
assess O
in O
vivo O
receptor O
occupancy O
(RO) O
in O
patients O
clinically O
treated O
with O
FLX O
(n O
= O
13 O
, O
5.7 O
+/- O
1.4 O
mg/day) O
in O
comparison O
with O

FLX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Occupancy O
of O
dopamine O
D(1) O
, O
D O
(2) O
and O
serotonin O
(2A) O
receptors O
in O
schizophrenic O
patients O
treated O
with O
flupentixol O
in O
comparison O
with O
risperidone O
and O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) B
and O
5-HT(2A) O
receptors O
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
. O
OBJECTIVES O
: O
To O
assess O
in O
vivo O
receptor O
occupancy O
(RO) O
in O
patients O
clinically O
treated O
with O
FLX O
(n O
= O
13 O
, O
5.7 O
+/- O
1.4 O
mg/day) O
in O
comparison O
with O

FLX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Occupancy O
of O
dopamine O
D(1) O
, O
D O
(2) O
and O
serotonin O
(2A) O
receptors O
in O
schizophrenic O
patients O
treated O
with O
flupentixol O
in O
comparison O
with O
risperidone O
and O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) O
and O
5-HT(2A) B
receptors I
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
. O
OBJECTIVES O
: O
To O
assess O
in O
vivo O
receptor O
occupancy O
(RO) O
in O
patients O
clinically O
treated O
with O
FLX O
(n O
= O
13 O
, O
5.7 O
+/- O
1.4 O
mg/day) O
in O
comparison O
with O

FLX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Occupancy O
of O
dopamine O
D(1) O
, O
D O
(2) O
and O
serotonin O
(2A) O
receptors O
in O
schizophrenic O
patients O
treated O
with O
flupentixol O
in O
comparison O
with O
risperidone O
and O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) O
and O
5-HT(2A) B
receptors O
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
. O
OBJECTIVES O
: O
To O
assess O
in O
vivo O
receptor O
occupancy O
(RO) O
in O
patients O
clinically O
treated O
with O
FLX O
(n O
= O
13 O
, O
5.7 O
+/- O
1.4 O
mg/day) O
in O
comparison O
with O

FLX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Occupancy O
of O
dopamine O
D(1) O
, O
D O
(2) O
and O
serotonin O
(2A) O
receptors O
in O
schizophrenic O
patients O
treated O
with O
flupentixol O
in O
comparison O
with O
risperidone O
and O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) O
and O
5-HT(2A) O
receptors O
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
. O
OBJECTIVES O
: O
To O
assess O
in O
vivo O
receptor O
occupancy O
(RO) O
in O
patients O
clinically O
treated O
with O
FLX O
(n O
= O
13 O
, O
5.7 O
+/- O
1.4 O
mg/day) O
in O
comparison O
with O

risperidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
serotonin O
(2A) O
receptors O
in O
schizophrenic O
patients O
treated O
with O
flupentixol O
in O
comparison O
with O
risperidone O
and O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) O
and O
5-HT(2A) O
receptors O
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
. O
OBJECTIVES O
: O
To O
assess O
in O
vivo O
receptor O
occupancy O
(RO) O
in O
patients O
clinically O
treated O
with O
FLX O
(n O
= O
13 O
, O
5.7 O
+/- O
1.4 O
mg/day) O
in O
comparison O
with O
risperidone O
(RIS O
, O
n O
= O
11 O
, O
3.6 O
+/- O

risperidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
serotonin O
(2A) O
receptors O
in O
schizophrenic O
patients O
treated O
with O
flupentixol O
in O
comparison O
with O
risperidone O
and O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) B
and O
5-HT(2A) O
receptors O
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
. O
OBJECTIVES O
: O
To O
assess O
in O
vivo O
receptor O
occupancy O
(RO) O
in O
patients O
clinically O
treated O
with O
FLX O
(n O
= O
13 O
, O
5.7 O
+/- O
1.4 O
mg/day) O
in O
comparison O
with O
risperidone O
(RIS O
, O
n O
= O
11 O
, O
3.6 O
+/- O

risperidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
serotonin O
(2A) O
receptors O
in O
schizophrenic O
patients O
treated O
with O
flupentixol O
in O
comparison O
with O
risperidone O
and O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) O
and O
5-HT(2A) B
receptors I
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
. O
OBJECTIVES O
: O
To O
assess O
in O
vivo O
receptor O
occupancy O
(RO) O
in O
patients O
clinically O
treated O
with O
FLX O
(n O
= O
13 O
, O
5.7 O
+/- O
1.4 O
mg/day) O
in O
comparison O
with O
risperidone O
(RIS O
, O
n O
= O
11 O
, O
3.6 O
+/- O

risperidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
serotonin O
(2A) O
receptors O
in O
schizophrenic O
patients O
treated O
with O
flupentixol O
in O
comparison O
with O
risperidone O
and O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) O
and O
5-HT(2A) B
receptors O
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
. O
OBJECTIVES O
: O
To O
assess O
in O
vivo O
receptor O
occupancy O
(RO) O
in O
patients O
clinically O
treated O
with O
FLX O
(n O
= O
13 O
, O
5.7 O
+/- O
1.4 O
mg/day) O
in O
comparison O
with O
risperidone O
(RIS O
, O
n O
= O
11 O
, O
3.6 O
+/- O

risperidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
serotonin O
(2A) O
receptors O
in O
schizophrenic O
patients O
treated O
with O
flupentixol O
in O
comparison O
with O
risperidone O
and O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) O
and O
5-HT(2A) O
receptors O
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
. O
OBJECTIVES O
: O
To O
assess O
in O
vivo O
receptor O
occupancy O
(RO) O
in O
patients O
clinically O
treated O
with O
FLX O
(n O
= O
13 O
, O
5.7 O
+/- O
1.4 O
mg/day) O
in O
comparison O
with O
risperidone O
(RIS O
, O
n O
= O
11 O
, O
3.6 O
+/- O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Ankyrin O
repeat O
and O
suppressors O
of O
cytokine O
signaling O
box O
protein O
asb-9 O
targets O
creatine O
kinase O
B O
for O
degradation.The O
suppressors O
of O
cytokine O
signaling O
(SOCS) O
proteins O
inhibit O
cytokine O
action O
by O
direct O
interaction O
with O
Janus O
kinases O
or O
activated O
cytokine O
receptors O
. O
In O
addition O
to O
the O
N O
terminal O
and O
Src B
homology I
2 I
domains I
that O
mediate O
these O
interactions O
, O
SOCS O
proteins O
contain O
a O
C-terminal O
SOCS O
box O
. O
DNA O
data O
base O
searches O
have O
identified O
a O
number O
of O
other O
protein O
families O
that O
possess O
a O
SOCS O
box O
, O
of O
which O
the O
ankyrin O
repeat O
and O
SOCS O
box-containing O
(Asb) O
proteins O
constitute O
the O
largest O
. O
Although O
it O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
of O
cytokine O
signaling O
box O
protein O
asb-9 O
targets O
creatine O
kinase O
B O
for O
degradation.The O
suppressors O
of O
cytokine O
signaling O
(SOCS) O
proteins O
inhibit O
cytokine O
action O
by O
direct O
interaction O
with O
Janus O
kinases O
or O
activated O
cytokine O
receptors O
. O
In O
addition O
to O
the O
N-terminal O
and O
Src O
homology O
2 O
domains O
that O
mediate O
these O
interactions O
, O
SOCS O
proteins O
contain O
a O
C O
terminal O
SOCS O
box O
. O
DNA O
data O
base O
searches O
have O
identified O
a O
number O
of O
other O
protein O
families O
that O
possess O
a O
SOCS O
box O
, O
of O
which O
the O
ankyrin O
repeat O
and O
SOCS O
box-containing O
(Asb) O
proteins O
constitute O
the O
largest O
. O
Although O
it O
is O
known O
that O
the O
SOCS O
proteins O
are O
involved O
in O
the O
negative O
regulation O
of O
cytokine O

GAL O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cortex O
, O
basal O
ganglia O
, O
septum O
and O
hippocampus) O
and O
the O
hypophysis O
, O
and O
that O
of O
butyrylcholinesterase O
(BuChE) O
in O
plasma O
and O
liver O
. O
RESULTS O
: O
Following O
administration O
of O
the O
highest O
of O
the O
GAL O
doses O
used O
(2.5; O
5; O
10 O
mg/kg O
i.m.) O
, O
AChE B
activity O
decreased O
mainly O
in O
the O
frontal O
cortex O
, O
hippocampus O
and O
hypophysis O
. O
In O
the O
interaction O
of O
GAL O
and O
CAR O
, O
AChE O
inhibition O
was O
stronger O
but O
without O
any O
statistical O
significance O
. O
The O
peripheral O
inhibition O
of O
BuChE O
was O
found O
to O
be O
dose-dependent O
. O
Premedication O
by O
CAR O
led O
to O
a O
slight O
change O
in O
the O
values O
of O
the O
activities O
monitored O
. O
CONCLUSIONS O
: O
CAR O
in O
terms O
of O
positive O
modulation O
of O
GAL O
targeting O
to O
the O
central O

galantamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effect O
of O
galantamine O
on O
acetylcholinesterase O
and O
butyrylcholinesterase O
activities O
in O
the O
presence O
of O
L-carnitine O
in O
rat O
selected O
brain O
and O
peripheral O
tissues.OBJECTIVES O
: O
The O
alkaloid O
galantamine O
(GAL) O
, O
which O
exhibits O
a O
combined O
anticholinesterase B
and O
direct O
parasympathomimetic O
mechanism O
of O
action O
, O
is O
employed O
in O
conjunction O
with O
therapeutic O
interventions O
in O
the O
stimulation O
of O
central O
cholinergic O
transfer O
in O
cognitive O
diseases O
. O
We O
attempted O
to O
achieve O
pharmacologically-induced O
enhancement O
of O
the O
parasympathomimetic O
activity O
of O
GAL O
in O
the O
key O
areas O
of O
rat O
brain O
, O
using O

GAL O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effect O
of O
galantamine O
on O
acetylcholinesterase O
and O
butyrylcholinesterase O
activities O
in O
the O
presence O
of O
L-carnitine O
in O
rat O
selected O
brain O
and O
peripheral O
tissues.OBJECTIVES O
: O
The O
alkaloid O
galantamine O
( O
GAL O
 O
, O
which O
exhibits O
a O
combined O
anticholinesterase B
and O
direct O
parasympathomimetic O
mechanism O
of O
action O
, O
is O
employed O
in O
conjunction O
with O
therapeutic O
interventions O
in O
the O
stimulation O
of O
central O
cholinergic O
transfer O
in O
cognitive O
diseases O
. O
We O
attempted O
to O
achieve O
pharmacologically-induced O
enhancement O
of O
the O
parasympathomimetic O
activity O
of O
GAL O
in O
the O
key O
areas O
of O
rat O
brain O
, O
using O

GAL O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
an O
interactive O
combination O
of O
the O
alkaloid O
with O
the O
transmembrane O
enhancer O
L-carnitine O
(CAR) O
. O
METHODS O
: O
We O
investigated O
activities O
of O
acetylcholinesterase O
(AChE) O
in O
brain O
areas O
(frontal O
cortex O
, O
basal O
ganglia O
, O
septum O
and O
hippocampus) O
and O
the O
hypophysis O
, O
and O
that O
of O
butyrylcholinesterase O
(BuChE) O
in O
plasma O
and O
liver O
. O
RESULTS O
: O
Following O
administration O
of O
the O
highest O
of O
the O
GAL O
doses O
used O
(2.5; O
5; O
10 O
mg/kg O
i.m.) O
, O
AChE B
activity O
decreased O
mainly O
in O
the O
frontal O
cortex O
, O
hippocampus O
and O
hypophysis O
. O
In O
the O
interaction O
of O
GAL O
and O
CAR O
, O
AChE O
inhibition O
was O
stronger O
but O
without O
any O
statistical O
significance O
. O
The O
peripheral O
inhibition O
of O
BuChE O
was O
found O
to O
be O
dose-dependent O
. O
Premedication O
by O
CAR O
led O
to O

warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
enzyme O
, O
vitamin O
K O
epoxide O
reductase O
complex O
1 O
VKORC1 O
, O
confirmed O
their O
influence O
on O
warfarin O
maintenance O
dose O
. O
Possession O
of O
CYP2C9*2 O
or O
CYP2C9*3 O
variant O
alleles O
, O
which O
result O
in O
decreased O
enzyme O
activity O
, O
is O
associated O
with O
a O
significant O
decrease O
in O
the O
mean O
warfarin O
dose O
. O
Several O
single O
nucleotide O
polymorphisms O
(SNPs) O
in O
VKORC1 B
are O
associated O
with O
warfarin O
dose O
across O
the O
normal O
dose O
range O
. O
Haplotypes O
based O
on O
these O
SNPs O
explain O
a O
large O
fraction O
of O
the O
interindividual O
variation O
in O
warfarin O
dose O
, O
and O
VKORC1 O
has O
an O
approximately O
three-fold O
greater O
effect O
than O
CYP2C9 O
. O
Algorithms O
incorporating O
genetic O
(CYP2C9 O
and O
VKORC1) O
, O
demographic O
, O
and O
clinical O
factors O
to O
estimate O
the O
warfarin O
dosage O
, O
could O
potentially O

warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
than O
10-fold O
interindividual O
variability O
in O
the O
dose O
required O
to O
attain O
a O
therapeutic O
response O
. O
Information O
from O
pharmacogenomics O
, O
the O
study O
of O
the O
interaction O
of O
an O
individual's O
genotype O
and O
drug O
response O
, O
can O
help O
optimize O
drug O
efficacy O
while O
minimizing O
adverse O
drug O
reactions O
. O
Pharmacogenetic O
analysis O
of O
two O
genes O
, O
the O
warfarin O
metabolic O
enzyme O
CYP2C9 O
and O
warfarin O
target O
enzyme O
, O
vitamin B
K I
epoxide I
reductase I
complex I
1 I
VKORC1 O
, O
confirmed O
their O
influence O
on O
warfarin O
maintenance O
dose O
. O
Possession O
of O
CYP2C9*2 O
or O
CYP2C9*3 O
variant O
alleles O
, O
which O
result O
in O
decreased O
enzyme O
activity O
, O
is O
associated O
with O
a O
significant O
decrease O
in O
the O
mean O
warfarin O
dose O
. O
Several O
single O
nucleotide O
polymorphisms O
(SNPs) O
in O
VKORC1 O
are O
associated O

warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
than O
10-fold O
interindividual O
variability O
in O
the O
dose O
required O
to O
attain O
a O
therapeutic O
response O
. O
Information O
from O
pharmacogenomics O
, O
the O
study O
of O
the O
interaction O
of O
an O
individual's O
genotype O
and O
drug O
response O
, O
can O
help O
optimize O
drug O
efficacy O
while O
minimizing O
adverse O
drug O
reactions O
. O
Pharmacogenetic O
analysis O
of O
two O
genes O
, O
the O
warfarin O
metabolic O
enzyme O
CYP2C9 O
and O
warfarin O
target O
enzyme O
, O
vitamin O
K O
epoxide O
reductase O
complex O
1 O
VKORC1 O
, O
confirmed O
their O
influence O
on O
warfarin O
maintenance O
dose O
. O
Possession O
of O
CYP2C9*2 O
or O
CYP2C9*3 O
variant O
alleles O
, O
which O
result O
in O
decreased O
enzyme O
activity O
, O
is O
associated O
with O
a O
significant O
decrease O
in O
the O
mean O
warfarin O
dose O
. O
Several O
single O
nucleotide O
polymorphisms O
(SNPs) O
in O
VKORC1 B
are O
associated O

warfarin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
anticoagulant O
, O
but O
there O
is O
greater O
than O
10-fold O
interindividual O
variability O
in O
the O
dose O
required O
to O
attain O
a O
therapeutic O
response O
. O
Information O
from O
pharmacogenomics O
, O
the O
study O
of O
the O
interaction O
of O
an O
individual's O
genotype O
and O
drug O
response O
, O
can O
help O
optimize O
drug O
efficacy O
while O
minimizing O
adverse O
drug O
reactions O
. O
Pharmacogenetic O
analysis O
of O
two O
genes O
, O
the O
warfarin O
metabolic O
enzyme O
CYP2C9 B
and O
warfarin O
target O
enzyme O
, O
vitamin O
K O
epoxide O
reductase O
complex O
1 O
VKORC1 O
, O
confirmed O
their O
influence O
on O
warfarin O
maintenance O
dose O
. O
Possession O
of O
CYP2C9*2 O
or O
CYP2C9*3 O
variant O
alleles O
, O
which O
result O
in O
decreased O
enzyme O
activity O
, O
is O
associated O
with O
a O
significant O
decrease O
in O
the O
mean O
warfarin O
dose O
. O
Several O
single O
nucleotide O
polymorphisms O

warfarin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
analysis O
of O
two O
genes O
, O
the O
warfarin O
metabolic O
enzyme O
CYP2C9 B
and O
warfarin O
target O
enzyme O
, O
vitamin O
K O
epoxide O
reductase O
complex O
1 O
VKORC1 O
, O
confirmed O
their O
influence O
on O
warfarin O
maintenance O
dose O
. O
Possession O
of O
CYP2C9*2 O
or O
CYP2C9*3 O
variant O
alleles O
, O
which O
result O
in O
decreased O
enzyme O
activity O
, O
is O
associated O
with O
a O
significant O
decrease O
in O
the O
mean O
warfarin O
dose O
. O
Several O
single O
nucleotide O
polymorphisms O
(SNPs) O
in O
VKORC1 O
are O
associated O
with O
warfarin O
dose O
across O
the O
normal O
dose O
range O
. O
Haplotypes O
based O
on O
these O
SNPs O
explain O
a O
large O
fraction O
of O
the O
interindividual O
variation O
in O
warfarin O
dose O
, O
and O
VKORC1 O
has O
an O
approximately O
three-fold O
greater O
effect O
than O
CYP2C9 O
. O
Algorithms O
incorporating O
genetic O
(CYP2C9 O
and O

warfarin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
analysis O
of O
two O
genes O
, O
the O
warfarin O
metabolic O
enzyme O
CYP2C9 B
and O
warfarin O
target O
enzyme O
, O
vitamin O
K O
epoxide O
reductase O
complex O
1 O
VKORC1 O
, O
confirmed O
their O
influence O
on O
warfarin O
maintenance O
dose O
. O
Possession O
of O
CYP2C9*2 O
or O
CYP2C9*3 O
variant O
alleles O
, O
which O
result O
in O
decreased O
enzyme O
activity O
, O
is O
associated O
with O
a O
significant O
decrease O
in O
the O
mean O
warfarin O
dose O
. O
Several O
single O
nucleotide O
polymorphisms O
(SNPs) O
in O
VKORC1 O
are O
associated O
with O
warfarin O
dose O
across O
the O
normal O
dose O
range O
. O
Haplotypes O
based O
on O
these O
SNPs O
explain O
a O
large O
fraction O
of O
the O
interindividual O
variation O
in O
warfarin O
dose O
, O
and O
VKORC1 O
has O
an O
approximately O
three-fold O
greater O
effect O
than O
CYP2C9 O
. O
Algorithms O
incorporating O
genetic O
(CYP2C9 O
and O

succinate O
acts O
as O
AGONIST O
for O
what O
entity O
? O
expression O
in O
platelets O
and O
other O
blood O
cells O
we O
demonstrated O
that O
G6b O
, O
G6f O
, O
and O
LRRC32 O
are O
restricted O
to O
the O
platelet O
lineage O
, O
whereas O
LAT2 O
and O
SUCNR1 O
were O
also O
detected O
in O
other O
blood O
cells O
. O
The O
identification O
of O
the O
succinate B
receptor I
SUCNR1 O
in O
platelets O
is O
of O
particular O
interest O
, O
because O
physiologically O
relevant O
concentrations O
of O
succinate O
were O
shown O
to O
potentiate O
the O
effect O
of O
low O
doses O
of O
a O
variety O
of O
platelet O
agonists O
. O

succinate O
acts O
as O
AGONIST O
for O
what O
entity O
? O
expression O
in O
platelets O
and O
other O
blood O
cells O
we O
demonstrated O
that O
G6b O
, O
G6f O
, O
and O
LRRC32 O
are O
restricted O
to O
the O
platelet O
lineage O
, O
whereas O
LAT2 O
and O
SUCNR1 B
were O
also O
detected O
in O
other O
blood O
cells O
. O
The O
identification O
of O
the O
succinate O
receptor O
SUCNR1 O
in O
platelets O
is O
of O
particular O
interest O
, O
because O
physiologically O
relevant O
concentrations O
of O
succinate O
were O
shown O
to O
potentiate O
the O
effect O
of O
low O
doses O
of O
a O
variety O
of O
platelet O
agonists O
. O

foscarnet O
acts O
as O
NOT O
for O
what O
entity O
? O
were O
synthesised O
in O
vitro O
by O
expression O
of O
UL54 O
under O
the O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases O
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A O
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O

foscarnet O
acts O
as O
NOT O
for O
what O
entity O
? O
were O
synthesised O
in O
vitro O
by O
expression O
of O
UL54 O
under O
the O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases O
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A B
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O

foscarnet O
acts O
as O
NOT O
for O
what O
entity O
? O
were O
synthesised O
in O
vitro O
by O
expression O
of O
UL54 O
under O
the O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases O
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A O
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O

foscarnet O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases B
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A O
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O
foscarnet O
in O
HCMV O
. O

foscarnet O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases O
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A O
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O
foscarnet O
in O
HCMV O
. O

foscarnet O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases O
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A B
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O
foscarnet O
in O
HCMV O
. O

foscarnet O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases O
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A O
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O
foscarnet O
in O
HCMV O
. O

foscarnet O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases B
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A O
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O
foscarnet O
in O
HCMV O
. O

foscarnet O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Development O
and O
validation O
of O
a O
non-radioactive O
DNA B
polymerase I
assay O
for O
studying O
cytomegalovirus O
resistance O
to O
foscarne O
.Phenotypic O
characterisation O
of O
the O
human O
cytomegalovirus O
(HCMV) O
pUL54 O
DNA O
polymerase O
is O
a O
useful O
tool O
for O
testing O
for O
mutations O
in O
the O
UL54 O
gene O
thought O
to O
render O
HCMV O
resistant O
to O
foscarnet O
. O
In O
this O
study O
, O
an O
in-house O
non-isotopic O
method O
for O
assessing O
polymerase O
enzymatic O
activity O
in O
the O
presence O
and O
absence O
of O
foscarnet O
was O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
recombinant O
human O
adenine O
phosphoribosyltransferase.Adenine O
phosphoribosyltransferase O
plays O
a O
role O
in O
purine O
salvage O
by O
catalyzing O
the O
direct O
conversion O
of O
adenine O
to O
adenosine O
monophosphate O
. O
The O
involvement O
of O
the O
purine O
salvage O
pathway O
in O
tumor O
proliferation O
and O
angiogenesis O
makes O
adenine O
phosphoribosyltransferase O
a O
potential O
target O
for O
oncology O
drug O
discovery O
. O
We O
have O
expressed O
and O
characterized O
recombinant O
, O
N O
terminally O
His-tagged O
human O
adenine O
phosphoribosyltransferase O
. O
Two O
assay O
formats O
were O
assessed O
for O
use O
in O
a O
high O
throughput O
screen O
: O
a O
spectrophotometric-based O
enzyme-coupled O
assay O
system O
and O
a O
radiometric O
ionic O
capture O
scintillation O
proximity O
bead O
assay O
format O
. O
Ultimately O
, O
the O
scintillation O
proximity O
assay O
format O
was O
chosen O
because O
of O
automated O
screening O
compatibility O
limitations O
of O
the O
coupled O

adenosine O
monophosphate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Configuration O
of O
a O
scintillation O
proximity O
assay O
for O
the O
activity O
assessment O
of O
recombinant O
human O
adenine O
phosphoribosyltransferase.Adenine O
phosphoribosyltransferase O
plays O
a O
role O
in O
purine O
salvage O
by O
catalyzing O
the O
direct O
conversion O
of O
adenine O
to O
adenosine O
monophosphate O
The O
involvement O
of O
the O
purine O
salvage O
pathway O
in O
tumor O
proliferation O
and O
angiogenesis O
makes O
adenine O
phosphoribosyltransferase O
a O
potential O
target O
for O
oncology O
drug O
discovery O
. O
We O
have O
expressed O
and O
characterized O
recombinant O
, O
N-terminally O
His-tagged O
human O
adenine O
phosphoribosyltransferase O
. O
Two O
assay O
formats O
were O
assessed O
for O
use O
in O
a O
high O
throughput O
screen O
: O
a O
spectrophotometric-based O
enzyme-coupled O
assay O

adenine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Configuration O
of O
a O
scintillation O
proximity O
assay O
for O
the O
activity O
assessment O
of O
recombinant O
human O
adenine O
phosphoribosyltransferase.Adenine O
phosphoribosyltransferase O
plays O
a O
role O
in O
purine O
salvage O
by O
catalyzing O
the O
direct O
conversion O
of O
adenine O
to O
adenosine O
monophosphate O
. O
The O
involvement O
of O
the O
purine O
salvage O
pathway O
in O
tumor O
proliferation O
and O
angiogenesis O
makes O
adenine O
phosphoribosyltransferase O
a O
potential O
target O
for O
oncology O
drug O
discovery O
. O
We O
have O
expressed O
and O
characterized O
recombinant O
, O
N-terminally O
His-tagged O
human O
adenine O
phosphoribosyltransferase O
. O
Two O
assay O
formats O
were O
assessed O
for O
use O
in O
a O
high O
throughput O
screen O
: O
a O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Antitumor O
activity O
of O
sorafeni O
in O
FLT3-driven O
leukemic O
cells.Activating O
internal O
tandem O
duplication O
(ITD) O
insertions O
in O
the O
juxtamembrane O
domain O
of O
the O
FLT3 B
tyrosine O
kinase O
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival O
. O
We O
show O
that O
sorafenib O
(BAY O
43-9006 O
, O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
MV4-11 O
and O
EOL-1 O
cells O
. O
The O
antitumor O
efficacy O
of O
sorafenib O
was O
evaluated O
against O
the O
MV4-11 O
leukemia O
grown O
subcutaneously O
in O
NCr O
nu/nu O
mice O
. O
Doses O
of O
3 O
and O
10 O
mg/kg O
administered O
orally O
for O
14 O
days O
resulted O
in O
six O
and O
nine O
out O
of O
10 O
animals O
with O
complete O
responses O
, O
respectively O
. O
The O
demonstration O
that O
sorafenib O
exhibits O
potent O
target O
inhibition O
and O
efficacy O
in O
FLT3-driven O
models O
suggests O
that O
this O
compound O
may O
have O
a O
therapeutic O
benefit O
for O
patients O
with O
FLT3-driven O
leukemias O
. O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
MV4-11 O
and O
EOL-1 O
cells O
. O
The O
antitumor O
efficacy O
of O
sorafenib O
was O
evaluated O
against O
the O
MV4-11 O
leukemia O
grown O
subcutaneously O
in O
NCr O
nu/nu O
mice O
. O
Doses O
of O
3 O
and O
10 O
mg/kg O
administered O
orally O
for O
14 O
days O
resulted O
in O
six O
and O
nine O
out O
of O
10 O
animals O
with O
complete O
responses O
, O
respectively O
. O
The O
demonstration O
that O
sorafenib O
exhibits O
potent O
target O
inhibition O
and O
efficacy O
in O
FLT3-driven O
models O
suggests O
that O
this O
compound O
may O
have O
a O
therapeutic O
benefit O
for O
patients O
with O
FLT3-driven O
leukemias O
. O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
activity O
of O
sorafenib O
in O
FLT3-driven O
leukemic O
cells.Activating O
internal O
tandem O
duplication O
(ITD) O
insertions O
in O
the O
juxtamembrane O
domain O
of O
the O
FLT3 B
tyrosine O
kinase O
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival O
. O
We O
show O
that O
sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
potently O
inhibits O
FLT3 O
enzymatic O
and O
signaling O
activities O
. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular O
signal-regulated O
kinase1/2 O
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O

BAY O
43-9006 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
sorafenib O
in O
FLT3-driven O
leukemic O
cells.Activating O
internal O
tandem O
duplication O
(ITD) O
insertions O
in O
the O
juxtamembrane O
domain O
of O
the O
FLT3 B
tyrosine O
kinase O
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival O
. O
We O
show O
that O
sorafenib O
( O
BAY O
43-9006 O
Nexavar) O
potently O
inhibits O
FLT3 O
enzymatic O
and O
signaling O
activities O
. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular O
signal-regulated O
kinase1/2 O
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O

Nexavar O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
FLT3-driven O
leukemic O
cells.Activating O
internal O
tandem O
duplication O
(ITD) O
insertions O
in O
the O
juxtamembrane O
domain O
of O
the O
FLT3 B
tyrosine O
kinase O
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival O
. O
We O
show O
that O
sorafenib O
(BAY O
43-9006 O
, O
Nexavar O
potently O
inhibits O
FLT3 O
enzymatic O
and O
signaling O
activities O
. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular O
signal-regulated O
kinase1/2 O
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O
and O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
kinase O
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival O
. O
We O
show O
that O
sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
potently O
inhibits O
FLT3 B
enzymatic O
and O
signaling O
activities O
. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular O
signal-regulated O
kinase1/2 O
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O
and O
inhibition O
of O
FLT3 O
signaling O
. O
The O
growth O
of O
the O
FLT3-independent O
RS4-11 O
cell O
line O
was O
only O
weakly O
inhibited O
by O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
kinase O
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival O
. O
We O
show O
that O
sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
potently O
inhibits O
FLT3 O
enzymatic O
and O
signaling O
activities O
. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular B
signal-regulated I
kinase1/2 I
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O
and O
inhibition O
of O
FLT3 O
signaling O
. O
The O
growth O
of O
the O
FLT3-independent O
RS4-11 O
cell O
line O
was O
only O
weakly O
inhibited O
by O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
kinase O
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival O
. O
We O
show O
that O
sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
potently O
inhibits O
FLT3 O
enzymatic O
and O
signaling O
activities O
. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular O
signal-regulated O
kinase1/2 O
and O
Stat5 B
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O
and O
inhibition O
of O
FLT3 O
signaling O
. O
The O
growth O
of O
the O
FLT3-independent O
RS4-11 O
cell O
line O
was O
only O
weakly O
inhibited O
by O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
survival O
. O
We O
show O
that O
sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
potently O
inhibits O
FLT3 B
enzymatic O
and O
signaling O
activities O
. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular O
signal-regulated O
kinase1/2 O
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O
and O
inhibition O
of O
FLT3 O
signaling O
. O
The O
growth O
of O
the O
FLT3-independent O
RS4-11 O
cell O
line O
was O
only O
weakly O
inhibited O
by O
sorafenib O
. O
Cell O
cycle O
arrest O
and O
induction O
of O
apoptosis O
were O
observed O
upon O
treatment O
with O
sorafenib O
in O
MV4-11 O
and O
EOL-1 O
cells O
. O
The O
antitumor O
efficacy O
of O
sorafenib O
was O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular O
signal-regulated O
kinase1/2 O
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O
and O
inhibition O
of O
FLT3 B
signaling O
. O
The O
growth O
of O
the O
FLT3-independent O
RS4-11 O
cell O
line O
was O
only O
weakly O
inhibited O
by O
sorafenib O
Cell O
cycle O
arrest O
and O
induction O
of O
apoptosis O
were O
observed O
upon O
treatment O
with O
sorafenib O
in O
MV4-11 O
and O
EOL-1 O
cells O
. O
The O
antitumor O
efficacy O
of O
sorafenib O
was O
evaluated O
against O
the O
MV4-11 O
leukemia O
grown O
subcutaneously O
in O
NCr O
nu/nu O
mice O
. O
Doses O
of O
3 O
and O
10 O
mg/kg O
administered O
orally O
for O
14 O
days O
resulted O
in O
six O

citrulline O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
(rhArg) O
inhibits O
ASS-positive O
HCCs O
. O
All O
the O
five O
human O
HCC O
cell O
lines O
we O
used O
were O
sensitive O
to O
rhArg B
but O
ADI O
had O
virtually O
no O
effect O
on O
these O
cells O
. O
They O
all O
expressed O
ASS O
, O
but O
not O
ornithine O
transcarbamylase O
(OTC) O
, O
the O
enzyme O
that O
converts O
ornithine O
, O
the O
product O
of O
degradation O
of O
arginine O
with O
rhArg O
, O
to O
citrulline O
which O
is O
converted O
back O
to O
arginine O
via O
ASS O
. O
Transfection O
of O
HCC O
cells O
with O
OTC O
resulted O
in O
resistance O
to O
rhArg O
. O
Thus O
, O
OTC O
expression O
alone O
may O
be O
sufficient O
to O
induce O
rhArg O
resistance O
in O
ASS-positive O
HCC O
cells O
. O
This O
surprising O
correlation O
between O
the O
lack O
of O
OTC O
expression O
and O
sensitivity O
of O
ASS-positive O
HCC O
cells O

ornithine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
reported O
. O
Here O
, O
we O
provide O
direct O
evidence O
that O
recombinant O
human O
arginase O
(rhArg) O
inhibits O
ASS-positive O
HCCs O
. O
All O
the O
five O
human O
HCC O
cell O
lines O
we O
used O
were O
sensitive O
to O
rhArg O
but O
ADI O
had O
virtually O
no O
effect O
on O
these O
cells O
. O
They O
all O
expressed O
ASS O
, O
but O
not O
ornithine B
transcarbamylase I
(OTC) O
, O
the O
enzyme O
that O
converts O
ornithine O
the O
product O
of O
degradation O
of O
arginine O
with O
rhArg O
, O
to O
citrulline O
, O
which O
is O
converted O
back O
to O
arginine O
via O
ASS O
. O
Transfection O
of O
HCC O
cells O
with O
OTC O
resulted O
in O
resistance O
to O
rhArg O
. O
Thus O
, O
OTC O
expression O
alone O
may O
be O
sufficient O
to O
induce O
rhArg O
resistance O
in O
ASS-positive O
HCC O
cells O
. O
This O
surprising O
correlation O
between O
the O

ornithine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
reported O
. O
Here O
, O
we O
provide O
direct O
evidence O
that O
recombinant O
human O
arginase O
(rhArg) O
inhibits O
ASS-positive O
HCCs O
. O
All O
the O
five O
human O
HCC O
cell O
lines O
we O
used O
were O
sensitive O
to O
rhArg O
but O
ADI O
had O
virtually O
no O
effect O
on O
these O
cells O
. O
They O
all O
expressed O
ASS O
, O
but O
not O
ornithine O
transcarbamylase O
(OTC) O
, O
the O
enzyme O
that O
converts O
ornithine O
the O
product O
of O
degradation O
of O
arginine O
with O
rhArg O
, O
to O
citrulline O
, O
which O
is O
converted O
back O
to O
arginine O
via O
ASS O
. O
Transfection O
of O
HCC O
cells O
with O
OTC B
resulted O
in O
resistance O
to O
rhArg O
. O
Thus O
, O
OTC O
expression O
alone O
may O
be O
sufficient O
to O
induce O
rhArg O
resistance O
in O
ASS-positive O
HCC O
cells O
. O
This O
surprising O
correlation O
between O
the O

arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
that O
recombinant O
human O
arginase O
(rhArg) O
inhibits O
ASS-positive O
HCCs O
. O
All O
the O
five O
human O
HCC O
cell O
lines O
we O
used O
were O
sensitive O
to O
rhArg B
but O
ADI O
had O
virtually O
no O
effect O
on O
these O
cells O
. O
They O
all O
expressed O
ASS O
, O
but O
not O
ornithine O
transcarbamylase O
(OTC) O
, O
the O
enzyme O
that O
converts O
ornithine O
, O
the O
product O
of O
degradation O
of O
arginine O
with O
rhArg O
, O
to O
citrulline O
, O
which O
is O
converted O
back O
to O
arginine O
via O
ASS O
. O
Transfection O
of O
HCC O
cells O
with O
OTC O
resulted O
in O
resistance O
to O
rhArg O
. O
Thus O
, O
OTC O
expression O
alone O
may O
be O
sufficient O
to O
induce O
rhArg O
resistance O
in O
ASS-positive O
HCC O
cells O
. O
This O
surprising O
correlation O
between O
the O
lack O
of O
OTC O
expression O
and O
sensitivity O

arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
five O
human O
HCC O
cell O
lines O
we O
used O
were O
sensitive O
to O
rhArg O
but O
ADI O
had O
virtually O
no O
effect O
on O
these O
cells O
. O
They O
all O
expressed O
ASS O
, O
but O
not O
ornithine O
transcarbamylase O
(OTC) O
, O
the O
enzyme O
that O
converts O
ornithine O
, O
the O
product O
of O
degradation O
of O
arginine O
with O
rhArg O
, O
to O
citrulline O
, O
which O
is O
converted O
back O
to O
arginine O
via O
ASS O
. O
Transfection O
of O
HCC O
cells O
with O
OTC O
resulted O
in O
resistance O
to O
rhArg O
. O
Thus O
, O
OTC O
expression O
alone O
may O
be O
sufficient O
to O
induce O
rhArg O
resistance O
in O
ASS-positive O
HCC O
cells O
. O
This O
surprising O
correlation O
between O
the O
lack O
of O
OTC O
expression O
and O
sensitivity O
of O
ASS-positive O
HCC O
cells O
shows O
that O
OTC-deficient O
HCCs O
are O
sensitive O

arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HCC O
cells O
with O
OTC O
resulted O
in O
resistance O
to O
rhArg O
. O
Thus O
, O
OTC O
expression O
alone O
may O
be O
sufficient O
to O
induce O
rhArg B
resistance O
in O
ASS-positive O
HCC O
cells O
. O
This O
surprising O
correlation O
between O
the O
lack O
of O
OTC O
expression O
and O
sensitivity O
of O
ASS-positive O
HCC O
cells O
shows O
that O
OTC-deficient O
HCCs O
are O
sensitive O
to O
rhArg-mediated O
arginine O
depletion O
. O
Therefore O
, O
pretreatment O
tumor O
gene O
expression O
profiling O
of O
ASS O
and O
OTC O
could O
aid O
in O
predicting O
tumor O
response O
to O
arginine O
depletion O
with O
arginine-depleting O
enzymes O
. O
We O
have O
also O
shown O
that O
the O
rhArg O
native O
enzyme O
and O
the O
pegylated O
rhArg O
(rhArg-peg(5,000mw)) O
gave O
similar O
anticancer O
efficacy O
in O
vitro O
. O
Furthermore O
, O
the O
growth O
of O
the O
OTC-deficient O

arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
induce O
rhArg O
resistance O
in O
ASS-positive O
HCC O
cells O
. O
This O
surprising O
correlation O
between O
the O
lack O
of O
OTC O
expression O
and O
sensitivity O
of O
ASS-positive O
HCC O
cells O
shows O
that O
OTC-deficient O
HCCs O
are O
sensitive O
to O
rhArg-mediated O
arginine O
depletion O
. O
Therefore O
, O
pretreatment O
tumor O
gene O
expression O
profiling O
of O
ASS O
and O
OTC O
could O
aid O
in O
predicting O
tumor O
response O
to O
arginine O
depletion O
with O
arginine-depleting O
enzymes O
. O
We O
have O
also O
shown O
that O
the O
rhArg O
native O
enzyme O
and O
the O
pegylated O
rhArg O
(rhArg-peg(5,000mw)) O
gave O
similar O
anticancer O
efficacy O
in O
vitro O
. O
Furthermore O
, O
the O
growth O
of O
the O
OTC-deficient O
Hep3B O
tumor O
cells O
(ASS-positive O
and O
ADI-resistant) O
in O
mice O
was O
inhibited O
by O
treatment O
with O
rhArg-peg(5,000mw) O
, O
which O
is O
active O
alone O
and O

all-trans-retinol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
retained O
in O
higher O
vertebrates O
and O
also O
the O
evolutionarily O
preserved O
activity O
of O
bacterial O
phytoene O
desaturases O
and O
plant O
carotenoid O
isomerases O
. O
Expression O
of O
zRetSat O
A O
was O
restricted O
to O
the O
liver O
and O
intestine O
of O
hatchlings O
and O
adult O
zebrafish O
, O
whereas O
zRetSat O
B O
was O
expressed O
in O
the O
same O
tissues O
but O
at O
earlier O
developmental O
stages O
. O
Exogenous O
all-trans-retinol O
all-trans-13,14-dihydroretinol O
, O
or O
all-trans-7,8-dihydroretinol O
led O
to O
the O
strong O
induction O
of O
the O
expression O
of O
the O
retinoic O
acid-metabolizing O
enzyme O
, O
Cyp26A1 O
, O
arguing O
for O
an O
active O
signaling O
function O
of O
dihydroretinoid O
metabolites O
in O
zebrafish O
. O
These O
findings O
point O
to O
a O
conserved O
function O
but O
altered O
specificity O
of O
RetSat O
in O
vertebrates O
, O
leading O
to O
the O
generation O
of O
various O
dihydroretinoid O

all-trans-13,14-dihydroretinol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
in O
higher O
vertebrates O
and O
also O
the O
evolutionarily O
preserved O
activity O
of O
bacterial O
phytoene O
desaturases O
and O
plant O
carotenoid O
isomerases O
. O
Expression O
of O
zRetSat O
A O
was O
restricted O
to O
the O
liver O
and O
intestine O
of O
hatchlings O
and O
adult O
zebrafish O
, O
whereas O
zRetSat O
B O
was O
expressed O
in O
the O
same O
tissues O
but O
at O
earlier O
developmental O
stages O
. O
Exogenous O
all-trans-retinol O
, O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
led O
to O
the O
strong O
induction O
of O
the O
expression O
of O
the O
retinoic O
acid-metabolizing O
enzyme O
, O
Cyp26A1 O
, O
arguing O
for O
an O
active O
signaling O
function O
of O
dihydroretinoid O
metabolites O
in O
zebrafish O
. O
These O
findings O
point O
to O
a O
conserved O
function O
but O
altered O
specificity O
of O
RetSat O
in O
vertebrates O
, O
leading O
to O
the O
generation O
of O
various O
dihydroretinoid O
compounds O
, O

all-trans-7,8-dihydroretinol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
vertebrates O
and O
also O
the O
evolutionarily O
preserved O
activity O
of O
bacterial O
phytoene O
desaturases O
and O
plant O
carotenoid O
isomerases O
. O
Expression O
of O
zRetSat O
A O
was O
restricted O
to O
the O
liver O
and O
intestine O
of O
hatchlings O
and O
adult O
zebrafish O
, O
whereas O
zRetSat O
B O
was O
expressed O
in O
the O
same O
tissues O
but O
at O
earlier O
developmental O
stages O
. O
Exogenous O
all-trans-retinol O
, O
all-trans-13,14-dihydroretinol O
, O
or O
all-trans-7,8-dihydroretinol O
led O
to O
the O
strong O
induction O
of O
the O
expression O
of O
the O
retinoic O
acid-metabolizing O
enzyme O
, O
Cyp26A1 O
, O
arguing O
for O
an O
active O
signaling O
function O
of O
dihydroretinoid O
metabolites O
in O
zebrafish O
. O
These O
findings O
point O
to O
a O
conserved O
function O
but O
altered O
specificity O
of O
RetSat O
in O
vertebrates O
, O
leading O
to O
the O
generation O
of O
various O
dihydroretinoid O
compounds O
, O
some O
of O

all-trans-retinoic O
acid O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Specificity O
of O
zebrafish O
retinol O
saturase O
: O
formation O
of O
all-trans-13,14-dihydroretinol O
and O
all-trans-7,8- O
dihydroretinol.Metabolism O
of O
vitamin O
A O
, O
all-trans-retinol O
, O
leads O
to O
the O
formation O
of O
11-cis-retinaldehyde O
, O
the O
visual O
chromophore O
, O
and O
all-trans-retinoic O
acid O
which O
is O
involved O
in O
the O
regulation O
of O
gene O
expression O
through O
the O
retinoic O
acid O
receptor O
. O
Enzymes O
and O
binding O
proteins O
involved O
in O
retinoid O
metabolism O
are O
highly O
conserved O
across O
species O
. O
We O
previously O
described O
a O
novel O
mammalian O
enzyme O
that O
saturates O
the O
13-14 O
double O
bond O
of O
all-trans-retinol O
to O
produce O
all-trans-13,14-dihydroretinol O
, O
which O
then O
follows O
the O

all-trans-13,14-dihydroretinol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Specificity O
of O
zebrafish O
retinol O
saturase O
: O
formation O
of O
all-trans-13,14-dihydroretino O
and O
all-trans-7,8- O
dihydroretinol.Metabolism O
of O
vitamin O
A O
, O
all-trans-retinol O
, O
leads O
to O
the O
formation O
of O
11-cis-retinaldehyde O
, O
the O
visual O
chromophore O
, O
and O
all-trans-retinoic O
acid O
, O
which O
is O
involved O
in O
the O
regulation O
of O
gene O
expression O
through O
the O
retinoic O
acid O
receptor O
. O
Enzymes O
and O
binding O
proteins O
involved O
in O
retinoid O
metabolism O
are O
highly O
conserved O
across O
species O
. O
We O
previously O
described O

all-trans-7,8- O
dihydroretinol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Specificity O
of O
zebrafish O
retinol O
saturase O
: O
formation O
of O
all-trans-13,14-dihydroretinol O
and O
all-trans-7,8- O
dihydroretino O
.Metabolism O
of O
vitamin O
A O
, O
all-trans-retinol O
, O
leads O
to O
the O
formation O
of O
11-cis-retinaldehyde O
, O
the O
visual O
chromophore O
, O
and O
all-trans-retinoic O
acid O
, O
which O
is O
involved O
in O
the O
regulation O
of O
gene O
expression O
through O
the O
retinoic O
acid O
receptor O
. O
Enzymes O
and O
binding O
proteins O
involved O
in O
retinoid O
metabolism O
are O
highly O
conserved O
across O
species O
. O
We O
previously O
described O
a O
novel O

all-trans-13,14-dihydroretinol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
zebrafish O
, O
one O
of O
which O
, O
zebrafish O
RetSat O
A O
(zRetSat O
A) O
, O
also O
had O
retinol O
saturase O
activity O
, O
whereas O
zebrafish O
RetSat O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat B
A I
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
, O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol O
(vitamin O
A2) O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O
activity O
of O
zRetSat O
A O
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O
higher O
vertebrates O
and O
also O

all-trans-7,8-dihydroretinol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
of O
which O
, O
zebrafish O
RetSat O
A O
(zRetSat O
A) O
, O
also O
had O
retinol O
saturase O
activity O
, O
whereas O
zebrafish O
RetSat O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat B
A I
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol O
(vitamin O
A2) O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O
activity O
of O
zRetSat O
A O
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O
higher O
vertebrates O
and O
also O
the O
evolutionarily O

all-trans-retinol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
putative O
RetSat O
homologues O
in O
zebrafish O
, O
one O
of O
which O
, O
zebrafish O
RetSat O
A O
(zRetSat O
A) O
, O
also O
had O
retinol O
saturase O
activity O
, O
whereas O
zebrafish O
RetSat O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat B
A I
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
, O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol O
(vitamin O
A2) O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O
activity O
of O
zRetSat O
A O
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O

all-trans-13,14-dihydroretinol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
expression O
through O
the O
retinoic O
acid O
receptor O
. O
Enzymes O
and O
binding O
proteins O
involved O
in O
retinoid O
metabolism O
are O
highly O
conserved O
across O
species O
. O
We O
previously O
described O
a O
novel O
mammalian O
enzyme O
that O
saturates O
the O
13-14 O
double O
bond O
of O
all-trans-retinol O
to O
produce O
all-trans-13,14-dihydroretinol O
, O
which O
then O
follows O
the O
same O
metabolic O
fate O
as O
that O
of O
all-trans-retinol O
. O
Specifically O
, O
all-trans-13,14-dihydroretinol O
is O
transiently O
oxidized O
to O
all-trans-13,14-dihydroretinoic O
acid O
before O
being O
oxidized O
further O
by O
Cyp26 B
enzymes O
. O
Here O
, O
we O
report O
the O
identification O
of O
two O
putative O
RetSat O
homologues O
in O
zebrafish O
, O
one O
of O
which O
, O
zebrafish O
RetSat O
A O
(zRetSat O
A) O
, O
also O
had O
retinol O
saturase O
activity O
, O
whereas O
zebrafish O
RetSat O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O

all-trans-3,4-didehydroretinol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
zebrafish O
RetSat O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat B
A I
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
, O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol O
(vitamin O
A2) O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O
activity O
of O
zRetSat O
A O
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O
higher O
vertebrates O
and O
also O
the O
evolutionarily O
preserved O
activity O
of O
bacterial O
phytoene O
desaturases O
and O
plant O
carotenoid O
isomerases O
. O
Expression O
of O
zRetSat O

vitamin O
A2 O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat B
A I
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
, O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol O
( O
vitamin O
A2 O
 O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O
activity O
of O
zRetSat O
A O
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O
higher O
vertebrates O
and O
also O
the O
evolutionarily O
preserved O
activity O
of O
bacterial O
phytoene O
desaturases O
and O
plant O
carotenoid O
isomerases O
. O
Expression O
of O
zRetSat O
A O

acetyl O
acts O
as O
PART-OF O
for O
what O
entity O
? O
and O
we O
now O
present O
immunoblot O
, O
proteomic O
, O
and O
biochemical O
evidence O
that O
the O
membrane-bound O
form O
of O
ASPA B
is O
intrinsic O
to O
purified O
myelin O
membranes O
. O
This O
was O
supported O
by O
a O
novel O
TLC-based O
method O
for O
the O
assay O
of O
ASPA O
. O
That O
observation O
, O
together O
with O
previous O
demonstrations O
of O
numerous O
lipid-synthesizing O
enzymes O
in O
myelin O
, O
suggests O
utilization O
of O
acetyl O
groups O
liberated O
by O
myelin-localized O
ASPA O
for O
lipid O
synthesis O
within O
the O
myelin O
sheath O
. O
Such O
synthesis O
might O
be O
selective O
and O
could O
explain O
the O
deficit O
of O
myelin O
lipids O
in O
animals O
lacking O
ASPA O
. O

acetyl O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
considering O
the O
various O
physiological O
roles O
that O
have O
been O
proposed O
for O
this O
relatively O
abundant O
molecule O
one O
is O
obliged O
to O
take O
into O
account O
its O
unusual O
metabolic O
compartmentalization O
, O
according O
to O
which O
synthesis O
and O
storage O
occur O
in O
the O
neuron O
and O
hydrolytic O
cleavage O
in O
the O
oligodendrocyte O
. O
The O
latter O
reaction O
, O
catalyzed O
by O
aspartoacylase B
(ASPA) O
, O
produces O
acetyl O
groups O
plus O
aspartate O
and O
has O
been O
proposed O
to O
occur O
in O
both O
soluble O
and O
membranous O
subfractions O
of O
white O
matter O
. O
Our O
study O
supports O
such O
bimodal O
occurrence O
and O
we O
now O
present O
immunoblot O
, O
proteomic O
, O
and O
biochemical O
evidence O
that O
the O
membrane-bound O
form O
of O
ASPA O
is O
intrinsic O
to O
purified O
myelin O
membranes O
. O
This O
was O
supported O
by O

acetyl O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
considering O
the O
various O
physiological O
roles O
that O
have O
been O
proposed O
for O
this O
relatively O
abundant O
molecule O
one O
is O
obliged O
to O
take O
into O
account O
its O
unusual O
metabolic O
compartmentalization O
, O
according O
to O
which O
synthesis O
and O
storage O
occur O
in O
the O
neuron O
and O
hydrolytic O
cleavage O
in O
the O
oligodendrocyte O
. O
The O
latter O
reaction O
, O
catalyzed O
by O
aspartoacylase O
(ASPA) O
, O
produces O
acetyl O
groups O
plus O
aspartate O
and O
has O
been O
proposed O
to O
occur O
in O
both O
soluble O
and O
membranous O
subfractions O
of O
white O
matter O
. O
Our O
study O
supports O
such O
bimodal O
occurrence O
and O
we O
now O
present O
immunoblot O
, O
proteomic O
, O
and O
biochemical O
evidence O
that O
the O
membrane-bound O
form O
of O
ASPA B
is O
intrinsic O
to O
purified O
myelin O
membranes O
. O
This O
was O
supported O
by O

aspartate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
physiological O
roles O
that O
have O
been O
proposed O
for O
this O
relatively O
abundant O
molecule O
one O
is O
obliged O
to O
take O
into O
account O
its O
unusual O
metabolic O
compartmentalization O
, O
according O
to O
which O
synthesis O
and O
storage O
occur O
in O
the O
neuron O
and O
hydrolytic O
cleavage O
in O
the O
oligodendrocyte O
. O
The O
latter O
reaction O
, O
catalyzed O
by O
aspartoacylase B
(ASPA) O
, O
produces O
acetyl O
groups O
plus O
aspartate O
and O
has O
been O
proposed O
to O
occur O
in O
both O
soluble O
and O
membranous O
subfractions O
of O
white O
matter O
. O
Our O
study O
supports O
such O
bimodal O
occurrence O
and O
we O
now O
present O
immunoblot O
, O
proteomic O
, O
and O
biochemical O
evidence O
that O
the O
membrane-bound O
form O
of O
ASPA O
is O
intrinsic O
to O
purified O
myelin O
membranes O
. O
This O
was O
supported O
by O
a O
novel O
TLC-based O

aspartate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
physiological O
roles O
that O
have O
been O
proposed O
for O
this O
relatively O
abundant O
molecule O
one O
is O
obliged O
to O
take O
into O
account O
its O
unusual O
metabolic O
compartmentalization O
, O
according O
to O
which O
synthesis O
and O
storage O
occur O
in O
the O
neuron O
and O
hydrolytic O
cleavage O
in O
the O
oligodendrocyte O
. O
The O
latter O
reaction O
, O
catalyzed O
by O
aspartoacylase O
(ASPA) O
, O
produces O
acetyl O
groups O
plus O
aspartate O
and O
has O
been O
proposed O
to O
occur O
in O
both O
soluble O
and O
membranous O
subfractions O
of O
white O
matter O
. O
Our O
study O
supports O
such O
bimodal O
occurrence O
and O
we O
now O
present O
immunoblot O
, O
proteomic O
, O
and O
biochemical O
evidence O
that O
the O
membrane-bound O
form O
of O
ASPA B
is O
intrinsic O
to O
purified O
myelin O
membranes O
. O
This O
was O
supported O
by O
a O
novel O
TLC-based O

lactate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
activity O
and O
gene O
expression O
in O
placentas O
from O
preeclamptic O
pregnancies O
[Tsoi O
SCM O
, O
Zheng O
J O
, O
Xu O
F O
, O
Kay O
HH O
. O
Differential O
expression O
of O
lactate O
dehydrogenase O
isozymes O
(LDH) O
in O
human O
placenta O
with O
high O
expression O
of O
LDH-A(4) O
isozyme O
in O
the O
endothelial O
cells O
of O
pre-eclampsia O
villi O
. O
Placenta O
2001;22:317-22] O
. O
LDH B
is O
responsible O
for O
pyruvate O
conversion O
to O
lactate O
through O
glycolysis O
. O
In O
this O
study O
, O
we O
further O
investigated O
the O
role O
of O
hypoxia O
in O
primary O
trophoblast O
cells O
and O
a O
cultured O
cell O
line O
, O
JEG3 O
cells O
, O
to O
obtain O
a O
better O
understanding O
of O
how O
it O
affects O
the O
activities O
of O
lactate O
dehydrogenase O
, O
lactate O
production O
and O
regulatory O
genes O
, O
as O
a O
possible O
model O
for O
preeclampsia O
. O
Primary O

pyruvate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
(LDH) O
has O
increased O
activity O
and O
gene O
expression O
in O
placentas O
from O
preeclamptic O
pregnancies O
[Tsoi O
SCM O
, O
Zheng O
J O
, O
Xu O
F O
, O
Kay O
HH O
. O
Differential O
expression O
of O
lactate O
dehydrogenase O
isozymes O
(LDH) O
in O
human O
placenta O
with O
high O
expression O
of O
LDH-A(4) O
isozyme O
in O
the O
endothelial O
cells O
of O
pre-eclampsia O
villi O
. O
Placenta O
2001;22:317-22] O
. O
LDH B
is O
responsible O
for O
pyruvate O
conversion O
to O
lactate O
through O
glycolysis O
. O
In O
this O
study O
, O
we O
further O
investigated O
the O
role O
of O
hypoxia O
in O
primary O
trophoblast O
cells O
and O
a O
cultured O
cell O
line O
, O
JEG3 O
cells O
, O
to O
obtain O
a O
better O
understanding O
of O
how O
it O
affects O
the O
activities O
of O
lactate O
dehydrogenase O
, O
lactate O
production O
and O
regulatory O
genes O
, O
as O
a O
possible O
model O

PUFA O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
alpha-Linolenic O
acid O
, O
Delta6-desaturase O
gene O
polymorphism O
, O
and O
the O
risk O
of O
nonfatal O
myocardial O
infarction.BACKGROUND O
: O
Delta(6)-Desaturase O
(FADS2) O
is O
the O
rate-limiting O
step O
in O
the O
polyunsaturated O
fatty O
acid O
(PUFA) O
biosynthetic O
pathway O
. O
OBJECTIVE O
: O
The O
aim O
was O
to O
test O
whether O
the O
common O
deletion O
[T/-] O
in O
the O
promoter O
of O
FADS2 B
affects O
the O
PUFA O
biosynthetic O
pathway O
and O
consequently O
modifies O
the O
effect O
of O
alpha-linolenic O
acid O
(ALA) O
on O
myocardial O
infarction O
(MI) O
. O
DESIGN O
: O
Case O
subjects O
(n O
=1694) O
with O
a O
first O
nonfatal O
acute O
MI O
were O
matched O
by O
age O
, O
sex O
, O
and O
area O
of O
residence O
to O
1694 O
population-based O
control O
subjects O
in O
Costa O
Rica O
. O
PUFAs O
were O
quantified O
by O
gas-liquid O
chromatography O

alpha-linolenic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
polymorphism O
, O
and O
the O
risk O
of O
nonfatal O
myocardial O
infarction.BACKGROUND O
: O
Delta(6)-Desaturase O
(FADS2) O
is O
the O
rate-limiting O
step O
in O
the O
polyunsaturated O
fatty O
acid O
(PUFA) O
biosynthetic O
pathway O
. O
OBJECTIVE O
: O
The O
aim O
was O
to O
test O
whether O
the O
common O
deletion O
[T/-] O
in O
the O
promoter O
of O
FADS2 B
affects O
the O
PUFA O
biosynthetic O
pathway O
and O
consequently O
modifies O
the O
effect O
of O
alpha-linolenic O
acid O
(ALA) O
on O
myocardial O
infarction O
(MI) O
. O
DESIGN O
: O
Case O
subjects O
(n O
=1694) O
with O
a O
first O
nonfatal O
acute O
MI O
were O
matched O
by O
age O
, O
sex O
, O
and O
area O
of O
residence O
to O
1694 O
population-based O
control O
subjects O
in O
Costa O
Rica O
. O
PUFAs O
were O
quantified O
by O
gas-liquid O
chromatography O
from O
plasma O
and O
adipose O
tissue O
samples O
. O
Least-squares O
means O
from O
generalized O

ALA O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
risk O
of O
nonfatal O
myocardial O
infarction.BACKGROUND O
: O
Delta(6)-Desaturase O
(FADS2) O
is O
the O
rate-limiting O
step O
in O
the O
polyunsaturated O
fatty O
acid O
(PUFA) O
biosynthetic O
pathway O
. O
OBJECTIVE O
: O
The O
aim O
was O
to O
test O
whether O
the O
common O
deletion O
[T/-] O
in O
the O
promoter O
of O
FADS2 B
affects O
the O
PUFA O
biosynthetic O
pathway O
and O
consequently O
modifies O
the O
effect O
of O
alpha-linolenic O
acid O
( O
ALA O
on O
myocardial O
infarction O
(MI) O
. O
DESIGN O
: O
Case O
subjects O
(n O
=1694) O
with O
a O
first O
nonfatal O
acute O
MI O
were O
matched O
by O
age O
, O
sex O
, O
and O
area O
of O
residence O
to O
1694 O
population-based O
control O
subjects O
in O
Costa O
Rica O
. O
PUFAs O
were O
quantified O
by O
gas-liquid O
chromatography O
from O
plasma O
and O
adipose O
tissue O
samples O
. O
Least-squares O
means O
from O
generalized O
linear O

milrinone O
acts O
as O
NOT O
for O
what O
entity O
? O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase B
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
( O
milrinone O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O

8-methoxymethyl-3-isobutyl-1-methylxanthine O
acts O
as O
NOT O
for O
what O
entity O
? O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase B
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
( O
8-methoxymethyl-3-isobutyl-1-methylxanthine O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O

erythro-9-(2-hydroxy-3-nonyl)adenine O
acts O
as O
NOT O
for O
what O
entity O
? O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase B
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[ O
erythro-9-(2-hydroxy-3-nonyl)adenine O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O

4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one O
acts O
as O
NOT O
for O
what O
entity O
? O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase B
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[ O
4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one O
 O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O

zaprinast O
acts O
as O
NOT O
for O
what O
entity O
? O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
( O
zaprinast O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O

BRL-50481 O
acts O
as O
NOT O
for O
what O
entity O
? O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[ O
BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O

5-nitro-2,N,N-trimethylbenzenesulfonamide O
acts O
as O
NOT O
for O
what O
entity O
? O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
( O
5-nitro-2,N,N-trimethylbenzenesulfonamide O
 O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O

dipyridamole O
acts O
as O
NOT O
for O
what O
entity O
? O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 B
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O

dipyridamole O
acts O
as O
NOT O
for O
what O
entity O
? O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O

dipyridamole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
Ecto-phosphodiesterase O
has O
some O
pharmacological O
characteristics O
similar O
to O
PDE8 O
. O

1,3-isobutyl-1-methylxanthine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase B
(PDE) O
inhibitor O
( O
1,3-isobutyl-1-methylxanthine O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O

1,3-isobutyl-1-methylxanthine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
( O
1,3-isobutyl-1-methylxanthine O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O

milrinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 B
( O
milrinone O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O

8-methoxymethyl-3-isobutyl-1-methylxanthine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 B
( O
8-methoxymethyl-3-isobutyl-1-methylxanthine O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O

erythro-9-(2-hydroxy-3-nonyl)adenine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 B
[ O
erythro-9-(2-hydroxy-3-nonyl)adenine O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O

4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 B
(Ro O
20-1724 O
[ O
4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one O
 O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O

zaprinast O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 B
and O
PDE6 O
( O
zaprinast O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O

zaprinast O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 B
( O
zaprinast O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O

BRL-50481 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 B
[ O
BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O

5-nitro-2,N,N-trimethylbenzenesulfonamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 B
[BRL-50481 O
( O
5-nitro-2,N,N-trimethylbenzenesulfonamide O
 O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O

dipyridamole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 B
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O

dipyridamole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O

dipyridamole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O

dipyridamole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O

dipyridamole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 B
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O

AMP O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O

adenosine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O

cAMP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O

AMP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O

IM O
acts O
as O
NOT O
for O
what O
entity O
? O
Kit O
to O
AXL O
. O
In O
GIST-R O
, O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase B
domain I
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
, O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

IM O
acts O
as O
NOT O
for O
what O
entity O
? O
Kit O
to O
AXL O
. O
In O
GIST-R O
, O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit B
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
, O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

IM O
acts O
as O
NOT O
for O
what O
entity O
? O
Kit O
to O
AXL O
. O
In O
GIST-R O
, O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
, O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

IM O
acts O
as O
NOT O
for O
what O
entity O
? O
Kit O
to O
AXL O
. O
In O
GIST-R O
, O
AXL B
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
, O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

tyrosine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
- O
AXL B
- O
in O
a O
'kinase O
switch' O
. O
Further O
, O
the O
two O
IM O
resistant O
GIST O
patients O
express O
AXL O
and O
not O
c-Kit O
, O
seen O
by O
immunohistochemistry O
(IHC) O
. O
Real O
time O
reverse O
transcriptase-polymerase O
chain O
reaction O
and O
Western O
blotting O
of O
the O
GIST-S O
and O
GIST-R O
cells O
confirmed O
the O
switch O
from O
Kit O
to O
AXL O
. O
In O
GIST-R O
, O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
, O
a O
novel O

MP470 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase B
domain I
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

MP470 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit B
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

MP470 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

MP470 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
AXL B
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

imatinib O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
A O
novel O
tyrosine B
kinase I
switch O
is O
a O
mechanism O
of O
imatini O
resistance O
in O
gastrointestinal O
stromal O
tumors.KIT O
or O
alpha-platelet-derived O
growth O
factor O
receptor O
(alpha-PDGFR) O
activating O
mutations O
are O
the O
pathogenic O
mechanisms O
that O
characterize O
gastrointestinal O
stromal O
tumors O
(GIST) O
. O
Despite O
excellent O
responses O
to O
imatinib O
mesylate O
(IM) O
, O
patients O
are O
relapsing O
. O
We O
developed O
an O
IM-resistant O
GIST O
cell O
line O
(GIST-R) O
from O
the O
IM-sensitive O
GIST882 O
cell O
line O
(GIST-S) O
by O

IM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
pathogenic O
mechanisms O
that O
characterize O
gastrointestinal O
stromal O
tumors O
(GIST) O
. O
Despite O
excellent O
responses O
to O
imatinib O
mesylate O
(IM) O
, O
patients O
are O
relapsing O
. O
We O
developed O
an O
IM-resistant O
GIST O
cell O
line O
(GIST-R) O
from O
the O
IM-sensitive O
GIST882 O
cell O
line O
(GIST-S) O
by O
growing O
these O
cells O
in O
IM O
. O
Gene O
expression O
profiling O
(GEP) O
of O
GIST-S O
, O
GIST-R O
cells O
and O
two O
IM O
resistant O
GIST O
patients O
demonstrated O
that O
KIT B
is O
downregulated O
implying O
a O
major O
role O
in O
IM O
resistance O
. O
Instead O
, O
GIST-R O
cells O
have O
acquired O
IM O
resistance O
by O
overexpressing O
the O
oncogenic O
receptor O
tyrosine O
kinase O
- O
AXL O
- O
in O
a O
'kinase O
switch' O
. O
Further O
, O
the O
two O
IM O
resistant O
GIST O
patients O
express O
AXL O
and O
not O
c-Kit O
, O
seen O

IM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(IM) O
, O
patients O
are O
relapsing O
. O
We O
developed O
an O
IM-resistant O
GIST O
cell O
line O
(GIST-R) O
from O
the O
IM-sensitive O
GIST882 O
cell O
line O
(GIST-S) O
by O
growing O
these O
cells O
in O
IM O
. O
Gene O
expression O
profiling O
(GEP) O
of O
GIST-S O
, O
GIST-R O
cells O
and O
two O
IM O
resistant O
GIST O
patients O
demonstrated O
that O
KIT B
is O
downregulated O
implying O
a O
major O
role O
in O
IM O
resistance O
. O
Instead O
, O
GIST-R O
cells O
have O
acquired O
IM O
resistance O
by O
overexpressing O
the O
oncogenic O
receptor O
tyrosine O
kinase O
- O
AXL O
- O
in O
a O
'kinase O
switch' O
. O
Further O
, O
the O
two O
IM O
resistant O
GIST O
patients O
express O
AXL O
and O
not O
c-Kit O
, O
seen O
by O
immunohistochemistry O
(IHC) O
. O
Real O
time O
reverse O
transcriptase-polymerase O
chain O
reaction O
and O
Western O
blotting O
of O
the O

MP470 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit B
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

MP470 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
AXL B
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

MP470 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase B
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

leflunomide O
acts O
as O
AGONIST O
for O
what O
entity O
? O
found O
to O
significantly O
induce O
Cyp1a1 O
in O
vivo O
but O
were O
not O
verified O
to O
bind O
or O
activate O
the O
AhR B
in O
vitro O
. O
Combining O
in O
vivo O
and O
in O
vitro O
findings O
, O
we O
identified O
nine O
AhR O
agonists O
, O
six O
of O
which O
are O
marketed O
therapeutics O
and O
have O
been O
approved O
by O
the O
U.S O
. O
Food O
and O
Drug O
Administration O
, O
including O
leflunomide O
flutamide O
, O
and O
nimodipine O
. O
These O
drugs O
do O
not O
produce O
dioxin-like O
toxicity O
in O
rats O
or O
in O
humans O
. O
These O
data O
demonstrate O
that O
induction O
of O
Cyp1a1 O
is O
a O
nonspecific O
biomarker O
of O
direct O
AhR O
affinity O
and O
activation O
and O
lend O
further O
support O
to O
the O
hypothesis O
that O
Cyp1a1 O
induction O
and/or O
AhR O
activation O
is O
not O
synonymous O
with O

flutamide O
acts O
as O
AGONIST O
for O
what O
entity O
? O
to O
significantly O
induce O
Cyp1a1 O
in O
vivo O
but O
were O
not O
verified O
to O
bind O
or O
activate O
the O
AhR B
in O
vitro O
. O
Combining O
in O
vivo O
and O
in O
vitro O
findings O
, O
we O
identified O
nine O
AhR O
agonists O
, O
six O
of O
which O
are O
marketed O
therapeutics O
and O
have O
been O
approved O
by O
the O
U.S O
. O
Food O
and O
Drug O
Administration O
, O
including O
leflunomide O
, O
flutamide O
and O
nimodipine O
. O
These O
drugs O
do O
not O
produce O
dioxin-like O
toxicity O
in O
rats O
or O
in O
humans O
. O
These O
data O
demonstrate O
that O
induction O
of O
Cyp1a1 O
is O
a O
nonspecific O
biomarker O
of O
direct O
AhR O
affinity O
and O
activation O
and O
lend O
further O
support O
to O
the O
hypothesis O
that O
Cyp1a1 O
induction O
and/or O
AhR O
activation O
is O
not O
synonymous O
with O
dioxin-like O

nimodipine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
induce O
Cyp1a1 O
in O
vivo O
but O
were O
not O
verified O
to O
bind O
or O
activate O
the O
AhR B
in O
vitro O
. O
Combining O
in O
vivo O
and O
in O
vitro O
findings O
, O
we O
identified O
nine O
AhR O
agonists O
, O
six O
of O
which O
are O
marketed O
therapeutics O
and O
have O
been O
approved O
by O
the O
U.S O
. O
Food O
and O
Drug O
Administration O
, O
including O
leflunomide O
, O
flutamide O
, O
and O
nimodipine O
These O
drugs O
do O
not O
produce O
dioxin-like O
toxicity O
in O
rats O
or O
in O
humans O
. O
These O
data O
demonstrate O
that O
induction O
of O
Cyp1a1 O
is O
a O
nonspecific O
biomarker O
of O
direct O
AhR O
affinity O
and O
activation O
and O
lend O
further O
support O
to O
the O
hypothesis O
that O
Cyp1a1 O
induction O
and/or O
AhR O
activation O
is O
not O
synonymous O
with O
dioxin-like O
toxicity O
. O

rolipram O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
mice O
, O
rolipram O
dose-dependently O
suppressed O
CAR O
(ED(50) O
= O
2.4 O
mg/kg); O
however O
, O
in O
knockout O
mice O
, O
their O
sensitivity O
to O
rolipram O
at O
the O
higher O
doses O
(1.0 O
and O
3.2 O
mg/kg) O
was O
reduced O
, O
resulting O
in O
a O
threefold O
shift O
in O
the O
ED(50) O
(7.3 O
mg/kg) O
, O
suggesting O
PDE4B B
is O
involved O
, O
at O
least O
in O
part O
, O
with O
the O
activity O
of O
rolipram O
Only O
the O
highest O
dose O
of O
rolipram O
(3.2 O
mg/kg) O
produced O
a O
modest O
but O
significant O
degree O
of O
catalepsy O
. O
CONCLUSIONS O
: O
Rolipram O
has O
a O
pharmacologic O
profile O
similar O
to O
that O
of O
the O
atypical O
antipsychotics O
and O
has O
low O
extrapyramidal O
symptom O
liability O
. O
These O
results O
suggest O
that O
PDE4B O
mediates O
the O
antipsychotic O
effects O
of O
rolipram O
in O
CAR O
and O

rolipram O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
activity O
of O
rolipram O
. O
Only O
the O
highest O
dose O
of O
rolipram O
(3.2 O
mg/kg) O
produced O
a O
modest O
but O
significant O
degree O
of O
catalepsy O
. O
CONCLUSIONS O
: O
Rolipram O
has O
a O
pharmacologic O
profile O
similar O
to O
that O
of O
the O
atypical O
antipsychotics O
and O
has O
low O
extrapyramidal O
symptom O
liability O
. O
These O
results O
suggest O
that O
PDE4B B
mediates O
the O
antipsychotic O
effects O
of O
rolipram O
in O
CAR O
and O
that O
the O
PDE4B-regulated O
cyclic O
adenosine O
monophosphate O
signaling O
pathway O
may O
play O
a O
role O
in O
the O
pathophysiology O
and O
pharmacotherapy O
of O
psychosis O
. O

rolipram O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Recent O
studies O
provide O
evidence O
for O
reduced O
phosphodiesterase-4B O
(PDE4B) O
as O
a O
genetic O
susceptibility O
factor O
as O
well O
as O
suggesting O
an O
association O
of O
several O
single O
nucleotide O
polymorphisms O
(SNPs) O
in O
PDE4B O
that O
are O
associated O
with O
an O
increased O
incidence O
of O
schizophrenia O
. O
OBJECTIVES O
: O
The O
aim O
of O
the O
current O
study O
was O
to O
assess O
the O
activity O
of O
rolipram O
a O
nonsubtype-selective O
PDE4 B
inhibitor O
, O
in O
several O
animal O
models O
predictive O
of O
antipsychotic-like O
efficacy O
and O
side-effect O
liability O
and O
to O
use O
PDE4B O
wild-type O
and O
knockout O
mice O
to O
begin O
to O
understand O
the O
subtypes O
involved O
in O
the O
activity O
of O
rolipram O
. O
RESULTS O
: O
In O
rats O
, O
rolipram O
antagonized O
both O
phencyclidine O
hydrochloride- O
and O
D-amphetamine-induced O
hyperactivity O
and O
inhibited O
conditioned O

cyclic O
adenosine O
monophosphate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
rolipram O
(3.2 O
mg/kg) O
produced O
a O
modest O
but O
significant O
degree O
of O
catalepsy O
. O
CONCLUSIONS O
: O
Rolipram O
has O
a O
pharmacologic O
profile O
similar O
to O
that O
of O
the O
atypical O
antipsychotics O
and O
has O
low O
extrapyramidal O
symptom O
liability O
. O
These O
results O
suggest O
that O
PDE4B B
mediates O
the O
antipsychotic O
effects O
of O
rolipram O
in O
CAR O
and O
that O
the O
PDE4B-regulated O
cyclic O
adenosine O
monophosphate O
signaling O
pathway O
may O
play O
a O
role O
in O
the O
pathophysiology O
and O
pharmacotherapy O
of O
psychosis O
. O

threonine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
mutation O
in O
KYNU O
encoding O
kynureninase.Massive O
urinary O
excretion O
of O
xanthurenic O
acid O
, O
3-hydroxykynurenine O
and O
kynurenine O
, O
known O
as O
xanthurenic O
aciduria O
or O
hydroxykynureninuria O
, O
in O
a O
young O
Somali O
boy O
suggested O
kynureninase B
deficiency O
. O
Mutation O
analysis O
of O
KYNU O
encoding O
kynureninase O
of O
the O
index O
case O
revealed O
homozygosity O
for O
a O
c.593 O
A O
> O
G O
substitution O
leading O
to O
a O
threonine O
to-alanine O
(T198A) O
shift O
. O
A O
younger O
brother O
was O
found O
to O
have O
a O
similar O
excretion O
pattern O
and O
the O
same O
genotype O
. O
At O
present O
, O
neither O
of O
the O
two O
boys O
has O
symptoms O
of O
niacin O
deficiency O
. O
This O
is O
the O
first O
report O
linking O
xanthurenic O
aciduria O
to O
a O
mutation O
in O
the O
gene O
encoding O
kynureninase O
. O

alanine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
in O
KYNU O
encoding O
kynureninase.Massive O
urinary O
excretion O
of O
xanthurenic O
acid O
, O
3-hydroxykynurenine O
and O
kynurenine O
, O
known O
as O
xanthurenic O
aciduria O
or O
hydroxykynureninuria O
, O
in O
a O
young O
Somali O
boy O
suggested O
kynureninase B
deficiency O
. O
Mutation O
analysis O
of O
KYNU O
encoding O
kynureninase O
of O
the O
index O
case O
revealed O
homozygosity O
for O
a O
c.593 O
A O
> O
G O
substitution O
leading O
to O
a O
threonine-to- O
alanine O
(T198A) O
shift O
. O
A O
younger O
brother O
was O
found O
to O
have O
a O
similar O
excretion O
pattern O
and O
the O
same O
genotype O
. O
At O
present O
, O
neither O
of O
the O
two O
boys O
has O
symptoms O
of O
niacin O
deficiency O
. O
This O
is O
the O
first O
report O
linking O
xanthurenic O
aciduria O
to O
a O
mutation O
in O
the O
gene O
encoding O
kynureninase O
. O

sitagliptin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 O
inactivation O
of O
the O
incretin O
hormones O
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin B
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
, O
sitagliptin O
100 O
or O
200mg O
once O
daily O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
was O
associated O
with O
significant O
improvements O
relative O
to O
placebo O
in O
overall O
glycaemic O
control O
and O
indices O
for O
insulin O
response O
and O
beta-cell O
function O
. O
Improvements O
from O
baseline O
in O
mean O
glycosylated O
haemoglobin O
(HbA(1c)) O
were O
significantly O
greater O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O

glipizide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
(HbA(1c)) O
were O
significantly O
greater O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes O
. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O
glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment O
, O
sitagliptin O
improved O
HbA(1c) B
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin O
or O
pioglitazone O
and O
was O
noninferior O
to O
glipizide O
when O
added O
to O
metformin O
. O
Sitagliptin O
was O
well O
tolerated O
when O
administered O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
, O
with O
an O
adverse O
event O
profile O
similar O
to O
that O
shown O
with O
placebo O
. O
The O
incidence O
of O
hypoglycaemia O
with O
sitagliptin O
was O
similar O
to O
that O
with O
placebo O
and O
, O
in O
combination O
with O
metformin O
, O
lower O
than O
that O
with O

sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
type O
2 O
diabetes O
mellitus O
, O
sitagliptin O
100 O
or O
200mg O
once O
daily O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
was O
associated O
with O
significant O
improvements O
relative O
to O
placebo O
in O
overall O
glycaemic O
control O
and O
indices O
for O
insulin O
response O
and O
beta-cell O
function O
. O
Improvements O
from O
baseline O
in O
mean O
glycosylated B
haemoglobin I
(HbA(1c)) O
were O
significantly O
greater O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes O
. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O
glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment O
, O
sitagliptin O
improved O
HbA(1c) O
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin O
or O
pioglitazone O
and O
was O
noninferior O
to O
glipizide O
when O
added O
to O
metformin O
. O
Sitagliptin O

sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
type O
2 O
diabetes O
mellitus O
, O
sitagliptin O
100 O
or O
200mg O
once O
daily O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
was O
associated O
with O
significant O
improvements O
relative O
to O
placebo O
in O
overall O
glycaemic O
control O
and O
indices O
for O
insulin O
response O
and O
beta-cell O
function O
. O
Improvements O
from O
baseline O
in O
mean O
glycosylated O
haemoglobin O
(HbA(1c)) O
were O
significantly O
greater O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes O
. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O
glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment O
, O
sitagliptin O
improved O
HbA(1c) B
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin O
or O
pioglitazone O
and O
was O
noninferior O
to O
glipizide O
when O
added O
to O
metformin O
. O
Sitagliptin O

sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
placebo O
in O
overall O
glycaemic O
control O
and O
indices O
for O
insulin O
response O
and O
beta-cell O
function O
. O
Improvements O
from O
baseline O
in O
mean O
glycosylated O
haemoglobin O
(HbA(1c)) O
were O
significantly O
greater O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes O
. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O
glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment O
, O
sitagliptin O
improved O
HbA(1c) B
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin O
or O
pioglitazone O
and O
was O
noninferior O
to O
glipizide O
when O
added O
to O
metformin O
. O
Sitagliptin O
was O
well O
tolerated O
when O
administered O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
, O
with O
an O
adverse O
event O
profile O
similar O
to O
that O
shown O
with O
placebo O
. O
The O

Sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Sitagliptin O
. O
Sitagliptin O
an O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 O
inactivation O
of O
the O
incretin B
hormones I
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O

Sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Sitagliptin O
. O
Sitagliptin O
an O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 O
inactivation O
of O
the O
incretin O
hormones O
glucagon-like B
peptide-1 I
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O

Sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Sitagliptin O
. O
Sitagliptin O
an O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 O
inactivation O
of O
the O
incretin O
hormones O
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O

metformin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Improvements O
from O
baseline O
in O
mean O
glycosylated O
haemoglobin O
(HbA(1c)) O
were O
significantly O
greater O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes O
. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O
glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment O
, O
sitagliptin O
improved O
HbA(1c) B
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin O
or O
pioglitazone O
and O
was O
noninferior O
to O
glipizide O
when O
added O
to O
metformin O
. O
Sitagliptin O
was O
well O
tolerated O
when O
administered O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
, O
with O
an O
adverse O
event O
profile O
similar O
to O
that O
shown O
with O
placebo O
. O
The O
incidence O
of O
hypoglycaemia O
with O
sitagliptin O
was O
similar O
to O
that O
with O
placebo O
and O
, O
in O

pioglitazone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
baseline O
in O
mean O
glycosylated O
haemoglobin O
(HbA(1c)) O
were O
significantly O
greater O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes O
. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O
glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment O
, O
sitagliptin O
improved O
HbA(1c) B
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin O
or O
pioglitazone O
and O
was O
noninferior O
to O
glipizide O
when O
added O
to O
metformin O
. O
Sitagliptin O
was O
well O
tolerated O
when O
administered O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
, O
with O
an O
adverse O
event O
profile O
similar O
to O
that O
shown O
with O
placebo O
. O
The O
incidence O
of O
hypoglycaemia O
with O
sitagliptin O
was O
similar O
to O
that O
with O
placebo O
and O
, O
in O
combination O
with O

metformin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes O
. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O
glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment O
, O
sitagliptin O
improved O
HbA(1c) B
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin O
or O
pioglitazone O
and O
was O
noninferior O
to O
glipizide O
when O
added O
to O
metformin O
Sitagliptin O
was O
well O
tolerated O
when O
administered O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
, O
with O
an O
adverse O
event O
profile O
similar O
to O
that O
shown O
with O
placebo O
. O
The O
incidence O
of O
hypoglycaemia O
with O
sitagliptin O
was O
similar O
to O
that O
with O
placebo O
and O
, O
in O
combination O
with O
metformin O
, O
lower O
than O
that O
with O
glipizide O
. O
Sitagliptin O
had O
a O

Sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sitagliptin O
. O
Sitagliptin O
an O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 B
inactivation O
of O
the O
incretin O
hormones O
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O

Sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sitagliptin O
. O
Sitagliptin O
an O
oral O
dipeptidyl B
peptidase-4 I
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 O
inactivation O
of O
the O
incretin O
hormones O
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O

Sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sitagliptin O
. O
Sitagliptin O
an O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 B
inactivation O
of O
the O
incretin O
hormones O
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta B
catenin I
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 B
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

Parathion O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Gene O
expression O
signature O
of O
parathion-transformed O
human O
breast O
epithelial O
cells.Environmental O
substances O
seem O
to O
be O
involved O
in O
the O
etiology O
of O
breast O
cancers O
. O
Many O
studies O
have O
found O
an O
association O
between O
human O
cancer O
and O
exposure O
to O
agricultural O
pesticides O
such O
as O
the O
organophosphorous O
pesticides O
. O
Parathion O
is O
a O
cholinesterase B
inhibitor O
that O
induces O
the O
hydrolysis O
of O
body O
choline O
esters O
, O
including O
acetylcholine O
at O
cholinergic O
synapses O
. O
The O
primary O
target O
of O
action O
in O
insects O
is O
the O
nervous O
system O
whereby O
pesticides O
inhibit O
the O
release O
of O
the O
enzyme O
acetylcholinesterase O
at O
the O
synaptic O
junction O
. O
Atropine O
is O
a O
parasympatholytic O
alkaloid O
used O
as O
an O

celecoxib O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
drug O
(NSAID) O
amtolmetin O
guacyl O
, O
a O
pro-drug O
of O
the O
NSAID O
tolmetin O
, O
on O
lipid O
peroxidation O
, O
glutathione O
levels O
and O
activity O
of O
antioxidant O
enzymes O
(superoxide O
dismutase O
, O
catalase O
, O
glutathione O
peroxidase O
and O
glutathione O
reductase) O
in O
rat O
gastric O
mucosa O
, O
colon O
mucosa O
and O
liver O
, O
were O
compared O
with O
the O
effects O
of O
non-selective O
(indomethacin O
, O
diclofenac) O
and O
COX-2 B
selective O
( O
celecoxib O
NSAIDs O
. O
2 O
. O
Indomethacin O
treatment O
led O
to O
an O
increase O
in O
lipid O
peroxidation O
, O
glutathione O
peroxidase O
and O
glucose-6-phosphate O
dehydrogenase O
activities O
and O
to O
a O
decrease O
in O
catalase O
activity O
and O
glutathione O
levels O
in O
gastric O
mucosa O
. O
In O
contrast O
, O
amtolmetin O
guacyl O
treatment O
was O
without O
effects O
in O
gastric O
and O
colon O
mucosa O
, O
or O
liver O
from O
control O
animals O
. O
Like O

Indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
amtolmetin O
guacyl O
, O
a O
pro-drug O
of O
the O
NSAID O
tolmetin O
, O
on O
lipid O
peroxidation O
, O
glutathione O
levels O
and O
activity O
of O
antioxidant O
enzymes O
(superoxide O
dismutase O
, O
catalase O
, O
glutathione B
peroxidase I
and O
glutathione O
reductase) O
in O
rat O
gastric O
mucosa O
, O
colon O
mucosa O
and O
liver O
, O
were O
compared O
with O
the O
effects O
of O
non-selective O
(indomethacin O
, O
diclofenac) O
and O
COX-2 O
selective O
(celecoxib) O
NSAIDs O
. O
2 O
. O
Indomethacin O
treatment O
led O
to O
an O
increase O
in O
lipid O
peroxidation O
, O
glutathione O
peroxidase O
and O
glucose-6-phosphate O
dehydrogenase O
activities O
and O
to O
a O
decrease O
in O
catalase O
activity O
and O
glutathione O
levels O
in O
gastric O
mucosa O
. O
In O
contrast O
, O
amtolmetin O
guacyl O
treatment O
was O
without O
effects O
in O
gastric O
and O
colon O
mucosa O
, O
or O
liver O
from O
control O
animals O
. O
Like O
amtolmetin O
guacyl O
, O
celecoxib O

Indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
amtolmetin O
guacyl O
, O
a O
pro-drug O
of O
the O
NSAID O
tolmetin O
, O
on O
lipid O
peroxidation O
, O
glutathione O
levels O
and O
activity O
of O
antioxidant O
enzymes O
(superoxide O
dismutase O
, O
catalase O
, O
glutathione O
peroxidase O
and O
glutathione O
reductase) O
in O
rat O
gastric O
mucosa O
, O
colon O
mucosa O
and O
liver O
, O
were O
compared O
with O
the O
effects O
of O
non-selective O
(indomethacin O
, O
diclofenac) O
and O
COX-2 O
selective O
(celecoxib) O
NSAIDs O
. O
2 O
. O
Indomethacin O
treatment O
led O
to O
an O
increase O
in O
lipid O
peroxidation O
, O
glutathione O
peroxidase O
and O
glucose-6-phosphate B
dehydrogenase I
activities O
and O
to O
a O
decrease O
in O
catalase O
activity O
and O
glutathione O
levels O
in O
gastric O
mucosa O
. O
In O
contrast O
, O
amtolmetin O
guacyl O
treatment O
was O
without O
effects O
in O
gastric O
and O
colon O
mucosa O
, O
or O
liver O
from O
control O
animals O
. O
Like O
amtolmetin O
guacyl O
, O
celecoxib O

Indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
amtolmetin O
guacyl O
, O
a O
pro-drug O
of O
the O
NSAID O
tolmetin O
, O
on O
lipid O
peroxidation O
, O
glutathione O
levels O
and O
activity O
of O
antioxidant O
enzymes O
(superoxide O
dismutase O
, O
catalase O
, O
glutathione O
peroxidase O
and O
glutathione O
reductase) O
in O
rat O
gastric O
mucosa O
, O
colon O
mucosa O
and O
liver O
, O
were O
compared O
with O
the O
effects O
of O
non-selective O
(indomethacin O
, O
diclofenac) O
and O
COX-2 O
selective O
(celecoxib) O
NSAIDs O
. O
2 O
. O
Indomethacin O
treatment O
led O
to O
an O
increase O
in O
lipid O
peroxidation O
, O
glutathione O
peroxidase O
and O
glucose-6-phosphate O
dehydrogenase O
activities O
and O
to O
a O
decrease O
in O
catalase B
activity O
and O
glutathione O
levels O
in O
gastric O
mucosa O
. O
In O
contrast O
, O
amtolmetin O
guacyl O
treatment O
was O
without O
effects O
in O
gastric O
and O
colon O
mucosa O
, O
or O
liver O
from O
control O
animals O
. O
Like O
amtolmetin O
guacyl O
, O
celecoxib O

Cisapride O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
initiation O
of O
cisapride O
treatment O
, O
increases O
in O
the O
dosage O
and O
the O
receipt O
of O
interacting O
medications O
. O
The O
relationships O
between O
the O
adverse O
events O
and O
the O
latter O
two O
factors O
exhibited O
biological O
gradients O
. O
Experimental O
evidence O
could O
be O
found O
from O
biological O
models O
, O
as O
well O
as O
reports O
of O
positive O
dechallenge O
and/or O
rechallenge O
found O
in O
individual O
patients O
. O
Cisapride O
was O
found O
to O
bind O
the O
human O
ether-a-go-go-related O
gene O
(HERG) O
potassium O
channel O
, O
which O
provides O
a O
plausible O
mechanism O
for O
QTc O
interval O
prolongation/arrhythmia O
. O
Other O
QTc O
interval-prolonging/arrhythmic O
drugs O
that O
also O
bind O
to O
HERG O
provided O
an O
analogy O
for O
cisapride O
causing O
QTc O
interval O
prolongation/arrhythmia O
via O
this O
mechanism O
. O
The O
evidence O
provided O
by O
clinical O
studies O
was O
inconsistent O
, O

cisapride O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
biological O
models O
, O
as O
well O
as O
reports O
of O
positive O
dechallenge O
and/or O
rechallenge O
found O
in O
individual O
patients O
. O
Cisapride O
was O
found O
to O
bind O
the O
human O
ether-a-go-go-related O
gene O
(HERG) O
potassium O
channel O
, O
which O
provides O
a O
plausible O
mechanism O
for O
QTc O
interval O
prolongation/arrhythmia O
. O
Other O
QTc O
interval-prolonging/arrhythmic O
drugs O
that O
also O
bind O
to O
HERG B
provided O
an O
analogy O
for O
cisapride O
causing O
QTc O
interval O
prolongation/arrhythmia O
via O
this O
mechanism O
. O
The O
evidence O
provided O
by O
clinical O
studies O
was O
inconsistent O
, O
and O
epidemiological O
studies O
failed O
to O
demonstrate O
an O
association O
. O
Nevertheless O
, O
this O
did O
not O
prevent O
the O
assessment O
of O
causation O
. O
DISCUSSION O
: O
This O
study O
showed O
how O
different O
types O
of O
evidence O
found O
in O
pharmacovigilance O
can O
be O
evaluated O
using O
the O

sulindac O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
14-3-3epsilon B
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O
activity O
. O
Overexpression O
of O
PPARdelta O
by O
adenoviral O
transfer O
rescued O
14-3-3epsilon O
proteins O
from O
elimination O
by O
sulindac O
or O
indomethacin O
. O
NSAID-induced O
14-3-3epsilon O
suppression O
was O
associated O
with O
reduced O
cytosolic O
Bad O
with O
elevation O
of O
mitochondrial O
Bad O
and O
increase O
in O
apoptosis O
which O
was O
rescued O
by O
Ad-PPARdelta O
transduction O
. O
Stable O
expression O
of O
14-3-3epsilon O
in O
HT-29 O
significantly O
protected O
cells O
from O
apoptosis O
. O
Our O
findings O
shed O
light O
on O
a O
novel O
mechanism O
by O
which O
NSAIDs O
induce O

indomethacin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
activity O
. O
As O
14-3-3epsilon B
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O
activity O
. O
Overexpression O
of O
PPARdelta O
by O
adenoviral O
transfer O
rescued O
14-3-3epsilon O
proteins O
from O
elimination O
by O
sulindac O
or O
indomethacin O
NSAID-induced O
14-3-3epsilon O
suppression O
was O
associated O
with O
reduced O
cytosolic O
Bad O
with O
elevation O
of O
mitochondrial O
Bad O
and O
increase O
in O
apoptosis O
which O
was O
rescued O
by O
Ad-PPARdelta O
transduction O
. O
Stable O
expression O
of O
14-3-3epsilon O
in O
HT-29 O
significantly O
protected O
cells O
from O
apoptosis O
. O
Our O
findings O
shed O
light O
on O
a O
novel O
mechanism O
by O
which O
NSAIDs O
induce O
colorectal O
cancer O

sulindac O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Nonsteroidal O
anti-inflammatory O
drugs O
induce O
colorectal O
cancer O
cell O
apoptosis O
by O
suppressing O
14-3-3epsilon.To O
determine O
the O
role O
of O
14-3-3 O
in O
colorectal O
cancer O
apoptosis O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
we O
evaluated O
the O
effects O
of O
sulindac O
on O
14-3-3epsilon B
protein I
expression O
in O
colorectal O
cancer O
cells O
. O
Sulindac O
sulfide O
inhibited O
14-3-3epsilon O
proteins O
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
Sulindac O
sulfone O
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
, O
a O
selective O
cyclooxygenase-2 O
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O

Sulindac O
sulfide O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
, O
a O
selective O
cyclooxygenase-2 O
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta B
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O
activity O
. O
Overexpression O
of O
PPARdelta O
by O
adenoviral O
transfer O
rescued O
14-3-3epsilon O
proteins O
from O
elimination O
by O
sulindac O
or O
indomethacin O
. O
NSAID-induced O
14-3-3epsilon O
suppression O
was O
associated O
with O
reduced O
cytosolic O
Bad O
with O
elevation O
of O
mitochondrial O
Bad O
and O
increase O
in O
apoptosis O
which O
was O
rescued O
by O
Ad-PPARdelta O
transduction O
. O
Stable O
expression O

Sulindac O
sulfide O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
, O
a O
selective O
cyclooxygenase-2 O
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta B
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O
activity O
. O
Overexpression O
of O
PPARdelta O
by O
adenoviral O
transfer O
rescued O
14-3-3epsilon O
proteins O
from O
elimination O
by O
sulindac O
or O
indomethacin O
. O
NSAID-induced O
14-3-3epsilon O
suppression O
was O
associated O
with O
reduced O
cytosolic O
Bad O
with O
elevation O
of O
mitochondrial O
Bad O
and O
increase O
in O
apoptosis O
which O
was O
rescued O
by O
Ad-PPARdelta O
transduction O
. O
Stable O
expression O

Sulindac O
sulfide O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Nonsteroidal O
anti-inflammatory O
drugs O
induce O
colorectal O
cancer O
cell O
apoptosis O
by O
suppressing O
14-3-3epsilon.To O
determine O
the O
role O
of O
14-3-3 O
in O
colorectal O
cancer O
apoptosis O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
we O
evaluated O
the O
effects O
of O
sulindac O
on O
14-3-3epsilon O
protein O
expression O
in O
colorectal O
cancer O
cells O
. O
Sulindac O
sulfide O
inhibited O
14-3-3epsilon B
proteins I
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
Sulindac O
sulfone O
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
, O
a O
selective O
cyclooxygenase-2 O
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O

Indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cancer O
apoptosis O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
we O
evaluated O
the O
effects O
of O
sulindac O
on O
14-3-3epsilon O
protein O
expression O
in O
colorectal O
cancer O
cells O
. O
Sulindac O
sulfide O
inhibited O
14-3-3epsilon O
proteins O
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
Sulindac O
sulfone O
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
, O
a O
selective O
cyclooxygenase-2 B
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O

Indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cancer O
apoptosis O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
we O
evaluated O
the O
effects O
of O
sulindac O
on O
14-3-3epsilon O
protein O
expression O
in O
colorectal O
cancer O
cells O
. O
Sulindac O
sulfide O
inhibited O
14-3-3epsilon O
proteins O
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
Sulindac O
sulfone O
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
, O
a O
selective O
cyclooxygenase-2 O
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O

SC-236 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
we O
evaluated O
the O
effects O
of O
sulindac O
on O
14-3-3epsilon O
protein O
expression O
in O
colorectal O
cancer O
cells O
. O
Sulindac O
sulfide O
inhibited O
14-3-3epsilon O
proteins O
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
Sulindac O
sulfone O
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
a O
selective O
cyclooxygenase-2 B
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O

SC-236 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
we O
evaluated O
the O
effects O
of O
sulindac O
on O
14-3-3epsilon O
protein O
expression O
in O
colorectal O
cancer O
cells O
. O
Sulindac O
sulfide O
inhibited O
14-3-3epsilon O
proteins O
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
Sulindac O
sulfone O
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
a O
selective O
cyclooxygenase-2 O
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O

N-ethylmaleimide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
cotransporter O
(KCC) O
isoform O
expression O
was O
characterized O
in O
corneal O
epithelial O
cells O
(CEC) O
. O
During O
exposure O
to O
a O
50% O
hypotonic O
challenge O
, O
the O
RVD O
response O
was O
larger O
in O
SV40-immortalized O
human O
CEC O
(HCEC) O
than O
in O
SV40-immortalized O
rabbit O
CEC O
(RCEC) O
. O
A O
KCC B
inhibitor-[(dihydroindenyl)oxy] O
alkanoic O
acid O
(DIOA)-blocked O
RVD O
more O
in O
HCEC O
than O
RCEC O
. O
Under O
isotonic O
conditions O
, O
N-ethylmaleimide O
(NEM) O
produced O
KCC O
activation O
and O
transient O
cell O
shrinkage O
. O
Both O
of O
these O
changes O
were O
greater O
in O
HCEC O
than O
in O
RCEC O
. O
Immunoblot O
analysis O
of O
HCEC O
, O
RCEC O
, O
primary O
human O
CEC O
(pHCEC) O
, O
and O
primary O
bovine O
CEC O
(BCEC) O
plasma O
membrane O
enriched O
fractions O
revealed O
KCC1 O
, O
KCC3 O
, O
and O
KCC4 O
isoform O
expression O
, O
whereas O
KCC2 O
was O
undetectable O
. O
During O

NEM O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
isoform O
expression O
was O
characterized O
in O
corneal O
epithelial O
cells O
(CEC) O
. O
During O
exposure O
to O
a O
50% O
hypotonic O
challenge O
, O
the O
RVD O
response O
was O
larger O
in O
SV40-immortalized O
human O
CEC O
(HCEC) O
than O
in O
SV40-immortalized O
rabbit O
CEC O
(RCEC) O
. O
A O
KCC B
inhibitor-[(dihydroindenyl)oxy] O
alkanoic O
acid O
(DIOA)-blocked O
RVD O
more O
in O
HCEC O
than O
RCEC O
. O
Under O
isotonic O
conditions O
, O
N-ethylmaleimide O
( O
NEM O
produced O
KCC O
activation O
and O
transient O
cell O
shrinkage O
. O
Both O
of O
these O
changes O
were O
greater O
in O
HCEC O
than O
in O
RCEC O
. O
Immunoblot O
analysis O
of O
HCEC O
, O
RCEC O
, O
primary O
human O
CEC O
(pHCEC) O
, O
and O
primary O
bovine O
CEC O
(BCEC) O
plasma O
membrane O
enriched O
fractions O
revealed O
KCC1 O
, O
KCC3 O
, O
and O
KCC4 O
isoform O
expression O
, O
whereas O
KCC2 O
was O
undetectable O
. O
During O
a O

[(dihydroindenyl)oxy] O
alkanoic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
epithelial O
cells.The O
dependence O
of O
regulatory O
volume O
decrease O
(RVD) O
activity O
on O
potassium-chloride O
cotransporter O
(KCC) O
isoform O
expression O
was O
characterized O
in O
corneal O
epithelial O
cells O
(CEC) O
. O
During O
exposure O
to O
a O
50% O
hypotonic O
challenge O
, O
the O
RVD O
response O
was O
larger O
in O
SV40-immortalized O
human O
CEC O
(HCEC) O
than O
in O
SV40-immortalized O
rabbit O
CEC O
(RCEC) O
. O
A O
KCC B
inhibitor- O
[(dihydroindenyl)oxy] O
alkanoic O
acid O
(DIOA)-blocked O
RVD O
more O
in O
HCEC O
than O
RCEC O
. O
Under O
isotonic O
conditions O
, O
N-ethylmaleimide O
(NEM) O
produced O
KCC O
activation O
and O
transient O
cell O
shrinkage O
. O
Both O
of O
these O
changes O
were O
greater O
in O
HCEC O
than O
in O
RCEC O
. O
Immunoblot O
analysis O
of O
HCEC O
, O
RCEC O
, O
primary O
human O
CEC O
(pHCEC) O
, O
and O
primary O
bovine O
CEC O
(BCEC) O
plasma O
membrane O
enriched O
fractions O

DIOA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dependence O
of O
regulatory O
volume O
decrease O
(RVD) O
activity O
on O
potassium-chloride O
cotransporter O
(KCC) O
isoform O
expression O
was O
characterized O
in O
corneal O
epithelial O
cells O
(CEC) O
. O
During O
exposure O
to O
a O
50% O
hypotonic O
challenge O
, O
the O
RVD O
response O
was O
larger O
in O
SV40-immortalized O
human O
CEC O
(HCEC) O
than O
in O
SV40-immortalized O
rabbit O
CEC O
(RCEC) O
. O
A O
KCC B
inhibitor-[(dihydroindenyl)oxy] O
alkanoic O
acid O
( O
DIOA O
-blocked O
RVD O
more O
in O
HCEC O
than O
RCEC O
. O
Under O
isotonic O
conditions O
, O
N-ethylmaleimide O
(NEM) O
produced O
KCC O
activation O
and O
transient O
cell O
shrinkage O
. O
Both O
of O
these O
changes O
were O
greater O
in O
HCEC O
than O
in O
RCEC O
. O
Immunoblot O
analysis O
of O
HCEC O
, O
RCEC O
, O
primary O
human O
CEC O
(pHCEC) O
, O
and O
primary O
bovine O
CEC O
(BCEC) O
plasma O
membrane O
enriched O
fractions O
revealed O

Dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase B
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O

Dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC B
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O

Dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O

Dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatini O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase B
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatini O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC B
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatini O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatini O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-35482 O
) O
: O
a O
potent O
oral O
multi-targeted O
kinase B
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-35482 O
) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC B
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-35482 O
) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-35482 O
) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase B
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
( O
BMS-354825 O
 O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC B
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
( O
BMS-354825 O
 O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
( O
BMS-354825 O
 O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
( O
BMS-354825 O
 O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O

lumiracoxib O
acts O
as O
NOT O
for O
what O
entity O
? O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 B
to I
Ala I
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O

lumiracoxib O
acts O
as O
NOT O
for O
what O
entity O
? O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 B
to I
Ala I
or I
Leu I
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O

lumiracoxib O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
with O
wild-type O
human O
COX-2 B
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib O
COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O
inhibition O
. O

aniline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
synthesized O
with O
or O
without O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O
demonstrated O
that O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
is O
required O
for O
COX-2 B
selectivity O
. O
The O
chemical O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O

2,6-dichloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 B
to I
Ile I
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro O
 O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O

2,6-dichloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human B
COX-2 I
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro O
 O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O

2,6-dimethyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 B
to I
Ile I
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl O
 O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O

2,6-dimethyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human B
COX-2 I
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl O
 O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O

2-chloro-6-methyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 B
to I
Ile I
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl O
substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O
inhibition O
. O

2-chloro-6-methyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human B
COX-2 I
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl O
substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O
inhibition O
. O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 B
to I
Ile I
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O
inhibition O
. O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human B
COX-2 I
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O
inhibition O
. O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s B
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O
inhibition O
. O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
selective O
inhibition O
of O
cyclooxygenase-2 O
by O
lumiracoxib.Lumiracoxib O
is O
the O
first O
example O
of O
a O
marketed O
COX-2 O
inhibitor O
of O
the O
arylacetic O
acid O
class O
, O
and O
it O
is O
reported O
to O
be O
the O
most O
selective O
COXIB O
in O
vivo O
. O
However O
, O
the O
molecular O
basis O
of O
its O
COX-2 O
inhibition O
has O
not O
been O
completely O
defined O
. O
Using O
standard O
assays O
, O
lumiracoxib O
was O
found O
to O
be O
a O
poor O
inhibitor O
of O
purified O
ovine B
COX-1 I
and O
a O
relatively O
weak O
inhibitor O
of O
purified O
human O
COX-2 O
. O
The O
extent O
of O
COX-2 O
inhibition O
plateaued O
at O
around O
50% O
and O
suggested O
that O
the O
inhibitor O
may O
be O
reversibly O
bound O
to O
the O
enzyme O
. O
Kinetic O
studies O
with O
lumiracoxib O
demonstrated O
that O
it O
was O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
selective O
inhibition O
of O
cyclooxygenase-2 O
by O
lumiracoxib.Lumiracoxib O
is O
the O
first O
example O
of O
a O
marketed O
COX-2 O
inhibitor O
of O
the O
arylacetic O
acid O
class O
, O
and O
it O
is O
reported O
to O
be O
the O
most O
selective O
COXIB O
in O
vivo O
. O
However O
, O
the O
molecular O
basis O
of O
its O
COX-2 O
inhibition O
has O
not O
been O
completely O
defined O
. O
Using O
standard O
assays O
, O
lumiracoxib O
was O
found O
to O
be O
a O
poor O
inhibitor O
of O
purified O
ovine O
COX-1 O
and O
a O
relatively O
weak O
inhibitor O
of O
purified O
human O
COX-2 O
. O
The O
extent O
of O
COX-2 O
inhibition O
plateaued O
at O
around O
50% O
and O
suggested O
that O
the O
inhibitor O
may O
be O
reversibly O
bound O
to O
the O
enzyme O
. O
Kinetic O
studies O
with O
lumiracoxib O
demonstrated O
that O
it O
was O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
defined O
. O
Using O
standard O
assays O
, O
lumiracoxib O
was O
found O
to O
be O
a O
poor O
inhibitor O
of O
purified O
ovine O
COX-1 O
and O
a O
relatively O
weak O
inhibitor O
of O
purified O
human O
COX-2 O
. O
The O
extent O
of O
COX-2 O
inhibition O
plateaued O
at O
around O
50% O
and O
suggested O
that O
the O
inhibitor O
may O
be O
reversibly O
bound O
to O
the O
enzyme O
. O
Kinetic O
studies O
with O
lumiracoxib O
demonstrated O
that O
it O
was O
a O
time-dependent O
and O
slowly O
reversible O
inhibitor O
of O
human B
COX-2 I
that O
exhibited O
at O
least O
two O
binding O
steps O
during O
inhibition O
. O
Derivatives O
of O
lumiracoxib O
were O
synthesized O
with O
or O
without O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O

arylacetic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Molecular O
determinants O
for O
the O
selective O
inhibition O
of O
cyclooxygenase-2 O
by O
lumiracoxib.Lumiracoxib O
is O
the O
first O
example O
of O
a O
marketed O
COX-2 B
inhibitor O
of O
the O
arylacetic O
acid O
class O
, O
and O
it O
is O
reported O
to O
be O
the O
most O
selective O
COXIB O
in O
vivo O
. O
However O
, O
the O
molecular O
basis O
of O
its O
COX-2 O
inhibition O
has O
not O
been O
completely O
defined O
. O
Using O
standard O
assays O
, O
lumiracoxib O
was O
found O
to O
be O
a O
poor O
inhibitor O
of O
purified O
ovine O
COX-1 O
and O
a O
relatively O
weak O
inhibitor O
of O
purified O
human O

Lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Molecular O
determinants O
for O
the O
selective O
inhibition O
of O
cyclooxygenase-2 O
by O
lumiracoxib O
. O
Lumiracoxib O
is O
the O
first O
example O
of O
a O
marketed O
COX-2 B
inhibitor O
of O
the O
arylacetic O
acid O
class O
, O
and O
it O
is O
reported O
to O
be O
the O
most O
selective O
COXIB O
in O
vivo O
. O
However O
, O
the O
molecular O
basis O
of O
its O
COX-2 O
inhibition O
has O
not O
been O
completely O
defined O
. O
Using O
standard O
assays O
, O
lumiracoxib O
was O
found O
to O
be O
a O
poor O

methyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
was O
a O
time-dependent O
and O
slowly O
reversible O
inhibitor O
of O
human O
COX-2 B
that O
exhibited O
at O
least O
two O
binding O
steps O
during O
inhibition O
. O
Derivatives O
of O
lumiracoxib O
were O
synthesized O
with O
or O
without O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O
demonstrated O
that O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
is O
required O
for O
COX-2 O
selectivity O
. O
The O
chemical O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O

phenylacetic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
slowly O
reversible O
inhibitor O
of O
human O
COX-2 B
that O
exhibited O
at O
least O
two O
binding O
steps O
during O
inhibition O
. O
Derivatives O
of O
lumiracoxib O
were O
synthesized O
with O
or O
without O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O
demonstrated O
that O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
is O
required O
for O
COX-2 O
selectivity O
. O
The O
chemical O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Molecular O
determinants O
for O
the O
selective O
inhibition O
of O
cyclooxygenase-2 B
by O
lumiracoxi O
.Lumiracoxib O
is O
the O
first O
example O
of O
a O
marketed O
COX-2 O
inhibitor O
of O
the O
arylacetic O
acid O
class O
, O
and O
it O
is O
reported O
to O
be O
the O
most O
selective O
COXIB O
in O
vivo O
. O
However O
, O
the O
molecular O
basis O
of O
its O
COX-2 O
inhibition O
has O
not O
been O
completely O
defined O
. O
Using O
standard O
assays O
, O
lumiracoxib O
was O
found O
to O
be O
a O

aniline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
synthesized O
with O
or O
without O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O
demonstrated O
that O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
is O
required O
for O
COX-2 O
selectivity O
. O
The O
chemical O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX B
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human B
COX-2 I
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O

Na(+) O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
SHR O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
, O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+) O
dependent O
l-alanine O
uptake O
through O
ASCT2 B
between O
WKY O
and O
SHR O
PTE O
cells O
correlated O
positively O
with O
differences O
in O
ASCT2 O
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O

l-alanine O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
, O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 B
between O
WKY O
and O
SHR O
PTE O
cells O
correlated O
positively O
with O
differences O
in O
ASCT2 O
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O

Na(+) O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
differences O
in O
ASCT2 B
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O
SHR O
and O
WKY O
PTE O
cells O
take O
up O
l-alanine O
mainly O
through O
a O
high-affinity O
Na(+) O
dependent O
amino O
acid O
transporter O
, O
with O
functional O
features O
of O
ASCT2 O
transport O
. O
The O
activity O
and O
expression O
of O
the O
ASCT2 O
transporter O
were O
considerably O
lower O
in O
the O
SHR O
cells O
. O

amino O
acid O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
in O
ASCT2 B
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O
SHR O
and O
WKY O
PTE O
cells O
take O
up O
l-alanine O
mainly O
through O
a O
high-affinity O
Na(+)-dependent O
amino O
acid O
transporter O
, O
with O
functional O
features O
of O
ASCT2 O
transport O
. O
The O
activity O
and O
expression O
of O
the O
ASCT2 O
transporter O
were O
considerably O
lower O
in O
the O
SHR O
cells O
. O

alanine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
was O
also O
evaluated O
. O
l-[(14)C]alanine O
uptake O
was O
highly O
dependent O
on O
extracellular O
Na(+) O
. O
Replacement O
of O
NaCl O
by O
LiCl O
or O
choline O
chloride O
abolished O
transport O
activity O
in O
SHR O
and O
WKY O
PTE O
cells O
. O
In O
the O
presence O
of O
the O
system O
L O
inhibitor O
BCH O
, O
Na(+)-dependent O
l-alanine O
uptake O
in O
WKY O
and O
SHR O
PTE O
cells O
was O
inhibited O
by O
alanine O
serine O
, O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 B
between O
WKY O

serine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
also O
evaluated O
. O
l-[(14)C]alanine O
uptake O
was O
highly O
dependent O
on O
extracellular O
Na(+) O
. O
Replacement O
of O
NaCl O
by O
LiCl O
or O
choline O
chloride O
abolished O
transport O
activity O
in O
SHR O
and O
WKY O
PTE O
cells O
. O
In O
the O
presence O
of O
the O
system O
L O
inhibitor O
BCH O
, O
Na(+)-dependent O
l-alanine O
uptake O
in O
WKY O
and O
SHR O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 B
between O
WKY O
and O

cysteine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
l-[(14)C]alanine O
uptake O
was O
highly O
dependent O
on O
extracellular O
Na(+) O
. O
Replacement O
of O
NaCl O
by O
LiCl O
or O
choline O
chloride O
abolished O
transport O
activity O
in O
SHR O
and O
WKY O
PTE O
cells O
. O
In O
the O
presence O
of O
the O
system O
L O
inhibitor O
BCH O
, O
Na(+)-dependent O
l-alanine O
uptake O
in O
WKY O
and O
SHR O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
, O
and O
cysteine O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 B
between O
WKY O
and O
SHR O
PTE O

l-alanine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
SHR O
PTE O
cells O
and O
kidney O
cortices O
from O
WKY O
and O
SHR O
was O
also O
evaluated O
. O
l-[(14)C]alanine O
uptake O
was O
highly O
dependent O
on O
extracellular O
Na(+) O
. O
Replacement O
of O
NaCl O
by O
LiCl O
or O
choline O
chloride O
abolished O
transport O
activity O
in O
SHR O
and O
WKY O
PTE O
cells O
. O
In O
the O
presence O
of O
the O
system O
L O
inhibitor O
BCH O
, O
Na(+)-dependent O
l-alanine O
uptake O
in O
WKY O
and O
SHR O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
, O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O

amino O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
on O
extracellular O
Na(+) O
. O
Replacement O
of O
NaCl O
by O
LiCl O
or O
choline O
chloride O
abolished O
transport O
activity O
in O
SHR O
and O
WKY O
PTE O
cells O
. O
In O
the O
presence O
of O
the O
system O
L O
inhibitor O
BCH O
, O
Na(+)-dependent O
l-alanine O
uptake O
in O
WKY O
and O
SHR O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
, O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 B
between O
WKY O
and O
SHR O
PTE O
cells O
correlated O
positively O
with O
differences O
in O

l-alanine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
, O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 B
between O
WKY O
and O
SHR O
PTE O
cells O
correlated O
positively O
with O
differences O
in O
ASCT2 O
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O

l-alanine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
PTE O
cells O
correlated O
positively O
with O
differences O
in O
ASCT2 O
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O
SHR O
and O
WKY O
PTE O
cells O
take O
up O
l-alanine O
mainly O
through O
a O
high-affinity O
Na(+)-dependent O
amino O
acid O
transporter O
, O
with O
functional O
features O
of O
ASCT2 O
transport O
. O
The O
activity O
and O
expression O
of O
the O
ASCT2 O
transporter O
were O
considerably O
lower O
in O
the O
SHR O
cells O
. O

l-alanine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
PTE O
cells O
correlated O
positively O
with O
differences O
in O
ASCT2 B
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O
SHR O
and O
WKY O
PTE O
cells O
take O
up O
l-alanine O
mainly O
through O
a O
high-affinity O
Na(+)-dependent O
amino O
acid O
transporter O
, O
with O
functional O
features O
of O
ASCT2 O
transport O
. O
The O
activity O
and O
expression O
of O
the O
ASCT2 O
transporter O
were O
considerably O
lower O
in O
the O
SHR O
cells O
. O

l-[(14)C]alanine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Underexpression O
of O
the O
Na+-dependent O
neutral O
amino O
acid O
transporter O
ASCT2 B
in O
the O
spontaneously O
hypertensive O
rat O
kidney.This O
study O
examined O
the O
inward O
transport O
of O
l-[(14)C]alanine O
an O
ASCT2 O
preferential O
substrate O
, O
in O
monolayers O
of O
immortalized O
renal O
proximal O
tubular O
epithelial O
(PTE) O
cells O
from O
Wistar-Kyoto O
(WKY) O
and O
spontaneously O
hypertensive O
(SHR) O
rats O
. O
The O
expression O
of O
ASCT2 O
in O
WKY O
and O
SHR O
PTE O
cells O
and O
kidney O
cortices O
from O
WKY O
and O
SHR O
was O
also O
evaluated O
. O
l-[(14)C]alanine O
uptake O
was O
highly O
dependent O
on O
extracellular O

glucose O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
of O
glucose O
and O
glucagon O
secretion O
after O
intravenous O
arginine O
. O
Islet O
morphology O
was O
examined O
and O
insulin B
secretion O
and O
glucose O
oxidation O
were O
measured O
in O
isolated O
islets O
. O
RESULTS O
: O
Fasting O
plasma O
glucose O
levels O
were O
reduced O
by O
GRA O
(6.0 O
+/- O
0.2 O
vs O
7.4 O
+/- O
0.5 O
mmol/l; O
p O
= O
0.017) O
. O
The O
acute O
insulin O
response O
to O
intravenous O
glucose O
was O
augmented O
(1,300 O
+/- O
110 O
vs O
790 O
+/- O
64 O
pmol/l; O
p O
< O
0.001) O
. O
The O
early O
insulin O
response O
to O
oral O
glucose O
was O
reduced O
in O
mice O
on O
HFD O
+ O
GRA O
(1,890 O
+/- O
160 O
vs O
3,040 O
+/- O
420 O
pmol/l; O
p O
= O
0.012) O
, O
but O
glucose O
excursions O
were O
improved O
. O
Intravenous O
arginine O
significantly O
increased O
the O

glucose O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
in O
isolated O
islets O
. O
RESULTS O
: O
Fasting O
plasma O
glucose O
levels O
were O
reduced O
by O
GRA O
(6.0 O
+/- O
0.2 O
vs O
7.4 O
+/- O
0.5 O
mmol/l; O
p O
= O
0.017) O
. O
The O
acute O
insulin B
response O
to O
intravenous O
glucose O
was O
augmented O
(1,300 O
+/- O
110 O
vs O
790 O
+/- O
64 O
pmol/l; O
p O
< O
0.001) O
. O
The O
early O
insulin O
response O
to O
oral O
glucose O
was O
reduced O
in O
mice O
on O
HFD O
+ O
GRA O
(1,890 O
+/- O
160 O
vs O
3,040 O
+/- O
420 O
pmol/l; O
p O
= O
0.012) O
, O
but O
glucose O
excursions O
were O
improved O
. O
Intravenous O
arginine O
significantly O
increased O
the O
acute O
glucagon O
response O
(129 O
+/- O
12 O
vs O
36 O
+/- O
6 O
ng/l O
in O
controls; O
p O
< O
0.01) O
, O
notably O
without O
affecting O
plasma O

arginine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
response O
to O
intravenous O
glucose O
was O
augmented O
(1,300 O
+/- O
110 O
vs O
790 O
+/- O
64 O
pmol/l; O
p O
< O
0.001) O
. O
The O
early O
insulin O
response O
to O
oral O
glucose O
was O
reduced O
in O
mice O
on O
HFD O
+ O
GRA O
(1,890 O
+/- O
160 O
vs O
3,040 O
+/- O
420 O
pmol/l; O
p O
= O
0.012) O
, O
but O
glucose O
excursions O
were O
improved O
. O
Intravenous O
arginine O
significantly O
increased O
the O
acute O
glucagon B
response O
(129 O
+/- O
12 O
vs O
36 O
+/- O
6 O
ng/l O
in O
controls; O
p O
< O
0.01) O
, O
notably O
without O
affecting O
plasma O
glucose O
. O
GRA O
caused O
a O
modest O
increase O
in O
alpha O
cell O
mass O
, O
while O
beta O
cell O
mass O
was O
similar O
to O
that O
in O
mice O
on O
HFD O
+ O
vehicle O
. O
Isolated O
islets O

glucose O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
acute O
glucagon O
response O
(129 O
+/- O
12 O
vs O
36 O
+/- O
6 O
ng/l O
in O
controls; O
p O
< O
0.01) O
, O
notably O
without O
affecting O
plasma O
glucose O
. O
GRA O
caused O
a O
modest O
increase O
in O
alpha O
cell O
mass O
, O
while O
beta O
cell O
mass O
was O
similar O
to O
that O
in O
mice O
on O
HFD O
+ O
vehicle O
. O
Isolated O
islets O
displayed O
improved O
glucose O
stimulated O
insulin B
secretion O
after O
GRA O
treatment O
(0.061 O
+/- O
0.007 O
vs O
0.030 O
+/- O
0.004 O
pmol O
islet(-1) O
h(-1) O
at O
16.7 O
mmol/l O
glucose; O
p O
< O
0.001) O
, O
without O
affecting O
islet O
glucose O
oxidation O
. O
CONCLUSIONS/INTERPRETATION O
: O
Chronic O
glucagon O
receptor O
antagonism O
in O
HFD-fed O
mice O
improves O
islet O
sensitivity O
to O
glucose O
and O
increases O
insulin O
secretion O
, O
suggesting O
improvement O
of O
key O

sodium O
hydrosulphide O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP B
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

sodium O
hydrosulphide O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A B
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

sodium O
hydrosulphide O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R B
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

NaHS O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP B
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
( O
NaHS O
 O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

NaHS O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A B
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
( O
NaHS O
 O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

NaHS O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R B
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
( O
NaHS O
 O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

Caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE B
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O

caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance B
P I
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein O
treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O

caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP B
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein O
treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O

caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP B
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein O
treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O

caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein O
treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O

caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein O
treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A B
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O

caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 B
receptor I
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein O
treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O

caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein O
treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O

Caerulein O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS B
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O

H(2)S O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP B
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O

H(2)S O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A B
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O

H(2)S O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R B
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O

DL-propargylglycine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
synthesizing O
enzymes O
, O
CSE B
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O

PAG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
CSE B
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
( O
PAG O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP B
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
( O
H(2)S O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE B
and O
CBS O
, O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
( O
H(2)S O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase B
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
( O
H(2)S O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
( O
H(2)S O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase B
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE B
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS B
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O

Hydrogen O
sulphide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells O
. O
Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE B
and O

Hydrogen O
sulphide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells O
. O
Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase B
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O

Hydrogen O
sulphide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells O
. O
Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O

Hydrogen O
sulphide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells O
. O
Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase B
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE B
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O

L-cysteine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE B
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O

L-cysteine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase B
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O

L-cysteine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O

L-cysteine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase B
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O

1400W O
dihydrochloride O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin B
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O

1400W O
dihydrochloride O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O

1400W O
dihydrochloride O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O

1400W O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
( O
1400W O
 O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin B
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O

1400W O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
( O
1400W O
 O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O

1400W O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
( O
1400W O
 O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O

DXM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin B
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O
These O
findings O
suggest O
that O
Th2-type O
cytokines O
may O
contribute O
to O
pulmonary O
neutrophilia O
during O
allergic O
inflammation O
by O

DXM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O
These O
findings O
suggest O
that O
Th2-type O
cytokines O
may O
contribute O
to O
pulmonary O
neutrophilia O
during O
allergic O
inflammation O
by O

1400W O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin B
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O
These O
findings O
suggest O
that O
Th2-type O
cytokines O
may O
contribute O
to O
pulmonary O
neutrophilia O
during O
allergic O
inflammation O
by O
the O
increased O

1400W O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O
These O
findings O
suggest O
that O
Th2-type O
cytokines O
may O
contribute O
to O
pulmonary O
neutrophilia O
during O
allergic O
inflammation O
by O
the O
increased O

Dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
either O
increased O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O

Dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
either O
increased O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O

Dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
either O
increased O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O

DXM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
( O
DXM O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O

DXM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
( O
DXM O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O

DXM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
( O
DXM O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O

1400W O
dihydrochloride O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O

1400W O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
( O
1400W O
 O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O

sotalol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
newborns O
. O
Therapy O
of O
choice O
seems O
to O
be O
the O
implantable O
cardioverter O
defibrillator O
because O
of O
the O
high O
incidence O
of O
sudden O
death O
. O
Pharmacological O
treatment O
has O
been O
studied O
and O
it O
could O
be O
demonstrated O
, O
that O
some O
mutant O
currents O
may O
be O
insufficiently O
suppressed O
by O
drugs O
targeted O
to O
block O
the O
specific O
current O
such O
as O
, O
e.g. O
, O
sotalol O
or O
ibutilide O
in O
patients O
with O
a O
mutation O
in O
the O
IKr-coding O
gene O
KCNH2 O
(HERG) O
. O
Quinidine O
proved O
to O
be O
efficient O
in O
prolonging O
the O
QT O
interval O
and O
normalizing O
the O
effective O
refractory O
periods O
in O
some O
patients O
. O

sotalol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
newborns O
. O
Therapy O
of O
choice O
seems O
to O
be O
the O
implantable O
cardioverter O
defibrillator O
because O
of O
the O
high O
incidence O
of O
sudden O
death O
. O
Pharmacological O
treatment O
has O
been O
studied O
and O
it O
could O
be O
demonstrated O
, O
that O
some O
mutant O
currents O
may O
be O
insufficiently O
suppressed O
by O
drugs O
targeted O
to O
block O
the O
specific O
current O
such O
as O
, O
e.g. O
, O
sotalol O
or O
ibutilide O
in O
patients O
with O
a O
mutation O
in O
the O
IKr-coding O
gene O
KCNH2 B
(HERG) O
. O
Quinidine O
proved O
to O
be O
efficient O
in O
prolonging O
the O
QT O
interval O
and O
normalizing O
the O
effective O
refractory O
periods O
in O
some O
patients O
. O

sotalol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
newborns O
. O
Therapy O
of O
choice O
seems O
to O
be O
the O
implantable O
cardioverter O
defibrillator O
because O
of O
the O
high O
incidence O
of O
sudden O
death O
. O
Pharmacological O
treatment O
has O
been O
studied O
and O
it O
could O
be O
demonstrated O
, O
that O
some O
mutant O
currents O
may O
be O
insufficiently O
suppressed O
by O
drugs O
targeted O
to O
block O
the O
specific O
current O
such O
as O
, O
e.g. O
, O
sotalol O
or O
ibutilide O
in O
patients O
with O
a O
mutation O
in O
the O
IKr-coding O
gene O
KCNH2 O
(HERG) O
. O
Quinidine O
proved O
to O
be O
efficient O
in O
prolonging O
the O
QT O
interval O
and O
normalizing O
the O
effective O
refractory O
periods O
in O
some O
patients O
. O

ibutilide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Therapy O
of O
choice O
seems O
to O
be O
the O
implantable O
cardioverter O
defibrillator O
because O
of O
the O
high O
incidence O
of O
sudden O
death O
. O
Pharmacological O
treatment O
has O
been O
studied O
and O
it O
could O
be O
demonstrated O
, O
that O
some O
mutant O
currents O
may O
be O
insufficiently O
suppressed O
by O
drugs O
targeted O
to O
block O
the O
specific O
current O
such O
as O
, O
e.g. O
, O
sotalol O
or O
ibutilide O
in O
patients O
with O
a O
mutation O
in O
the O
IKr-coding O
gene O
KCNH2 O
(HERG) O
. O
Quinidine O
proved O
to O
be O
efficient O
in O
prolonging O
the O
QT O
interval O
and O
normalizing O
the O
effective O
refractory O
periods O
in O
some O
patients O
. O

ibutilide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Therapy O
of O
choice O
seems O
to O
be O
the O
implantable O
cardioverter O
defibrillator O
because O
of O
the O
high O
incidence O
of O
sudden O
death O
. O
Pharmacological O
treatment O
has O
been O
studied O
and O
it O
could O
be O
demonstrated O
, O
that O
some O
mutant O
currents O
may O
be O
insufficiently O
suppressed O
by O
drugs O
targeted O
to O
block O
the O
specific O
current O
such O
as O
, O
e.g. O
, O
sotalol O
or O
ibutilide O
in O
patients O
with O
a O
mutation O
in O
the O
IKr-coding O
gene O
KCNH2 B
(HERG) O
. O
Quinidine O
proved O
to O
be O
efficient O
in O
prolonging O
the O
QT O
interval O
and O
normalizing O
the O
effective O
refractory O
periods O
in O
some O
patients O
. O

ibutilide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Therapy O
of O
choice O
seems O
to O
be O
the O
implantable O
cardioverter O
defibrillator O
because O
of O
the O
high O
incidence O
of O
sudden O
death O
. O
Pharmacological O
treatment O
has O
been O
studied O
and O
it O
could O
be O
demonstrated O
, O
that O
some O
mutant O
currents O
may O
be O
insufficiently O
suppressed O
by O
drugs O
targeted O
to O
block O
the O
specific O
current O
such O
as O
, O
e.g. O
, O
sotalol O
or O
ibutilide O
in O
patients O
with O
a O
mutation O
in O
the O
IKr-coding O
gene O
KCNH2 O
(HERG) O
. O
Quinidine O
proved O
to O
be O
efficient O
in O
prolonging O
the O
QT O
interval O
and O
normalizing O
the O
effective O
refractory O
periods O
in O
some O
patients O
. O

PLP O
acts O
as O
PART-OF O
for O
what O
entity O
? O
unclear O
. O
In O
this O
study O
, O
we O
cloned O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine O
racemase O
from O
barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine B
racemases I
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP O
interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine O
racemase O
activity O
is O
increased O
by O
ATP O
. O
In O
addition O
to O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
In O
this O
study O
, O
we O
cloned O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine O
racemase O
from O
barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine B
racemases I
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine O
racemase O
activity O
is O
increased O
by O
ATP O
. O
In O
addition O
to O
the O
results O
regarding O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
represent O
a O
distinct O
eukaryotic O
group O
: O
gene O
cloning O
and O
recombinant O
protein O
characterization.Several O
d-amino O
acids O
have O
been O
identified O
in O
plants O
. O
However O
, O
the O
biosynthetic O
pathway O
to O
them O
is O
unclear O
. O
In O
this O
study O
, O
we O
cloned O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine B
racemase I
from O
barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine O
racemases O
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
gene O
cloning O
and O
recombinant O
protein O
characterization.Several O
d-amino O
acids O
have O
been O
identified O
in O
plants O
. O
However O
, O
the O
biosynthetic O
pathway O
to O
them O
is O
unclear O
. O
In O
this O
study O
, O
we O
cloned O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine O
racemase O
from O
barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine B
racemases I
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O

pyridoxal O
5-phosphate O
acts O
as O
PART-OF O
for O
what O
entity O
? O
biosynthetic O
pathway O
to O
them O
is O
unclear O
. O
In O
this O
study O
, O
we O
cloned O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine O
racemase O
from O
barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine B
racemases I
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine O
racemase O
activity O
is O
increased O
by O
ATP O
. O

PLP O
acts O
as O
PART-OF O
for O
what O
entity O
? O
them O
is O
unclear O
. O
In O
this O
study O
, O
we O
cloned O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine O
racemase O
from O
barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine B
racemases I
and O
contained O
conserved O
pyridoxal O
5-phosphate O
( O
PLP O
-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine O
racemase O
activity O
is O
increased O
by O
ATP O
. O

lysine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
them O
is O
unclear O
. O
In O
this O
study O
, O
we O
cloned O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine O
racemase O
from O
barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine B
racemases I
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine O
racemase O
activity O
is O
increased O
by O
ATP O
. O
In O
addition O

ATP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine B
racemase I
activity O
is O
increased O
by O
ATP O
In O
addition O
to O
the O
results O
regarding O
the O
effect O
of O
ATP O
on O
enzyme O
activity O
and O
the O
phylogenetic O
analysis O
of O
eukaryotic O
serine O
racemases O
, O
the O
antiserum O
against O
Arabidopsis O
serine O
racemase O
did O
not O
form O
a O
precipitate O
with O
barley O
and O
rice O
serine O
racemases O
. O
This O
suggests O
that O
plant O
serine O
racemases O
represent O
a O
distinct O
group O
in O

PLP O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine O
racemases O
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine B
racemase I
activity O
is O
increased O
by O
ATP O
. O
In O
addition O
to O
the O
results O
regarding O
the O
effect O
of O
ATP O
on O
enzyme O
activity O
and O
the O
phylogenetic O
analysis O
of O
eukaryotic O
serine O
racemases O
, O
the O
antiserum O
against O
Arabidopsis O
serine O
racemase O
did O

Ca(2+) O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine O
racemases O
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine B
racemase I
activity O
is O
increased O
by O
ATP O
. O
In O
addition O
to O
the O
results O
regarding O
the O
effect O
of O
ATP O
on O
enzyme O
activity O
and O
the O
phylogenetic O
analysis O
of O
eukaryotic O
serine O
racemases O
, O
the O
antiserum O
against O
Arabidopsis O
serine O
racemase O
did O
not O
form O
a O
precipitate O
with O
barley O

Mg(2+) O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine O
racemases O
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine B
racemase I
activity O
is O
increased O
by O
ATP O
. O
In O
addition O
to O
the O
results O
regarding O
the O
effect O
of O
ATP O
on O
enzyme O
activity O
and O
the O
phylogenetic O
analysis O
of O
eukaryotic O
serine O
racemases O
, O
the O
antiserum O
against O
Arabidopsis O
serine O
racemase O
did O
not O
form O
a O
precipitate O
with O
barley O
and O

Mn(2+) O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
significant O
identity O
to O
plant O
and O
mammalian O
serine O
racemases O
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
but O
not O
ATP O
, O
whereas O
mammalian O
serine B
racemase I
activity O
is O
increased O
by O
ATP O
. O
In O
addition O
to O
the O
results O
regarding O
the O
effect O
of O
ATP O
on O
enzyme O
activity O
and O
the O
phylogenetic O
analysis O
of O
eukaryotic O
serine O
racemases O
, O
the O
antiserum O
against O
Arabidopsis O
serine O
racemase O
did O
not O
form O
a O
precipitate O
with O
barley O
and O
rice O
serine O

warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
warfarin O
dose O
. O
METHODS O
: O
Sixty-five O
patients O
with O
stable O
anticoagulation O
were O
genotyped O
for O
CYP2C9 B
and O
VKORC1 O
with O
Tag-It O
allele-specific O
primer O
extension O
technology O
. O
Plasma O
S-warfarin O
concentrations O
and O
warfarin O
maintenance O
dose O
were O
compared O
among O
patients O
on O
the O
basis O
of O
the O
VKORC1 O
-1639G>A O
genotype O
. O
RESULTS O
: O
Eighty O
percent O
of O
CYP2C9*1/*1 O
patients O
stabilized O
on O
<4.0 O
mg/day O
warfarin O
had O
at O
least O
1 O
VKORC1 O
-1639A O
allele O
. O
Mean O
warfarin O
doses O
(SD) O
were O
6.7 O
(3.3) O
, O
4.3 O
(2.2) O
, O
and O
2.7 O
(1.2) O
mg/day O
for O
patients O
with O
the O
VKORC1 O
-1639GG O
, O
GA O
, O
and O
AA O
genotypes O
, O
respectively O
. O
Steady-state O
plasma O
concentrations O
of O
S-warfarin O
were O
lowest O
in O
patients O
with O
the O
VKORC1 O
-1639AA O
genotype O
and O
demonstrated O
a O
positive O

warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
warfarin O
dose O
. O
METHODS O
: O
Sixty-five O
patients O
with O
stable O
anticoagulation O
were O
genotyped O
for O
CYP2C9 O
and O
VKORC1 B
with O
Tag-It O
allele-specific O
primer O
extension O
technology O
. O
Plasma O
S-warfarin O
concentrations O
and O
warfarin O
maintenance O
dose O
were O
compared O
among O
patients O
on O
the O
basis O
of O
the O
VKORC1 O
-1639G>A O
genotype O
. O
RESULTS O
: O
Eighty O
percent O
of O
CYP2C9*1/*1 O
patients O
stabilized O
on O
<4.0 O
mg/day O
warfarin O
had O
at O
least O
1 O
VKORC1 O
-1639A O
allele O
. O
Mean O
warfarin O
doses O
(SD) O
were O
6.7 O
(3.3) O
, O
4.3 O
(2.2) O
, O
and O
2.7 O
(1.2) O
mg/day O
for O
patients O
with O
the O
VKORC1 O
-1639GG O
, O
GA O
, O
and O
AA O
genotypes O
, O
respectively O
. O
Steady-state O
plasma O
concentrations O
of O
S-warfarin O
were O
lowest O
in O
patients O
with O
the O
VKORC1 O
-1639AA O
genotype O
and O
demonstrated O
a O
positive O

warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Estimation O
of O
warfarin O
maintenance O
dose O
based O
on O
VKORC1 B
(-1639 O
G>A) O
and O
CYP2C9 O
genotypes.BACKGROUND O
: O
CYP2C9 O
polymorphisms O
are O
associated O
with O
decreased O
S-warfarin O
clearance O
and O
lower O
maintenance O
dosage O
. O
Decreased O
expression O
of O
VKORC1 O
resulting O
from O
the O
-1639G>A O
substitution O
has O
also O
been O
implicated O
in O
lower O
warfarin O
dose O
requirements O
. O
We O
investigated O
the O
additional O
contribution O
of O
this O
polymorphism O
to O
the O
variance O
in O
warfarin O
dose O
. O
METHODS O
: O
Sixty-five O
patients O
with O
stable O
anticoagulation O
were O
genotyped O
for O
CYP2C9 O
and O
VKORC1 O
with O
Tag-It O
allele-specific O
primer O
extension O
technology O
. O
Plasma O
S-warfarin O
concentrations O
and O
warfarin O
maintenance O
dose O
were O
compared O
among O
patients O
on O
the O
basis O
of O

S-warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Estimation O
of O
warfarin O
maintenance O
dose O
based O
on O
VKORC1 O
(-1639 O
G>A) O
and O
CYP2C9 B
genotypes.BACKGROUND O
: O
CYP2C9 O
polymorphisms O
are O
associated O
with O
decreased O
S-warfarin O
clearance O
and O
lower O
maintenance O
dosage O
. O
Decreased O
expression O
of O
VKORC1 O
resulting O
from O
the O
-1639G>A O
substitution O
has O
also O
been O
implicated O
in O
lower O
warfarin O
dose O
requirements O
. O
We O
investigated O
the O
additional O
contribution O
of O
this O
polymorphism O
to O
the O
variance O
in O
warfarin O
dose O
. O
METHODS O
: O
Sixty-five O
patients O
with O
stable O
anticoagulation O
were O
genotyped O
for O
CYP2C9 O
and O
VKORC1 O

AGGACA O
acts O
as O
PART-OF O
for O
what O
entity O
? O
not O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma O
is O
indirectly O
necessary O
for O
both O
cAspAT B
basal O
expression O
and O
TZD O
responsiveness O
because O
they O
are O
, O
respectively O
, O
diminished O
and O
abolished O
by O
ectopic O
overexpression O
of O
a O
dominant O
negative O
PPARgamma O
. O
The O
cAspAT O
TZD-responsive O
site O
was O
restricted O
to O
a O
single O
AGGACA O
hexanucleotide O
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O

hexanucleotide O
acts O
as O
PART-OF O
for O
what O
entity O
? O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma O
is O
indirectly O
necessary O
for O
both O
cAspAT B
basal O
expression O
and O
TZD O
responsiveness O
because O
they O
are O
, O
respectively O
, O
diminished O
and O
abolished O
by O
ectopic O
overexpression O
of O
a O
dominant O
negative O
PPARgamma O
. O
The O
cAspAT O
TZD-responsive O
site O
was O
restricted O
to O
a O
single O
AGGACA O
hexanucleotide O
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O

TZD O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha B
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O
adipocytes O
. O

TZD O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma B
in O
adipocytes O
. O

TZD O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
rosiglitazone O
. O
Conversely O
, O
the O
ratio O
of O
fatty O
acid O
to O
glycerol O
released O
into O
the O
medium O
decreased O
. O
Regulation O
of O
cAspAT O
gene O
expression O
was O
specific O
to O
differentiated O
adipocytes O
and O
did O
not O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma B
is O
indirectly O
necessary O
for O
both O
cAspAT O
basal O
expression O
and O
TZD O
responsiveness O
because O
they O
are O
, O
respectively O
, O
diminished O
and O
abolished O
by O
ectopic O
overexpression O
of O
a O
dominant O
negative O
PPARgamma O
. O
The O
cAspAT O
TZD-responsive O
site O
was O
restricted O
to O
a O
single O
AGGACA O
hexanucleotide O
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O

TZD O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
was O
specific O
to O
differentiated O
adipocytes O
and O
did O
not O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma O
is O
indirectly O
necessary O
for O
both O
cAspAT B
basal O
expression O
and O
TZD O
responsiveness O
because O
they O
are O
, O
respectively O
, O
diminished O
and O
abolished O
by O
ectopic O
overexpression O
of O
a O
dominant O
negative O
PPARgamma O
. O
The O
cAspAT O
TZD O
responsive O
site O
was O
restricted O
to O
a O
single O
AGGACA O
hexanucleotide O
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O

thiazolidinedione O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Cytosolic O
aspartate O
aminotransferase O
, O
a O
new O
partner O
in O
adipocyte O
glyceroneogenesis O
and O
an O
atypical O
target O
of O
thiazolidinedion O
.We O
show O
that O
cytosolic O
aspartate O
aminotransferase O
(cAspAT) O
is O
involved O
in O
adipocyte O
glyceroneogenesis O
, O
a O
regulated O
pathway O
that O
controls O
fatty O
acid O
homeostasis O
by O
promoting O
glycerol O
3-phosphate O
formation O
for O
fatty O
acid O
re-esterification O
during O
fasting O
. O
cAspAT O
activity O
, O
as O
well O
as O
the O
incorporation O
of O
[(14)C]aspartate O
into O
the O
neutral O
lipid O
fraction O
of O
3T3-F442A O
adipocytes O
was O

thiazolidinedione O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
cytosolic O
aspartate O
aminotransferase O
(cAspAT) O
is O
involved O
in O
adipocyte O
glyceroneogenesis O
, O
a O
regulated O
pathway O
that O
controls O
fatty O
acid O
homeostasis O
by O
promoting O
glycerol O
3-phosphate O
formation O
for O
fatty O
acid O
re-esterification O
during O
fasting O
. O
cAspAT B
activity O
, O
as O
well O
as O
the O
incorporation O
of O
[(14)C]aspartate O
into O
the O
neutral O
lipid O
fraction O
of O
3T3-F442A O
adipocytes O
was O
stimulated O
by O
the O
thiazolidinedione O
(TZD) O
rosiglitazone O
. O
Conversely O
, O
the O
ratio O
of O
fatty O
acid O
to O
glycerol O
released O
into O
the O
medium O
decreased O
. O
Regulation O
of O
cAspAT O
gene O
expression O
was O
specific O
to O
differentiated O
adipocytes O
and O
did O
not O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma O
is O
indirectly O
necessary O
for O
both O
cAspAT O
basal O
expression O

TZD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
aminotransferase O
(cAspAT) O
is O
involved O
in O
adipocyte O
glyceroneogenesis O
, O
a O
regulated O
pathway O
that O
controls O
fatty O
acid O
homeostasis O
by O
promoting O
glycerol O
3-phosphate O
formation O
for O
fatty O
acid O
re-esterification O
during O
fasting O
. O
cAspAT B
activity O
, O
as O
well O
as O
the O
incorporation O
of O
[(14)C]aspartate O
into O
the O
neutral O
lipid O
fraction O
of O
3T3-F442A O
adipocytes O
was O
stimulated O
by O
the O
thiazolidinedione O
( O
TZD O
rosiglitazone O
. O
Conversely O
, O
the O
ratio O
of O
fatty O
acid O
to O
glycerol O
released O
into O
the O
medium O
decreased O
. O
Regulation O
of O
cAspAT O
gene O
expression O
was O
specific O
to O
differentiated O
adipocytes O
and O
did O
not O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma O
is O
indirectly O
necessary O
for O
both O
cAspAT O
basal O
expression O
and O

rosiglitazone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
aminotransferase O
(cAspAT) O
is O
involved O
in O
adipocyte O
glyceroneogenesis O
, O
a O
regulated O
pathway O
that O
controls O
fatty O
acid O
homeostasis O
by O
promoting O
glycerol O
3-phosphate O
formation O
for O
fatty O
acid O
re-esterification O
during O
fasting O
. O
cAspAT B
activity O
, O
as O
well O
as O
the O
incorporation O
of O
[(14)C]aspartate O
into O
the O
neutral O
lipid O
fraction O
of O
3T3-F442A O
adipocytes O
was O
stimulated O
by O
the O
thiazolidinedione O
(TZD) O
rosiglitazone O
Conversely O
, O
the O
ratio O
of O
fatty O
acid O
to O
glycerol O
released O
into O
the O
medium O
decreased O
. O
Regulation O
of O
cAspAT O
gene O
expression O
was O
specific O
to O
differentiated O
adipocytes O
and O
did O
not O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma O
is O
indirectly O
necessary O
for O
both O
cAspAT O
basal O
expression O
and O
TZD O

rosiglitazone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
negative O
PPARgamma O
. O
The O
cAspAT O
TZD-responsive O
site O
was O
restricted O
to O
a O
single O
AGGACA O
hexanucleotide O
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha B
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O
adipocytes O
. O

rosiglitazone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
negative O
PPARgamma O
. O
The O
cAspAT B
TZD-responsive O
site O
was O
restricted O
to O
a O
single O
AGGACA O
hexanucleotide O
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O
adipocytes O
. O

TZD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha B
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O
adipocytes O
. O

TZD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT B
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O
adipocytes O
. O

TZD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT B
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O
adipocytes O
. O

4-HNE O
acts O
as O
NOT O
for O
what O
entity O
? O
cells O
in O
the O
absence O
of O
4-HNE O
, O
and O
a O
trend O
towards O
increased O
growth O
at O
low O
dose O
exposures O
to O
4-HNE O
. O
However O
, O
the O
hGSTA4 B
cells O
did O
not O
exhibit O
a O
growth O
advantage O
relative O
to O
control O
cells O
at O
higher O
4-HNE O
exposures O
associated O
with O
increased O
GSH O
utilization O
. O
As O
expected O
, O
the O
hGSTA4 O
cells O
showed O
resistance O
to O
4-HNE O
stimulated O
lipid O
peroxidation O
at O
all O
4-HNE O
doses O
. O
In O
summary O
, O
our O
data O
indicates O
that O
over-expression O
of O
hGSTA4 O
at O
levels O
conferring O
high O
GST-4-HNE O
conjugating O
activity O
confers O
a O
partial O
growth O
advantage O
to O
HepG2 O
cells O
and O
protects O
against O
4-HNE O
oxidative O
injury O
. O
However O
, O
the O
loss O
of O
proliferative O
capacity O
of O
hGSTA4 O
cells O
challenged O
with O
levels O

4-HNE O
acts O
as O
NOT O
for O
what O
entity O
? O
and O
a O
trend O
towards O
increased O
growth O
at O
low O
dose O
exposures O
to O
4-HNE O
. O
However O
, O
the O
hGSTA4 B
cells O
did O
not O
exhibit O
a O
growth O
advantage O
relative O
to O
control O
cells O
at O
higher O
4-HNE O
exposures O
associated O
with O
increased O
GSH O
utilization O
. O
As O
expected O
, O
the O
hGSTA4 O
cells O
showed O
resistance O
to O
4-HNE O
stimulated O
lipid O
peroxidation O
at O
all O
4-HNE O
doses O
. O
In O
summary O
, O
our O
data O
indicates O
that O
over-expression O
of O
hGSTA4 O
at O
levels O
conferring O
high O
GST-4-HNE O
conjugating O
activity O
confers O
a O
partial O
growth O
advantage O
to O
HepG2 O
cells O
and O
protects O
against O
4-HNE O
oxidative O
injury O
. O
However O
, O
the O
loss O
of O
proliferative O
capacity O
of O
hGSTA4 O
cells O
challenged O
with O
levels O
of O
4-HNE O
associated O
with O
severe O
oxidative O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
did O
not O
exhibit O
a O
growth O
advantage O
relative O
to O
control O
cells O
at O
higher O
4-HNE O
exposures O
associated O
with O
increased O
GSH O
utilization O
. O
As O
expected O
, O
the O
hGSTA4 O
cells O
showed O
resistance O
to O
4-HNE O
stimulated O
lipid O
peroxidation O
at O
all O
4-HNE O
doses O
. O
In O
summary O
, O
our O
data O
indicates O
that O
over-expression O
of O
hGSTA4 O
at O
levels O
conferring O
high O
GST- O
4-HNE O
conjugating O
activity O
confers O
a O
partial O
growth O
advantage O
to O
HepG2 O
cells O
and O
protects O
against O
4-HNE O
oxidative O
injury O
. O
However O
, O
the O
loss O
of O
proliferative O
capacity O
of O
hGSTA4 O
cells O
challenged O
with O
levels O
of O
4-HNE O
associated O
with O
severe O
oxidative O
stress O
indicates O
a O
role O
of O
other O
aldehyde O
metabolizing O
enzymes O
, O
and/or O
GSH-electrophile O
transporter O
proteins O
, O
in O
providing O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
( O
4-HNE O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione B
S-transferase I
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
( O
4-HNE O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione O
S-transferase O
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
lipid O
peroxidation O
at O
all O
4-HNE O
doses O
. O
In O
summary O
, O
our O
data O
indicates O
that O
over-expression O
of O
hGSTA4 B
at O
levels O
conferring O
high O
GST-4-HNE O
conjugating O
activity O
confers O
a O
partial O
growth O
advantage O
to O
HepG2 O
cells O
and O
protects O
against O
4-HNE O
oxidative O
injury O
. O
However O
, O
the O
loss O
of O
proliferative O
capacity O
of O
hGSTA4 O
cells O
challenged O
with O
levels O
of O
4-HNE O
associated O
with O
severe O
oxidative O
stress O
indicates O
a O
role O
of O
other O
aldehyde O
metabolizing O
enzymes O
, O
and/or O
GSH-electrophile O
transporter O
proteins O
, O
in O
providing O
full O
cellular O
protection O
against O
4-HNE O
toxicity O
. O

4-Hydroxynonenal O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury O
. O
4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione B
S-transferase I
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O

4-Hydroxynonenal O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury O
. O
4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione O
S-transferase O
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione O
S-transferase O
(GST) O
isoforms O
. O
The O
alpha O
class O
human B
GSTA4-4 I
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O
enzymes O
that O
detoxify O
4-HNE O
. O
In O
the O
current O
study O
, O
we O
determined O
the O
effect O
of O
over-expression O
of O
hGSTA4 O
mRNA O
on O
the O
sensitivity O
of O
HepG2 O
cells O
to O
4-HNE O
injury O
. O
HepG2 O
cells O
transfected O
with O
an O
hGSTA4 O
vector O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione O
S-transferase O
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O
enzymes O
that O
detoxify O
4-HNE O
. O
In O
the O
current O
study O
, O
we O
determined O
the O
effect O
of O
over-expression O
of O
hGSTA4 O
mRNA O
on O
the O
sensitivity O
of O
HepG2 O
cells O
to O
4-HNE O
injury O
. O
HepG2 O
cells O
transfected O
with O
an O
hGSTA4 O
vector O

alpha,beta-unsaturated O
aldehyde O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione B
S-transferase I
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O
enzymes O
that O
detoxify O
4-HNE O
. O
In O

alpha,beta-unsaturated O
aldehyde O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione O
S-transferase O
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O
enzymes O
that O
detoxify O
4-HNE O
. O
In O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O
enzymes O
that O
detoxify O
4-HNE O
. O
In O
the O
current O
study O
, O
we O
determined O
the O
effect O
of O
over-expression O
of O
hGSTA4 O
mRNA O
on O
the O
sensitivity O
of O
HepG2 O
cells O
to O
4-HNE O
injury O
. O
HepG2 O
cells O
transfected O
with O
an O
hGSTA4 O
vector O
construct O
exhibited O
high O
steady-state O
hGSTA4 O
mRNA O
, O
high O
GST- O
4-HNE O
catalytic O
activities O
, O
but O
lower O
basal O
glutathione O
(GSH) O
concentrations O
relative O
to O
insert-free O
vector O
(control) O
cells O
. O
Exposure O
to O
4-HNE O
elicited O
an O
increase O
in O
GSH O
concentrations O
in O
the O
control O
and O
hGSTA4 O
cells O
, O
although O
the O
dose-response O
of O
GSH O
induction O
differed O
among O
the O
two O
cell O
types O
. O
Specifically O
, O
hGSTA4 O
cells O
had O
significantly O
higher O
GSH O
concentrations O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
glutathione O
(GSH) O
concentrations O
relative O
to O
insert-free O
vector O
(control) O
cells O
. O
Exposure O
to O
4-HNE O
elicited O
an O
increase O
in O
GSH O
concentrations O
in O
the O
control O
and O
hGSTA4 B
cells O
, O
although O
the O
dose-response O
of O
GSH O
induction O
differed O
among O
the O
two O
cell O
types O
. O
Specifically O
, O
hGSTA4 O
cells O
had O
significantly O
higher O
GSH O
concentrations O
when O
exposed O
to O
5-15 O
microM O
4-HNE O
but O
not O
at O
20 O
microM O
4-HNE O
, O
suggesting O
extensive O
GSH O
utilization O
at O
high O
concentrations O
of O
4-HNE O
. O
The O
hGSTA4 O
cells O
exhibited O
a O
significant O
growth O
advantage O
relative O
to O
control O
cells O
in O
the O
absence O
of O
4-HNE O
, O
and O
a O
trend O
towards O
increased O
growth O
at O
low O
dose O
exposures O
to O
4-HNE O
. O
However O
, O
the O
hGSTA4 O
cells O
did O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
vector O
(control) O
cells O
. O
Exposure O
to O
4-HNE O
elicited O
an O
increase O
in O
GSH O
concentrations O
in O
the O
control O
and O
hGSTA4 B
cells O
, O
although O
the O
dose-response O
of O
GSH O
induction O
differed O
among O
the O
two O
cell O
types O
. O
Specifically O
, O
hGSTA4 O
cells O
had O
significantly O
higher O
GSH O
concentrations O
when O
exposed O
to O
5-15 O
microM O
4-HNE O
, O
but O
not O
at O
20 O
microM O
4-HNE O
suggesting O
extensive O
GSH O
utilization O
at O
high O
concentrations O
of O
4-HNE O
. O
The O
hGSTA4 O
cells O
exhibited O
a O
significant O
growth O
advantage O
relative O
to O
control O
cells O
in O
the O
absence O
of O
4-HNE O
, O
and O
a O
trend O
towards O
increased O
growth O
at O
low O
dose O
exposures O
to O
4-HNE O
. O
However O
, O
the O
hGSTA4 O
cells O
did O
not O
exhibit O
a O
growth O
advantage O
relative O

saccharin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
caloric O
advantage O
they O
provide O
, O
one O
key O
concern O
in O
their O
use O
is O
their O
aversive O
aftertaste O
that O
has O
been O
characterized O
on O
a O
sensory O
level O
as O
bitter O
and/or O
metallic O
. O
Recently O
, O
it O
has O
been O
shown O
that O
the O
activation O
of O
particular O
T2R B
bitter O
taste O
receptors O
is O
partially O
involved O
with O
the O
bitter O
aftertaste O
sensation O
of O
saccharin O
and O
acesulfame-K O
. O
To O
more O
fully O
understand O
the O
biology O
behind O
these O
phenomena O
we O
have O
addressed O
the O
question O
of O
whether O
AS O
could O
stimulate O
transient O
receptor O
potential O
vanilloid-1 O
(TRPV1) O
receptors O
, O
as O
these O
receptors O
are O
activated O
by O
a O
large O
range O
of O
structurally O
different O
chemicals O
. O
Moreover O
, O
TRPV1 O
receptors O
and/or O
their O
variants O
are O
found O
in O

acesulfame-K O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
they O
provide O
, O
one O
key O
concern O
in O
their O
use O
is O
their O
aversive O
aftertaste O
that O
has O
been O
characterized O
on O
a O
sensory O
level O
as O
bitter O
and/or O
metallic O
. O
Recently O
, O
it O
has O
been O
shown O
that O
the O
activation O
of O
particular O
T2R B
bitter O
taste O
receptors O
is O
partially O
involved O
with O
the O
bitter O
aftertaste O
sensation O
of O
saccharin O
and O
acesulfame-K O
To O
more O
fully O
understand O
the O
biology O
behind O
these O
phenomena O
we O
have O
addressed O
the O
question O
of O
whether O
AS O
could O
stimulate O
transient O
receptor O
potential O
vanilloid-1 O
(TRPV1) O
receptors O
, O
as O
these O
receptors O
are O
activated O
by O
a O
large O
range O
of O
structurally O
different O
chemicals O
. O
Moreover O
, O
TRPV1 O
receptors O
and/or O
their O
variants O
are O
found O
in O
taste O
receptor O

CuSO(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
imaging O
on O
TRPV1 B
receptors O
heterologously O
expressed O
in O
the O
human O
embryonic O
kidney O
(HEK) O
293 O
cells O
and O
on O
dissociated O
primary O
sensory O
neurons O
, O
we O
find O
that O
in O
both O
systems O
, O
AS O
activate O
TRPV1 O
receptors O
, O
and O
, O
moreover O
, O
they O
sensitize O
these O
channels O
to O
acid O
and O
heat O
. O
We O
also O
found O
that O
TRPV1 O
receptors O
are O
activated O
by O
CuSO(4) O
ZnSO(4) O
, O
and O
FeSO(4) O
, O
three O
salts O
known O
to O
produce O
a O
metallic O
taste O
sensation O
. O
In O
summary O
, O
our O
results O
identify O
a O
novel O
group O
of O
compounds O
that O
activate O
TRPV1 O
and O
, O
consequently O
, O
provide O
a O
molecular O
mechanism O
that O
may O
account O
for O
off O
tastes O
of O
sweeteners O
and O
metallic O
tasting O
salts O
. O

ZnSO(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
on O
TRPV1 B
receptors O
heterologously O
expressed O
in O
the O
human O
embryonic O
kidney O
(HEK) O
293 O
cells O
and O
on O
dissociated O
primary O
sensory O
neurons O
, O
we O
find O
that O
in O
both O
systems O
, O
AS O
activate O
TRPV1 O
receptors O
, O
and O
, O
moreover O
, O
they O
sensitize O
these O
channels O
to O
acid O
and O
heat O
. O
We O
also O
found O
that O
TRPV1 O
receptors O
are O
activated O
by O
CuSO(4) O
, O
ZnSO(4) O
and O
FeSO(4) O
, O
three O
salts O
known O
to O
produce O
a O
metallic O
taste O
sensation O
. O
In O
summary O
, O
our O
results O
identify O
a O
novel O
group O
of O
compounds O
that O
activate O
TRPV1 O
and O
, O
consequently O
, O
provide O
a O
molecular O
mechanism O
that O
may O
account O
for O
off O
tastes O
of O
sweeteners O
and O
metallic O
tasting O
salts O
. O

FeSO(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
receptors O
heterologously O
expressed O
in O
the O
human O
embryonic O
kidney O
(HEK) O
293 O
cells O
and O
on O
dissociated O
primary O
sensory O
neurons O
, O
we O
find O
that O
in O
both O
systems O
, O
AS O
activate O
TRPV1 B
receptors O
, O
and O
, O
moreover O
, O
they O
sensitize O
these O
channels O
to O
acid O
and O
heat O
. O
We O
also O
found O
that O
TRPV1 O
receptors O
are O
activated O
by O
CuSO(4) O
, O
ZnSO(4) O
, O
and O
FeSO(4) O
three O
salts O
known O
to O
produce O
a O
metallic O
taste O
sensation O
. O
In O
summary O
, O
our O
results O
identify O
a O
novel O
group O
of O
compounds O
that O
activate O
TRPV1 O
and O
, O
consequently O
, O
provide O
a O
molecular O
mechanism O
that O
may O
account O
for O
off O
tastes O
of O
sweeteners O
and O
metallic O
tasting O
salts O
. O

anthocyanin O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
vinifera O
cv O
. O
Cardinal) O
stored O
at O
0 O
degrees O
C O
. O
In O
the O
present O
work O
, O
we O
analyzed O
whether O
total O
anthocyanin O
content O
, O
the O
molecular O
mechanism O
implicated O
in O
their O
biosynthesis O
and O
antioxidant O
activity O
is O
related O
to O
the O
beneficial O
effect O
of O
this O
gaseous O
treatment O
. O
We O
isolated O
partial O
cDNAs O
that O
codified O
for O
enzymes O
implicated O
in O
the O
anthocyanin O
biosynthesis O
such O
as O
l-phenylalanine B
ammonia-lyase I
(PAL) O
and O
chalcone O
synthase O
(CHS) O
, O
and O
an O
antioxidant O
enzyme O
such O
as O
ascorbate O
peroxidase O
(APX) O
. O
Low O
temperatures O
induced O
an O
accumulation O
of O
total O
anthocyanin O
content O
in O
the O
skin O
of O
both O
treated O
and O
non-treated O
grapes O
, O
although O
levels O
were O
lower O
in O
CO2-treated O
fruit O
. O
By O
contrast O
, O
antioxidant O
activity O
decreased O

anthocyanin O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
vinifera O
cv O
. O
Cardinal) O
stored O
at O
0 O
degrees O
C O
. O
In O
the O
present O
work O
, O
we O
analyzed O
whether O
total O
anthocyanin O
content O
, O
the O
molecular O
mechanism O
implicated O
in O
their O
biosynthesis O
and O
antioxidant O
activity O
is O
related O
to O
the O
beneficial O
effect O
of O
this O
gaseous O
treatment O
. O
We O
isolated O
partial O
cDNAs O
that O
codified O
for O
enzymes O
implicated O
in O
the O
anthocyanin O
biosynthesis O
such O
as O
l-phenylalanine O
ammonia-lyase O
(PAL) O
and O
chalcone O
synthase O
(CHS) O
, O
and O
an O
antioxidant O
enzyme O
such O
as O
ascorbate O
peroxidase O
(APX) O
. O
Low O
temperatures O
induced O
an O
accumulation O
of O
total O
anthocyanin O
content O
in O
the O
skin O
of O
both O
treated O
and O
non-treated O
grapes O
, O
although O
levels O
were O
lower O
in O
CO2-treated O
fruit O
. O
By O
contrast O
, O
antioxidant O
activity O
decreased O

anthocyanin O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
vinifera O
cv O
. O
Cardinal) O
stored O
at O
0 O
degrees O
C O
. O
In O
the O
present O
work O
, O
we O
analyzed O
whether O
total O
anthocyanin O
content O
, O
the O
molecular O
mechanism O
implicated O
in O
their O
biosynthesis O
and O
antioxidant O
activity O
is O
related O
to O
the O
beneficial O
effect O
of O
this O
gaseous O
treatment O
. O
We O
isolated O
partial O
cDNAs O
that O
codified O
for O
enzymes O
implicated O
in O
the O
anthocyanin O
biosynthesis O
such O
as O
l-phenylalanine O
ammonia-lyase O
(PAL) O
and O
chalcone B
synthase I
(CHS) O
, O
and O
an O
antioxidant O
enzyme O
such O
as O
ascorbate O
peroxidase O
(APX) O
. O
Low O
temperatures O
induced O
an O
accumulation O
of O
total O
anthocyanin O
content O
in O
the O
skin O
of O
both O
treated O
and O
non-treated O
grapes O
, O
although O
levels O
were O
lower O
in O
CO2-treated O
fruit O
. O
By O
contrast O
, O
antioxidant O
activity O
decreased O

anthocyanin O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
vinifera O
cv O
. O
Cardinal) O
stored O
at O
0 O
degrees O
C O
. O
In O
the O
present O
work O
, O
we O
analyzed O
whether O
total O
anthocyanin O
content O
, O
the O
molecular O
mechanism O
implicated O
in O
their O
biosynthesis O
and O
antioxidant O
activity O
is O
related O
to O
the O
beneficial O
effect O
of O
this O
gaseous O
treatment O
. O
We O
isolated O
partial O
cDNAs O
that O
codified O
for O
enzymes O
implicated O
in O
the O
anthocyanin O
biosynthesis O
such O
as O
l-phenylalanine O
ammonia-lyase O
(PAL) O
and O
chalcone O
synthase O
(CHS) O
, O
and O
an O
antioxidant O
enzyme O
such O
as O
ascorbate O
peroxidase O
(APX) O
. O
Low O
temperatures O
induced O
an O
accumulation O
of O
total O
anthocyanin O
content O
in O
the O
skin O
of O
both O
treated O
and O
non-treated O
grapes O
, O
although O
levels O
were O
lower O
in O
CO2-treated O
fruit O
. O
By O
contrast O
, O
antioxidant O
activity O
decreased O

anthocyanin O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
vinifera O
cv O
. O
Cardinal) O
stored O
at O
0 O
degrees O
C O
. O
In O
the O
present O
work O
, O
we O
analyzed O
whether O
total O
anthocyanin O
content O
, O
the O
molecular O
mechanism O
implicated O
in O
their O
biosynthesis O
and O
antioxidant O
activity O
is O
related O
to O
the O
beneficial O
effect O
of O
this O
gaseous O
treatment O
. O
We O
isolated O
partial O
cDNAs O
that O
codified O
for O
enzymes O
implicated O
in O
the O
anthocyanin O
biosynthesis O
such O
as O
l-phenylalanine O
ammonia-lyase O
(PAL) O
and O
chalcone O
synthase O
(CHS) O
, O
and O
an O
antioxidant O
enzyme O
such O
as O
ascorbate B
peroxidase I
(APX) O
. O
Low O
temperatures O
induced O
an O
accumulation O
of O
total O
anthocyanin O
content O
in O
the O
skin O
of O
both O
treated O
and O
non-treated O
grapes O
, O
although O
levels O
were O
lower O
in O
CO2-treated O
fruit O
. O
By O
contrast O
, O
antioxidant O
activity O
decreased O

anthocyanin O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
vinifera O
cv O
. O
Cardinal) O
stored O
at O
0 O
degrees O
C O
. O
In O
the O
present O
work O
, O
we O
analyzed O
whether O
total O
anthocyanin O
content O
, O
the O
molecular O
mechanism O
implicated O
in O
their O
biosynthesis O
and O
antioxidant O
activity O
is O
related O
to O
the O
beneficial O
effect O
of O
this O
gaseous O
treatment O
. O
We O
isolated O
partial O
cDNAs O
that O
codified O
for O
enzymes O
implicated O
in O
the O
anthocyanin O
biosynthesis O
such O
as O
l-phenylalanine O
ammonia-lyase O
(PAL) O
and O
chalcone O
synthase O
(CHS) O
, O
and O
an O
antioxidant O
enzyme O
such O
as O
ascorbate O
peroxidase O
(APX) O
. O
Low O
temperatures O
induced O
an O
accumulation O
of O
total O
anthocyanin O
content O
in O
the O
skin O
of O
both O
treated O
and O
non-treated O
grapes O
, O
although O
levels O
were O
lower O
in O
CO2-treated O
fruit O
. O
By O
contrast O
, O
antioxidant O
activity O
decreased O

candesartan O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
treatment O
, O
providing O
24-h O
blood O
pressure O
(BP) O
control O
with O
a O
trough:peak O
ratio O
close O
to O
100% O
. O
SCOPE O
: O
A O
Medline O
literature O
search O
was O
undertaken O
to O
identify O
randomised O
, O
controlled O
trials O
that O
examined O
the O
efficacy O
and O
cardiovascular O
outcomes O
associated O
with O
candesartan O
cilexetil O
in O
hypertension O
and O
chronic O
heart O
failure O
(CHF) O
. O
FINDINGS O
: O
Compared O
with O
other O
ARBs O
, O
candesartan O
demonstrates O
the O
strongest O
binding O
affinity O
to O
the O
angiotensin O
II O
type O
1 O
receptor O
. O
Clinical O
trials O
have O
demonstrated O
that O
candesartan O
is O
well O
tolerated O
in O
combination O
with O
diuretics O
or O
calcium O
channel O
blockers O
(CCBs) O
, O
making O
it O
a O
suitable O
treatment O
option O
for O
patients O
whose O
hypertension O
is O
not O
adequately O
controlled O
by O
monotherapy O
. O
Subsequently O
, O
candesartan O
became O

candesartan O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
search O
was O
undertaken O
to O
identify O
randomised O
, O
controlled O
trials O
that O
examined O
the O
efficacy O
and O
cardiovascular O
outcomes O
associated O
with O
candesartan O
cilexetil O
in O
hypertension O
and O
chronic O
heart O
failure O
(CHF) O
. O
FINDINGS O
: O
Compared O
with O
other O
ARBs O
, O
candesartan O
demonstrates O
the O
strongest O
binding O
affinity O
to O
the O
angiotensin O
II O
type O
1 O
receptor O
. O
Clinical O
trials O
have O
demonstrated O
that O
candesartan O
is O
well O
tolerated O
in O
combination O
with O
diuretics O
or O
calcium B
channel I
blockers O
(CCBs) O
, O
making O
it O
a O
suitable O
treatment O
option O
for O
patients O
whose O
hypertension O
is O
not O
adequately O
controlled O
by O
monotherapy O
. O
Subsequently O
, O
candesartan O
became O
the O
only O
ARB O
licensed O
in O
the O
UK O
to O
treat O
patients O
with O
CHF O
and O
left O
ventricular O
ejection O
fraction O
< O

phenolics O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
we O
observed O
significant O
overexpression O
of O
glutathione O
peroxidase O
(6 O
h O
after O
treatment O
: O
P<.05) O
, O
glutathione O
reductase O
and O
gamma-glutamylcysteine O
synthetase O
(12 O
h O
after O
treatment O
: O
P<.05) O
. O
Notably O
, O
when O
GSH O
depletion O
occurred O
, O
p66Shc B
protein O
expression O
increased O
by O
about O
300% O
with O
respect O
to O
control O
(P<.001; O
LipE O
vs O
. O
control) O
. O
These O
effects O
were O
fully O
counteracted O
by O
dietary O
phenolics O
which O
inhibited O
ROS O
overproduction O
and O
GSH O
consumption O
, O
rendered O
the O
reactive O
transcription O
of O
glutathione-associated O
enzymes O
unnecessary O
and O
blocked O
the O
intracellular O
signals O
leading O
to O
the O
overexpression O
and O
rearrangement O
of O
p66Shc O
signalling O
molecule O
. O
Altogether O
, O
these O
results O
suggest O
that O
the O
impairment O
of O
the O
antioxidant O
system O
hijacks O
intestinal O
cells O
towards O
an O
apoptotic-prone O
phenotype O
via O

sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Efficacy O
and O
safety O
of O
the O
dipeptidyl B
peptidase-4 I
inhibitor O
, O
sitagliptin O
, O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
inadequately O
controlled O
on O
glimepiride O
alone O
or O
on O
glimepiride O
and O
metformin.AIM O
: O
To O
assess O
the O
efficacy O
and O
safety O
of O
a O
24-week O
treatment O
with O
sitagliptin O
a O
highly O
selective O
once-daily O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
in O
patients O
with O
type O
2 O
diabetes O
who O
had O
inadequate O
glycaemic O
control O
[glycosylated O
haemoglobin O
(HbA(1c)) O
>or=7.5% O
and O
<or=10.5%] O
while O
on O
glimepiride O
alone O
or O
in O
combination O
with O
metformin O
. O
METHODS O
: O
After O
a O
screening O
, O
diet/exercise O
run-in O
and O
drug O
wash-off O
period O
, O
a O
glimepiride O
+/- O
metformin O

sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Efficacy O
and O
safety O
of O
the O
dipeptidyl O
peptidase-4 O
inhibitor O
, O
sitagliptin O
, O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
inadequately O
controlled O
on O
glimepiride O
alone O
or O
on O
glimepiride O
and O
metformin.AIM O
: O
To O
assess O
the O
efficacy O
and O
safety O
of O
a O
24-week O
treatment O
with O
sitagliptin O
a O
highly O
selective O
once-daily O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
in O
patients O
with O
type O
2 O
diabetes O
who O
had O
inadequate O
glycaemic O
control O
[glycosylated O
haemoglobin O
(HbA(1c)) O
>or=7.5% O
and O
<or=10.5%] O
while O
on O
glimepiride O
alone O
or O
in O
combination O
with O
metformin O
. O
METHODS O
: O
After O
a O
screening O
, O
diet/exercise O
run-in O
and O
drug O
wash-off O
period O
, O
a O
glimepiride O
+/- O
metformin O

sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Efficacy O
and O
safety O
of O
the O
dipeptidyl B
peptidase-4 I
inhibitor O
, O
sitaglipti O
 O
, O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
inadequately O
controlled O
on O
glimepiride O
alone O
or O
on O
glimepiride O
and O
metformin.AIM O
: O
To O
assess O
the O
efficacy O
and O
safety O
of O
a O
24-week O
treatment O
with O
sitagliptin O
, O
a O
highly O
selective O
once-daily O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
in O
patients O
with O
type O
2 O
diabetes O
who O
had O
inadequate O
glycaemic O

NE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
not O
change O
these O
parameters O
. O
Indeed O
, O
CORT O
, O
NE O
and O
antibody O
synthesis O
were O
similar O
after O
T9 O
contusion O
or O
transection O
SCI O
. O
In O
contrast O
, O
high-level O
SCI O
(T3) O
caused O
sustained O
increases O
in O
CORT O
and O
splenic O
NE O
along O
with O
impaired O
antibody O
synthesis O
and O
elevated O
splenocyte O
apoptosis O
. O
The O
immunosuppressive O
effects O
of O
T3 O
SCI O
were O
caused O
by O
NE O
acting O
at O
beta2-adrenergic B
receptors I
(beta2AR) O
and O
could O
be O
reversed O
using O
beta2AR O
blockers O
. O
Interestingly O
, O
impaired O
antibody O
after O
T3 O
SCI O
could O
be O
mimicked O
after O
T9 O
SCI O
with O
a O
beta2AR O
agonist O
. O
These O
data O
illustrate O
the O
immunosuppressive O
effects O
of O
the O
SNS O
after O
high-level O
SCI O
and O
indicate O
that O
immune O
deficits O
may O
be O
overcome O
using O

NE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
not O
change O
these O
parameters O
. O
Indeed O
, O
CORT O
, O
NE O
and O
antibody O
synthesis O
were O
similar O
after O
T9 O
contusion O
or O
transection O
SCI O
. O
In O
contrast O
, O
high-level O
SCI O
(T3) O
caused O
sustained O
increases O
in O
CORT O
and O
splenic O
NE O
along O
with O
impaired O
antibody O
synthesis O
and O
elevated O
splenocyte O
apoptosis O
. O
The O
immunosuppressive O
effects O
of O
T3 O
SCI O
were O
caused O
by O
NE O
acting O
at O
beta2-adrenergic O
receptors O
(beta2AR) O
and O
could O
be O
reversed O
using O
beta2AR B
blockers O
. O
Interestingly O
, O
impaired O
antibody O
after O
T3 O
SCI O
could O
be O
mimicked O
after O
T9 O
SCI O
with O
a O
beta2AR O
agonist O
. O
These O
data O
illustrate O
the O
immunosuppressive O
effects O
of O
the O
SNS O
after O
high-level O
SCI O
and O
indicate O
that O
immune O
deficits O
may O
be O
overcome O
using O

Miglustat O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
effects O
over O
1 O
year.Niemann-Pick O
disease O
type O
C O
(NP-C) O
is O
a O
lipid O
storage O
disorder O
characterized O
by O
the O
accumulation O
of O
unesterified O
cholesterol O
and O
glycolipids O
in O
the O
lysosomal/late O
endosomal O
system O
of O
certain O
cells O
in O
the O
central O
nervous O
system O
(CNS) O
and O
visceral O
organs O
. O
Clinical O
symptoms O
include O
progressive O
neurological O
deterioration O
and O
visceral O
organomegaly O
. O
Miglustat O
a O
small O
iminosugar O
molecule O
approved O
for O
the O
treatment O
of O
Gaucher O
disease O
, O
reversibly O
inhibits O
glucosylceramide O
synthase O
, O
which O
catalyses O
the O
first O
committed O
step O
in O
glycosphingolipid O
synthesis O
. O
The O
physicochemical O
properties O
of O
miglustat O
allow O
it O
to O
cross O
the O
blood-brain O
barrier O
and O
suggest O
possible O
benefits O
in O
lysosomal O
storage O
diseases O
affecting O
the O
CNS O
. O
Here O
, O
we O

MPH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
daily O
from O
postnatal O
day O
7 O
(PND7)-PND35 O
. O
At O
the O
end O
of O
administration O
(PND35) O
or O
in O
adulthood O
(PND135) O
, O
brain O
sections O
from O
littermate O
pairs O
were O
immunocytochemically O
labeled O
for O
neurotransmitters O
and O
cytological O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine B
hydroxylase I
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O

MPH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
daily O
from O
postnatal O
day O
7 O
(PND7)-PND35 O
. O
At O
the O
end O
of O
administration O
(PND35) O
or O
in O
adulthood O
(PND135) O
, O
brain O
sections O
from O
littermate O
pairs O
were O
immunocytochemically O
labeled O
for O
neurotransmitters O
and O
cytological O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine O
hydroxylase O
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O

MPH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine O
hydroxylase O
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH O
receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O
neural O
cell O
adhesion O
molecule) O
. O
In O
medial O
striatum O
, O
TH-ir O
decreased O
by O
21% O
, O
and O
in O
hypothalamus O
neuropeptide O
Y-ir O
increased O
by O
10% O
in O
MPH-exposed O
rats O
. O
At O
PND135 O
, O
MPH-exposed O
rats O
exhibited O

MPH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine O
hydroxylase O
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH O
receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O
neural O
cell O
adhesion O
molecule) O
. O
In O
medial O
striatum O
, O
TH-ir O
decreased O
by O
21% O
, O
and O
in O
hypothalamus O
neuropeptide O
Y-ir O
increased O
by O
10% O
in O
MPH-exposed O
rats O
. O
At O
PND135 O
, O
MPH-exposed O
rats O
exhibited O

MPH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O
neural O
cell O
adhesion O
molecule) O
. O
In O
medial O
striatum O
, O
TH-ir O
decreased O
by O
21% O
, O
and O
in O
hypothalamus O
neuropeptide O
Y-ir O
increased O
by O
10% O
in O
MPH O
exposed O
rats O
. O
At O
PND135 O
, O
MPH-exposed O
rats O
exhibited O
decreased O
anxiety O
in O
the O
elevated O
plus-maze O
and O
a O
trend O
for O
decreased O
TH-ir O
in O
the O
mPFC O
. O
Neither O
PND35 O
nor O
PND135 O
rats O
showed O
major O
structural O
differences O
with O
MPH O
exposure O
. O
These O
findings O
suggest O
that O
developmental O
exposure O
to O
high O
therapeutic O
doses O
of O
MPH O
has O
short-term O
effects O

MPH O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
daily O
from O
postnatal O
day O
7 O
(PND7)-PND35 O
. O
At O
the O
end O
of O
administration O
(PND35) O
or O
in O
adulthood O
(PND135) O
, O
brain O
sections O
from O
littermate O
pairs O
were O
immunocytochemically O
labeled O
for O
neurotransmitters O
and O
cytological O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine O
hydroxylase O
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine B
transporter I
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O

MPH O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
daily O
from O
postnatal O
day O
7 O
(PND7)-PND35 O
. O
At O
the O
end O
of O
administration O
(PND35) O
or O
in O
adulthood O
(PND135) O
, O
brain O
sections O
from O
littermate O
pairs O
were O
immunocytochemically O
labeled O
for O
neurotransmitters O
and O
cytological O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine O
hydroxylase O
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O

MPH O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine O
hydroxylase O
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH O
receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O
neural O
cell O
adhesion O
molecule) O
. O
In O
medial O
striatum O
, O
TH-ir O
decreased O
by O
21% O
, O
and O
in O
hypothalamus O
neuropeptide O
Y-ir O
increased O
by O
10% O
in O
MPH-exposed O
rats O
. O
At O
PND135 O
, O
MPH-exposed O
rats O
exhibited O

MPH O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O
neural O
cell O
adhesion O
molecule) O
. O
In O
medial O
striatum O
, O
TH-ir O
decreased O
by O
21% O
, O
and O
in O
hypothalamus O
neuropeptide O
Y-ir O
increased O
by O
10% O
in O
MPH O
exposed O
rats O
. O
At O
PND135 O
, O
MPH-exposed O
rats O
exhibited O
decreased O
anxiety O
in O
the O
elevated O
plus-maze O
and O
a O
trend O
for O
decreased O
TH-ir O
in O
the O
mPFC O
. O
Neither O
PND35 O
nor O
PND135 O
rats O
showed O
major O
structural O
differences O
with O
MPH O
exposure O
. O
These O
findings O
suggest O
that O
developmental O
exposure O
to O
high O
therapeutic O
doses O
of O
MPH O
has O
short-term O
effects O

phenylephrine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
were O
tested O
against O
the O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist)-induced O
contraction O
in O
isolated O
hamster O
ureteral O
preparations O
using O
a O
functional O
experimental O
approach O
. O
In O
the O
smooth O
muscle O
, O
relative O
mRNA O
expression O
levels O
for O
alpha(1a)- O
, O
alpha(1b)- O
and O
alpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor B
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor O
antagonist) O
competitively O
antagonized O
the O
phenylephrine-induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O

phenylephrine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor B
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor O
antagonist) O
competitively O
antagonized O
the O
phenylephrine O
induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O
ureters O
, O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
were O
more O
prevalent O
than O
the O
alpha(1B)-adrenoceptor O
, O
with O
contraction O
being O
mediated O
mainly O
via O
alpha(1A)-adrenoceptors O
. O
If O
these O
findings O
hold O
true O

phenylephrine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor O
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor B
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor O
antagonist) O
competitively O
antagonized O
the O
phenylephrine O
induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O
ureters O
, O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
were O
more O
prevalent O
than O
the O
alpha(1B)-adrenoceptor O
, O
with O
contraction O
being O
mediated O
mainly O
via O
alpha(1A)-adrenoceptors O
. O
If O
these O
findings O
hold O
true O

phenylephrine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor O
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor B
antagonist) O
competitively O
antagonized O
the O
phenylephrine O
induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O
ureters O
, O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
were O
more O
prevalent O
than O
the O
alpha(1B)-adrenoceptor O
, O
with O
contraction O
being O
mediated O
mainly O
via O
alpha(1A)-adrenoceptors O
. O
If O
these O
findings O
hold O
true O

phenylephrine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
subtypes O
in O
hamster O
ureters O
according O
to O
gene O
and O
protein O
expressions O
and O
contractile O
function O
. O
Real-time O
quantitative O
reverse-transcription O
polymerase O
chain O
reaction O
and O
immunohistochemical O
analysis O
were O
performed O
to O
determine O
mRNA O
levels O
and O
receptor O
protein O
expressions O
respectively O
, O
for O
alpha(1A)- O
, O
alpha(1B)- O
and O
alpha(1D)-adrenoceptors O
in O
hamster O
ureteral O
smooth O
muscle O
. O
alpha(1)-Adrenoceptor O
antagonists O
were O
tested O
against O
the O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist)-induced O
contraction O
in O
isolated O
hamster O
ureteral O
preparations O
using O
a O
functional O
experimental O
approach O
. O
In O
the O
smooth O
muscle O
, O
relative O
mRNA O
expression O
levels O
for O
alpha(1a)- O
, O
alpha(1b)- O
and O
alpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O

Noradrenaline O
acts O
as O
AGONIST O
for O
what O
entity O
? O
alpha(1)-Adrenoceptor O
antagonists O
were O
tested O
against O
the O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist)-induced O
contraction O
in O
isolated O
hamster O
ureteral O
preparations O
using O
a O
functional O
experimental O
approach O
. O
In O
the O
smooth O
muscle O
, O
relative O
mRNA O
expression O
levels O
for O
alpha(1a)- O
, O
alpha(1b)- O
and O
alpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor B
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor O
antagonist) O
competitively O
antagonized O
the O
phenylephrine-induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O

Prazosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
approach O
. O
In O
the O
smooth O
muscle O
, O
relative O
mRNA O
expression O
levels O
for O
alpha(1a)- O
, O
alpha(1b)- O
and O
alpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor B
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor O
antagonist) O
competitively O
antagonized O
the O
phenylephrine-induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O
ureters O
, O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
were O

silodosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
muscle O
, O
relative O
mRNA O
expression O
levels O
for O
alpha(1a)- O
, O
alpha(1b)- O
and O
alpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor O
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor B
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor O
antagonist) O
competitively O
antagonized O
the O
phenylephrine-induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O
ureters O
, O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
were O
more O
prevalent O
than O
the O

BMY-7378 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
for O
alpha(1a)- O
, O
alpha(1b)- O
and O
alpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor O
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor B
antagonist) O
competitively O
antagonized O
the O
phenylephrine-induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O
ureters O
, O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
were O
more O
prevalent O
than O
the O
alpha(1B)-adrenoceptor O
, O
with O
contraction O
being O
mediated O

8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
alpha(1b)- O
and O
alpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor O
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
( O
8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride O
(selective O
alpha(1D)-adrenoceptor B
antagonist) O
competitively O
antagonized O
the O
phenylephrine-induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O
ureters O
, O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
were O
more O
prevalent O
than O
the O
alpha(1B)-adrenoceptor O
, O
with O
contraction O
being O
mediated O
mainly O
via O

tryptophan O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
IFN-gamma-induced O
IDO B
and O
WRS O
expression O
in O
microglia O
is O
differentially O
regulated O
by O
IL-4.Indoleamine O
2,3-dioxygenase O
(IDO) O
, O
a O
tryptophan O
catabolizing O
enzyme O
, O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
various O
neurological O
disorders O
. O
IDO O
expression O
is O
induced O
by O
IFN-gamma O
and O
leads O
to O
neurotoxicity O
by O
generating O
quinolinic O
acid O
. O
Additionally O
, O
it O
inhibits O
the O
immune O
response O
through O
both O
tryptophan O
depletion O
and O
generating O
other O
tryptophan O
catabolites O
. O
IL-4 O
and O
IL-13 O
have O
been O
shown O
to O
control O

tryptophan O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
IFN-gamma-induced O
IDO O
and O
WRS O
expression O
in O
microglia O
is O
differentially O
regulated O
by O
IL-4.Indoleamine O
2,3-dioxygenase O
(IDO) O
, O
a O
tryptophan O
catabolizing O
enzyme O
, O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
various O
neurological O
disorders O
. O
IDO O
expression O
is O
induced O
by O
IFN-gamma O
and O
leads O
to O
neurotoxicity O
by O
generating O
quinolinic O
acid O
. O
Additionally O
, O
it O
inhibits O
the O
immune O
response O
through O
both O
tryptophan O
depletion O
and O
generating O
other O
tryptophan O
catabolites O
. O
IL-4 O
and O
IL-13 O
have O
been O
shown O
to O
control O

Dexmedetomidine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
by O
2-fold O
and O
skin O
vascular O
resistance O
increased O
from O
13.2 O
+/- O
2.3 O
to O
20.1 O
+/- O
2.2 O
resistance O
units O
while O
mean O
arterial O
pressure O
increased O
by O
14 O
+/- O
3 O
mm O
Hg O
and O
heart O
rate O
by O
18 O
+/- O
3 O
beats/min O
(p O
< O
0.01) O
. O
Dexmedetomidine O
abolished O
these O
increases O
, O
whereas O
intravenous O
saline O
was O
without O
effect O
. O
Dexmedetomidine O
was O
effective O
in O
blocking O
these O
sympathomimetic O
actions O
of O
cocaine O
even O
in O
all O
7 O
subjects O
who O
were O
homozygous O
for O
the O
Del322-325 O
polymorphism O
in O
the O
alpha2C O
AR O
, O
a O
loss-of-function O
mutation O
that O
is O
highly O
enriched O
in O
blacks O
. O
CONCLUSIONS O
: O
The O
data O
advance O
the O
novel O
hypothesis O
that O
central O
sympatholysis O
with O
dexmedetomidine O
constitutes O
a O
highly O

dexmedetomidine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
was O
without O
effect O
. O
Dexmedetomidine O
was O
effective O
in O
blocking O
these O
sympathomimetic O
actions O
of O
cocaine O
even O
in O
all O
7 O
subjects O
who O
were O
homozygous O
for O
the O
Del322-325 O
polymorphism O
in O
the O
alpha2C B
AR O
, O
a O
loss-of-function O
mutation O
that O
is O
highly O
enriched O
in O
blacks O
. O
CONCLUSIONS O
: O
The O
data O
advance O
the O
novel O
hypothesis O
that O
central O
sympatholysis O
with O
dexmedetomidine O
constitutes O
a O
highly O
effective O
countermeasure O
for O
cocaine's O
sympathomimetic O
actions O
on O
the O
human O
cardiovascular O
system O
, O
even O
in O
individuals O
carrying O
the O
alpha2CDel322-325 O
polymorphism O
. O
(Study O
to O
Improve O
Scientific O
Understanding O
of O
the O
Cardiovascular O
Actions O
of O
Cocaine; O
http://clinicaltrials.gov/ct/show/NCT00338546?order=1; O
NCT00338546) O
. O

dexmedetomidine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Central O
sympatholysis O
as O
a O
novel O
countermeasure O
for O
cocaine-induced O
sympathetic O
activation O
and O
vasoconstriction O
in O
humans.OBJECTIVES O
: O
The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
cocaine's O
sympathomimetic O
actions O
can O
be O
reversed O
by O
a O
potent O
centrally O
acting O
alpha2 B
adrenergic I
receptor I
(AR) O
agonist O
( O
dexmedetomidine O
 O
. O
BACKGROUND O
: O
We O
recently O
showed O
that O
cocaine O
stimulates O
the O
human O
cardiovascular O
system O
primarily O
by O
acting O
in O
the O
brain O
to O
increase O
sympathetic O
nerve O
activity O
(SNA) O
, O
the O
neural O
stimulus O
to O
norepinephrine O
release O
. O
Thus O
, O
SNA O
constitutes O
a O
putative O
new O
drug O
target O
to O
block O
cocaine's O
adverse O
cardiovascular O
effects O
at O
their O
origin O
. O
METHODS O
: O
In O

dexmedetomidine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Central O
sympatholysis O
as O
a O
novel O
countermeasure O
for O
cocaine-induced O
sympathetic O
activation O
and O
vasoconstriction O
in O
humans.OBJECTIVES O
: O
The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
cocaine's O
sympathomimetic O
actions O
can O
be O
reversed O
by O
a O
potent O
centrally O
acting O
alpha2 O
adrenergic O
receptor O
(AR) O
agonist O
( O
dexmedetomidine O
 O
. O
BACKGROUND O
: O
We O
recently O
showed O
that O
cocaine O
stimulates O
the O
human O
cardiovascular O
system O
primarily O
by O
acting O
in O
the O
brain O
to O
increase O
sympathetic O
nerve O
activity O
(SNA) O
, O
the O
neural O
stimulus O
to O
norepinephrine O
release O
. O
Thus O
, O
SNA O
constitutes O
a O
putative O
new O
drug O
target O
to O
block O
cocaine's O
adverse O
cardiovascular O
effects O
at O
their O
origin O
. O
METHODS O
: O
In O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
preferential O
COX-2 B
blockade O
. O
Ex O
vivo O
COX O
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O
B(2) O
and O
lipopolysaccharide-induced O
prostaglandin O
E(2) O
were O
measured O
ex O
vivo O
and O
in O
vitro O
in O
human O
whole O
blood O
as O
indices O
of O
COX-1 O
and O
COX-2 O
activity O
. O
In O
vitro O
, O
acetaminophen O
elicited O
a O
4.4-fold O
selectivity O
toward O
COX-2 O
inhibition O
(IC(50)=113.7 O
micromol/L O
for O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O
inhibitions O
were O
56% O
(COX-1) O
and O
83% O
(COX-2) O
. O
Acetaminophen O
plasma O
concentrations O
remained O
above O
the O
in O
vitro O
IC(50) O
for O
COX-2 O
for O
at O
least O
5 O
h O
postadministration O
. O
Ex O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
preferential O
COX-2 O
blockade O
. O
Ex O
vivo O
COX O
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O
B(2) O
and O
lipopolysaccharide-induced O
prostaglandin O
E(2) O
were O
measured O
ex O
vivo O
and O
in O
vitro O
in O
human O
whole O
blood O
as O
indices O
of O
COX-1 B
and O
COX-2 O
activity O
. O
In O
vitro O
, O
acetaminophen O
elicited O
a O
4.4-fold O
selectivity O
toward O
COX-2 O
inhibition O
(IC(50)=113.7 O
micromol/L O
for O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O
inhibitions O
were O
56% O
(COX-1) O
and O
83% O
(COX-2) O
. O
Acetaminophen O
plasma O
concentrations O
remained O
above O
the O
in O
vitro O
IC(50) O
for O
COX-2 O
for O
at O
least O
5 O
h O
postadministration O
. O
Ex O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
preferential O
COX-2 B
blockade O
. O
Ex O
vivo O
COX O
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O
B(2) O
and O
lipopolysaccharide-induced O
prostaglandin O
E(2) O
were O
measured O
ex O
vivo O
and O
in O
vitro O
in O
human O
whole O
blood O
as O
indices O
of O
COX-1 O
and O
COX-2 O
activity O
. O
In O
vitro O
, O
acetaminophen O
elicited O
a O
4.4-fold O
selectivity O
toward O
COX-2 O
inhibition O
(IC(50)=113.7 O
micromol/L O
for O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O
inhibitions O
were O
56% O
(COX-1) O
and O
83% O
(COX-2) O
. O
Acetaminophen O
plasma O
concentrations O
remained O
above O
the O
in O
vitro O
IC(50) O
for O
COX-2 O
for O
at O
least O
5 O
h O
postadministration O
. O
Ex O

Acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
vivo O
and O
in O
vitro O
in O
human O
whole O
blood O
as O
indices O
of O
COX-1 O
and O
COX-2 B
activity O
. O
In O
vitro O
, O
acetaminophen O
elicited O
a O
4.4-fold O
selectivity O
toward O
COX-2 O
inhibition O
(IC(50)=113.7 O
micromol/L O
for O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O
inhibitions O
were O
56% O
(COX-1) O
and O
83% O
(COX-2) O
. O
Acetaminophen O
plasma O
concentrations O
remained O
above O
the O
in O
vitro O
IC(50) O
for O
COX-2 O
for O
at O
least O
5 O
h O
postadministration O
. O
Ex O
vivo O
IC(50) O
values O
(COX-1 O
: O
105.2 O
micromol/L; O
COX-2 O
: O
26.3 O
micromol/L) O
of O
acetaminophen O
compared O
favorably O
with O
its O
in O
vitro O
IC(50) O
values O
. O
In O
contrast O
to O
previous O
concepts O
, O
acetaminophen O
inhibited O
COX-2 O
by O
more O
than O
80% O
, O
i.e. O
, O

paracetamol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Acetaminophen O
(paracetamo O
) O
is O
a O
selective O
cyclooxygenase-2 B
inhibitor O
in O
man.For O
more O
than O
three O
decades O
, O
acetaminophen O
(INN O
, O
paracetamol) O
has O
been O
claimed O
to O
be O
devoid O
of O
significant O
inhibition O
of O
peripheral O
prostanoids O
. O
Meanwhile O
, O
attempts O
to O
explain O
its O
action O
by O
inhibition O
of O
a O
central O
cyclooxygenase O
(COX)-3 O
have O
been O
rejected O
. O
The O
fact O
that O
acetaminophen O
acts O
functionally O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O
inhibitions O
were O
56% O
(COX-1) O
and O
83% O
(COX-2) O
. O
Acetaminophen O
plasma O
concentrations O
remained O
above O
the O
in O
vitro O
IC(50) O
for O
COX-2 O
for O
at O
least O
5 O
h O
postadministration O
. O
Ex O
vivo O
IC(50) O
values O
(COX-1 O
: O
105.2 O
micromol/L; O
COX-2 O
: O
26.3 O
micromol/L) O
of O
acetaminophen O
compared O
favorably O
with O
its O
in O
vitro O
IC(50) O
values O
. O
In O
contrast O
to O
previous O
concepts O
, O
acetaminophen O
inhibited O
COX-2 O
by O
more O
than O
80% O
, O
i.e. O
, O
to O
a O
degree O
comparable O
to O
nonsteroidal O
antiinflammatory O
drugs O
(NSAIDs) O
and O
selective O
COX-2 O
inhibitors O
. O
However O
, O
a O
>95% O
COX-1 B
blockade O
relevant O
for O
suppression O
of O
platelet O
function O
was O
not O
achieved O
. O
Our O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O
inhibitions O
were O
56% O
(COX-1) O
and O
83% O
(COX-2) O
. O
Acetaminophen O
plasma O
concentrations O
remained O
above O
the O
in O
vitro O
IC(50) O
for O
COX-2 B
for O
at O
least O
5 O
h O
postadministration O
. O
Ex O
vivo O
IC(50) O
values O
(COX-1 O
: O
105.2 O
micromol/L; O
COX-2 O
: O
26.3 O
micromol/L) O
of O
acetaminophen O
compared O
favorably O
with O
its O
in O
vitro O
IC(50) O
values O
. O
In O
contrast O
to O
previous O
concepts O
, O
acetaminophen O
inhibited O
COX-2 O
by O
more O
than O
80% O
, O
i.e. O
, O
to O
a O
degree O
comparable O
to O
nonsteroidal O
antiinflammatory O
drugs O
(NSAIDs) O
and O
selective O
COX-2 O
inhibitors O
. O
However O
, O
a O
>95% O
COX-1 O
blockade O
relevant O
for O
suppression O
of O
platelet O
function O
was O
not O
achieved O
. O
Our O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibitions O
were O
56% O
(COX-1) O
and O
83% O
(COX-2) O
. O
Acetaminophen O
plasma O
concentrations O
remained O
above O
the O
in O
vitro O
IC(50) O
for O
COX-2 B
for O
at O
least O
5 O
h O
postadministration O
. O
Ex O
vivo O
IC(50) O
values O
(COX-1 O
: O
105.2 O
micromol/L; O
COX-2 O
: O
26.3 O
micromol/L) O
of O
acetaminophen O
compared O
favorably O
with O
its O
in O
vitro O
IC(50) O
values O
. O
In O
contrast O
to O
previous O
concepts O
, O
acetaminophen O
inhibited O
COX-2 O
by O
more O
than O
80% O
, O
i.e. O
, O
to O
a O
degree O
comparable O
to O
nonsteroidal O
antiinflammatory O
drugs O
(NSAIDs) O
and O
selective O
COX-2 O
inhibitors O
. O
However O
, O
a O
>95% O
COX-1 O
blockade O
relevant O
for O
suppression O
of O
platelet O
function O
was O
not O
achieved O
. O
Our O
data O
may O
explain O
acetaminophen's O
analgesic O
and O
antiinflammatory O
action O
as O
well O
as O
its O
superior O
overall O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
suppression O
of O
platelet O
function O
was O
not O
achieved O
. O
Our O
data O
may O
explain O
acetaminophen's O
analgesic O
and O
antiinflammatory O
action O
as O
well O
as O
its O
superior O
overall O
gastrointestinal O
safety O
profile O
compared O
with O
NSAIDs O
. O
In O
view O
of O
its O
substantial O
COX-2 B
inhibition O
, O
recently O
defined O
cardiovascular O
warnings O
for O
use O
of O
COX-2 O
inhibitors O
should O
also O
be O
considered O
for O
acetaminophen O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Acetaminophen O
(paracetamol) O
is O
a O
selective O
cyclooxygenase-2 O
inhibitor O
in O
man.For O
more O
than O
three O
decades O
, O
acetaminophen O
(INN O
, O
paracetamol) O
has O
been O
claimed O
to O
be O
devoid O
of O
significant O
inhibition O
of O
peripheral O
prostanoids O
. O
Meanwhile O
, O
attempts O
to O
explain O
its O
action O
by O
inhibition O
of O
a O
central O
cyclooxygenase O
(COX)-3 O
have O
been O
rejected O
. O
The O
fact O
that O
acetaminophen O
acts O
functionally O
as O
a O
selective O
COX-2 B
inhibitor O
led O
us O
to O
investigate O
the O
hypothesis O
of O
whether O
it O
works O
via O
preferential O
COX-2 O
blockade O
. O
Ex O
vivo O
COX O
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O
B(2) O
and O
lipopolysaccharide-induced O
prostaglandin O
E(2) O
were O
measured O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
prostanoids O
. O
Meanwhile O
, O
attempts O
to O
explain O
its O
action O
by O
inhibition O
of O
a O
central O
cyclooxygenase O
(COX)-3 O
have O
been O
rejected O
. O
The O
fact O
that O
acetaminophen O
acts O
functionally O
as O
a O
selective O
COX-2 O
inhibitor O
led O
us O
to O
investigate O
the O
hypothesis O
of O
whether O
it O
works O
via O
preferential O
COX-2 O
blockade O
. O
Ex O
vivo O
COX B
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O
B(2) O
and O
lipopolysaccharide-induced O
prostaglandin O
E(2) O
were O
measured O
ex O
vivo O
and O
in O
vitro O
in O
human O
whole O
blood O
as O
indices O
of O
COX-1 O
and O
COX-2 O
activity O
. O
In O
vitro O
, O
acetaminophen O
elicited O
a O
4.4-fold O
selectivity O
toward O
COX-2 O
inhibition O
(IC(50)=113.7 O
micromol/L O
for O

thromboxane O
B(2) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
(COX)-3 O
have O
been O
rejected O
. O
The O
fact O
that O
acetaminophen O
acts O
functionally O
as O
a O
selective O
COX-2 O
inhibitor O
led O
us O
to O
investigate O
the O
hypothesis O
of O
whether O
it O
works O
via O
preferential O
COX-2 O
blockade O
. O
Ex O
vivo O
COX O
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O
B(2) O
and O
lipopolysaccharide-induced O
prostaglandin O
E(2) O
were O
measured O
ex O
vivo O
and O
in O
vitro O
in O
human O
whole O
blood O
as O
indices O
of O
COX-1 B
and O
COX-2 O
activity O
. O
In O
vitro O
, O
acetaminophen O
elicited O
a O
4.4-fold O
selectivity O
toward O
COX-2 O
inhibition O
(IC(50)=113.7 O
micromol/L O
for O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O

prostaglandin O
E(2) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
The O
fact O
that O
acetaminophen O
acts O
functionally O
as O
a O
selective O
COX-2 B
inhibitor O
led O
us O
to O
investigate O
the O
hypothesis O
of O
whether O
it O
works O
via O
preferential O
COX-2 O
blockade O
. O
Ex O
vivo O
COX O
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O
B(2) O
and O
lipopolysaccharide-induced O
prostaglandin O
E(2) O
were O
measured O
ex O
vivo O
and O
in O
vitro O
in O
human O
whole O
blood O
as O
indices O
of O
COX-1 O
and O
COX-2 O
activity O
. O
In O
vitro O
, O
acetaminophen O
elicited O
a O
4.4-fold O
selectivity O
toward O
COX-2 O
inhibition O
(IC(50)=113.7 O
micromol/L O
for O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O
inhibitions O
were O
56% O
(COX-1) O

cibenzoline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion B
channel I
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
have O
been O
found O
to O
have O
an O
NCX O
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

cibenzoline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion O
channel O
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
have O
been O
found O
to O
have O
an O
NCX B
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

KB-R7943 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
There O
are O
three O
mammalian O
NCX B
isoforms O
: O
NCX1 O
is O
widely O
expressed O
in O
the O
heart O
, O
kidney O
, O
brain O
, O
blood O
vessels O
, O
and O
so O
on; O
whereas O
the O
expression O
of O
NCX2 O
and O
NCX3 O
is O
limited O
mainly O
to O
the O
brain O
and O
skeletal O
muscle O
. O
The O
pharmacology O
of O
NCX O
inhibitors O
has O
been O
studied O
extensively O
since O
the O
development O
of O
KB-R7943 O
a O
prototype O
benzyloxyphenyl O
NCX O
inhibitor O
, O
in O
1996 O
. O
Currently O
, O
experiments O
are O
actively O
progressing O
with O
more O
selective O
inhibitors O
: O
SEA0400 O
, O
SN-6 O
, O
and O
YM-244769 O
. O
Intriguingly O
, O
the O
inhibitory O
potency O
of O
benzyloxyphenyl O
NCX O
inhibitors O
is O
directly O
coupled O
to O
the O
rate O
of O
Na(+)(i)-dependent O
inactivation O
. O
Therefore O
, O
the O
benzyloxyphenyl O
inhibitors O
are O
apparently O
dormant O
during O
the O
forward O
mode O
under O

benzyloxyphenyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mammalian O
NCX B
isoforms O
: O
NCX1 O
is O
widely O
expressed O
in O
the O
heart O
, O
kidney O
, O
brain O
, O
blood O
vessels O
, O
and O
so O
on; O
whereas O
the O
expression O
of O
NCX2 O
and O
NCX3 O
is O
limited O
mainly O
to O
the O
brain O
and O
skeletal O
muscle O
. O
The O
pharmacology O
of O
NCX O
inhibitors O
has O
been O
studied O
extensively O
since O
the O
development O
of O
KB-R7943 O
, O
a O
prototype O
benzyloxyphenyl O
NCX O
inhibitor O
, O
in O
1996 O
. O
Currently O
, O
experiments O
are O
actively O
progressing O
with O
more O
selective O
inhibitors O
: O
SEA0400 O
, O
SN-6 O
, O
and O
YM-244769 O
. O
Intriguingly O
, O
the O
inhibitory O
potency O
of O
benzyloxyphenyl O
NCX O
inhibitors O
is O
directly O
coupled O
to O
the O
rate O
of O
Na(+)(i)-dependent O
inactivation O
. O
Therefore O
, O
the O
benzyloxyphenyl O
inhibitors O
are O
apparently O
dormant O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O

benzyloxyphenyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
NCX3 O
is O
limited O
mainly O
to O
the O
brain O
and O
skeletal O
muscle O
. O
The O
pharmacology O
of O
NCX B
inhibitors O
has O
been O
studied O
extensively O
since O
the O
development O
of O
KB-R7943 O
, O
a O
prototype O
benzyloxyphenyl O
NCX O
inhibitor O
, O
in O
1996 O
. O
Currently O
, O
experiments O
are O
actively O
progressing O
with O
more O
selective O
inhibitors O
: O
SEA0400 O
, O
SN-6 O
, O
and O
YM-244769 O
. O
Intriguingly O
, O
the O
inhibitory O
potency O
of O
benzyloxyphenyl O
NCX O
inhibitors O
is O
directly O
coupled O
to O
the O
rate O
of O
Na(+)(i)-dependent O
inactivation O
. O
Therefore O
, O
the O
benzyloxyphenyl O
inhibitors O
are O
apparently O
dormant O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O

amiodarone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dormant O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion B
channel I
blockers O
, O
such O
as O
amiodarone O
dronedarone O
, O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX O
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

amiodarone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dormant O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion O
channel O
blockers O
, O
such O
as O
amiodarone O
dronedarone O
, O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX B
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

dronedarone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion B
channel I
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX O
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

dronedarone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion O
channel O
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX B
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

bepridil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion B
channel I
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX O
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

bepridil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion O
channel O
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX B
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

aprindine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion B
channel I
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
, O
aprindine O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX O
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

aprindine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion O
channel O
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
, O
aprindine O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX B
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

Ca(2+) O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Na+/Ca2+ O
exchange O
inhibitors O
: O
a O
new O
class O
of O
calcium O
regulators.The O
Na(+)/Ca(2+) B
exchanger I
(NCX) O
is O
a O
bidirectional O
transporter O
that O
normally O
extrudes O
Ca(2+) O
from O
the O
cell O
(forward O
mode) O
, O
but O
also O
brings O
Ca(2+) O
into O
the O
cell O
(reverse O
mode) O
under O
special O
conditions O
such O
as O
intracellular O
Na(+) O
(Na(+)(i)) O
accumulation O
or O
membrane O
depolarization O
. O
There O
are O
three O
mammalian O
NCX O
isoforms O
: O
NCX1 O
is O
widely O
expressed O
in O
the O
heart O
, O
kidney O
, O
brain O
, O
blood O
vessels O
, O
and O
so O
on; O
whereas O
the O
expression O
of O
NCX2 O
and O
NCX3 O
is O
limited O
mainly O
to O
the O

Ca(2+) O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Na+/Ca2+ O
exchange O
inhibitors O
: O
a O
new O
class O
of O
calcium O
regulators.The O
Na(+)/Ca(2+) B
exchanger I
(NCX) O
is O
a O
bidirectional O
transporter O
that O
normally O
extrudes O
Ca(2+) O
from O
the O
cell O
(forward O
mode) O
, O
but O
also O
brings O
Ca(2+) O
into O
the O
cell O
(reverse O
mode) O
under O
special O
conditions O
such O
as O
intracellular O
Na(+) O
(Na(+)(i)) O
accumulation O
or O
membrane O
depolarization O
. O
There O
are O
three O
mammalian O
NCX O
isoforms O
: O
NCX1 O
is O
widely O
expressed O
in O
the O
heart O
, O
kidney O
, O
brain O
, O
blood O
vessels O
, O
and O
so O
on; O
whereas O
the O
expression O

Conivaptan O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
critical O
role O
in O
the O
regulation O
of O
serum O
osmolality O
and O
in O
circulatory O
homeostasis O
. O
The O
actions O
of O
AVP O
are O
mediated O
by O
three O
receptor O
subtypes O
V1a O
, O
V2 O
, O
and O
V1b O
. O
The O
V1a O
receptor O
regulates O
vasodilation O
and O
cellular O
hypertrophy O
while O
the O
V2 O
receptor O
regulates O
free O
water O
excretion O
. O
The O
V1b O
receptor O
regulates O
adrenocorticotropin O
hormone O
release O
. O
Conivaptan O
is O
a O
nonpeptide O
dual O
V1a/V2 B
AVP I
receptor I
antagonist O
. O
It O
binds O
with O
high O
affinity O
, O
competitively O
, O
and O
reversibly O
to O
the O
V1a/V2 O
receptor O
subtypes; O
its O
antagonistic O
effect O
is O
concentration O
dependent O
. O
It O
inhibits O
CYP3A4 O
liver O
enzyme O
and O
elevates O
plasma O
levels O
of O
other O
drugs O
metabolized O
by O
this O
enzyme O
. O
It O
is O
approved O
only O
for O
short-term O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Kinetic O
characterization O
of O
adenylosuccinate O
synthetase O
from O
the O
thermophilic O
archaea O
Methanocaldococcus O
jannaschii.Adenylosuccinate O
synthetase O
(AdSS) O
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
, O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS B
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O
short O
AdSS O
has O
two O
large O
deletions O
that O
map O
to O
the O
middle O
and O
C-terminus O
of O
the O
protein O
. O
This O
article O
discusses O
the O
detailed O
kinetic O
characterization O
of O
MjAdSS O
. O
Initial O
velocity O
and O
product O
inhibition O
studies O
, O
carried O
out O
at O
70 O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Kinetic O
characterization O
of O
adenylosuccinate O
synthetase O
from O
the O
thermophilic O
archaea O
Methanocaldococcus O
jannaschii.Adenylosuccinate O
synthetase O
(AdSS) O
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
, O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS O
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O
short O
AdSS O
has O
two O
large O
deletions O
that O
map O
to O
the O
middle O
and O
C-terminus O
of O
the O
protein O
. O
This O
article O
discusses O
the O
detailed O
kinetic O
characterization O
of O
MjAdSS O
. O
Initial O
velocity O
and O
product O
inhibition O
studies O
, O
carried O
out O
at O
70 O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Methanocaldococcus O
jannaschii.Adenylosuccinate O
synthetase O
(AdSS) O
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
, O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS B
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O
short O
AdSS O
has O
two O
large O
deletions O
that O
map O
to O
the O
middle O
and O
C-terminus O
of O
the O
protein O
. O
This O
article O
discusses O
the O
detailed O
kinetic O
characterization O
of O
MjAdSS O
. O
Initial O
velocity O
and O
product O
inhibition O
studies O
, O
carried O
out O
at O
70 O
degrees O
C O
, O
suggest O
a O
rapid O
equilibrium O
random O
AB O
steady-state O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS B
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O
short O
AdSS O
has O
two O
large O
deletions O
that O
map O
to O
the O
middle O
and O
C O
terminus O
of O
the O
protein O
. O
This O
article O
discusses O
the O
detailed O
kinetic O
characterization O
of O
MjAdSS O
. O
Initial O
velocity O
and O
product O
inhibition O
studies O
, O
carried O
out O
at O
70 O
degrees O
C O
, O
suggest O
a O
rapid O
equilibrium O
random O
AB O
steady-state O
ordered O
C O
kinetic O
mechanism O
for O
the O
MjAdSS O
catalyzed O
reaction O
. O
AdSS O
are O
known O
to O
exhibit O
monomer-dimer O
equilibrium O
with O

Phosphate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
show O
that O
MjAdSS B
is O
an O
equilibrium O
mixture O
of O
dimers O
and O
tetramers O
with O
the O
tetramer O
being O
the O
catalytically O
active O
form O
. O
The O
tetramer O
dissociates O
into O
dimers O
with O
a O
minor O
increase O
in O
ionic O
strength O
of O
the O
buffer O
, O
while O
the O
dimer O
is O
extremely O
stable O
and O
does O
not O
dissociate O
even O
at O
1.2 O
M O
NaCl O
. O
Phosphate O
a O
product O
of O
the O
reaction O
, O
was O
found O
to O
be O
a O
potent O
inhibitor O
of O
MjAdSS O
showing O
biphasic O
inhibition O
of O
enzyme O
activity O
. O
The O
inhibition O
was O
competitive O
with O
IMP O
and O
noncompetitive O
with O
GTP O
. O
MjAdSS O
, O
like O
the O
mouse O
acidic O
isozyme O
, O
exhibits O
substrate O
inhibition O
, O
with O
IMP O
inhibiting O
enzyme O
activity O
at O
subsaturating O
GTP O
concentrations O
. O
Regulation O

Mg2+ O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
Kinetic O
characterization O
of O
adenylosuccinate O
synthetase O
from O
the O
thermophilic O
archaea O
Methanocaldococcus O
jannaschii.Adenylosuccinate O
synthetase O
(AdSS) O
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
, O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS O
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O

adenylosuccinate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Kinetic O
characterization O
of O
adenylosuccinate O
synthetase O
from O
the O
thermophilic O
archaea O
Methanocaldococcus O
jannaschii.Adenylosuccinate O
synthetase O
(AdSS) O
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS O
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O
short O
AdSS O
has O
two O
large O
deletions O
that O
map O
to O
the O
middle O
and O

adenylosuccinate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Kinetic O
characterization O
of O
adenylosuccinate O
synthetase O
from O
the O
thermophilic O
archaea O
Methanocaldococcus O
jannaschii.Adenylosuccinate O
synthetase O
(AdSS) O
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS B
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O
short O
AdSS O
has O
two O
large O
deletions O
that O
map O
to O
the O
middle O
and O

Mg2+ O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Kinetic O
characterization O
of O
adenylosuccinate O
synthetase O
from O
the O
thermophilic O
archaea O
Methanocaldococcus O
jannaschii.Adenylosuccinate O
synthetase O
(AdSS) O
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
, O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS B
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O

Vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 B
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil O
and O
sildenafil O
. O
Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O
domain O

Vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 O
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil O
and O
sildenafil O
. O
Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O
domain O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 B
catalytic I
domain I
in O
complex O
with O
vardenafil O
The O
structure O
shows O
that O
the O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1-vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 O
and O
its O
complexes O
with O
the O
inhibitors O
. O
In O
addition O
, O
the O
molecular O
configuration O
of O
vardenafil O
differs O
from O
that O
of O
sildenafil O
when O
bound O
to O
PDE5 O
. O
It O
is O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 B
catalytic O
domain O
in O
complex O
with O
vardenafil O
. O
The O
structure O
shows O
that O
the O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1- O
vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 O
and O
its O
complexes O
with O
the O
inhibitors O
. O
In O
addition O
, O
the O
molecular O
configuration O
of O
vardenafil O
differs O
from O
that O
of O
sildenafil O
when O
bound O
to O
PDE5 O
. O
It O
is O
noteworthy O
that O
the O
binding O
of O
vardenafil O
causes O
loss O
of O
the O
divalent O
metal O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O
domain O
in O
complex O
with O
vardenafil O
. O
The O
structure O
shows O
that O
the O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1-vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 B
and O
its O
complexes O
with O
the O
inhibitors O
. O
In O
addition O
, O
the O
molecular O
configuration O
of O
vardenafil O
differs O
from O
that O
of O
sildenafil O
when O
bound O
to O
PDE5 O
. O
It O
is O
noteworthy O
that O
the O
binding O
of O
vardenafil O
causes O
loss O
of O
the O
divalent O
metal O
ions O
that O
have O
been O
observed O
in O
all O
the O
previously O
published O
PDE O
structures O
. O
The O
conformational O
variation O
of O
both O
PDE5 O
and O
the O
inhibitors O
provides O
structural O
insight O
into O
the O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
PDE5A1 O
catalytic O
domain O
in O
complex O
with O
vardenafil O
. O
The O
structure O
shows O
that O
the O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1-vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 B
and O
its O
complexes O
with O
the O
inhibitors O
. O
In O
addition O
, O
the O
molecular O
configuration O
of O
vardenafil O
differs O
from O
that O
of O
sildenafil O
when O
bound O
to O
PDE5 O
. O
It O
is O
noteworthy O
that O
the O
binding O
of O
vardenafil O
causes O
loss O
of O
the O
divalent O
metal O
ions O
that O
have O
been O
observed O
in O
all O
the O
previously O
published O
PDE O
structures O
. O
The O
conformational O
variation O
of O
both O
PDE5 O
and O
the O
inhibitors O
provides O
structural O
insight O
into O
the O
different O
potencies O
of O
the O
drugs O
. O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 B
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil O
and O
sildenafil.Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O
domain O
in O
complex O
with O
vardenafil O
. O
The O
structure O
shows O
that O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 O
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil O
and O
sildenafil.Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O
domain O
in O
complex O
with O
vardenafil O
. O
The O
structure O
shows O
that O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1-vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 O
and O
its O
complexes O
with O
the O
inhibitors O
. O
In O
addition O
, O
the O
molecular O
configuration O
of O
vardenafil O
differs O
from O
that O
of O
sildenafil O
when O
bound O
to O
PDE5 O
. O
It O
is O
noteworthy O
that O
the O
binding O
of O
vardenafil O
causes O
loss O
of O
the O
divalent O
metal O
ions O
that O
have O
been O
observed O
in O
all O
the O
previously O
published O
PDE B
structures O
. O
The O
conformational O
variation O
of O
both O
PDE5 O
and O
the O
inhibitors O
provides O
structural O
insight O
into O
the O
different O
potencies O
of O
the O
drugs O
. O

vardenafil O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 B
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafi O
and O
sildenafil.Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O

sildenafil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 B
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil O
and O
sildenafi O
.Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O

Tyr O
acts O
as O
PART-OF O
for O
what O
entity O
? O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 B
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr O
612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

Gln O
acts O
as O
PART-OF O
for O
what O
entity O
? O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 B
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln O
817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

Phe O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 B
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe O
820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

Tyr O
acts O
as O
PART-OF O
for O
what O
entity O
? O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic I
(C) I
domain I
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr O
612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O

Gln O
acts O
as O
PART-OF O
for O
what O
entity O
? O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic I
(C) I
domain I
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln O
817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O

Phe O
acts O
as O
PART-OF O
for O
what O
entity O
? O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic I
(C) I
domain I
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe O
820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O

Val O
acts O
as O
PART-OF O
for O
what O
entity O
? O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic I
(C) I
domain I
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val O
782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O

His O
acts O
as O
PART-OF O
for O
what O
entity O
? O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic I
(C) I
domain I
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His O
613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O

Leu O
acts O
as O
PART-OF O
for O
what O
entity O
? O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic I
(C) I
domain I
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu O
765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O

Phe O
acts O
as O
PART-OF O
for O
what O
entity O
? O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic I
(C) I
domain I
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe O
786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Critical O
amino O
acid O
in O
phosphodiesterase-5 B
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A B
for O
cGMP O
, O
vardenafil O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A B
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O

tadalafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A B
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A B
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A B
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A B
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A B
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A B
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A B
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A B
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A B
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A B
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O

tadalafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A B
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

tadalafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A B
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 B
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 B
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O

tadalafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O

tadalafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O

3-isobutyl-1-methylxanthine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O

3-isobutyl-1-methylxanthine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O

3-isobutyl-1-methylxanthine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
( O
IBMX O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
( O
IBMX O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
( O
IBMX O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O

cyclic O
guanosine O
monophosphate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase B
5 I
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O

cyclic O
guanosine O
monophosphate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase B
5 I
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
( O
cGMP O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
( O
cGMP O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O

cyclic O
guanosine O
monophosphate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 B
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphat O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A B
for O
cGMP O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O

tadalafil O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O

atorvastatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
dipeptidyl O
peptidase-IV O
(DPP-IV) O
by O
atorvastatin.Dipeptidyl O
peptidase-IV O
(DPP-IV) O
is O
an O
enzyme O
responsible O
for O
the O
inactivation O
of O
the O
glucoregulatory O
incretin O
hormones O
glucagon-like O
peptide-1 O
(GLP-1) O
and O
glucose-dependent O
insulinotropic O
polypeptide O
(GIP) O
. O
In O
this O
report O
, O
we O
show O
that O
the O
hypolipidemic O
agent O
atorvastatin O
is O
a O
competitive O
inhibitor O
of O
porcine B
DPP-IV I
in O
vitro O
, O
with O
K(i)=57.8+/-2.3 O
microM O
. O
These O
results O
may O
have O
implications O
in O
the O
development O
of O
novel O
DPP-IV O
inhibitors O
based O
on O
the O
use O
of O
atorvastatin O
as O
a O
lead O
compound O
for O
the O
treatment O
of O
type O
2 O
diabetes O
. O

atorvastatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
incretin O
hormones O
glucagon-like O
peptide-1 O
(GLP-1) O
and O
glucose-dependent O
insulinotropic O
polypeptide O
(GIP) O
. O
In O
this O
report O
, O
we O
show O
that O
the O
hypolipidemic O
agent O
atorvastatin O
is O
a O
competitive O
inhibitor O
of O
porcine O
DPP-IV B
in O
vitro O
, O
with O
K(i)=57.8+/-2.3 O
microM O
. O
These O
results O
may O
have O
implications O
in O
the O
development O
of O
novel O
DPP-IV O
inhibitors O
based O
on O
the O
use O
of O
atorvastatin O
as O
a O
lead O
compound O
for O
the O
treatment O
of O
type O
2 O
diabetes O
. O

atorvastatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
dipeptidyl B
peptidase-IV I
(DPP-IV) O
by O
atorvastati O
.Dipeptidyl O
peptidase-IV O
(DPP-IV) O
is O
an O
enzyme O
responsible O
for O
the O
inactivation O
of O
the O
glucoregulatory O
incretin O
hormones O
glucagon-like O
peptide-1 O
(GLP-1) O
and O
glucose-dependent O
insulinotropic O
polypeptide O
(GIP) O
. O
In O
this O
report O
, O
we O
show O
that O
the O
hypolipidemic O
agent O
atorvastatin O
is O
a O
competitive O
inhibitor O
of O
porcine O
DPP-IV O
in O
vitro O
, O
with O
K(i)=57.8+/-2.3 O
microM O
. O
These O
results O
may O
have O

atorvastatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
dipeptidyl O
peptidase-IV O
(DPP-IV) O
by O
atorvastati O
.Dipeptidyl O
peptidase-IV O
(DPP-IV) O
is O
an O
enzyme O
responsible O
for O
the O
inactivation O
of O
the O
glucoregulatory O
incretin O
hormones O
glucagon-like O
peptide-1 O
(GLP-1) O
and O
glucose-dependent O
insulinotropic O
polypeptide O
(GIP) O
. O
In O
this O
report O
, O
we O
show O
that O
the O
hypolipidemic O
agent O
atorvastatin O
is O
a O
competitive O
inhibitor O
of O
porcine O
DPP-IV B
in O
vitro O
, O
with O
K(i)=57.8+/-2.3 O
microM O
. O
These O
results O
may O
have O

Eprosartan O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Not O
only O
have O
ARBs O
shown O
good O
efficacy O
and O
tolerability O
, O
they O
also O
appear O
to O
have O
a O
protective O
effect O
that O
goes O
beyond O
that O
expected O
from O
the O
reduction O
of O
blood O
pressure O
. O
The O
ARB O
eprosartan O
is O
a O
nonbiphenyl O
nontetrazole O
angiotensin O
II O
type O
1 O
receptor O
(AT1) O
antagonist O
, O
which O
acts O
to O
decrease O
total O
peripheral O
resistance O
. O
Eprosartan O
acts O
at O
vascular O
AT1 B
receptors I
(postsynaptically) O
and O
at O
presynaptic O
AT1 O
receptors O
, O
where O
it O
inhibits O
noradrenaline O
release O
. O
In O
clinical O
studies O
, O
eprosartan O
has O
been O
shown O
to O
significantly O
reduce O
cardiovascular O
and O
cerebrovascular O
events O
, O
whilst O
avoiding O
the O
persistent O
cough O
that O
commonly O
occurs O
with O
the O
use O
of O
angiotensin-converting O
enzyme O
inhibitors O
. O
Eprosartan O
can O
also O
be O

Eprosartan O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Not O
only O
have O
ARBs O
shown O
good O
efficacy O
and O
tolerability O
, O
they O
also O
appear O
to O
have O
a O
protective O
effect O
that O
goes O
beyond O
that O
expected O
from O
the O
reduction O
of O
blood O
pressure O
. O
The O
ARB O
eprosartan O
is O
a O
nonbiphenyl O
nontetrazole O
angiotensin O
II O
type O
1 O
receptor O
(AT1) O
antagonist O
, O
which O
acts O
to O
decrease O
total O
peripheral O
resistance O
. O
Eprosartan O
acts O
at O
vascular O
AT1 B
receptors I
(postsynaptically) O
and O
at O
presynaptic O
AT1 O
receptors O
, O
where O
it O
inhibits O
noradrenaline O
release O
. O
In O
clinical O
studies O
, O
eprosartan O
has O
been O
shown O
to O
significantly O
reduce O
cardiovascular O
and O
cerebrovascular O
events O
, O
whilst O
avoiding O
the O
persistent O
cough O
that O
commonly O
occurs O
with O
the O
use O
of O
angiotensin-converting O
enzyme O
inhibitors O
. O
Eprosartan O
can O
also O
be O

eprosartan O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
blood O
pressure O
and O
treating O
heart O
failure O
in O
a O
broad O
range O
of O
patients O
, O
including O
those O
with O
diabetes O
and O
the O
elderly O
. O
Not O
only O
have O
ARBs O
shown O
good O
efficacy O
and O
tolerability O
, O
they O
also O
appear O
to O
have O
a O
protective O
effect O
that O
goes O
beyond O
that O
expected O
from O
the O
reduction O
of O
blood O
pressure O
. O
The O
ARB O
eprosartan O
is O
a O
nonbiphenyl O
nontetrazole O
angiotensin B
II I
type I
1 I
receptor I
(AT1) O
antagonist O
, O
which O
acts O
to O
decrease O
total O
peripheral O
resistance O
. O
Eprosartan O
acts O
at O
vascular O
AT1 O
receptors O
(postsynaptically) O
and O
at O
presynaptic O
AT1 O
receptors O
, O
where O
it O
inhibits O
noradrenaline O
release O
. O
In O
clinical O
studies O
, O
eprosartan O
has O
been O
shown O
to O
significantly O
reduce O
cardiovascular O
and O
cerebrovascular O
events O
, O

eprosartan O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
blood O
pressure O
and O
treating O
heart O
failure O
in O
a O
broad O
range O
of O
patients O
, O
including O
those O
with O
diabetes O
and O
the O
elderly O
. O
Not O
only O
have O
ARBs O
shown O
good O
efficacy O
and O
tolerability O
, O
they O
also O
appear O
to O
have O
a O
protective O
effect O
that O
goes O
beyond O
that O
expected O
from O
the O
reduction O
of O
blood O
pressure O
. O
The O
ARB O
eprosartan O
is O
a O
nonbiphenyl O
nontetrazole O
angiotensin O
II O
type O
1 O
receptor O
(AT1) O
antagonist O
, O
which O
acts O
to O
decrease O
total O
peripheral O
resistance O
. O
Eprosartan O
acts O
at O
vascular O
AT1 B
receptors O
(postsynaptically) O
and O
at O
presynaptic O
AT1 O
receptors O
, O
where O
it O
inhibits O
noradrenaline O
release O
. O
In O
clinical O
studies O
, O
eprosartan O
has O
been O
shown O
to O
significantly O
reduce O
cardiovascular O
and O
cerebrovascular O
events O
, O

lomustine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
reaction O
products O
at O
times O
yields O
mass O
spectra O
hard O
to O
interpret O
. O
Chromatographic O
separation O
at O
protein O
level O
could O
reduce O
the O
complexity O
of O
a O
sample O
, O
thus O
allowing O
more O
accurate O
mass O
spectrometric O
analysis O
. O
In O
this O
report O
, O
we O
demonstrate O
the O
utility O
of O
reversed-phase O
protein O
chromatography O
and O
FT-ICR O
mass O
spectrometry O
in O
analyzing O
CCNU O
( O
lomustine O
1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea O
, O
MW O
: O
233.7Da) O
modification O
of O
stathmin O
. O
With O
this O
combined O
approach O
, O
we O
determined O
the O
stoichiometry O
as O
well O
as O
sites O
of O
CCNU O
incorporation O
into O
the O
protein O
, O
demonstrating O
differential O
reactivity O
of O
several O
lysyl O
residues O
to O
CCNU O
alkylation O
. O

1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
reaction O
products O
at O
times O
yields O
mass O
spectra O
hard O
to O
interpret O
. O
Chromatographic O
separation O
at O
protein O
level O
could O
reduce O
the O
complexity O
of O
a O
sample O
, O
thus O
allowing O
more O
accurate O
mass O
spectrometric O
analysis O
. O
In O
this O
report O
, O
we O
demonstrate O
the O
utility O
of O
reversed-phase O
protein O
chromatography O
and O
FT-ICR O
mass O
spectrometry O
in O
analyzing O
CCNU O
(lomustine O
, O
1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea O
MW O
: O
233.7Da) O
modification O
of O
stathmin O
. O
With O
this O
combined O
approach O
, O
we O
determined O
the O
stoichiometry O
as O
well O
as O
sites O
of O
CCNU O
incorporation O
into O
the O
protein O
, O
demonstrating O
differential O
reactivity O
of O
several O
lysyl O
residues O
to O
CCNU O
alkylation O
. O

rolipram O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
modulate O
human O
eosinophil O
or O
neutrophil O
apoptosis O
or O
beta O
2-adrenoceptor O
agonist- O
or O
cytokine-afforded O
survival O
. O
We O
also O
evaluated O
whether O
a O
PDE4 B
inhibitor O
could O
modulate O
the O
effect O
of O
a O
corticosteroid O
on O
eosinophil O
and O
neutrophil O
apoptosis O
. O
Apoptosis O
was O
measured O
by O
using O
the O
relative O
DNA O
fragmentation O
assay O
and O
Annexin-V O
binding O
. O
Inhibitors O
of O
PDE4 O
( O
rolipram O
0.1-10 O
microM) O
and O
PDE3 O
(cilostazol; O
0.1-10 O
microM) O
delayed O
spontaneous O
eosinophil O
apoptosis O
maximally O
by O
25% O
and O
15% O
, O
respectively O
. O
A O
combination O
of O
a O
PDE4 O
or O
PDE3 O
inhibitor O
(10 O
microM) O
with O
salbutamol O
(100 O
nM) O
further O
delayed O
eosinophil O
apoptosis O
maximally O
by O
42-49% O
. O
In O
neutrophils O
, O
rolipram O
(10 O
microM) O
also O
decreased O
apoptosis O
with O
a O
maximal O

cilostazol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
apoptosis O
or O
beta O
2-adrenoceptor O
agonist- O
or O
cytokine-afforded O
survival O
. O
We O
also O
evaluated O
whether O
a O
PDE4 O
inhibitor O
could O
modulate O
the O
effect O
of O
a O
corticosteroid O
on O
eosinophil O
and O
neutrophil O
apoptosis O
. O
Apoptosis O
was O
measured O
by O
using O
the O
relative O
DNA O
fragmentation O
assay O
and O
Annexin-V O
binding O
. O
Inhibitors O
of O
PDE4 O
(rolipram; O
0.1-10 O
microM) O
and O
PDE3 B
( O
cilostazol O
0.1-10 O
microM) O
delayed O
spontaneous O
eosinophil O
apoptosis O
maximally O
by O
25% O
and O
15% O
, O
respectively O
. O
A O
combination O
of O
a O
PDE4 O
or O
PDE3 O
inhibitor O
(10 O
microM) O
with O
salbutamol O
(100 O
nM) O
further O
delayed O
eosinophil O
apoptosis O
maximally O
by O
42-49% O
. O
In O
neutrophils O
, O
rolipram O
(10 O
microM) O
also O
decreased O
apoptosis O
with O
a O
maximal O
inhibition O
of O
13% O
. O
The O
combination O

zaprinast O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(10 O
microM) O
with O
salbutamol O
(100 O
nM) O
further O
delayed O
eosinophil O
apoptosis O
maximally O
by O
42-49% O
. O
In O
neutrophils O
, O
rolipram O
(10 O
microM) O
also O
decreased O
apoptosis O
with O
a O
maximal O
inhibition O
of O
13% O
. O
The O
combination O
of O
rolipram O
(10 O
microM) O
and O
salbutamol O
(100 O
nM) O
produced O
a O
27% O
inhibition O
of O
neutrophil O
apoptosis O
. O
Inhibitor O
of O
cGMP-specific B
PDE5 I
( O
zaprinast O
0.1-10 O
microM) O
did O
not O
affect O
eosinophil O
apoptosis O
and O
only O
slightly O
increased O
spontaneous O
neutrophil O
apoptosis O
. O
The O
effect O
of O
budesonide O
on O
apoptosis O
was O
not O
significantly O
modulated O
by O
a O
PDE4 O
inhibitor O
in O
eosinophils O
or O
neutrophils O
. O
The O
present O
results O
show O
that O
selective O
inhibitors O
of O
cAMP-hydrolyzing O
PDEs O
(PDE3 O
and O
PDE4) O
delay O
eosinophil O
apoptosis O
and O
, O

carboxylic O
acid O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
hypercholesterolemia O
. O
Recently O
, O
they O
are O
reported O
to O
have O
beneficial O
effects O
on O
certain O
cancers O
. O
In O
this O
study O
, O
we O
show O
that O
statins O
inhibited O
the O
histone O
deacetylase O
(HDAC) O
activity O
and O
increased O
the O
accumulation O
of O
acetylated O
histone-H3 O
and O
the O
expression O
of O
p21(WAF/CIP) O
in O
human O
cancer O
cells O
. O
Computational O
modeling O
showed O
the O
direct O
interaction O
of O
the O
carboxylic O
acid O
moiety O
of O
statins O
with O
the O
catalytic O
site O
of O
HDAC2 O
. O
In O
the O
subsequent O
enzymatic O
assay O
, O
it O
was O
shown O
that O
lovastatin O
inhibited O
HDAC2 B
activity O
competitively O
with O
a O
K(i) O
value O
of O
31.6 O
micromol/L O
. O
Sp1 O
but O
not O
p53 O
sites O
were O
found O
to O
be O
the O
statins-responsive O
element O
shown O
by O
p21 O
luciferase-promoter O
assays O
. O
DNA O
affinity O

Statins O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Statins O
increase O
p21 O
through O
inhibition O
of O
histone O
deacetylase O
activity O
and O
release O
of O
promoter-associated O
HDAC1/2 O
. O
Statins O
are O
3-hydroxy-3-methylglutaryl-CoA B
reductase I
inhibitors O
broadly O
used O
for O
the O
control O
of O
hypercholesterolemia O
. O
Recently O
, O
they O
are O
reported O
to O
have O
beneficial O
effects O
on O
certain O
cancers O
. O
In O
this O
study O
, O
we O
show O
that O
statins O
inhibited O
the O
histone O
deacetylase O
(HDAC) O
activity O
and O
increased O
the O
accumulation O
of O
acetylated O
histone-H3 O
and O
the O
expression O
of O
p21(WAF/CIP) O
in O
human O

lovastatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
histone O
deacetylase O
(HDAC) O
activity O
and O
increased O
the O
accumulation O
of O
acetylated O
histone-H3 O
and O
the O
expression O
of O
p21(WAF/CIP) O
in O
human O
cancer O
cells O
. O
Computational O
modeling O
showed O
the O
direct O
interaction O
of O
the O
carboxylic O
acid O
moiety O
of O
statins O
with O
the O
catalytic O
site O
of O
HDAC2 O
. O
In O
the O
subsequent O
enzymatic O
assay O
, O
it O
was O
shown O
that O
lovastatin O
inhibited O
HDAC2 B
activity O
competitively O
with O
a O
K(i) O
value O
of O
31.6 O
micromol/L O
. O
Sp1 O
but O
not O
p53 O
sites O
were O
found O
to O
be O
the O
statins-responsive O
element O
shown O
by O
p21 O
luciferase-promoter O
assays O
. O
DNA O
affinity O
protein O
binding O
assay O
and O
chromatin O
immunoprecipitation O
assay O
showed O
the O
dissociation O
of O
HDAC1/2 O
and O
association O
of O
CBP O
, O
leading O
to O
the O

